22921020_3	0	Chemical	1,1	steroid
22921020_3	0	Gene_or_protein	11,12	SFRS3
22921020_3	0	Gene_or_protein	14,15	FKBP4
22921020_3	0	Pharmacodynamic_phenotype	1,2	steroid response
22921020_3	0	Limited_variation	8,10,14,15	alleles in the FKBP4
22921020_3	0	Limited_variation	8,12	alleles in the SFRS3
22684019_11	0	Chemical	4,5	IM3829
22684019_11	0	Disease	12,13	lung cancer
22684019_11	0	Phenotype	19,23	high expression of Nrf2
22684019_11	0	Gene_or_protein	22,23	Nrf2
22862823_4	0	Gene_or_protein	6,7	GATA4
22862823_4	0	Chemical	9,9	alcohol
22862823_4	0	Limited_variation	26,27	rs13273672
22862823_4	0	Disease	9,10	alcohol dependence
15947090_8	0	Limited_variation	5,9	CYP2C9 genotype
15947090_8	0	Gene_or_protein	5,8	CYP2C9
15947090_8	0	Chemical	13,15	S-warfarin
15947090_8	0	Chemical	18,18	warfarin
15947090_8	0	Chemical	30,32	R- warfarin
15947090_8	0	Pharmacokinetic_phenotype	13,15,19,19	S-warfarin clearance
15947090_8	0	Pharmacokinetic_phenotype	30,33	R- warfarin clearance
15947090_8	0	Pharmacokinetic_phenotype	17,19	total warfarin clearance
15947090_8	0	Phenotype	0,0	Age
15947090_8	0	Phenotype	2,2	height
15947090_8	0	Phenotype	23,23	age
15947090_8	0	Phenotype	25,26	body size
23792568_2	0	Chemical	0,0	Sorafenib
23792568_2	0	Gene_or_protein	8,8	BRAF
23792568_2	0	Disease	44,45	brain cancer
23792568_2	0	Disease	30,31	liver cancer
23792568_2	0	Disease	8,10	BRAF mutant melanoma
23792568_2	0	Disease	40,40,45,45	thyroid cancer
23792568_2	0	Disease	42,42,45,45	lung cancer
23792568_2	0	Limited_variation	8,9	BRAF mutant
23792568_2	0	Chemical	14,17	multi-kinase inhibitor
23792568_2	0	Disease	27,27,31,31	kidney cancer
24325099_2	0	Gene_or_protein	19,20	hepatic lipase
24325099_2	0	Gene_or_protein	23,23	LIPC
24325099_2	0	Chemical	36,36	carbohydrate
24325099_2	0	Genomic_factor	16,21	promoter region of hepatic lipase gene
24325099_2	0	Limited_variation	9,24	250G/A polymorphism in the promoter region of hepatic lipase gene ( LIPC )
24325099_2	0	Phenotype	26,28	serum lipid profile
24325099_2	0	Phenotype	34,40	high- carbohydrate /low-fat
24325099_2	0	Phenotype	42,44	HC/LF
24325099_2	0	Phenotype	48,50	serum lipid profiles
17105675_6	0	Limited_variation	5,8	A-241G
17105675_6	0	Chemical	16,16	risperidone
17105675_6	0	Limited_variation	81,82	rs1076562
17105675_6	0	Limited_variation	84,86	T939C
17105675_6	0	Chemical	99,99	risperidone
17105675_6	0	Pharmacodynamic_phenotype	14,17	efficacy of risperidone treatment
17105675_6	0	Limited_variation	72,77	-141 C Ins/Del
17105675_6	0	Limited_variation	79,79	TaqIB
17105675_6	0	Limited_variation	88,88	TaqIA
17105675_6	0	Pharmacodynamic_phenotype	97,99	response to risperidone
17105675_6	0	Limited_variation	25,26	A allele
17105675_6	0	Limited_variation	34,35	G allele
20172524_1	0	Pharmacodynamic_phenotype	1,5	effects of magnesium lithospermate B
20172524_1	0	Chemical	3,5	magnesium lithospermate B
20172524_1	0	Disease	7,8	diabetic atherosclerosis
20172524_1	0	Gene_or_protein	10,16	Nrf2 -ARE- NQO1
20172524_1	0	Genomic_factor	10,18	Nrf2 -ARE- NQO1 transcriptional pathway
17412797_15	0	Limited_variation	22,24	transferrin genetic variants
17412797_15	0	Gene_or_protein	22,22	transferrin
17412797_15	0	Disease	8,9	alcohol abuse
17412797_15	0	Gene_or_protein	5,5	CDT
19817501_20	0	Gene_or_protein	3,6	CYP2D6
19817501_20	0	Pharmacokinetic_phenotype	26,27,31,31	activity towards dextromethorphan
19817501_20	0	Pharmacokinetic_phenotype	26,27,33,33	activity towards risperidone
19817501_20	0	Pharmacokinetic_phenotype	26,27,35,35	activity towards codeine
19817501_20	0	Pharmacokinetic_phenotype	26,27,37,37	activity towards haloperidol
19817501_20	0	Haplotype	3,8	CYP2D6 * 17
19817501_20	0	Phenotype	16,17	reduced function
19817501_20	0	Chemical	28,28	substrates
19817501_20	0	Pharmacokinetic_phenotype	26,28	activity towards substrates
19817501_20	0	Chemical	31,31	dextromethorphan
19817501_20	0	Chemical	33,33	risperidone
19817501_20	0	Chemical	35,35	codeine
19817501_20	0	Chemical	37,37	haloperidol
15544431_6	0	Gene_or_protein	28,31	CYP2A6
15544431_6	0	Chemical	48,64	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
15544431_6	0	Chemical	66,66	NNK
15544431_6	0	Chemical	72,72	nitrosamine
15544431_6	0	Gene_or_protein	87,90	CYP2A6
15544431_6	0	Gene_or_protein	17,20	CYP2A8
15544431_6	0	Chemical	82,82	NNK
22298798_1	0	Chemical	10,10	clopidogrel
22298798_1	0	Gene_or_protein	3,4	ABCB1
22298798_1	0	Limited_variation	3,7	ABCB1 C3435T
22298798_1	0	Pharmacodynamic_phenotype	10,11	clopidogrel response
22298798_1	0	Disease	15,16	stent thrombosis
22298798_1	0	Disease	20,21	coronary stenting
25870087_1	0	Chemical	9,10	AUY922
25870087_1	0	Gene_or_protein	6,7	HSP90
25870087_1	0	Chemical	12,12	Erlotinib
25870087_1	0	Gene_or_protein	14,14	EGFR
25870087_1	0	Gene_or_protein	23,26	Epidermal Growth Factor Receptor
25870087_1	0	Limited_variation	14,16	EGFR -Mutant
25870087_1	0	Disease	14,18	EGFR -Mutant Lung Cancer
25870087_1	0	Chemical	23,29	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
25870087_1	0	Chemical	6,8	HSP90 Inhibitor
25870087_1	0	Pharmacodynamic_phenotype	20,29	Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
21351275_1	0	Disease	6,7	thyroid cancer
21351275_1	0	Gene_or_protein	12,12	MEK
21351275_1	0	Chemical	25,25	temsirolimus
21351275_1	0	Gene_or_protein	23,23	mTOR
21351275_1	0	Gene_or_protein	0,0	BRAF
21351275_1	0	Limited_variation	0,1	BRAF mutation
21351275_1	0	Phenotype	0,8	BRAF mutation -selective inhibition of thyroid cancer cells
21351275_1	0	Chemical	12,13	MEK inhibitor
21351275_1	0	Chemical	14,15	RDEA119
21351275_1	0	Phenotype	17,20	genetic-potentiated synergism
21351275_1	0	Chemical	23,24	mTOR inhibitor
11245458_9	0	Gene_or_protein	4,5	p53
11245458_9	0	Chemical	18,18	DDP
11245458_9	0	Gene_or_protein	7,7	MMR
11245458_9	0	Pharmacodynamic_phenotype	15,18	cytotoxic effect of DDP
11245458_9	0	Disease	27,28	colon cance
19019258_1	0	Disease	2,3	breast cancer
19019258_1	0	Gene_or_protein	7,10	CYP2D6
19019258_1	0	Chemical	16,16	tamoxifen
19019258_1	0	Pharmacokinetic_phenotype	16,17	tamoxifen metabolism
19019258_1	0	Pharmacodynamic_phenotype	16,16,19,20	tamoxifen drug response
18797455_1	0	Gene_or_protein	0,1	GSTP1
18797455_1	0	Limited_variation	0,5	GSTP1 Ile105Val polymorphism
18797455_1	0	Chemical	19,19	irinotecan
18797455_1	0	Disease	13,13	MCRC
18797455_1	0	Phenotype	8,11	progression-free survival
18797455_1	0	Disease	26,27	Colorectal Cancer
25043824_3	0	Chemical	4,4	serotonin
25043824_3	0	Limited_variation	8,13	variation in the 5-HTTLPR
25043824_3	0	Gene_or_protein	11,13	5-HTTLPR
25043824_3	0	Pharmacokinetic_phenotype	4,5	serotonin metabolism
12070798_4	0	Gene_or_protein	6,10	c-erbB-2
12070798_4	0	Chemical	27,27	carboplatin
12070798_4	0	Chemical	29,29	cisplatin
12070798_4	0	Chemical	31,31	cyclophosphamide
12070798_4	0	Phenotype	13,13	survival
12070798_4	0	Chemical	25,27	chemotherapy with carboplatin
12070798_4	0	Chemical	25,26,29,31	chemotherapy with cisplatin and cyclophosphamide
12070798_4	0	Phenotype	4,11	expression of c-erbB-2 mRNA
12070798_4	0	Genomic_factor	6,11	c-erbB-2 mRNA
25474278_1	0	Phenotype	6,8	p53 expression
25474278_1	0	Gene_or_protein	6,7	p53
25474278_1	0	Disease	10,12	metastatic colorectal cancer
25474278_1	0	Chemical	15,15	oxaliplatin
25474278_1	0	Chemical	17,17	fluoropyrimidine
25474278_1	0	Chemical	15,20	oxaliplatin and fluoropyrimidine -based chemotherapy
25474278_1	0	Genomic_factor	3,4	microsatellite instability
19014491_7	0	Limited_variation	14,16	SIRT1 variants
19014491_7	0	Gene_or_protein	14,15	SIRT1
19014491_7	0	Phenotype	23,23	weight
19014491_7	0	Phenotype	25,26	body fat
19014491_7	0	Phenotype	31,32	blood glucose
19014491_7	0	Pharmacodynamic_phenotype	34,35	insulin sensitivity
19014491_7	0	Phenotype	37,38	insulin secretion
19014491_7	0	Phenotype	40,41	liver fat
19014491_7	0	Phenotype	21,21	anthropometrics
19014491_7	0	Phenotype	28,29	metabolic characteristics
19014491_7	0	Chemical	34,34	insulin
25941087_7	0	Chemical	14,14	ritodrine
25941087_7	0	Gene_or_protein	1,4	SULT1A3
25941087_7	0	Pharmacokinetic_phenotype	11,14	sulfating activity toward ritodrine
24841934_9	0	Chemical	2,3	folic acid
24841934_9	0	Gene_or_protein	14,14	MTHFR
24841934_9	0	Limited_variation	14,17	MTHFR C677T
24841934_9	0	Disease	27,27	ARM
24841934_9	0	Disease	31,31	ARM
9142901_2	0	Chemical	4,4	somatostatin
9142901_2	0	Phenotype	7,8,13,15	expression of c-fos
9142901_2	0	Gene_or_protein	13,15	c-fos
25841872_2	0	Chemical	2,2	Ezetimibe
25841872_2	0	Gene_or_protein	27,30	NPC1L1
25841872_2	0	Gene_or_protein	17,25	Niemann-Pick C1-Like protein 1
25841872_2	0	Pharmacodynamic_phenotype	4,14	plasma levels of low-density lipoprotein ( LDL ) cholesterol
18573584_4	0	Chemical	9,9	haloperidol
18573584_4	0	Chemical	11,11	risperidone
18573584_4	0	Disease	18,18	schizophrenia
18573584_4	0	Phenotype	28,32	relapse of these psychotic disorders
18573584_4	0	Disease	31,32	psychotic disorders
18573584_4	0	Disease	20,20	schizophreniform
18573584_4	0	Limited_variation	43,49	5-HTTLPR L and S alleles
18573584_4	0	Limited_variation	64,66	La/g
18573584_4	0	Disease	22,23	schizoaffective disorders
18573584_4	0	Limited_variation	54,62	A/G functional variant within the L alelle
17404720_1	0	Limited_variation	4,6	MDR1 polymorphism
17404720_1	0	Gene_or_protein	4,5	MDR1
17404720_1	0	Chemical	8,8	digoxin
17404720_1	0	Pharmacokinetic_phenotype	8,10	digoxin pharmacokinetic parameters
26481697_2	0	Chemical	1,1	chemotherapy
26481697_2	0	Chemical	3,9	epidermal growth factor receptor tyrosine kinase inhibitors
26481697_2	0	Gene_or_protein	3,6	epidermal growth factor receptor
26481697_2	0	Gene_or_protein	11,11	EGFR
26481697_2	0	Chemical	11,12	EGFR TKIs
26481697_2	0	Disease	21,26	non-small cell lung cancer
26481697_2	0	Disease	28,28	NSCLC
26481697_2	0	Pharmacodynamic_phenotype	33,33	efficacy
21302482_2	0	Disease	7,9	blood stasis syndrome
21302482_2	0	Disease	11,11	BSS
21302482_2	0	Limited_variation	14,19	CYP2C19 gene polymorphism
21302482_2	0	Gene_or_protein	14,17	CYP2C19
21302482_2	0	Pharmacodynamic_phenotype	21,22	clopidogrel resistance
21302482_2	0	Chemical	21,21	clopidogrel
21302482_2	0	Pharmacodynamic_phenotype	24,24	CR
21302482_2	0	Phenotype	27,30	post-PCI prognosis
10580024_9	0	Phenotype	16,18	TPMT enzyme activity
10580024_9	0	Gene_or_protein	16,16	TPMT
10580024_9	0	Chemical	32,34	6-mercaptopurine
10580024_9	0	Pharmacodynamic_phenotype	6,8	thioguanine nucleotide concentrations
10580024_9	0	Phenotype	3,3	sex
10580024_9	0	Chemical	6,6	thioguanine
10580024_9	0	Pharmacodynamic_phenotype	30,34	dose of 6-mercaptopurine
22179112_4	0	Gene_or_protein	2,2	Rhes
22179112_4	0	Gene_or_protein	12,12	mTOR
22179112_4	0	Chemical	23,25	L-DOPA
22179112_4	0	Gene_or_protein	33,33	Rhes
22179112_4	0	Limited_variation	2,7	Rhes ( - / - )
22179112_4	0	Pharmacodynamic_phenotype	20,21	motor improvement
22179112_4	0	Chemical	33,36	Rhes -binding drugs
22179112_4	0	Phenotype	11,13	striatal mTOR signaling
22179112_4	0	Disease	16,16	dyskinesia
22179112_4	0	Pharmacodynamic_phenotype	20,25	motor improvement on L-DOPA
22015057_6	0	Chemical	19,19	sunitinib
22015057_6	0	Limited_variation	31,32	rs2305948
22015057_6	0	Gene_or_protein	28,29	VEGFR2
22015057_6	0	Limited_variation	34,35	rs1870377
22015057_6	0	Limited_variation	41,42	rs307826
22015057_6	0	Gene_or_protein	38,39	VEGFR3
22015057_6	0	Limited_variation	44,45	rs448012
22015057_6	0	Limited_variation	48,49	rs307821
22015057_6	0	Gene_or_protein	52,54	PDGFR-a
22015057_6	0	Limited_variation	56,57	rs35597368
22015057_6	0	Limited_variation	64,65	rs2010963
22015057_6	0	Gene_or_protein	60,62	VEGF-A
22015057_6	0	Limited_variation	67,68	rs699947
22015057_6	0	Limited_variation	71,72	rs1570360
22015057_6	0	Gene_or_protein	75,76	IL8
22015057_6	0	Limited_variation	78,79	rs1126647
22015057_6	0	Gene_or_protein	82,85	CYP3A4
22015057_6	0	Limited_variation	87,88	rs2740574
22015057_6	0	Gene_or_protein	91,94	CYP3A5
22015057_6	0	Limited_variation	96,97	rs776746
22015057_6	0	Limited_variation	103,104	rs1045642
22015057_6	0	Gene_or_protein	100,101	ABCB1
22015057_6	0	Limited_variation	106,107	rs1128503
22015057_6	0	Limited_variation	110,111	rs2032582
22015057_6	0	Gene_or_protein	115,116	ABCB2
22015057_6	0	Limited_variation	118,119	rs2231142
22015057_6	0	Phenotype	2,3	RECIST response
22015057_6	0	Phenotype	5,8	progression-free survival
22015057_6	0	Phenotype	10,10	PFS
22015057_6	0	Phenotype	13,14	overall survival
22015057_6	0	Pharmacodynamic_phenotype	17,19	toxicity of sunitinib
22015057_6	0	Limited_variation	23,23	polymorphisms
15470329_7	0	Gene_or_protein	0,4	beta 1 -Adrenergic receptor
15470329_7	0	Limited_variation	0,8	beta 1 -Adrenergic receptor polymorphisms Ser49Gly
15470329_7	0	Chemical	26,26	metoprolol
15470329_7	0	Limited_variation	0,5,10,12	beta 1 -Adrenergic receptor polymorphisms Arg 389Gly
15470329_7	0	Pharmacokinetic_phenotype	21,21,24,26	pharmacokinetic relationship of metoprolol
15470329_7	0	Pharmacodynamic_phenotype	23,26	pharmacodynamic relationship of metoprolol
19559544_5	0	Phenotype	0,2	Pdyn gene deficiency
19559544_5	0	Gene_or_protein	0,0	Pdyn
19559544_5	0	Chemical	4,4	nalbuphine
19559544_5	0	Gene_or_protein	14,16	c-Fos
19559544_5	0	Pharmacodynamic_phenotype	4,11	nalbuphine -induced behavioral sensitization of locomotor activity
19559544_5	0	Phenotype	13,17	accumbal c-Fos expression
19559544_5	0	Pharmacodynamic_phenotype	7,11	behavioral sensitization of locomotor activity
23894460_7	0	Gene_or_protein	0,0	Egfr
23894460_7	0	Gene_or_protein	12,13	p53
23894460_7	0	Chemical	18,18	cyclophosphamide
23894460_7	0	Limited_variation	0,1	Egfr mutant
23894460_7	0	Phenotype	6,6	proliferation
23894460_7	0	Phenotype	8,8	apoptosis
23894460_7	0	Phenotype	12,16	p53 -positive cells
17217931_1	0	Chemical	14,14	sumatriptan
17217931_1	0	Gene_or_protein	4,7	serotonin 1B receptor
17217931_1	0	Genomic_factor	4,8	serotonin 1B receptor promoter
17217931_1	0	Disease	17,19	alcohol -dependent
17217931_1	0	Genomic_variation	0,8	Diplotypes of the human serotonin 1B receptor promoter
17217931_1	0	Pharmacodynamic_phenotype	10,14	growth hormone responses to sumatriptan
12796525_2	0	Gene_or_protein	14,15	dopamine transporter
12796525_2	0	Gene_or_protein	18,18	DAT
12796525_2	0	Gene_or_protein	8,9	dopamine receptor
12796525_2	0	Limited_variation	5,10	polymorphisms in the dopamine receptor genes
12796525_2	0	Pharmacodynamic_phenotype	23,28	adverse effects of L - dopa
12796525_2	0	Limited_variation	5,5,12,16	polymorphisms in the dopamine transporter gene
12796525_2	0	Chemical	26,28	L - dopa
19655247_7	0	Gene_or_protein	17,20	SLC6A4
19655247_7	0	Chemical	30,30	alosetron
19655247_7	0	Gene_or_protein	25,28	5-HT3
19655247_7	0	Gene_or_protein	33,36	5-HT4
19655247_7	0	Chemical	39,39	tegaserod
19655247_7	0	Chemical	25,29	5-HT3 antagonist
19655247_7	0	Chemical	33,37	5-HT4 agonist
19655247_7	0	Pharmacodynamic_phenotype	22,30	responses to the 5-HT3 antagonist alosetron
19655247_7	0	Pharmacodynamic_phenotype	22,23,32,39	responses to the 5-HT4 agonist , tegaserod
19655247_7	0	Pharmacodynamic_phenotype	10,12	response to therapy
19374522_1	0	Gene_or_protein	0,3	CYP2D6
19374522_1	0	Chemical	10,10	risperidone
19374522_1	0	Limited_variation	0,4	CYP2D6 genotyping
26698676_2	0	Disease	31,31	infertility
26698676_2	0	Disease	47,48	ovarian cancer
26698676_2	0	Limited_variation	53,54,58,58	BRCA1 mutation
26698676_2	0	Gene_or_protein	53,54	BRCA1
26698676_2	0	Gene_or_protein	56,57	BRCA2
26698676_2	0	Chemical	17,23	selective estrogen receptor [ ER ] modulator
26698676_2	0	Chemical	25,25	gonadotropin
26698676_2	0	Limited_variation	56,58	BRCA2 mutation
26698676_2	0	Chemical	9,10	fertility medication
19843683_7	0	Chemical	10,12	8-oxoGua
19843683_7	0	Gene_or_protein	21,23	hOGG1 glycosylase
19843683_7	0	Pharmacokinetic_phenotype	9,12	urinary 8-oxoGua
22948856_1	0	Chemical	5,5	pridopidine
22948856_1	0	Gene_or_protein	13,16	CYP2D6
22948856_1	0	Pharmacodynamic_phenotype	2,5	tolerability profile of pridopidine
22948856_1	0	Pharmacokinetic_phenotype	0,0,4,5	Pharmacokinetic of pridopidine
22948856_1	0	Pharmacokinetic_phenotype	12,17	extensive CYP2D6 metabolizers
22948856_1	0	Pharmacokinetic_phenotype	10,10,13,17	poor CYP2D6 metabolizers
16257348_2	0	Chemical	12,12	tryptophan
16257348_2	0	Gene_or_protein	17,18	TPH1
16257348_2	0	Limited_variation	17,21	TPH1 A218C
16257348_2	0	Phenotype	25,28	age of alcoholism onset
16257348_2	0	Gene_or_protein	12,13	tryptophan hydroxylase
16257348_2	0	Limited_variation	12,15	tryptophan hydroxylase gene polymorphism
16257348_2	0	Disease	27,27	alcoholism
22234350_11	0	Haplotype	11,13	NFATc4 haplotypes
22234350_11	0	Gene_or_protein	11,12	NFATc4
22234350_11	0	Disease	39,39	NODAT
22234350_11	0	Chemical	26,27	CNI-
22495427_3	0	Gene_or_protein	15,15	XDH
22495427_3	0	Gene_or_protein	17,18	AOX1
22495427_3	0	Gene_or_protein	21,21	MOCOS
22495427_3	0	Pharmacodynamic_phenotype	31,33	drug side effects
22495427_3	0	Chemical	43,43	azathioprine
22495427_3	0	Chemical	45,45	AZA
22495427_3	0	Disease	38,39	kidney transplant
22495427_3	0	Limited_variation	8,15	single nucleotide polymorphisms ( SNPs ) in XDH
22495427_3	0	Limited_variation	8,14,17,18	single nucleotide polymorphisms ( SNPs ) in AOX1
22495427_3	0	Limited_variation	8,14,21,21	single nucleotide polymorphisms ( SNPs ) in MOCOS
22495427_3	0	Chemical	52,53	immunosuppressive regimen
22461642_7	0	Chemical	2,2	oridonin
22461642_7	0	Phenotype	5,12	activity of c-Kit ( + )
22461642_7	0	Gene_or_protein	7,9	c-Kit
22461642_7	0	Limited_variation	7,12	c-Kit ( + )
24638003_10	0	Chemical	6,6	imatinib
24638003_10	0	Limited_variation	17,20	KIT exon 11 deletion
24638003_10	0	Gene_or_protein	17,17	KIT
24638003_10	0	Limited_variation	28,31	KIT exon 11 insertion
24638003_10	0	Gene_or_protein	28,28	KIT
24638003_10	0	Limited_variation	36,39	KIT exon 9 mutation
24638003_10	0	Gene_or_protein	36,36	KIT
24638003_10	0	Limited_variation	41,42	PDGFRA mutation
24638003_10	0	Gene_or_protein	41,41	PDGFRA
24638003_10	0	Phenotype	12,12	RFS
24638003_10	0	Limited_variation	28,30,33,34	KIT exon 11 point mutation
24638003_10	0	Limited_variation	45,47	wild-type
24638003_10	0	Disease	45,48	wild-type tumor
24638003_10	0	Disease	17,20,48,48	KIT exon 11 deletion tumor
24638003_10	0	Disease	28,31,48,48	KIT exon 11 insertion tumor
24638003_10	0	Disease	28,30,33,34,48,48	KIT exon 11 point mutation tumor
24638003_10	0	Disease	36,39,48,48	KIT exon 9 mutation tumor
24638003_10	0	Disease	41,42,48,48	PDGFRA mutation tumor
24638003_10	0	Genomic_factor	17,19	KIT exon 11
8018460_1	0	Chemical	0,0	Maprotiline
8018460_1	0	Pharmacokinetic_phenotype	17,19	hydroxylation of debrisoquine
8018460_1	0	Gene_or_protein	12,15	CYP2D6
8018460_1	0	Chemical	19,19	debrisoquine
8018460_1	0	Pharmacokinetic_phenotype	0,1	Maprotiline metabolism
8018460_1	0	Limited_variation	12,16	CYP2D6 polymorphic
8018460_1	0	Pharmacokinetic_phenotype	12,19	CYP2D6 polymorphic hydroxylation of debrisoquine
15016420_6	0	Chemical	2,2	propranolol
15016420_6	0	Phenotype	10,13	suppression of NK cytotoxicity
15016420_6	0	Disease	13,13	cytotoxicity
15016420_6	0	Phenotype	20,21	Fos expression
15016420_6	0	Gene_or_protein	20,20	Fos
7753410_9	0	Chemical	1,7	angiotensin II -AT1 receptor antagonist
7753410_9	0	Chemical	9,9	losartan
7753410_9	0	Chemical	17,18	angiotensin II
7753410_9	0	Pharmacodynamic_phenotype	22,30	angiotensin II -induced immediate early gene protein expression
7753410_9	0	Chemical	22,23	angiotensin II
7753410_9	0	Gene_or_protein	1,6	angiotensin II -AT1 receptor
7753410_9	0	Pharmacodynamic_phenotype	26,30	immediate early gene protein expression
7635999_7	0	Limited_variation	3,7	CYP2D6 genotype
7635999_7	0	Gene_or_protein	3,6	CYP2D6
7635999_7	0	Chemical	11,11	debrisoquine
7635999_7	0	Pharmacokinetic_phenotype	10,12	ultrarapid debrisoquine hydroxylation
22206814_8	0	Gene_or_protein	4,4	PXR
22206814_8	0	Chemical	8,9	okadaic acid
22206814_8	0	Chemical	32,34	pectenotoxin-2
22206814_8	0	Chemical	14,16	CiVDR/PXRa
11320258_1	0	Chemical	3,3	cocaine
11320258_1	0	Gene_or_protein	7,7,10,10	dopamine transporter
11320258_1	0	Gene_or_protein	9,10	serotonin transporter
11320258_1	0	Chemical	13,13	cocaine
11320258_1	0	Genomic_variation	9,11	serotonin transporter knockouts
11320258_1	0	Genomic_variation	7,7,11,11	dopamine knockouts
11320258_1	0	Phenotype	13,15	cocaine place preference
17014716_6	0	Gene_or_protein	3,4	CD4
17014716_6	0	Chemical	14,14	prostratin
17014716_6	0	Gene_or_protein	16,18	Cyclin T1
17014716_6	0	Gene_or_protein	29,31	Cyclin T1
17014716_6	0	Gene_or_protein	33,38	Cyclin-dependent kinase-9
17014716_6	0	Gene_or_protein	40,41	CDK9
17014716_6	0	Gene_or_protein	20,22	P-TEFb
17014716_6	0	Genomic_factor	16,22	Cyclin T1 / P-TEFb
17014716_6	0	Gene_or_protein	45,45	Tat
17014716_6	0	Gene_or_protein	26,26	kinase
1315265_5	0	Chemical	21,21	dexamethasone
1315265_5	0	Gene_or_protein	27,27	Fos
1315265_5	0	Gene_or_protein	9,10	glucocorticoid receptor
1315265_5	0	Phenotype	27,29	Fos -LI
1315265_5	0	Chemical	18,19	synthetic glucocorticoid
24120259_13	0	Limited_variation	5,9	CYP3A5 genotype
24120259_13	0	Gene_or_protein	5,8	CYP3A5
24120259_13	0	Pharmacodynamic_phenotype	23,23	toxicity
24120259_13	0	Chemical	29,29	tacrolimus
24120259_13	0	Chemical	18,19	immunosuppressive treatment
24120259_13	0	Pharmacodynamic_phenotype	27,30	doses of tacrolimus required
24120259_13	0	Disease	39,40	kidney transplant
17151111_6	0	Gene_or_protein	12,13	GP2
17151111_6	0	Limited_variation	3,4,9,15	mutation of N -linked GP2 glycosylation sites
17151111_6	0	Phenotype	21,21,24,25	antigenicity of GP
17151111_6	0	Phenotype	23,25	immunogenicity of GP
17151111_6	0	Gene_or_protein	25,25	GP
17151111_6	0	Genomic_factor	12,15	GP2 glycosylation sites
18024866_6	0	Chemical	2,2	Tamoxifen
18024866_6	0	Gene_or_protein	8,11	CYP2D6
18024866_6	0	Phenotype	37,40	recurrences of breast cancer
18024866_6	0	Disease	39,40	breast cancer
18024866_6	0	Haplotype	8,14	CYP2D6 alleles * 4
18024866_6	0	Haplotype	8,12,16,17	CYP2D6 alleles * 5
18024866_6	0	Haplotype	8,12,19,20	CYP2D6 alleles * 10
18024866_6	0	Haplotype	8,12,22,23	CYP2D6 alleles * 41
18024866_6	0	Phenotype	43,46	relapse-free periods
18024866_6	0	Phenotype	78,82	event-free survival rates
18024866_6	0	Pharmacodynamic_phenotype	28,32	impaired formation of antiestrogenic metabolites
22289787_11	0	Chemical	2,4	VPA / HU
22289787_11	0	Phenotype	8,8,13,14	expression of EGFR
22289787_11	0	Gene_or_protein	14,14	EGFR
22289787_11	0	Phenotype	10,14	cell surface localization of EGFR
22289787_11	0	Chemical	2,2	VPA
22289787_11	0	Chemical	4,4	HU
26220844_12	0	Limited_variation	3,7	TT genotype of STMN1
26220844_12	0	Gene_or_protein	6,7	STMN1
26220844_12	0	Chemical	19,20	platinum compounds
26220844_12	0	Chemical	22,22	vinorelbine
26220844_12	0	Disease	27,27	NSCLC
26220844_12	0	Chemical	16,16	chemotherapy
26220844_12	0	Chemical	19,22	platinum compounds and vinorelbine
21118736_18	0	Gene_or_protein	2,5	CYP3A5
21118736_18	0	Chemical	19,19	tacrolimus
21118736_18	0	Disease	26,26	DGF
21118736_18	0	Gene_or_protein	30,33	CYP3A5
21118736_18	0	Disease	38,38	DGF
21118736_18	0	Haplotype	2,7	CYP3A5 * 3
21118736_18	0	Haplotype	30,35	CYP3A5 * 1
21118736_18	0	Pharmacodynamic_phenotype	19,21	tacrolimus dose requirements
21118736_18	0	Pharmacodynamic_phenotype	47,48	dose requirements
25940539_9	0	Chemical	4,6	CUDC-101
25940539_9	0	Gene_or_protein	13,14	p21
25940539_9	0	Gene_or_protein	16,18	E-cadherin
25940539_9	0	Gene_or_protein	26,26	XIAP
25940539_9	0	Gene_or_protein	28,30	b-catenin
25940539_9	0	Gene_or_protein	32,34	N-cadherin
25940539_9	0	Gene_or_protein	37,37	Vimentin
25940539_9	0	Pharmacodynamic_phenotype	1,6	anticancer effect of CUDC-101
25940539_9	0	Gene_or_protein	24,24	survivin
25940539_9	0	Phenotype	10,14	increased expression of p21
25940539_9	0	Phenotype	10,12,16,18	increased expression of E-cadherin
25940539_9	0	Phenotype	21,24	reduced expression of survivin
25940539_9	0	Phenotype	21,23,26,26	reduced expression of XIAP
25940539_9	0	Phenotype	21,23,28,30	reduced expression of b-catenin
25940539_9	0	Phenotype	21,23,32,34	reduced expression of N-cadherin
25940539_9	0	Phenotype	21,23,37,37	reduced expression of Vimentin
23394127_3	0	Gene_or_protein	13,14	NAT2
23394127_3	0	Gene_or_protein	17,22	cytochrome P450 2E1
23394127_3	0	Gene_or_protein	24,27	CYP2E1
23394127_3	0	Chemical	36,36	INH
23394127_3	0	Gene_or_protein	7,11	N-acetyl transferase 2
23394127_3	0	Pharmacodynamic_phenotype	31,36	hepatotoxicity of patients treated with INH
25487141_10	0	Limited_variation	14,19	CYP3A5 gene polymorphisms
25487141_10	0	Gene_or_protein	14,17	CYP3A5
25487141_10	0	Limited_variation	22,30	IL-18 A-607C gene polymorphisms
25487141_10	0	Gene_or_protein	22,24	IL-18
25487141_10	0	Chemical	37,37	tacrolimus
25487141_10	0	Gene_or_protein	9,9	hemoglobin
25487141_10	0	Gene_or_protein	11,11	Hb
25487141_10	0	Phenotype	7,7	age
25487141_10	0	Pharmacodynamic_phenotype	37,41	tacrolimus C/D ratios
10529724_11	0	Gene_or_protein	5,5	nNOS
10529724_11	0	Pharmacodynamic_phenotype	13,17	METH -induced behavioral sensitization
10529724_11	0	Chemical	13,13	METH
10529724_11	0	Gene_or_protein	8,8	iNOS
10529724_11	0	Phenotype	8,9	iNOS deficiency
10529724_11	0	Phenotype	5,6	nNOS deficiency
10529724_11	0	Pharmacodynamic_phenotype	16,17	behavioral sensitization
25007187_2	0	Chemical	15,17	6-mercaptopurine
25007187_2	0	Gene_or_protein	20,20	TPMT
25007187_2	0	Chemical	23,23	methotrexate
25007187_2	0	Chemical	25,25	MTX
25007187_2	0	Gene_or_protein	29,30	ABCB1
25007187_2	0	Gene_or_protein	33,34	MDR1
25007187_2	0	Gene_or_protein	37,38	ABCC2
25007187_2	0	Gene_or_protein	40,43	SLC19A1
25007187_2	0	Gene_or_protein	46,47	RFC1
25007187_2	0	Gene_or_protein	51,54	SLCO1B1
25007187_2	0	Chemical	58,58	MTX
25007187_2	0	Gene_or_protein	61,61	MTHFR
25007187_2	0	Gene_or_protein	63,63	TYMS
25007187_2	0	Chemical	79,79	MTX
25007187_2	0	Pharmacokinetic_phenotype	79,80	MTX clearance
25007187_2	0	Pharmacodynamic_phenotype	74,75	treatment toxicity
25007187_2	0	Pharmacokinetic_phenotype	15,18	6-mercaptopurine detoxification
25007187_2	0	Pharmacokinetic_phenotype	23,27	methotrexate ( MTX ) metabolism
25007187_2	0	Pharmacodynamic_phenotype	58,59	MTX effect
25007187_2	0	Limited_variation	70,70	polymorphisms
25007187_2	0	Limited_variation	10,12	polymorphisms in genes
20107067_3	0	Limited_variation	4,6	deletion of SR
20107067_3	0	Gene_or_protein	6,6	SR
20107067_3	0	Chemical	13,15	D-serine
20107067_3	0	Disease	21,21	neurotoxicity
20107067_3	0	Disease	23,23	stroke
20107067_3	0	Gene_or_protein	17,18	NMDA receptor
20107067_3	0	Disease	17,21	NMDA receptor -mediated neurotoxicity
20107067_3	0	Disease	17,20,23,23	NMDA receptor -mediated stroke
26091798_14	0	Gene_or_protein	4,5	p53
26091798_14	0	Chemical	13,13	arsenic
26091798_14	0	Chemical	15,18	Cr(VI)
26091798_14	0	Disease	42,43	lung cancer
26091798_14	0	Chemical	35,35	arsenic
26091798_14	0	Chemical	37,40	Cr(VI)
26091798_14	0	Disease	37,43	Cr(VI) induced lung cancer
26091798_14	0	Disease	35,35,41,43	arsenic induced lung cancer
17495880_6	0	Chemical	12,12	tacrolimus
17495880_6	0	Gene_or_protein	17,20	CYP3A4
17495880_6	0	Gene_or_protein	24,27	CYP3A5
17495880_6	0	Gene_or_protein	31,34	CYP3A4
17495880_6	0	Gene_or_protein	39,42	CYP3A5
17495880_6	0	Chemical	49,49	tacrolimus
17495880_6	0	Haplotype	17,22	CYP3A4 * 1
17495880_6	0	Haplotype	24,29	CYP3A5 * 1
17495880_6	0	Haplotype	31,37	CYP3A4 * 1B
17495880_6	0	Haplotype	39,44	CYP3A5 * 1
17495880_6	0	Pharmacodynamic_phenotype	49,52	tacrolimus -related nephrotoxicity
17495880_6	0	Pharmacodynamic_phenotype	60,63	concentrations of toxic metabolites
17495880_6	0	Haplotype	17,29,45,45	CYP3A4 * 1 / CYP3A5 * 1 genotypes
17495880_6	0	Haplotype	31,45	CYP3A4 * 1B / CYP3A5 * 1 genotypes
17495880_6	0	Pharmacodynamic_phenotype	52,52	nephrotoxicity
21457551_10	0	Chemical	7,7	estrogen
21457551_10	0	Disease	21,22	breast cancer
21457551_10	0	Limited_variation	44,45	rs4149013
21457551_10	0	Gene_or_protein	47,50	SLCO1B1
21457551_10	0	Chemical	9,9	progestin
21457551_10	0	Chemical	6,10	combined estrogen - progestin therapy
21457551_10	0	Chemical	12,12	EPT
21457551_10	0	Phenotype	19,19	OR
11692082_6	0	Chemical	13,13	ivermectin
11692082_6	0	Phenotype	19,21	mdr1 expression
11692082_6	0	Gene_or_protein	19,20	mdr1
11692082_6	0	Chemical	1,1	ivermectin
11692082_6	0	Pharmacodynamic_phenotype	13,16	ivermectin -sensitive collies
11692082_6	0	Gene_or_protein	6,8	P-gp
20528747_6	0	Gene_or_protein	8,12	membrane type-1 MMP
20528747_6	0	Gene_or_protein	14,17	MT1-MMP
20528747_6	0	Gene_or_protein	26,31	tissue inhibitor of MMP-2
20528747_6	0	Gene_or_protein	33,35	TIMP-2
20528747_6	0	Chemical	39,39	theaflavin
20528747_6	0	Phenotype	45,48	MMP-2 activation
20528747_6	0	Gene_or_protein	45,47	MMP-2
20528747_6	0	Phenotype	5,18	protein expression of membrane type-1 MMP ( MT1-MMP )
20528747_6	0	Phenotype	23,36	protein expression of tissue inhibitor of MMP-2 ( TIMP-2 )
20528747_6	0	Phenotype	3,3,6,18	mRNA expression of membrane type-1 MMP ( MT1-MMP )
20528747_6	0	Phenotype	21,21,24,36	mRNA expression of tissue inhibitor of MMP-2 ( TIMP-2 )
21445620_10	0	Gene_or_protein	6,6	COMT
21445620_10	0	Chemical	23,23	EGCG
21445620_10	0	Limited_variation	6,13	COMT Val ( 158/108 ) Met
21445620_10	0	Pharmacokinetic_phenotype	23,24	EGCG absorption
21445620_10	0	Pharmacokinetic_phenotype	23,23,26,26	EGCG elimination
16015387_9	0	Limited_variation	3,6	KIT exon 8 mutations
16015387_9	0	Gene_or_protein	3,3	KIT
16015387_9	0	Chemical	24,24	imatinib
16015387_9	0	Gene_or_protein	13,13	kinase
16015387_9	0	Phenotype	13,14	kinase activation
16015387_9	0	Pharmacodynamic_phenotype	22,24	concentrations of imatinib
16015387_9	0	Genomic_factor	3,5	KIT exon 8
27522730_20	0	Limited_variation	6,10	interleukin 28B gene polymorphism
27522730_20	0	Gene_or_protein	6,8	interleukin 28B
27522730_20	0	Chemical	32,36	pegylated interferon a-2
27522730_20	0	Chemical	38,38	ribavirin
27522730_20	0	Chemical	30,38	AVT with pegylated interferon a-2 and ribavirin
27522730_20	0	Disease	22,22	fibrosis
27522730_20	0	Phenotype	18,18,22,22	SVR fibrosis
27522730_20	0	Phenotype	20,22	dynamics of fibrosis
27522730_20	0	Disease	26,28	CHC-I
27522730_20	0	Chemical	52,55	interferon-free therapy
24204751_5	0	Gene_or_protein	0,0	CFTR
24204751_5	0	Chemical	20,20	cAMP
24204751_5	0	Chemical	13,16	b-adrenergic cocktail
24204751_5	0	Gene_or_protein	23,24	muscarinic receptors
24204751_5	0	Phenotype	0,3	CFTR -dependent secretion
24204751_5	0	Phenotype	5,7	C-sweat
19442155_4	0	Chemical	12,12	lithium
19442155_4	0	Gene_or_protein	37,42	inositol polyphosphate-1-phosphatase
19442155_4	0	Gene_or_protein	44,44	IPPase
19442155_4	0	Gene_or_protein	53,56	GSK-3 beta
19442155_4	0	Gene_or_protein	30,32	inositol mono phosphatase
19442155_4	0	Gene_or_protein	34,34	IMPase
19442155_4	0	Gene_or_protein	47,51	glycogen sinthase kinase 3 beta
19344737_12	0	Disease	11,12	conduct disorder
19344737_12	0	Disease	18,18	impulsivity
19344737_12	0	Chemical	22,22	alcohol
19344737_12	0	Gene_or_protein	38,39	DRD2
19344737_12	0	Disease	21,25	problematic alcohol / drug use
19344737_12	0	Limited_variation	32,39	A1 carrier status of the DRD2
19344737_12	0	Chemical	24,24	drug
23467639_5	0	Chemical	2,2	aspirin
23467639_5	0	Gene_or_protein	4,7	P2Y12
23467639_5	0	Disease	21,21	bleeding
23467639_5	0	Chemical	4,8	P2Y12 inhibitors
23467639_5	0	Chemical	11,12	antiplatelet drugs
23467639_5	0	Phenotype	16,19	inhibition of platelet function
17949449_9	0	Disease	5,9	Dukes ' C colorectal cancer
17949449_9	0	Disease	18,18	tumour
17949449_9	0	Chemical	22,24	5-FU
17949449_9	0	Limited_variation	30,33	p53 mutation status
17949449_9	0	Gene_or_protein	30,31	p53
17949449_9	0	Chemical	22,28	5-FU -based adjuvant chemotherapy
17949449_9	0	Phenotype	46,49	metastasis-free survival
17949449_9	0	Disease	13,14	surgical resection
17949449_9	0	Phenotype	44,44,49,49	overall survival
27027150_2	0	Disease	10,10	melanoma
27027150_2	0	Disease	13,13	tumors
27027150_2	0	Limited_variation	15,18,23,23	BRAF V600E mutations
27027150_2	0	Gene_or_protein	15,15	BRAF
27027150_2	0	Limited_variation	15,15,20,23	BRAF V600K mutations
27027150_2	0	Chemical	25,26	BRAF inhibitors
27027150_2	0	Chemical	29,29	dabrafenib
20153935_3	0	Limited_variation	1,3	A118G
20153935_3	0	Limited_variation	5,7	N40D
20153935_3	0	Limited_variation	17,19	C77G
20153935_3	0	Limited_variation	21,23	P26R
20153935_3	0	Phenotype	52,55	predilection towards alcohol consumption
20153935_3	0	Chemical	54,54	alcohol
20153935_3	0	Phenotype	44,45	physiological measures
20153935_3	0	Phenotype	49,50	behavioral measures
20153935_3	0	Phenotype	37,38	ligand binding
22205192_1	0	Chemical	9,9	codeine
22205192_1	0	Gene_or_protein	15,20	cytochrome P450 2D6
22205192_1	0	Gene_or_protein	22,25	CYP2D6
22205192_1	0	Limited_variation	15,27	cytochrome P450 2D6 ( CYP2D6 ) genotype
24597986_7	0	Limited_variation	4,8	RFC1 G80A
24597986_7	0	Gene_or_protein	4,5	RFC1
24597986_7	0	Chemical	19,19	MTX
24597986_7	0	Pharmacodynamic_phenotype	19,22	MTX -related toxicity
24597986_7	0	Disease	25,25	ALL
24597986_7	0	Pharmacodynamic_phenotype	22,22	toxicity
22175791_7	0	Gene_or_protein	5,6	GSTT1
22175791_7	0	Chemical	18,18	APAP
22175791_7	0	Gene_or_protein	25,26	GSTP1
22175791_7	0	Chemical	37,37	APAP
22175791_7	0	Limited_variation	5,9	GSTT1 homozygous deletion genotype
22175791_7	0	Disease	18,19	APAP poisoning
22175791_7	0	Limited_variation	25,29	GSTP1 homozygous variant genotype
22175791_7	0	Disease	37,38	APAP poisoned
22588330_3	0	Chemical	9,10	nitric oxide
22588330_3	0	Chemical	12,16	prostaglandin E(2)
22588330_3	0	Phenotype	27,35	expression of inducible nitric oxide synthase ( iNOS )
22588330_3	0	Gene_or_protein	29,32	inducible nitric oxide synthase
22588330_3	0	Gene_or_protein	34,34	iNOS
22588330_3	0	Gene_or_protein	40,42	COX-2
22588330_3	0	Gene_or_protein	37,38	cyclooxygenase 2
22588330_3	0	Chemical	4,4	LDF
22588330_3	0	Phenotype	27,28,37,43	expression of cyclooxygenase 2 ( COX-2 )
22588330_3	0	Pharmacodynamic_phenotype	6,10,17,17	LPS -induced nitric oxide production
22588330_3	0	Pharmacodynamic_phenotype	12,17	prostaglandin E(2) production
22588330_3	0	Chemical	6,6	LPS
22588330_3	0	Pharmacodynamic_phenotype	6,8,12,17	LPS -induced prostaglandin E(2) production
22588330_3	0	Pharmacodynamic_phenotype	9,10,17,17	nitric oxide production
24088005_4	0	Gene_or_protein	6,9	CYP2C19
24088005_4	0	Phenotype	15,16	platelet aggregation
24088005_4	0	Chemical	20,20	clopidogrel
24088005_4	0	Haplotype	6,11	CYP2C19 * 2
11923351_9	0	Limited_variation	6,12	T69N /S/A
11923351_9	0	Chemical	21,21	zidovudine
15638955_4	0	Gene_or_protein	3,6	epidermal growth factor receptor
15638955_4	0	Gene_or_protein	8,8	EGFR
15638955_4	0	Disease	41,47	non-small-cell lung cancer
15638955_4	0	Disease	49,49	NSCLC
15638955_4	0	Chemical	17,28	inhibitors of the tyrosine kinase ( TK ) domain of the receptor
15638955_4	0	Gene_or_protein	23,23	TK
15638955_4	0	Gene_or_protein	20,21	tyrosine kinase
15638955_4	0	Chemical	11,12	monoclonal antibodies
15638955_4	0	Pharmacodynamic_phenotype	36,37	antitumor activities
21676217_3	0	Gene_or_protein	0,1	HER2
21676217_3	0	Chemical	8,8	lapatinib
21676217_3	0	Gene_or_protein	16,17	HER2
21676217_3	0	Disease	16,22	HER2 -- positive breast cancer
21676217_3	0	Chemical	6,6	trastuzumab
21676217_3	0	Chemical	0,5	HER2 -related target drugs
21676217_3	0	Phenotype	16,20	HER2 -- positive
17121920_9	0	Gene_or_protein	10,10	XIAP
17121920_9	0	Chemical	15,16	mithramycin A
17121920_9	0	Phenotype	21,24	transcription of XIAP gene
17121920_9	0	Gene_or_protein	23,23	XIAP
17121920_9	0	Gene_or_protein	28,29	Sp1
17121920_9	0	Phenotype	28,33	Sp1 binding to its promoter
17121920_9	0	Genomic_factor	10,11	XIAP promoter
22027477_9	0	Genomic_factor	8,10	MSI -H
22027477_9	0	Gene_or_protein	16,16	BRAF
22027477_9	0	Disease	19,19	CRC
22027477_9	0	Chemical	0,0	PMH
22027477_9	0	Limited_variation	16,18	BRAF -mutated
22027477_9	0	Phenotype	12,14	CIMP-positive
22027477_9	0	Disease	8,10,19,19	MSI -H CRC
22027477_9	0	Disease	12,14,19,19	CIMP-positive CRC
22027477_9	0	Disease	16,19	BRAF -mutated CRC
23012624_2	0	Limited_variation	5,11	inosine triphosphatase ( ITPA ) gene variants
23012624_2	0	Gene_or_protein	5,6	inosine triphosphatase
23012624_2	0	Gene_or_protein	8,8	ITPA
23012624_2	0	Pharmacodynamic_phenotype	17,17	anemia
23012624_2	0	Chemical	14,14	ribavirin
23012624_2	0	Disease	22,24	chronic hepatitis C
23012624_2	0	Pharmacodynamic_phenotype	14,17	ribavirin -induced anemia
18855539_7	0	Gene_or_protein	6,8	HLA-B
18855539_7	0	Chemical	21,21	abacavir
18855539_7	0	Haplotype	6,10	HLA-B * 5701
18855539_7	0	Pharmacodynamic_phenotype	21,23	abacavir hypersensitivity reactions
21912425_8	0	Limited_variation	4,5	rs9263726
21912425_8	0	Chemical	12,12	allopurinol
21912425_8	0	Pharmacodynamic_phenotype	15,17	SJS / TEN
21912425_8	0	Pharmacodynamic_phenotype	12,17	allopurinol -related SJS / TEN
10677041_7	0	Gene_or_protein	2,4	DOR-1
10677041_7	0	Gene_or_protein	21,23	DOR-1
10677041_7	0	Limited_variation	2,5	DOR-1 mutant
10677041_7	0	Chemical	13,13	morphine
10677041_7	0	Pharmacodynamic_phenotype	10,13	analgesic tolerance to morphine
18695635_12	0	Chemical	7,7	MPAG
18695635_12	0	Gene_or_protein	13,16	SLCO1B1
18695635_12	0	Limited_variation	18,22	SLCO1B3 polymorphisms
18695635_12	0	Gene_or_protein	18,21	SLCO1B3
18695635_12	0	Limited_variation	26,27	UGT polymorphisms
18695635_12	0	Gene_or_protein	26,26	UGT
18695635_12	0	Pharmacokinetic_phenotype	7,8	MPAG pharmacokinetics
18695635_12	0	Limited_variation	13,16,22,22	SLCO1B1 polymorphisms
19229528_4	0	Gene_or_protein	14,14	TPMT
19229528_4	0	Limited_variation	16,18	ITPA gene polymorphisms
19229528_4	0	Gene_or_protein	16,16	ITPA
19229528_4	0	Chemical	32,32	azathioprine
19229528_4	0	Chemical	34,34	AZA
19229528_4	0	Limited_variation	14,14,17,18	TPMT gene polymorphisms
19229528_4	0	Pharmacodynamic_phenotype	20,21	drug intolerance
19229528_4	0	Disease	27,28	renal transplant
20555338_2	0	Limited_variation	28,29	rs9923231
20555338_2	0	Chemical	23,23	warfarin
20555338_2	0	Gene_or_protein	26,27	VKORC1
20555338_2	0	Limited_variation	35,36	rs1799853
20555338_2	0	Gene_or_protein	31,34	CYP2C9
20555338_2	0	Limited_variation	42,43	rs1057910
20555338_2	0	Gene_or_protein	38,41	CYP2C9
20555338_2	0	Gene_or_protein	45,48	CYP4F2
20555338_2	0	Limited_variation	49,50	rs2108622
20555338_2	0	Pharmacodynamic_phenotype	23,24	warfarin dosing
20555338_2	0	Limited_variation	18,19	genetic polymorphisms
20731819_13	0	Gene_or_protein	5,8	CYP2D6
20731819_13	0	Chemical	39,39	tamoxifen
20731819_13	0	Chemical	43,43	tamoxifen
20731819_13	0	Haplotype	5,10	CYP2D6 * 4
20731819_13	0	Phenotype	34,34	BCSS
20731819_13	0	Phenotype	26,27	clinical outcomes
18589174_8	0	Chemical	9,9	TAC
18589174_8	0	Gene_or_protein	14,16	MDR-1
18589174_8	0	Genomic_variation	14,19	MDR-1 -3435CC
18589174_8	0	Pharmacodynamic_phenotype	2,5	C/D ratio
25145853_6	0	Chemical	2,5	TLR9 ligand CpG
25145853_6	0	Gene_or_protein	2,3	TLR9
25145853_6	0	Gene_or_protein	19,20	Th2
25145853_6	0	Phenotype	22,24	Th1 response
25145853_6	0	Gene_or_protein	22,23	Th1
25145853_6	0	Phenotype	29,38	change in the IgG2a : IgG1 ratio
25145853_6	0	Gene_or_protein	32,34	IgG2a
25145853_6	0	Gene_or_protein	36,37	IgG1
25145853_6	0	Pharmacodynamic_phenotype	12,13	antibody response
25145853_6	0	Chemical	0,8	Conjugation of TLR9 ligand CpG to LDH nanoparticles
25145853_6	0	Chemical	7,7	LDH
25145853_6	0	Phenotype	19,20,24,24	Th2 response
10377355_6	0	Chemical	0,0	Norepinephrine
10377355_6	0	Phenotype	11,15	CRH neurons in the PVN
10377355_6	0	Chemical	2,2	NE
10377355_6	0	Gene_or_protein	11,11	CRH
26060059_10	0	Limited_variation	0,7	IL28B rs8099917 / rs12979860
26060059_10	0	Gene_or_protein	0,2	IL28B
26060059_10	0	Disease	14,17	MC -positive HCV
26060059_10	0	Chemical	20,24	PEG-IFN and ribavirin
26060059_10	0	Chemical	24,24	ribavirin
26060059_10	0	Disease	54,54	HCV
26060059_10	0	Limited_variation	27,30	TT/CC genotype
26060059_10	0	Phenotype	34,34	SVR
26060059_10	0	Limited_variation	37,39	TG/TC
26060059_10	0	Phenotype	41,43	non-SVR
26060059_10	0	Disease	17,17	HCV
26060059_10	0	Disease	52,54	MC in HCV
26060059_10	0	Limited_variation	45,47	TT/CC
26060059_10	0	Chemical	20,22	PEG-IFN
26060059_10	0	Disease	14,14	MC
26060059_10	0	Disease	52,52	MC
26666244_1	0	Chemical	7,8	AZD6244
26666244_1	0	Chemical	5,5	selumetinib
26666244_1	0	Chemical	10,12	ARRY-142866
26666244_1	0	Gene_or_protein	16,19	MEK1/2
26666244_1	0	Disease	27,29	refractory solid tumors
26666244_1	0	Disease	31,34	KRAS mutant colorectal cancer
26666244_1	0	Gene_or_protein	31,31	KRAS
26666244_1	0	Chemical	16,20	MEK1/2 inhibitor
26666244_1	0	Chemical	25,25	cetuximab
26666244_1	0	Limited_variation	31,32	KRAS mutant
26666244_1	0	Chemical	5,5,22,25	selumetinib in combination with cetuximab
17667795_9	0	Chemical	7,7	haloperidol
17667795_9	0	Limited_variation	14,18	CYP2D6 alleles
17667795_9	0	Gene_or_protein	14,17	CYP2D6
17667795_9	0	Pharmacodynamic_phenotype	7,9	haloperidol plasma concentration
17034599_14	0	Limited_variation	1,5	variants in the ATM gene
17034599_14	0	Gene_or_protein	4,4	ATM
17034599_14	0	Pharmacodynamic_phenotype	21,23	adverse radiotherapy responses
23543259_1	0	Limited_variation	2,3	eNOS polymorphisms
23543259_1	0	Gene_or_protein	2,2	eNOS
23543259_1	0	Chemical	5,5	salbutamol
23543259_1	0	Pharmacodynamic_phenotype	5,9	salbutamol evoked endothelium dependent vasodilation
23543259_1	0	Pharmacodynamic_phenotype	7,9	endothelium dependent vasodilation
21389156_11	0	Limited_variation	1,2	rs8099917
21389156_11	0	Chemical	14,16	PEG -IFN
21389156_11	0	Pharmacodynamic_phenotype	11,19	response to the PEG -IFN / RBV treatment
21389156_11	0	Disease	22,24	chronic hepatitis C
21389156_11	0	Chemical	18,18	RBV
21389156_11	0	Chemical	14,18	PEG -IFN / RBV
26086150_11	0	Pharmacodynamic_phenotype	6,13	co-trimoxazole -induced SJS / TEN
26086150_11	0	Chemical	6,8	co-trimoxazole
26086150_11	0	Gene_or_protein	18,20	HLA-B
26086150_11	0	Gene_or_protein	26,28	HLA-C
26086150_11	0	Gene_or_protein	35,37	HLA-C
26086150_11	0	Haplotype	18,24	HLA-B * 15:02
26086150_11	0	Haplotype	26,32	HLA-C * 06:02
26086150_11	0	Haplotype	35,41	HLA-C * 08:01
26086150_11	0	Pharmacodynamic_phenotype	11,13	SJS / TEN
24465960_12	0	Gene_or_protein	0,3	CYP3A5
24465960_12	0	Gene_or_protein	7,10	CYP3A4
24465960_12	0	Gene_or_protein	15,18	CYP3A4
24465960_12	0	Limited_variation	15,23	CYP3A4 rs4646437 T>C
24465960_12	0	Gene_or_protein	25,27	IL-10
24465960_12	0	Limited_variation	25,32	IL-10 rs1800871 C>T
24465960_12	0	Chemical	42,42	tacrolimus
24465960_12	0	Haplotype	0,5	CYP3A5 * 3
24465960_12	0	Haplotype	7,13	CYP3A4 * 1G
24465960_12	0	Pharmacokinetic_phenotype	42,43	tacrolimus metabolism
24465960_12	0	Disease	46,47	renal transplant
17116677_8	0	Limited_variation	5,7	D123G
17116677_8	0	Limited_variation	9,11	F227L
17116677_8	0	Limited_variation	14,16	T369I
17116677_8	0	Phenotype	25,29	concentrations of VRX-480773
17116677_8	0	Chemical	27,29	VRX-480773
26575001_3	0	Chemical	0,0	Afatinib
26575001_3	0	Gene_or_protein	7,7	EGFR
26575001_3	0	Gene_or_protein	9,11	ErbB-2
26575001_3	0	Gene_or_protein	14,16	ErbB-4
26575001_3	0	Chemical	19,19	erlotinib
26575001_3	0	Gene_or_protein	26,26	EGFR
16242410_4	0	Genomic_factor	2,3	cFos promoter
16242410_4	0	Gene_or_protein	2,2	cFos
16242410_4	0	Chemical	31,31	cocaine
16242410_4	0	Gene_or_protein	37,37	cFos
16242410_4	0	Pharmacodynamic_phenotype	5,7	H4 hyperacetylation
16242410_4	0	Pharmacodynamic_phenotype	21,22	histone modifications
16242410_4	0	Chemical	16,16	cocaine
16242410_4	0	Chemical	27,27	cocaine
25122903_3	0	Limited_variation	8,13	intronic SNP ( rs9479757 )
25122903_3	0	Chemical	18,18	heroin
25122903_3	0	Chemical	25,25	heroin
25122903_3	0	Disease	18,19	heroin addiction
25122903_3	0	Disease	25,26	heroin addicts
21817190_8	0	Limited_variation	3,6	variants of the ITPA
21817190_8	0	Gene_or_protein	6,6	ITPA
21817190_8	0	Disease	13,14	haemolytic anaemia
21817190_8	0	Chemical	16,16	RBV
21817190_8	0	Chemical	30,32	PEG-IFN
21817190_8	0	Chemical	34,34	RBV
21817190_8	0	Limited_variation	45,53	TT genotype at rs8099917 of IL28B
21817190_8	0	Gene_or_protein	51,53	IL28B
21817190_8	0	Pharmacodynamic_phenotype	27,34	SVR by standard PEG-IFN and RBV
21817190_8	0	Pharmacodynamic_phenotype	16,18	RBV dose reduction
21817190_8	0	Limited_variation	48,49	rs8099917
21817190_8	0	Chemical	30,34	PEG-IFN and RBV
20947785_6	0	Limited_variation	6,9	NPHS2 pathogenic mutations
20947785_6	0	Gene_or_protein	6,7	NPHS2
20947785_6	0	Disease	23,23	SRNS
20947785_6	0	Disease	17,21	steroid -resistant nephrotic syndrome
20947785_6	0	Chemical	17,17	steroid
9488225_8	0	Chemical	3,3	captopril
9488225_8	0	Gene_or_protein	25,27	Bk2r
9488225_8	0	Limited_variation	25,30	Bk2r - / -
9488225_8	0	Disease	22,22	SBP
9488225_8	0	Limited_variation	32,34	J129 Sv
24947927_1	0	Gene_or_protein	9,9	MEK
24947927_1	0	Chemical	11,12	RO4987655
24947927_1	0	Chemical	14,15	CH4987655
24947927_1	0	Disease	22,22	cancer
24947927_1	0	Limited_variation	24,27	RAS- RAF mutations
24947927_1	0	Gene_or_protein	24,26	RAS- RAF
24947927_1	0	Chemical	9,10	MEK inhibitor
15154117_7	0	Haplotype	16,18	CHRNA4 haplotype
15154117_7	0	Gene_or_protein	16,17	CHRNA4
15154117_7	0	Chemical	32,32	nicotine
15154117_7	0	Disease	32,33	nicotine addiction
15154117_7	0	Phenotype	58,58,74,74	FTND scores
15154117_7	0	Phenotype	73,74	RTQ scores
15154117_7	0	Haplotype	20,20	GCTATA
17358097_9	0	Limited_variation	6,10	CYP3A5 genotype
17358097_9	0	Gene_or_protein	6,9	CYP3A5
17358097_9	0	Chemical	20,20	lansoprazole
17358097_9	0	Pharmacokinetic_phenotype	17,20	enantioselective disposition of lansoprazole
12153842_2	0	Gene_or_protein	14,15	ADH2
12153842_2	0	Haplotype	14,17	ADH2 * 2
12153842_2	0	Gene_or_protein	23,24	alcohol dehydrogenase
12153842_2	0	Phenotype	29,30	heavy drinking
16245360_6	0	Chemical	8,9	CpG ODN
16245360_6	0	Phenotype	24,30	development of Th2 -mediated responses
16245360_6	0	Gene_or_protein	26,27	Th2
19784640_11	0	Gene_or_protein	4,7	CYP3A4
19784640_11	0	Chemical	18,18	fentanyl
19784640_11	0	Gene_or_protein	39,42	CYP3A4
19784640_11	0	Gene_or_protein	61,64	CYP3A4
19784640_11	0	Haplotype	4,14	CYP3A4 * 1G / * 1G
19784640_11	0	Phenotype	33,33	pain
19784640_11	0	Haplotype	39,47	CYP3A4 * 1 / * 1
19784640_11	0	Haplotype	61,70	CYP3A4 * 1 / * 1G
23071495_3	0	Chemical	0,0	Bucindolol
23071495_3	0	Limited_variation	14,31	polymorphisms in the primary target ( b ( 1 ) adrenergic receptor [ AR ] Arg389 Gly
23071495_3	0	Gene_or_protein	24,25	adrenergic receptor
23071495_3	0	Pharmacodynamic_phenotype	0,0,10,10	Bucindolol efficacy
23071495_3	0	Limited_variation	14,16,37,63	polymorphisms in the a secondary target modifier ( a ( 2C ) AR Ins [ wild-type ( Wt ) ] 322-325 deletion [ Del ]
23071495_3	0	Chemical	3,5	b-blocker
23071495_3	0	Chemical	7,8	sympatholytic agent
23071495_3	0	Gene_or_protein	27,27	AR
23071495_3	0	Gene_or_protein	47,47	AR
26678339_4	0	Gene_or_protein	13,14	IDH1
26678339_4	0	Disease	13,16	IDH1 mutant cancer
26678339_4	0	Gene_or_protein	20,21	IDH1
26678339_4	0	Limited_variation	13,15	IDH1 mutant
26678339_4	0	Phenotype	27,34	vulnerability to depletion of the coenzyme NAD+
26678339_4	0	Chemical	3,5	metabolic therapeutic targets
26678339_4	0	Gene_or_protein	33,34	NAD+
18568343_13	0	Limited_variation	5,8,14,14	UGT1A8 variants
18568343_13	0	Limited_variation	10,14	UGT1A9 variants
18568343_13	0	Pharmacokinetic_phenotype	16,17	MPA metabolism
18568343_13	0	Chemical	16,16	MPA
18568343_13	0	Chemical	24,25	calcineurin inhibitor
18568343_13	0	Gene_or_protein	24,24	calcineurin
18568343_13	0	Gene_or_protein	5,8	UGT1A8
18568343_13	0	Gene_or_protein	10,13	UGT1A9
19114005_9	0	Disease	5,5	glioma
19114005_9	0	Chemical	7,7	cilengitide
19114005_9	0	Phenotype	9,11	phosphorylation of FAK
19114005_9	0	Gene_or_protein	11,11	FAK
19114005_9	0	Gene_or_protein	13,13	Src
19114005_9	0	Gene_or_protein	15,15	Akt
19114005_9	0	Phenotype	9,10,15,15	phosphorylation of Akt
19114005_9	0	Phenotype	9,10,13,13	phosphorylation of Src
9006118_1	0	Chemical	4,5	manganese sulfate
9006118_1	0	Chemical	7,9	5-azacytidine
9006118_1	0	Gene_or_protein	16,18	c-myc
9006118_1	0	Phenotype	14,18	overexpressing the c-myc
9006118_1	0	Pharmacodynamic_phenotype	2,5	transformation by manganese sulfate
9006118_1	0	Pharmacodynamic_phenotype	2,3,7,9	transformation by 5-azacytidine
17143476_3	0	Gene_or_protein	13,13	CHFR
17143476_3	0	Pharmacodynamic_phenotype	28,30	sensitivity to taxanes
17143476_3	0	Chemical	30,30	taxanes
17143476_3	0	Disease	32,33	endometrial cancer
17143476_3	0	Gene_or_protein	15,22	checkpoint with forkhead-associated and ring finger
17143476_3	0	Phenotype	10,23	hypermethylation of the CHFR ( checkpoint with forkhead-associated and ring finger )
17143476_3	0	Gene_or_protein	24,26	mitotic checkpoint gene
8904964_10	0	Gene_or_protein	10,11	ADH2
8904964_10	0	Chemical	25,25	alcohol
8904964_10	0	Haplotype	30,33	ADH2 * 1
8904964_10	0	Gene_or_protein	30,31	ADH2
8904964_10	0	Haplotype	10,13	ADH2 * 3
8904964_10	0	Pharmacokinetic_phenotype	25,26	alcohol elimination
27228223_9	0	Chemical	8,8	oseltamivir
27228223_9	0	Limited_variation	30,32	CES1 variants
27228223_9	0	Gene_or_protein	30,31	CES1
27228223_9	0	Limited_variation	37,39	G143E
27228223_9	0	Pharmacokinetic_phenotype	8,9	oseltamivir activation
19748123_12	0	Chemical	4,7	WY14,643
19748123_12	0	Gene_or_protein	16,18	Cyclin B1
19748123_12	0	Phenotype	13,18	mRNA expression of Cyclin B1
19748123_12	0	Phenotype	11,11,14,18	protein expression of Cyclin B1
17286538_5	0	Phenotype	3,7	CYP2A6 activity
17286538_5	0	Gene_or_protein	3,6	CYP2A6
17286538_5	0	Chemical	13,13	coumarin
17286538_5	0	Pharmacokinetic_phenotype	11,13	shunting of coumarin
21192345_5	0	Gene_or_protein	7,8	EPHX1
21192345_5	0	Chemical	25,25	warfarin
21192345_5	0	Phenotype	28,31	stable international normalized ratio
21192345_5	0	Genomic_factor	5,8	exons of EPHX1
22076562_5	0	Chemical	8,8	lansoprazole
22076562_5	0	Phenotype	17,21	CYP2C19 activity
22076562_5	0	Gene_or_protein	17,20	CYP2C19
10070957_8	0	Limited_variation	8,13	A2/A2 genotype
10070957_8	0	Chemical	19,19	estrone
10070957_8	0	Chemical	34,34	estradiol
10070957_8	0	Chemical	49,49	testosterone
10070957_8	0	Chemical	64,64	androstenedione
10070957_8	0	Chemical	79,79	dehydroepiandrosterone
10070957_8	0	Chemical	95,96	dehydroepiandrosterone sulfate
10070957_8	0	Limited_variation	115,120	A1/A1 genotype
10070957_8	0	Pharmacodynamic_phenotype	17,19	levels of estrone
10070957_8	0	Pharmacodynamic_phenotype	17,18,34,34	levels of estradiol
10070957_8	0	Pharmacodynamic_phenotype	17,18,49,49	levels of testosterone
10070957_8	0	Pharmacodynamic_phenotype	17,18,64,64	levels of androstenedione
10070957_8	0	Pharmacodynamic_phenotype	17,18,79,79	levels of dehydroepiandrosterone
10070957_8	0	Pharmacodynamic_phenotype	17,18,95,96	levels of dehydroepiandrosterone sulfate
23679233_4	0	Gene_or_protein	14,15	HER2
23679233_4	0	Disease	34,35	breast cancers
23679233_4	0	Chemical	43,43	paclitaxel
23679233_4	0	Chemical	45,45	cyclophosphamid
23679233_4	0	Chemical	47,47	epirubicin
23679233_4	0	Chemical	49,49	fluorouracil
23679233_4	0	Chemical	52,52	trastuzumab
23679233_4	0	Chemical	40,41	neoadjuvant chemotherapy
23679233_4	0	Genomic_variation	2,3	Genomic alterations
21731042_5	0	Chemical	0,0	Folate
21731042_5	0	Gene_or_protein	17,17	MTHFR
21731042_5	0	Limited_variation	17,20	MTHFR C677T
24342753_5	0	Chemical	20,23	4a- PDD
24342753_5	0	Limited_variation	0,2,9,13	Substituting F617 in TM5 with leucine
24342753_5	0	Pharmacodynamic_phenotype	15,16	channel sensitivity
24342753_5	0	Limited_variation	0,0,4,5,9,13	Substituting Y621 in TM5 with leucine
24342753_5	0	Gene_or_protein	10,11	TM5
24342753_5	0	Limited_variation	0,0,7,13	Substituting F624 in TM5 with leucine
24342753_5	0	Phenotype	43,48	activation in response to cell swelling
24342753_5	0	Limited_variation	33,35	F617L
24342753_5	0	Limited_variation	37,39	Y621L
21052032_12	0	Gene_or_protein	3,5	MC1R
21052032_12	0	Disease	11,13	major depressive disorder
21052032_12	0	Pharmacodynamic_phenotype	17,19	response to desipramine
21052032_12	0	Chemical	19,19	desipramine
25871911_11	0	Gene_or_protein	11,11	ER
25871911_11	0	Gene_or_protein	20,21	HER2
25871911_11	0	Pharmacodynamic_phenotype	33,37	sensitivity to 5-fluorouracil
25871911_11	0	Chemical	35,37	5-fluorouracil
25871911_11	0	Genomic_factor	41,44	deficiencies in chromatin remodeling
25871911_11	0	Disease	11,13,24,24	ER -positive metastases
25871911_11	0	Genomic_variation	46,48	homologous recombination genes
25871911_11	0	Chemical	15,16	endocrine therapy
25871911_11	0	Disease	20,24	HER2 -negative metastases
25871911_11	0	Phenotype	11,13	ER -positive
25871911_11	0	Phenotype	20,23	HER2 -negative
23103366_1	0	Limited_variation	3,5,11,16	Arg194Trp polymorphisms of the XRCC1 gene
23103366_1	0	Limited_variation	8,16	Arg399Gln polymorphisms of the XRCC1 gene
23103366_1	0	Gene_or_protein	14,15	XRCC1
23103366_1	0	Disease	30,31	breast cancer
23103366_1	0	Chemical	24,25	adjuvant therapy
23103366_1	0	Pharmacodynamic_phenotype	22,25	response to adjuvant therapy
20127344_13	0	Gene_or_protein	3,4	IDH1
20127344_13	0	Chemical	9,9	NADPH
20127344_13	0	Chemical	14,14	NADPH
20127344_13	0	Limited_variation	2,4	mutated IDH1
20127344_13	0	Pharmacodynamic_phenotype	14,15	NADPH levels
23570465_7	0	Chemical	8,8	tamoxifen
23570465_7	0	Phenotype	24,29	reduced CYP2D6 activity
23570465_7	0	Gene_or_protein	25,28	CYP2D6
23570465_7	0	Disease	48,49	breast cancer
23570465_7	0	Phenotype	48,52	breast cancer -specific mortality
23570465_7	0	Phenotype	39,39	recurrence
14631118_5	0	Gene_or_protein	21,21	PPARalpha
14631118_5	0	Chemical	35,37	Wy-14643
14631118_5	0	Gene_or_protein	43,43	PPARalpha
14631118_5	0	Chemical	5,9	EA extract of bitter gourd
25264278_1	0	Chemical	0,0	Wogonin
25264278_1	0	Disease	8,9	myelogenous leukemia
25264278_1	0	Phenotype	19,21	MRP1 expression
25264278_1	0	Gene_or_protein	19,20	MRP1
25264278_1	0	Genomic_factor	24,27	Nrf2 /ARE
25264278_1	0	Pharmacodynamic_phenotype	2,5	multi-drug resistance
25264278_1	0	Gene_or_protein	24,25	Nrf2
27097961_8	0	Gene_or_protein	6,6	NAA
27097961_8	0	Gene_or_protein	8,8	Cr
27097961_8	0	Gene_or_protein	11,11	Cho
27097961_8	0	Chemical	18,18	MPH
27097961_8	0	Limited_variation	24,28	DAT1 gene VNTR polymorphisms
27097961_8	0	Gene_or_protein	24,25	DAT1
27097961_8	0	Phenotype	11,12	Cho levels
27097961_8	0	Phenotype	8,8,12,12	Cr levels
27097961_8	0	Phenotype	6,6,12,12	NAA levels
18729643_4	0	Gene_or_protein	13,17	catechol-O-methyltransferase
18729643_4	0	Chemical	10,10	dopamine
18729643_4	0	Gene_or_protein	19,19	COMT
18729643_4	0	Limited_variation	19,22	COMT Val158Met
18729643_4	0	Disease	30,30	anxiety
18729643_4	0	Disease	33,33	anxiety
18729643_4	0	Limited_variation	2,2,13,17	variant catechol-O-methyltransferase
18729643_4	0	Phenotype	33,36	anxiety -related temperament
18729643_4	0	Phenotype	38,43	altered neural responses to affective stimuli
22892524_4	0	Limited_variation	29,31	N236T
22892524_4	0	Limited_variation	36,40	A181V/T
22892524_4	0	Chemical	43,43	TDF
22892524_4	0	Gene_or_protein	16,17	HBV polymerase
22892524_4	0	Limited_variation	16,19	HBV polymerase gene variants
22892524_4	0	Chemical	26,26	ADV
22892524_4	0	Pharmacodynamic_phenotype	24,26	resistance against ADV
20078613_12	0	Chemical	5,5	Oxa
20078613_12	0	Gene_or_protein	30,30	XPD
20078613_12	0	Gene_or_protein	23,23	GSTpi
20078613_12	0	Limited_variation	23,27	GSTpi 105 Val / Val
20078613_12	0	Limited_variation	30,32	XPD 751Lys
20078613_12	0	Phenotype	11,14	progression-free survival
20078613_12	0	Pharmacodynamic_phenotype	5,6	Oxa pharmacodynamics
20078613_12	0	Pharmacodynamic_phenotype	19,19	outcome
21172311_1	0	Limited_variation	3,9	5- HTR1B gene polymorphisms
21172311_1	0	Gene_or_protein	3,7	5- HTR1B
21172311_1	0	Disease	11,12	alcohol dependence
21172311_1	0	Chemical	11,11	alcohol
21635144_12	0	Phenotype	4,8	CYP3A4 activity
21635144_12	0	Gene_or_protein	4,7	CYP3A4
21635144_12	0	Gene_or_protein	13,16	CYP3A4
21635144_12	0	Chemical	35,35	tacrolimus
21635144_12	0	Gene_or_protein	38,41	CYP3A5
21635144_12	0	Haplotype	13,22	CYP3A4 * 1 / * 1G
21635144_12	0	Pharmacokinetic_phenotype	35,36	tacrolimus pharmacokinetics
21635144_12	0	Limited_variation	29,29	polymorphism
23407558_2	0	Gene_or_protein	10,13	epidermal growth factor receptor
23407558_2	0	Gene_or_protein	15,15	EGFR
23407558_2	0	Gene_or_protein	27,27	EGFR
23407558_2	0	Chemical	17,19	tyrosine kinase inhibitors
23407558_2	0	Chemical	21,21	TKI
23407558_2	0	Limited_variation	27,29	EGFR -mutant
23407558_2	0	Pharmacodynamic_phenotype	5,5	resistance
23407558_2	0	Gene_or_protein	17,18	tyrosine kinase
23407558_2	0	Disease	27,31	EGFR -mutant lung cancers
23407558_2	0	Chemical	10,19	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors
14515062_8	0	Gene_or_protein	5,8	IL-1B
14515062_8	0	Limited_variation	5,10	IL-1B allele 2
14515062_8	0	Pharmacodynamic_phenotype	29,33	adenosine -stimulated myocardial flow
14515062_8	0	Pharmacodynamic_phenotype	35,35	ASMF
14515062_8	0	Pharmacodynamic_phenotype	32,33	myocardial flow
14515062_8	0	Phenotype	27,27,32,33	basal myocardial flow
14515062_8	0	Chemical	29,29	adenosine
15205357_10	0	Chemical	0,0	DFMO
15205357_10	0	Gene_or_protein	14,16	ER-alpha
15205357_10	0	Phenotype	9,16	methylated CpG sites in the ER-alpha
15358623_4	0	Chemical	10,10	warfarin
15358623_4	0	Limited_variation	16,19	VKORC1 gene mutations
15358623_4	0	Gene_or_protein	16,17	VKORC1
15358623_4	0	Pharmacodynamic_phenotype	30,31	anticoagulation intensity
15358623_4	0	Pharmacodynamic_phenotype	22,24	doses of drug
15358623_4	0	Pharmacodynamic_phenotype	8,8	anticoagulation
2753981_6	0	Gene_or_protein	19,19	cAMP
2753981_6	0	Chemical	37,45	1,25-(OH)2D
2753981_6	0	Pharmacodynamic_phenotype	12,13	serum calcium
2753981_6	0	Pharmacodynamic_phenotype	18,19	nephrogenous cAMP
2753981_6	0	Pharmacodynamic_phenotype	36,45	serum 1,25-(OH)2D
2753981_6	0	Chemical	1,7	PTH - ( 1-34 )
2753981_6	0	Pharmacodynamic_phenotype	24,26	renal phosphate reabsorption
21869714_2	0	Disease	10,15	non-small cell lung cancer
21869714_2	0	Disease	17,17	NSCLC
21869714_2	0	Gene_or_protein	31,34	epidermal growth factor receptor
21869714_2	0	Gene_or_protein	36,36	EGFR
21869714_2	0	Limited_variation	53,54	EGFR mutations
21869714_2	0	Gene_or_protein	53,53	EGFR
21869714_2	0	Phenotype	25,28	progression-free survival
21869714_2	0	Chemical	31,40	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor
21869714_2	0	Gene_or_protein	38,39	tyrosine kinase
21869714_2	0	Chemical	48,48	chemotherapy
21869714_2	0	Pharmacodynamic_phenotype	22,23	response rate
16467864_3	0	Limited_variation	1,3	AML1 mutations
16467864_3	0	Gene_or_protein	1,2	AML1
16467864_3	0	Disease	15,17	MDS /AML
16467864_3	0	Genomic_variation	22,23	genetic alterations
21596890_6	0	Chemical	5,5	CDCA
21596890_6	0	Gene_or_protein	8,10	C /EBPb
21596890_6	0	Phenotype	18,18	phosphorylation
21596890_6	0	Phenotype	20,21	nuclear accumulation
21596890_6	0	Phenotype	24,24	expression
15692831_8	0	Phenotype	19,20	mEH activity
15692831_8	0	Gene_or_protein	19,19	mEH
15692831_8	0	Gene_or_protein	29,30	EPHX1
15692831_8	0	Chemical	35,37	CBZ-epoxide
15692831_8	0	Pharmacokinetic_phenotype	1,9	plasma CBZ-diol / CBZ-epoxide ratios
15692831_8	0	Pharmacokinetic_phenotype	11,14	diol / epoxide ratios
15692831_8	0	Genomic_variation	26,31	diplotypes in each EPHX1 block
15692831_8	0	Pharmacokinetic_phenotype	35,38	CBZ-epoxide metabolism
15692831_8	0	Chemical	2,4	CBZ-diol
15692831_8	0	Chemical	6,8	CBZ-epoxide
25137520_6	0	Limited_variation	8,12	SNPs in TNF-a
25137520_6	0	Gene_or_protein	10,12	TNF-a
25137520_6	0	Gene_or_protein	14,16	TNF-b
25137520_6	0	Gene_or_protein	22,22	VDR
25137520_6	0	Gene_or_protein	24,24	MBP
25137520_6	0	Gene_or_protein	27,27	APOE
25137520_6	0	Chemical	32,32	mercury
25137520_6	0	Chemical	30,30	lead
25137520_6	0	Chemical	35,35	solvents
25137520_6	0	Gene_or_protein	18,20	TCA-b
25137520_6	0	Limited_variation	8,9,14,16	SNPs in TNF-b
25137520_6	0	Limited_variation	8,9,18,20	SNPs in TCA-b
25137520_6	0	Limited_variation	8,9,22,22	SNPs in VDR
25137520_6	0	Limited_variation	8,9,24,24	SNPs in MBP
25137520_6	0	Limited_variation	8,9,27,27	SNPs in APOE
17452407_12	0	Disease	7,7	ESRD
17452407_12	0	Gene_or_protein	11,11	ERalpha
17452407_12	0	Limited_variation	11,15	ERalpha Ser10Ser CC
17452407_12	0	Chemical	25,25	triglyceride
17452407_12	0	Disease	21,21	PEW
17452407_12	0	Chemical	29,29	albumin
17452407_12	0	Chemical	32,32	hsCRP
17452407_12	0	Phenotype	19,21	prevalence of PEW
17452407_12	0	Pharmacodynamic_phenotype	24,25	serum triglyceride
17452407_12	0	Pharmacodynamic_phenotype	28,29	serum albumin
17452407_12	0	Pharmacodynamic_phenotype	32,33	hsCRP levels
17412797_2	0	Gene_or_protein	7,7	CDT
17412797_2	0	Chemical	14,14	alcohol
17412797_2	0	Gene_or_protein	2,5	Carbohydrate -deficient transferrin
17412797_2	0	Disease	14,15	alcohol abuse
6938173_4	0	Phenotype	18,18,23,24	ABO blood groups
6938173_4	0	Phenotype	20,20,23,24	Rh blood groups
6938173_4	0	Chemical	48,49	lead oxides
6938173_4	0	Phenotype	22,24	MN blood groups
6938173_4	0	Phenotype	29,32	ability to taste PTC
6938173_4	0	Phenotype	34,36	ear lobe type
6938173_4	0	Phenotype	38,41	mid-digital hair
6938173_4	0	Genomic_factor	12,13	chromosomic damage
6938173_4	0	Genomic_variation	5,6	genetic variability
20655300_4	0	Gene_or_protein	10,10	BDNF
20655300_4	0	Chemical	22,22	heroin
20655300_4	0	Limited_variation	10,13	BDNF val66met
20655300_4	0	Phenotype	18,23	ages of onset for heroin abuse
20655300_4	0	Disease	22,23	heroin abuse
21047202_5	0	Limited_variation	3,8	polymorphisms in CYP3A5
21047202_5	0	Gene_or_protein	5,8	CYP3A5
21047202_5	0	Limited_variation	11,16	polymorphism in CYP3A4
21047202_5	0	Gene_or_protein	13,16	CYP3A4
21047202_5	0	Chemical	24,24	tacrolimus
21047202_5	0	Pharmacodynamic_phenotype	24,26	tacrolimus stable dose
17968354_8	0	Pharmacodynamic_phenotype	13,14	dystrophin expression
17968354_8	0	Gene_or_protein	13,13	dystrophin
17968354_8	0	Chemical	2,5	PNA-AAV6
17968354_8	0	Chemical	0,0	PNA
17968354_8	0	Chemical	0,11	PNA and PNA-AAV6 , PNA-AAV8 conjugates
17968354_8	0	Chemical	7,10	PNA-AAV8
26940072_9	0	Gene_or_protein	1,2	VKORC1
26940072_9	0	Pharmacodynamic_phenotype	5,7	daily warfarin dose
26940072_9	0	Limited_variation	23,24	rs9923231
26940072_9	0	Limited_variation	26,27	rs9934438
26940072_9	0	Limited_variation	29,30	rs2884737
26940072_9	0	Chemical	6,6	warfarin
26940072_9	0	Limited_variation	36,39	wild-type genotype
26940072_9	0	Pharmacodynamic_phenotype	40,43	requiring the highest dose
26791794_9	0	Disease	5,5	tumors
26791794_9	0	Gene_or_protein	15,17	PIK3CA
26791794_9	0	Gene_or_protein	25,27	PIK3CA
26791794_9	0	Limited_variation	25,33	PIK3CA - p.Glu542Lys
26791794_9	0	Chemical	38,38	crizotinib
26791794_9	0	Gene_or_protein	42,44	PIK3CA
26791794_9	0	Phenotype	7,10	high level MET amplification
26791794_9	0	Limited_variation	42,47	PIK3CA co-mutation
26791794_9	0	Pharmacodynamic_phenotype	51,52	clinical response
26791794_9	0	Gene_or_protein	9,9	MET
26791794_9	0	Limited_variation	12,17	wild-type PIK3CA
26791794_9	0	Limited_variation	19,23	MET exon 14 skipping mutation
26791794_9	0	Gene_or_protein	19,19	MET
26791794_9	0	Pharmacodynamic_phenotype	36,38	responses to crizotinib
26791794_9	0	Genomic_variation	9,10	MET amplification
26791794_9	0	Genomic_factor	19,21	MET exon 14
19067682_10	0	Limited_variation	0,5	CYP3A5 genetic polymorphism
19067682_10	0	Gene_or_protein	0,3	CYP3A5
19067682_10	0	Chemical	10,10	tacrolimus
19067682_10	0	Pharmacodynamic_phenotype	10,13	tacrolimus -related nephrotoxicity
19067682_10	0	Pharmacodynamic_phenotype	13,13	nephrotoxicity
17998284_10	0	Gene_or_protein	2,2	KRAS
17998284_10	0	Chemical	11,11	CTX
17998284_10	0	Limited_variation	2,4	KRAS WT status
17998284_10	0	Phenotype	8,9	survival benefit
17998284_10	0	Disease	13,13	mCRC
19366808_3	0	Chemical	8,8	sorafenib
19366808_3	0	Gene_or_protein	29,31	BCR/ABL
19366808_3	0	Gene_or_protein	36,38	interleukin-3
19366808_3	0	Phenotype	10,10	proliferation
19366808_3	0	Phenotype	13,13	apoptosis
19366808_3	0	Chemical	6,7	multikinase inhibitor
20442314_9	0	Gene_or_protein	2,4	Bcr-Abl
20442314_9	0	Chemical	19,19	imatinib
20442314_9	0	Phenotype	11,15	death activated by spindle defects
20442314_9	0	Phenotype	2,7	Bcr-Abl -expressing cells
17392718_12	0	Chemical	5,5	talinolol
17392718_12	0	Phenotype	13,15	MDR1 expression
17392718_12	0	Gene_or_protein	13,14	MDR1
17392718_12	0	Chemical	3,3	SJW
17392718_12	0	Chemical	19,19	SJW
17392718_12	0	Gene_or_protein	27,29	P-glycoprotein
17392718_12	0	Pharmacokinetic_phenotype	5,6	talinolol AUC
23020798_1	0	Limited_variation	0,3	Polymorphisms in ERCC1
23020798_1	0	Gene_or_protein	2,3	ERCC1
23020798_1	0	Gene_or_protein	5,5	GSTs
23020798_1	0	Gene_or_protein	7,7	TS
23020798_1	0	Gene_or_protein	9,9	MTHFR
23020798_1	0	Phenotype	11,15	clinical outcomes of gastric cancer
23020798_1	0	Limited_variation	0,1,7,7	Polymorphisms in TS
23020798_1	0	Limited_variation	0,1,9,9	Polymorphisms in MTHFR
23020798_1	0	Limited_variation	0,1,5,5	Polymorphisms in GSTs
23020798_1	0	Chemical	19,26	platinum /5-Fu -based chemotherapy
23020798_1	0	Disease	14,15	gastric cancer
23020798_1	0	Chemical	19,23	platinum /5-Fu
23302800_3	0	Disease	4,4	tumour
23302800_3	0	Gene_or_protein	13,13	BRAF
23302800_3	0	Disease	13,16	BRAF -mutated melanoma
23302800_3	0	Pharmacodynamic_phenotype	19,23	response to treatment with vemurafenib
23302800_3	0	Gene_or_protein	30,30	BRAF
23302800_3	0	Phenotype	32,33	melanoma maintenance
23302800_3	0	Phenotype	4,5	tumour regression
23302800_3	0	Phenotype	7,8	improved survival
23302800_3	0	Limited_variation	13,15	BRAF -mutated
23302800_3	0	Chemical	23,23	vemurafenib
23302800_3	0	Disease	32,32	melanoma
10223459_12	0	Chemical	7,7	clotrimazole
10223459_12	0	Disease	18,18	glioblastoma
10223459_12	0	Chemical	30,30	cisplatin
10223459_12	0	Phenotype	9,10	cell proliferation
10223459_12	0	Limited_variation	33,37	wild-type p53
10223459_12	0	Pharmacodynamic_phenotype	27,30	antitumor effect of cisplatin
10223459_12	0	Phenotype	33,40	wild-type p53 -mediated apoptosis
10223459_12	0	Gene_or_protein	36,37	p53
10223459_12	0	Phenotype	13,14	morphological changes
26505133_3	0	Chemical	0,0	Sorafenib
26505133_3	0	Gene_or_protein	9,10	FLT3
26505133_3	0	Disease	19,19	leukemia
26505133_3	0	Gene_or_protein	16,17	FLT3
26505133_3	0	Disease	16,19	FLT3 mutated leukemia
26505133_3	0	Chemical	3,5	oral multikinase inhibitor
26505133_3	0	Limited_variation	16,18	FLT3 mutated
21309949_1	0	Gene_or_protein	0,0	COMT
21309949_1	0	Gene_or_protein	2,3	ALDH2
21309949_1	0	Chemical	12,12	alcohol
21309949_1	0	Limited_variation	0,0,4,4	COMT polymorphisms
21309949_1	0	Limited_variation	2,4	ALDH2 polymorphisms
21309949_1	0	Phenotype	8,12	implicit drinking motives with alcohol
22035418_1	0	Gene_or_protein	7,8	NME1
22035418_1	0	Limited_variation	1,17	T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T
22035418_1	0	Chemical	25,25	cytarabine
22035418_1	0	Disease	31,33	acute myeloid leukemia
22035418_1	0	Pharmacodynamic_phenotype	25,27	cytarabine induced neurotoxicity
22035418_1	0	Genomic_factor	7,9	NME1 promoter
22035418_1	0	Pharmacodynamic_phenotype	27,27	neurotoxicity
23029188_2	0	Gene_or_protein	19,21	IL28B
23029188_2	0	Chemical	37,37	ribavirin
23029188_2	0	Chemical	39,39	RBV
23029188_2	0	Limited_variation	11,22	single nucleotide polymorphisms ( SNP ) near the IL28B gene
23029188_2	0	Pharmacodynamic_phenotype	24,40	response to the combined treatments of pegylated-interferon ( PegIFN ) and ribavirin ( RBV )
23029188_2	0	Chemical	30,32	pegylated-interferon
23029188_2	0	Chemical	34,34	PegIFN
23029188_2	0	Disease	43,43	HCV
23029188_2	0	Chemical	27,40	combined treatments of pegylated-interferon ( PegIFN ) and ribavirin ( RBV )
17250611_11	0	Limited_variation	3,8	allele of TAS2R16
17250611_11	0	Gene_or_protein	5,8	TAS2R16
17250611_11	0	Chemical	17,17	alcohol
17250611_11	0	Disease	17,18	alcohol dependence
17250611_11	0	Phenotype	24,26	mean Maxdrinks scores
9607827_2	0	Limited_variation	10,12	Q151M
9607827_2	0	Pharmacodynamic_phenotype	18,21	multi- dideoxynucleoside resistance
9607827_2	0	Chemical	20,20	dideoxynucleoside
9607827_2	0	Pharmacodynamic_phenotype	23,23	MDR
9607827_2	0	Limited_variation	1,6	set of five reverse transcriptase mutations
9607827_2	0	Disease	26,30	human immunodeficiency virus type 1
9607827_2	0	Disease	32,34	HIV-1
19414633_2	0	Chemical	3,3	clopidogrel
19414633_2	0	Chemical	5,5	prasugrel
19414633_2	0	Gene_or_protein	12,14	cytochrome P450
19414633_2	0	Gene_or_protein	16,16	CYP
16821082_1	0	Gene_or_protein	3,4	CCT5
16821082_1	0	Gene_or_protein	6,7	RGS3
16821082_1	0	Gene_or_protein	10,11	YKT6
16821082_1	0	Gene_or_protein	17,18	p53
16821082_1	0	Chemical	25,25	docetaxel
16821082_1	0	Disease	28,29	breast cancers
16821082_1	0	Disease	17,21	p53 -mutated tumors
16821082_1	0	Pharmacodynamic_phenotype	23,25	resistance to docetaxel
16821082_1	0	Limited_variation	17,20	p53 -mutated
19127598_11	0	Phenotype	5,9	COX-2 mRNA suppression
19127598_11	0	Gene_or_protein	5,7	COX-2
19127598_11	0	Phenotype	11,14	p21 mRNA stimulation
19127598_11	0	Gene_or_protein	11,12	p21
19127598_11	0	Chemical	17,17	isoflavone
19127598_11	0	Pharmacodynamic_phenotype	16,18	serum isoflavone levels
19127598_11	0	Genomic_factor	5,8	COX-2 mRNA
19127598_11	0	Genomic_factor	11,13	p21 mRNA
25366762_3	0	Gene_or_protein	19,21	GRIN2A
25366762_3	0	Chemical	49,49	heroin
25366762_3	0	Disease	49,50	heroin addiction
25366762_3	0	Gene_or_protein	7,17	glutamate receptor , N-methyl D-aspartate 2A
25366762_3	0	Gene_or_protein	28,42	2A subunit of the N-methyl D-aspartate ( NMDA ) receptor
25366762_3	0	Limited_variation	0,23	Genetic polymorphisms in functional regions of the glutamate receptor , N-methyl D-aspartate 2A ( GRIN2A ) gene
10585223_5	0	Gene_or_protein	6,8	mdr1a
10585223_5	0	Gene_or_protein	15,17	mdr1a
10585223_5	0	Chemical	37,37	digoxin
10585223_5	0	Limited_variation	6,13	mdr1a ( + / + )
10585223_5	0	Limited_variation	15,22	mdr1a ( - / - )
10585223_5	0	Pharmacokinetic_phenotype	37,38	digoxin accumulation
10585223_5	0	Pharmacokinetic_phenotype	0,4	Brain concentration-time profiles
9259617_1	0	Pharmacodynamic_phenotype	1,5	effect of aflatoxin B1
9259617_1	0	Gene_or_protein	14,18	transforming growth factor-alpha
9259617_1	0	Chemical	20,21	CCl4
9259617_1	0	Pharmacodynamic_phenotype	20,25	CCl4 induced rat liver injury
9259617_1	0	Chemical	3,5	aflatoxin B1
9259617_1	0	Phenotype	8,12	expression of early response genes
9259617_1	0	Pharmacodynamic_phenotype	24,25	liver injury
9259617_1	0	Phenotype	8,9,14,18	expression of transforming growth factor-alpha
22961402_1	0	Limited_variation	0,2	CD55 polymorphisms
22961402_1	0	Gene_or_protein	0,1	CD55
22961402_1	0	Chemical	6,6	aspirin
22961402_1	0	Pharmacodynamic_phenotype	6,10	aspirin - exacerbated respiratory disease
22961402_1	0	Pharmacodynamic_phenotype	9,10	respiratory disease
25251606_7	0	Gene_or_protein	11,11	MARCKS
25251606_7	0	Phenotype	14,23	content of PI(4,5)P2
25251606_7	0	Chemical	16,23	PI(4,5)P2
25251606_7	0	Phenotype	30,31	behavioral abnormalities
25643589_10	0	Chemical	1,3	lenalidomide / azacitidine
25643589_10	0	Chemical	3,3	azacitidine
25643589_10	0	Limited_variation	16,18	NPM1 mutation
25643589_10	0	Gene_or_protein	16,17	NPM1
25643589_10	0	Chemical	1,1	lenalidomide
25643589_10	0	Phenotype	6,10	function of cytotoxic T lymphocytes
12456499_2	0	Limited_variation	14,22	one within subunit A ( Val34Leu )
12456499_2	0	Pharmacodynamic_phenotype	37,40	prothrombotic effects of estrogen
12456499_2	0	Chemical	57,59	hormone replacement therapy
12456499_2	0	Disease	50,52	arterial thrombotic events
12456499_2	0	Limited_variation	24,32	one within subunit B ( His95Arg )
12456499_2	0	Chemical	40,40	estrogen
12456499_2	0	Gene_or_protein	9,11	coagulation factor XIII
12456499_2	0	Limited_variation	9,12	coagulation factor XIII polymorphisms
17961161_11	0	Gene_or_protein	2,3	ERCC1
17961161_11	0	Chemical	14,17	platinum -based chemotherapy
17961161_11	0	Gene_or_protein	22,23	ERCC1
17961161_11	0	Phenotype	40,40	survival
17961161_11	0	Pharmacodynamic_phenotype	12,17	response to platinum -based chemotherapy
17961161_11	0	Disease	2,6	ERCC1 -negative tumors
17961161_11	0	Disease	22,26	ERCC1 -positive tumors
17961161_11	0	Chemical	14,14	platinum
17961161_11	0	Phenotype	2,5	ERCC1 -negative
17961161_11	0	Phenotype	22,25	ERCC1 -positive
17961161_11	0	Pharmacodynamic_phenotype	32,33	response rates
21562147_9	0	Limited_variation	12,16	SNPs in the POR gene
21562147_9	0	Gene_or_protein	15,15	POR
21562147_9	0	Chemical	24,24	warfarin
21562147_9	0	Pharmacodynamic_phenotype	24,26	warfarin maintenance dose
18079739_5	0	Chemical	10,11	ITF2357
18079739_5	0	Limited_variation	20,26	JAK2 (V617F )
18079739_5	0	Gene_or_protein	45,46	JAK2
18079739_5	0	Gene_or_protein	20,21	JAK2
18079739_5	0	Gene_or_protein	30,31	pSTAT5
18079739_5	0	Gene_or_protein	33,34	pSTAT3
18079739_5	0	Limited_variation	42,46	wild-type JAK2
18079739_5	0	Limited_variation	42,44,48,48	wild-type STAT
18079739_5	0	Gene_or_protein	48,48	STAT
15910869_1	0	Gene_or_protein	4,8	cholesterol 7alpha-hydroxylase
15910869_1	0	Gene_or_protein	11,12	apolipoprotein E
15910869_1	0	Chemical	21,21	atorvastatin
15910869_1	0	Limited_variation	1,8	promoter polymorphism in cholesterol 7alpha-hydroxylase
15910869_1	0	Limited_variation	11,13	apolipoprotein E genotype
15910869_1	0	Pharmacodynamic_phenotype	16,21	LDL-lowering response to atorvastatin
15910869_1	0	Genomic_factor	1,1	promoter
26369533_2	0	Disease	2,3	Breast cancer
26369533_2	0	Phenotype	8,13	reduced CYP2D6 activity
26369533_2	0	Gene_or_protein	9,12	CYP2D6
26369533_2	0	Chemical	23,23	tamoxifen
26369533_2	0	Pharmacodynamic_phenotype	17,18	endoxifen levels
26369533_2	0	Chemical	17,17	endoxifen
26369533_2	0	Phenotype	6,6,9,13	absent CYP2D6 activity
23358500_5	0	Limited_variation	7,9	CHRNA5 polymorphisms
23358500_5	0	Gene_or_protein	7,8	CHRNA5
23358500_5	0	Chemical	20,20	nicotine
23358500_5	0	Chemical	24,24	nicotine
23358500_5	0	Chemical	36,36	nicotine
23358500_5	0	Phenotype	11,12	smoking topography
23358500_5	0	Chemical	34,34	placebo
8807668_1	0	Chemical	5,9	(S)-mephenytoin
8807668_1	0	Haplotype	14,19	haplotypes of CYP2C19
8807668_1	0	Gene_or_protein	16,19	CYP2C19
8807668_1	0	Pharmacokinetic_phenotype	2,9	poor metabolizers of (S)-mephenytoin
21628721_5	0	Gene_or_protein	4,7	CYP2C19
21628721_5	0	Chemical	48,48	clopidogrel
21628721_5	0	Haplotype	4,9	CYP2C19 * 2
21628721_5	0	Phenotype	12,13	platelet function
21628721_5	0	Disease	53,54	coronary stenting
16359408_4	0	Gene_or_protein	11,14	CYP2C8
16359408_4	0	Chemical	19,21	N-desethylaminodiaquine
16359408_4	0	Chemical	4,4	AQ
16359408_4	0	Gene_or_protein	8,10	cytochrome P450
24123531_7	0	Gene_or_protein	11,11	EGFR
24123531_7	0	Gene_or_protein	13,13	KRAS
24123531_7	0	Pharmacodynamic_phenotype	16,17	erlotinib sensitivity
24123531_7	0	Chemical	16,16	erlotinib
24123531_7	0	Chemical	22,22	erlotinib
24123531_7	0	Limited_variation	33,37	HRAS G12D mutation
24123531_7	0	Gene_or_protein	33,33	HRAS
24123531_7	0	Limited_variation	7,11	wild-type for EGFR
24123531_7	0	Limited_variation	7,10,13,13	wild-type for KRAS
24123531_7	0	Pharmacodynamic_phenotype	22,26	erlotinib -resistant cell line
23091097_11	0	Limited_variation	9,10	ATM mutation
23091097_11	0	Gene_or_protein	9,9	ATM
23091097_11	0	Chemical	30,31	alkylating agents
23091097_11	0	Chemical	33,34	purine analogs
23091097_11	0	Genomic_variation	5,7	11q deletion
23091097_11	0	Phenotype	22,23	overall survival
23091097_11	0	Disease	12,12	CLL
23091097_11	0	Chemical	30,34	alkylating agents and purine analogs
17980418_4	0	Gene_or_protein	8,9	FCER2
17980418_4	0	Chemical	22,22	budesonide
17980418_4	0	Disease	27,28	Childhood Asthma
17980418_4	0	Limited_variation	8,12	FCER2 single nucleotide polymorphisms
12005453_12	0	Chemical	16,16	butyrate
12005453_12	0	Gene_or_protein	24,25	GLUT2
12005453_12	0	Gene_or_protein	27,27	proglucagon
12005453_12	0	Phenotype	27,28	proglucagon expression
12005453_12	0	Chemical	38,38	SCFAs
12005453_12	0	Phenotype	24,25,28,28	GLUT2 expression
8998185_4	0	Phenotype	10,13	p53 protein expression
8998185_4	0	Gene_or_protein	10,11	p53
8998185_4	0	Disease	16,16	tumors
8998185_4	0	Disease	22,23	prostate cancer
8998185_4	0	Chemical	37,38	androgen blockade
22974536_2	0	Disease	11,13	acute coronary syndromes
22974536_2	0	Disease	15,15	ACS
22974536_2	0	Gene_or_protein	22,25	CYP2C19
22974536_2	0	Chemical	38,38	thienopyridines
22974536_2	0	Pharmacodynamic_phenotype	45,47	adverse cardiac events
22974536_2	0	Chemical	49,49	clopidogrel
22974536_2	0	Chemical	54,54	prasugrel
22974536_2	0	Haplotype	22,27	CYP2C19 * 2
20101393_3	0	Chemical	11,11	ecstasy
20101393_3	0	Disease	14,14	depressive
20101393_3	0	Disease	16,16	anxiety
20101393_3	0	Limited_variation	26,30	polymorphism of the serotonin transporter
20101393_3	0	Gene_or_protein	29,30	serotonin transporter
20101393_3	0	Disease	36,36	depression
20101393_3	0	Disease	38,39	anxiety disorders
26299806_7	0	Chemical	7,7	fisetin
26299806_7	0	Chemical	9,9	sorafenib
26299806_7	0	Gene_or_protein	12,12	RAF
26299806_7	0	Phenotype	25,26	tumor growth
26299806_7	0	Chemical	7,9	fisetin and sorafenib
26299806_7	0	Phenotype	20,21	cell proliferation
26299806_7	0	Phenotype	23,23	apoptosis
26299806_7	0	Chemical	12,13	RAF inhibitor
24521898_3	0	Chemical	8,8	warfarin
24521898_3	0	Gene_or_protein	17,20	CYP2C9
24521898_3	0	Gene_or_protein	22,23	VKORC1
24521898_3	0	Gene_or_protein	25,28	CYP4F2
24521898_3	0	Pharmacodynamic_phenotype	8,9	warfarin hypersensitive
15952058_9	0	Chemical	0,0	Tamoxifen
15952058_9	0	Gene_or_protein	5,8	UGT2B15
15952058_9	0	Phenotype	19,19	survival
15952058_9	0	Phenotype	14,16	risk of recurrence
15952058_9	0	Limited_variation	5,11	UGT2B15 high activity genotypes
10568834_5	0	Phenotype	1,3	p53 overexpression
10568834_5	0	Gene_or_protein	1,2	p53
10568834_5	0	Chemical	32,34	5-fluorouracil
10568834_5	0	Chemical	36,36	levamisole
10568834_5	0	Phenotype	11,12	patient survival
10568834_5	0	Limited_variation	1,2,5,5	p53 mutation
10568834_5	0	Chemical	30,36	chemotherapy with 5-fluorouracil and levamisole
17529886_13	0	Limited_variation	0,3,9,11	UGT1A7 I399 polymorphisms
17529886_13	0	Gene_or_protein	0,3	UGT1A7
17529886_13	0	Gene_or_protein	5,8	UGT1A9
17529886_13	0	Chemical	19,19	MPA
17529886_13	0	Limited_variation	5,11	UGT1A9 I399 polymorphisms
17529886_13	0	Pharmacokinetic_phenotype	19,20	MPA pharmacokinetics
25143362_5	0	Disease	5,6	muscular dystrophy
25143362_5	0	Gene_or_protein	16,16	dysferlin
25143362_5	0	Chemical	21,21	bortezomib
25143362_5	0	Phenotype	24,25	dysferlin expression
25143362_5	0	Gene_or_protein	24,24	dysferlin
25143362_5	0	Limited_variation	10,16	homozygous Arg555Trp mutation in dysferlin
25143362_5	0	Chemical	19,20	proteasome inhibitor
24948056_9	0	Gene_or_protein	13,14	TLR9
24948056_9	0	Phenotype	24,28	immunity to S. pneumoniae
24948056_9	0	Chemical	9,11	PC-BSA
24948056_9	0	Chemical	6,16	EC immunization with PC-BSA plus TLR9 ligand CpG
24948056_9	0	Chemical	13,16	TLR9 ligand CpG
25523423_4	0	Gene_or_protein	8,14	APPswe , PSEN1dE985Dbo
25523423_4	0	Gene_or_protein	16,19	APP/PS1
25523423_4	0	Disease	24,24	AD
25523423_4	0	Chemical	34,36	Bryostatin-1
25523423_4	0	Phenotype	39,40	cognitive deficits
8923461_9	0	Gene_or_protein	2,4	c-fos
8923461_9	0	Gene_or_protein	6,8	c-jun
8923461_9	0	Gene_or_protein	14,15	TNF alpha
8923461_9	0	Chemical	22,22	DEX
8923461_9	0	Phenotype	0,4,9,9	Levels of c-fos proteins
8923461_9	0	Phenotype	0,1,6,9	Levels of c-jun proteins
11016647_4	0	Disease	7,7	tumors
11016647_4	0	Phenotype	13,16	depletion of tumor MGMT
11016647_4	0	Gene_or_protein	16,16	MGMT
11016647_4	0	Disease	15,16	tumor MGMT
11016647_4	0	Chemical	18,21	O6-benzylguanine
11016647_4	0	Chemical	23,25	6-BG
11016647_4	0	Chemical	45,47	6-BG
11016647_4	0	Gene_or_protein	50,50	MGMT
11016647_4	0	Limited_variation	45,51	6-BG -resistant MGMT mutants
11016647_4	0	Phenotype	28,31	protection of sensitive tissues
23301703_1	0	Chemical	2,3	GZD824
23301703_1	0	Gene_or_protein	14,18	breakpoint cluster region-Abelson
23301703_1	0	Gene_or_protein	20,22	Bcr-Abl
23301703_1	0	Pharmacodynamic_phenotype	27,34	clinically acquired mutation -induced resistance against imatinib
23301703_1	0	Chemical	34,34	imatinib
23301703_1	0	Pharmacodynamic_phenotype	32,34	resistance against imatinib
23301703_1	0	Limited_variation	29,29	mutation
26716652_7	0	Chemical	0,3	RY10-4
26716652_7	0	Chemical	5,5	DAPT
26716652_7	0	Gene_or_protein	10,11	HER2
26716652_7	0	Chemical	22,25	RY10-4
26716652_7	0	Chemical	29,29	DAPT
26716652_7	0	Chemical	0,5	RY10-4 plus DAPT
26716652_7	0	Phenotype	7,7	apoptosis
26716652_7	0	Phenotype	36,36	apoptosis
26716652_7	0	Phenotype	10,13	HER2 -overexpressing
22753902_3	0	Chemical	34,34	cytarabine
22753902_3	0	Chemical	36,36	anthracycline
22753902_3	0	Disease	44,44	Cancer
22753902_3	0	Disease	46,46	Leukemia
22753902_3	0	Limited_variation	54,56	RUNX1 mutations
22753902_3	0	Gene_or_protein	54,55	RUNX1
22753902_3	0	Disease	28,30	CN-AML
22753902_3	0	Chemical	34,36	cytarabine / anthracycline
18075464_1	0	Disease	17,18	nonischemic cardiomyopathy
18075464_1	0	Disease	21,22	heart failure
18075464_1	0	Chemical	27,27	carvedilol
18075464_1	0	Limited_variation	0,8	Arg389Gly- beta1 -adrenergic receptors
18075464_1	0	Phenotype	12,15	left ventricular systolic function
18075464_1	0	Gene_or_protein	4,8	beta1 -adrenergic receptors
15975707_3	0	Genomic_factor	5,6	hTERT promoter
15975707_3	0	Chemical	15,15	polyphenols
15975707_3	0	Chemical	17,25	(-)-epigallocatechin-3-gallate
15975707_3	0	Chemical	30,34	(-)-epigallocatechin
15975707_3	0	Phenotype	42,43	hTERT transcription
15975707_3	0	Gene_or_protein	42,42	hTERT
15975707_3	0	Pharmacodynamic_phenotype	12,15	effects of tea polyphenols
15975707_3	0	Chemical	27,27	EGCG
15975707_3	0	Chemical	36,36	EGC
15975707_3	0	Pharmacodynamic_phenotype	12,13,30,37	effects of (-)-epigallocatechin ( EGC )
15975707_3	0	Pharmacodynamic_phenotype	12,13,17,28	effects of (-)-epigallocatechin-3-gallate ( EGCG )
15975707_3	0	Gene_or_protein	5,5	hTERT
18349701_12	0	Chemical	5,5	pindolol
18349701_12	0	Chemical	18,18	lithium
18349701_12	0	Limited_variation	25,28	5-HTTLPR genotypes
18349701_12	0	Limited_variation	7,11	s/s-allele
18349701_12	0	Pharmacodynamic_phenotype	16,19	benefit from lithium augmentation
16390351_6	0	Chemical	73,73	repaglinide
16390351_6	0	Gene_or_protein	83,86	CYP2C8
16390351_6	0	Haplotype	83,89	CYP2C8 * 3 mutant
16390351_6	0	Pharmacokinetic_phenotype	4,5,73,73	mean AUC repaglinide
16390351_6	0	Pharmacodynamic_phenotype	40,44,73,73	mean C ( max ) repaglinide
16390351_6	0	Haplotype	93,95	wild-types
18977767_5	0	Gene_or_protein	13,14	SkM1
18977767_5	0	Gene_or_protein	26,29	Nav1.5
18977767_5	0	Gene_or_protein	45,48	Nav1.5
18977767_5	0	Pharmacodynamic_phenotype	51,55	tetrodotoxin ( TTX ) sensitivity
18977767_5	0	Chemical	51,51	tetrodotoxin
18977767_5	0	Chemical	53,53	TTX
18977767_5	0	Limited_variation	41,42,45,48	point mutation Nav1.5
18977767_5	0	Gene_or_protein	5,11	skeletal Na(+) channel isoform
18977767_5	0	Gene_or_protein	18,24	cardiac Na(+) channel isoform
10678749_3	0	Chemical	15,15	quinpirole
10678749_3	0	Pharmacodynamic_phenotype	23,27	striatal c-Fos expression
10678749_3	0	Chemical	18,20	RU-24969
10678749_3	0	Gene_or_protein	24,26	c-Fos
10678749_3	0	Pharmacodynamic_phenotype	18,27	RU-24969 -induced striatal c-Fos expression
10678749_3	0	Chemical	9,14	D2-like dopamine agonist
28035401_6	0	Gene_or_protein	7,8	HDAC6
28035401_6	0	Pharmacodynamic_phenotype	10,11	vemurafenib resistance
28035401_6	0	Chemical	10,10	vemurafenib
17719176_3	0	Limited_variation	5,7	WFS1 polymorphisms
17719176_3	0	Gene_or_protein	5,6	WFS1
17719176_3	0	Disease	9,11	medication overuse headache
17719176_3	0	Disease	13,13	MOH
17719176_3	0	Disease	17,19	chronic headache condition
17719176_3	0	Disease	29,29	MOH
17719176_3	0	Limited_variation	33,38	WFS1 His611Arg polymorphism
17719176_3	0	Gene_or_protein	33,34	WFS1
17719176_3	0	Limited_variation	48,50	Arg / Arg
17719176_3	0	Limited_variation	52,54	R/R
17719176_3	0	Limited_variation	57,61	non-R/R
17719176_3	0	Phenotype	45,46	clinical features
17719176_3	0	Disease	23,24	drugs overuse
20401433_11	0	Gene_or_protein	6,8	ADH1C
20401433_11	0	Gene_or_protein	12,14	ADH1B
20401433_11	0	Gene_or_protein	19,21	ADH1C
20401433_11	0	Gene_or_protein	28,30	ADH1B
20401433_11	0	Chemical	38,38	alcohol
20401433_11	0	Haplotype	6,10	ADH1C * 1
20401433_11	0	Haplotype	12,16	ADH1B * 1
20401433_11	0	Disease	38,39	alcohol dependence
20401433_11	0	Haplotype	19,26	ADH1C * 1 / * 1
20401433_11	0	Haplotype	28,35	ADH1B * 1 / * 1
22030088_4	0	Limited_variation	12,18	UGT1A6 T181A
22030088_4	0	Gene_or_protein	12,15	UGT1A6
22030088_4	0	Limited_variation	12,15,20,22	UGT1A6 R184S
22030088_4	0	Disease	31,31	Adenoma
22030088_4	0	Chemical	34,34	Celecoxib
22030088_4	0	Chemical	50,50	aspirin
22030088_4	0	Disease	54,54	adenomas
22030088_4	0	Chemical	72,72	celecoxib
22030088_4	0	Chemical	5,8	combining aspirin and celecoxib
22030088_4	0	Chemical	6,6	aspirin
22030088_4	0	Chemical	8,8	celecoxib
22030088_4	0	Pharmacodynamic_phenotype	3,8	effect of combining aspirin and celecoxib
22030088_4	0	Chemical	58,58	placebo
25657029_9	0	Gene_or_protein	7,8	MIA2
25657029_9	0	Limited_variation	7,14	MIA2 ( I141M ) variant
25657029_9	0	Phenotype	16,20	high levels of ERN1
25657029_9	0	Gene_or_protein	19,20	ERN1
25657029_9	0	Pharmacodynamic_phenotype	24,26	sensitive to gemcitabine
25657029_9	0	Chemical	26,26	gemcitabine
25657029_9	0	Disease	2,2	PDAC
10877911_6	0	Gene_or_protein	5,11	glial cell line-derived neurotrophic factor
10877911_6	0	Gene_or_protein	13,13	GDNF
10877911_6	0	Chemical	23,25	6-hydroxydopamine
10877911_6	0	Disease	28,31	Parkinson's disease
26167638_1	0	Limited_variation	0,6,12,13	VKORC1 - 1639G/A Genetic Polymorphisms
26167638_1	0	Gene_or_protein	0,1	VKORC1
26167638_1	0	Limited_variation	0,2,8,13	VKORC1 - 1173 C/T Genetic Polymorphisms
26167638_1	0	Chemical	18,18	Warfarin
26167638_1	0	Pharmacodynamic_phenotype	18,20	Warfarin Maintenance Dose
16963807_2	0	Chemical	9,9	curcumin
16963807_2	0	Phenotype	15,17	LDL receptor expression
16963807_2	0	Gene_or_protein	15,16	LDL receptor
16963807_2	0	Chemical	20,20	sterol
16963807_2	0	Chemical	56,56	sterol
16963807_2	0	Pharmacodynamic_phenotype	7,9	effect of curcumin
16963807_2	0	Gene_or_protein	44,46	green fluorescence protein
16963807_2	0	Gene_or_protein	48,48	GFP
16963807_2	0	Gene_or_protein	56,60	sterol regulatory element-1
16963807_2	0	Gene_or_protein	62,64	SRE-1
22948856_4	0	Chemical	7,7	pridopidine
22948856_4	0	Pharmacokinetic_phenotype	4,7	pharmacokinetic profile of pridopidine
22948856_4	0	Gene_or_protein	18,21	CYP2D6
22948856_4	0	Pharmacokinetic_phenotype	17,22	poor CYP2D6 metabolizers
22948856_4	0	Pharmacodynamic_phenotype	12,13	dose adjustment
12835613_12	0	Gene_or_protein	4,7	CYP2C19
12835613_12	0	Chemical	20,20	carisoprodol
12835613_12	0	Pharmacokinetic_phenotype	19,20	metabolizing carisoprodol
12835613_12	0	Haplotype	4,12	CYP2C19 * 1 / * 2
12835613_12	0	Pharmacokinetic_phenotype	28,29	intermediate metabolizers
25522765_1	0	Chemical	3,3	Erlotinib
25522765_1	0	Phenotype	5,12	Growth of Non-Small Cell Lung Cancer
25522765_1	0	Disease	7,12	Non-Small Cell Lung Cancer
25522765_1	0	Limited_variation	15,16	EGFR Mutations
25522765_1	0	Gene_or_protein	15,15	EGFR
25522765_1	0	Phenotype	18,19	HGF Overexpression
25522765_1	0	Gene_or_protein	18,18	HGF
25522765_1	0	Chemical	1,1	Onartuzumab
25522765_1	0	Chemical	1,3	Onartuzumab with Erlotinib
21932012_4	0	Disease	0,0	GACI
21932012_4	0	Limited_variation	4,9	mutations in the ENPP1 gene
21932012_4	0	Gene_or_protein	7,8	ENPP1
21932012_4	0	Chemical	18,19	inorganic pyrophosphate
21932012_4	0	Chemical	21,24	PP(i)
21932012_4	0	Chemical	31,31	hydroxyapatite
24265036_2	0	Chemical	1,1	tamoxifen
24265036_2	0	Disease	4,5	breast cancer
24265036_2	0	Gene_or_protein	17,18	estrogen receptor
24265036_2	0	Gene_or_protein	29,30	estrogen receptor
24265036_2	0	Phenotype	10,11	hot flashes
24265036_2	0	Phenotype	17,19	estrogen receptor antagonism
24265036_2	0	Limited_variation	22,24,29,30	genetic variations of estrogen receptor
24265036_2	0	Limited_variation	22,26	genetic variations of metabolic enzymes
24265036_2	0	Gene_or_protein	25,26	metabolic enzymes
26273667_5	0	Chemical	14,14	sulphonylureas
26273667_5	0	Chemical	16,16	biguanides
26273667_5	0	Gene_or_protein	18,19	alpha glucosidase
26273667_5	0	Chemical	23,23	thiazolidinediones
26273667_5	0	Disease	29,29	hyperglycemia
26273667_5	0	Chemical	18,20	alpha glucosidase inhibitors
15610939_3	0	Phenotype	2,9	5-HTT uptake ( function ) level
15610939_3	0	Gene_or_protein	2,4	5-HTT
15610939_3	0	Chemical	11,11	paroxetine
15610939_3	0	Gene_or_protein	23,25	5-HTT
15610939_3	0	Phenotype	23,27	5-HTT expression rate
15610939_3	0	Limited_variation	29,29,35,35	LL genotypes
15610939_3	0	Limited_variation	31,31,35,35	LS genotypes
15610939_3	0	Limited_variation	34,35	SS genotypes
15610939_3	0	Phenotype	11,12	paroxetine binding
15610939_3	0	Disease	19,19	alcoholics
19300499_1	0	Gene_or_protein	7,8	VKORC1
19300499_1	0	Gene_or_protein	10,13	CYP2C9
19300499_1	0	Gene_or_protein	16,19	CYP4F2
19300499_1	0	Pharmacodynamic_phenotype	25,26	warfarin dose
19300499_1	0	Chemical	25,25	warfarin
22506971_7	0	Gene_or_protein	11,12	dopamine transporter
22506971_7	0	Gene_or_protein	14,14	DAT
22506971_7	0	Chemical	21,21	alcohol
22506971_7	0	Chemical	27,27	alcohol
22506971_7	0	Phenotype	5,15	hypermethylation of the promoter of the dopamine transporter ( DAT )
22506971_7	0	Disease	21,22	alcohol dependence
22506971_7	0	Disease	27,28	alcohol craving
22506971_7	0	Genomic_factor	8,12	promoter of the dopamine transporter
25862379_3	0	Chemical	4,4	dopamine
25862379_3	0	Gene_or_protein	9,10	dopamine transporter
25862379_3	0	Pharmacodynamic_phenotype	3,5	extracellular dopamine concentration
25862379_3	0	Chemical	9,9	dopamine
25695221_15	0	Chemical	3,3	Gefitinib
25695221_15	0	Limited_variation	30,32	EGFR gene mutations
25695221_15	0	Gene_or_protein	30,30	EGFR
25695221_15	0	Limited_variation	37,41	EGFR exon 19 deletion mutations
25695221_15	0	Gene_or_protein	37,37	EGFR
25695221_15	0	Chemical	7,7	bevacizumab
25695221_15	0	Disease	27,27	NSCLC
25695221_15	0	Chemical	3,7	Gefitinib in combination with bevacizumab
25695221_15	0	Genomic_factor	37,39	EGFR exon 19
23245376_1	0	Limited_variation	4,6	NRXN3 SNPs
23245376_1	0	Gene_or_protein	4,5	NRXN3
23245376_1	0	Disease	8,10	borderline personality disorder
23245376_1	0	Disease	8,15	borderline personality disorder phenotypes in heroin dependent cases
23245376_1	0	Chemical	13,13	heroin
23245376_1	0	Disease	13,14	heroin dependent
9563874_17	0	Gene_or_protein	8,8	EGFR
9563874_17	0	Gene_or_protein	20,20	EGFR
9563874_17	0	Chemical	24,25	cAMP analogues
9563874_17	0	Disease	34,34	cancer
9563874_17	0	Gene_or_protein	10,10	PKAI
9563874_17	0	Chemical	13,14	pharmacological agents
9563874_17	0	Chemical	18,22	anti- EGFR blocking MAbs
9563874_17	0	Pharmacodynamic_phenotype	29,31	cooperative antiproliferative effect
18628428_8	0	Disease	4,5	breast cancer
18628428_8	0	Chemical	8,10	E+P
18628428_8	0	Limited_variation	24,32	CYP1A1 Ile(462)Val
18628428_8	0	Gene_or_protein	24,27	CYP1A1
18628428_8	0	Gene_or_protein	34,37	CYP1A1
18628428_8	0	Limited_variation	40,48	CYP1B1 Asn(453)Ser
18628428_8	0	Gene_or_protein	40,43	CYP1B1
18628428_8	0	Gene_or_protein	51,51	PGR
18628428_8	0	Limited_variation	51,56	PGR Val(660)Leu
18628428_8	0	Limited_variation	34,38	CYP1A1 MspI
18628428_8	0	Pharmacodynamic_phenotype	4,10	breast cancer associated with E+P
18628428_8	0	Limited_variation	61,65	homozygous for the common allele
10087449_9	0	Phenotype	0,9	PACAP -induced expression of the c-fos gene
10087449_9	0	Gene_or_protein	0,0	PACAP
10087449_9	0	Gene_or_protein	6,9	c-fos gene
10087449_9	0	Chemical	21,30	PACAP - ( 6-38 ) - NH2
10087449_9	0	Chemical	17,19	PACAP receptor antagonist
10087449_9	0	Gene_or_protein	17,17	PACAP
10087449_9	0	Gene_or_protein	21,21	PACAP
27916449_4	0	Limited_variation	4,7	GNAO1 missense mutation
27916449_4	0	Gene_or_protein	4,5	GNAO1
27916449_4	0	Chemical	15,15	topiramate
27916449_4	0	Disease	23,23	chorea
27916449_4	0	Phenotype	10,13	age of 18years
11561767_10	0	Gene_or_protein	0,1	MUC1
11561767_10	0	Disease	5,5	tumours
11561767_10	0	Chemical	12,12	tamoxifen
11561767_10	0	Chemical	23,23	tamoxifen
11561767_10	0	Phenotype	0,2	MUC1 levels
21114867_1	0	Gene_or_protein	4,7	endothelial nitric oxide synthase
21114867_1	0	Disease	15,21	non-small-cell lung cancer
21114867_1	0	Chemical	25,29	platinum -based doublet chemotherapy
21114867_1	0	Limited_variation	1,7	polymorphisms in the endothelial nitric oxide synthase
21114867_1	0	Phenotype	11,12	overall survival
21114867_1	0	Chemical	25,25	platinum
17492376_9	0	Disease	2,3	Breast cancers
17492376_9	0	Gene_or_protein	5,6	BRCA1
17492376_9	0	Chemical	14,14	docetaxel
17492376_9	0	Pharmacodynamic_phenotype	12,14	sensitivity to docetaxel
21639946_8	0	Gene_or_protein	12,15	CYP2C9
21639946_8	0	Gene_or_protein	19,22	CYP2C9
21639946_8	0	Limited_variation	27,28	rs9332127
21639946_8	0	Limited_variation	35,36	rs2108622
21639946_8	0	Gene_or_protein	31,34	CYP4F2
21639946_8	0	Limited_variation	39,40	rs12714145
21639946_8	0	Gene_or_protein	38,38	GGCX
21639946_8	0	Limited_variation	44,45	rs4653436
21639946_8	0	Gene_or_protein	42,43	EPHX1
21639946_8	0	Limited_variation	48,49	rs1799809
21639946_8	0	Gene_or_protein	47,47	PROC
21639946_8	0	Pharmacodynamic_phenotype	51,52	warfarin sensitivity
21639946_8	0	Chemical	51,51	warfarin
21639946_8	0	Haplotype	12,17	CYP2C9 * 3
21639946_8	0	Limited_variation	19,25	CYP2C9 C-65
21919924_3	0	Chemical	2,2	alcohol
21919924_3	0	Disease	5,5	AD
21919924_3	0	Genomic_factor	12,17	3 ' region of GABRA2
21919924_3	0	Gene_or_protein	16,17	GABRA2
21919924_3	0	Gene_or_protein	42,43	GABRG1
21919924_3	0	Disease	2,3	alcohol dependence
22661198_3	0	Limited_variation	9,27	T102C polymorphism in the 5-HT receptor subtype 2A gene ( HTR2A )
22661198_3	0	Gene_or_protein	15,21	5-HT receptor subtype 2A
22661198_3	0	Gene_or_protein	24,26	HTR2A
22661198_3	0	Chemical	29,29	alcohol
22661198_3	0	Disease	29,30	alcohol dependence
15083067_2	0	Chemical	0,0	Bupropion
15083067_2	0	Gene_or_protein	8,16	cytochrome P450 ( CYP ) 2B6
15083067_2	0	Phenotype	26,26	expression
15083067_2	0	Pharmacokinetic_phenotype	28,28	catalysis
24495780_6	0	Limited_variation	5,6	rs4795893
24495780_6	0	Limited_variation	8,9	rs1024611
24495780_6	0	Limited_variation	11,12	rs4586
24495780_6	0	Limited_variation	14,15	rs2857657
24495780_6	0	Gene_or_protein	20,21	CCL2
24495780_6	0	Disease	45,45	schizophrenic
24495780_6	0	Chemical	65,65	risperidone
24495780_6	0	Phenotype	30,34	Positive and Negative Syndrome Scale
24495780_6	0	Phenotype	36,36	PANSS
24495780_6	0	Limited_variation	3,3	SNPs
24098690_10	0	Disease	11,11	restenosis
24098690_10	0	Limited_variation	14,16	ACE DD genotype
24098690_10	0	Gene_or_protein	14,14	ACE
22348413_9	0	Chemical	0,0	Itraconazole
22348413_9	0	Gene_or_protein	6,9	CYP3A4
22348413_9	0	Chemical	17,17	midazolam
22348413_9	0	Chemical	19,19	triazolam
22348413_9	0	Chemical	21,21	buspirone
22348413_9	0	Chemical	23,23	lovastatin
22348413_9	0	Chemical	25,25	simvastatin
22348413_9	0	Chemical	27,27	oxycodone
22348413_9	0	Chemical	30,30	rifampicin
22348413_9	0	Pharmacodynamic_phenotype	13,14,17,17	exposure to midazolam
22348413_9	0	Pharmacodynamic_phenotype	13,14,19,19	exposure to triazolam
22348413_9	0	Pharmacodynamic_phenotype	13,14,21,21	exposure to buspirone
22348413_9	0	Pharmacodynamic_phenotype	13,14,23,23	exposure to lovastatin
22348413_9	0	Pharmacodynamic_phenotype	13,14,25,25	exposure to simvastatin
22348413_9	0	Pharmacodynamic_phenotype	13,14,27,27	exposure to oxycodone
22348413_9	0	Chemical	4,9	inhibitors of CYP3A4
22348413_9	0	Pharmacodynamic_phenotype	34,35	plasma concentrations
27569869_5	0	Chemical	0,0	Capecitabine
27569869_5	0	Chemical	4,6	5-FU
27569869_5	0	Gene_or_protein	10,10	CDA
27569869_5	0	Gene_or_protein	12,12	TYMP
27569869_5	0	Limited_variation	16,18	SNPs in CDA
27569869_5	0	Gene_or_protein	18,18	CDA
27569869_5	0	Gene_or_protein	20,21	CES2
27569869_5	0	Gene_or_protein	8,8	CES
27569869_5	0	Limited_variation	16,17,20,21	SNPs in CES2
27569869_5	0	Pharmacodynamic_phenotype	28,28	efficacy
27569869_5	0	Pharmacodynamic_phenotype	30,30	toxicity
18589587_5	0	Disease	10,10	toxicity
18589587_5	0	Phenotype	15,24	inhibition of cytochrome P450 ( CYP450 ) isoforms
18589587_5	0	Gene_or_protein	17,19	cytochrome P450
18589587_5	0	Gene_or_protein	21,22	CYP450
18589587_5	0	Chemical	26,26	isoniazid
18589587_5	0	Gene_or_protein	28,31	CYP2C19
18589587_5	0	Gene_or_protein	33,35	CYP3A
18589587_5	0	Chemical	40,40	INH
18589587_5	0	Pharmacokinetic_phenotype	3,4	slow acetylation
18589587_5	0	Pharmacodynamic_phenotype	40,42	INH plasmatic concentration
18852012_19	0	Chemical	19,21	5-aminosalicylate
18852012_19	0	Gene_or_protein	16,17	NAT1
18852012_19	0	Chemical	23,26	p-aminobenzoic acid
18852012_19	0	Gene_or_protein	30,31	NAT2
18852012_19	0	Chemical	33,33	sulphamethazine
18852012_19	0	Chemical	12,17	substrate specificities of human NAT1
18852012_19	0	Chemical	12,14,29,31	substrate specificities of human NAT2
25696877_6	0	Chemical	6,6	clopidogrel
25696877_6	0	Limited_variation	18,27	CYP2C19 loss-of-function alleles
25696877_6	0	Gene_or_protein	18,21	CYP2C19
25696877_6	0	Disease	50,51	cardiovascular death
25696877_6	0	Disease	53,54	myocardial infarction
25696877_6	0	Disease	57,57	stroke
25696877_6	0	Phenotype	34,36	adverse cardiovascular outcomes
25696877_6	0	Disease	69,70	stent thrombosis
25696877_6	0	Disease	9,11	percutaneous coronary intervention
12517791_13	0	Limited_variation	7,8	AR mutation
12517791_13	0	Gene_or_protein	7,7	AR
12517791_13	0	Disease	15,15	AWS
12517791_13	0	Chemical	19,19	flutamide
12517791_13	0	Chemical	35,35	bicalutamide
12517791_13	0	Disease	30,31	refractory PC
19531897_9	0	Limited_variation	2,6	CYP2C19 polymorphisms
19531897_9	0	Gene_or_protein	2,5	CYP2C19
19531897_9	0	Chemical	17,17	clopidogrel
19531897_9	0	Pharmacodynamic_phenotype	14,17	antiplatelet effect of clopidogrel
16314758_1	0	Gene_or_protein	6,7	Homer1
16314758_1	0	Limited_variation	3,8	polymorphism in the Homer1 gene
16314758_1	0	Disease	10,11	cocaine dependence
16314758_1	0	Chemical	10,10	cocaine
15967990_10	0	Phenotype	17,19	TPMT protein function
15967990_10	0	Gene_or_protein	17,17	TPMT
15967990_10	0	Chemical	29,29	thiopurine
15967990_10	0	Pharmacodynamic_phenotype	27,29	response to thiopurine
15967990_10	0	Limited_variation	15,15	polymorphisms
15710601_1	0	Chemical	0,0	Evodiamine
15710601_1	0	Phenotype	11,13	IkappaBalpha kinase activation
15710601_1	0	Gene_or_protein	11,11	IkappaBalpha
15710601_1	0	Phenotype	5,8	NF-kappaB activation
15710601_1	0	Gene_or_protein	5,7	NF-kappaB
15710601_1	0	Gene_or_protein	17,19	NF-kappaB
15710601_1	0	Phenotype	17,22,25,26	NF-kappaB -regulated antiapoptotic gene expression
15710601_1	0	Phenotype	17,21,24,26	NF-kappaB -regulated metastatic gene expression
15710601_1	0	Phenotype	31,31	apoptosis
15710601_1	0	Phenotype	35,35	invasion
23097010_11	0	Limited_variation	4,7	POR 28 genetic polymorphism
23097010_11	0	Gene_or_protein	4,4	POR
23097010_11	0	Chemical	18,18	tacrolimus
23097010_11	0	Limited_variation	21,27	CYP3A5 3 genetic polymorphism
23097010_11	0	Gene_or_protein	21,24	CYP3A5
23097010_11	0	Pharmacodynamic_phenotype	16,18	variability of tacrolimus
17851539_6	0	Phenotype	5,8	c-Fos activation
17851539_6	0	Gene_or_protein	5,7	c-Fos
17851539_6	0	Chemical	12,12	ethanol
17851539_6	0	Gene_or_protein	29,31	c-Jun
17851539_6	0	Gene_or_protein	36,40	extracellular signal-regulated kinases
17851539_6	0	Gene_or_protein	42,48	c-Jun N -terminal kinases
23360489_5	0	Disease	3,4	lung cancer
23360489_5	0	Gene_or_protein	11,13	c-Met
23360489_5	0	Chemical	24,25	SU11274
23360489_5	0	Gene_or_protein	18,20	c-Met
23360489_5	0	Gene_or_protein	29,29	EGFR
23360489_5	0	Genomic_variation	8,13	gene amplification of c-Met
23360489_5	0	Chemical	29,32	EGFR -targeted drugs
23360489_5	0	Pharmacodynamic_phenotype	15,16,24,25	sensitive to SU11274
23360489_5	0	Pharmacodynamic_phenotype	15,15,27,32	sensitive not to EGFR -targeted drugs
23360489_5	0	Chemical	18,23	c-Met -targeted drug
21916909_1	0	Gene_or_protein	2,3	ABCB1
21916909_1	0	Gene_or_protein	5,8	CYP3A4
21916909_1	0	Gene_or_protein	13,16	CYP3A5
21916909_1	0	Chemical	24,24	tacrolimus
21916909_1	0	Haplotype	5,11	CYP3A4 * 18B
21916909_1	0	Haplotype	13,18	CYP3A5 * 3
21916909_1	0	Pharmacokinetic_phenotype	22,24	pharmacokinetics of tacrolimus
23012624_1	0	Limited_variation	2,2,7,7	ITPA genotypes
23012624_1	0	Gene_or_protein	2,2	ITPA
23012624_1	0	Limited_variation	4,7	IL28B genotypes
23012624_1	0	Gene_or_protein	4,6	IL28B
23012624_1	0	Chemical	15,17	peginterferon plus ribavirin
23012624_1	0	Disease	9,11	chronic hepatitis C
23012624_1	0	Chemical	15,15	peginterferon
23012624_1	0	Chemical	17,17	ribavirin
16773681_6	0	Gene_or_protein	40,43	thiopurine S-methyltransferase
16773681_6	0	Gene_or_protein	45,45	TPMT
16773681_6	0	Chemical	53,53	thiopurine
16773681_6	0	Disease	25,25	IBD
16773681_6	0	Limited_variation	40,48	thiopurine S-methyltransferase ( TPMT ) gene polymorphisms
16773681_6	0	Pharmacodynamic_phenotype	50,53	hematological toxicity of thiopurine
16773681_6	0	Pharmacodynamic_phenotype	50,51	hematological toxicity
23082737_9	0	Chemical	3,3	vemurafenib
23082737_9	0	Disease	13,13	melanoma
23082737_9	0	Disease	17,17	tumors
23082737_9	0	Limited_variation	21,27	BRAF (V600E ) mutation
23082737_9	0	Phenotype	10,15	abnormal signaling for melanoma cellular growth
23082737_9	0	Gene_or_protein	21,21	BRAF
23175182_5	0	Gene_or_protein	3,5	mGlu3 receptor
23175182_5	0	Pharmacodynamic_phenotype	11,13	action of paclitaxel
23175182_5	0	Pharmacodynamic_phenotype	11,12,15,15	action of etoposide
23175182_5	0	Pharmacodynamic_phenotype	11,12,17,19	action of cis-platinum
23175182_5	0	Pharmacodynamic_phenotype	11,12,22,22	action of irinotecan
23175182_5	0	Chemical	3,6	mGlu3 receptor blockade
23175182_5	0	Chemical	13,13	paclitaxel
23175182_5	0	Chemical	15,15	etoposide
23175182_5	0	Chemical	17,19	cis-platinum
23175182_5	0	Chemical	22,22	irinotecan
26341921_8	0	Gene_or_protein	7,7	EGFR
26341921_8	0	Chemical	19,19	afatinib
26341921_8	0	Limited_variation	31,36	EGFR ( L858R )
26341921_8	0	Gene_or_protein	31,31	EGFR
26341921_8	0	Phenotype	42,43	tumor relapse
26341921_8	0	Disease	39,40	lung adenocarcinomas
26341921_8	0	Disease	42,42	tumor
26341921_8	0	Chemical	21,21	cetuximab
26341921_8	0	Chemical	19,21	afatinib plus cetuximab
26341921_8	0	Pharmacodynamic_phenotype	45,47	drug-resistance
26341921_8	0	Disease	7,11	EGFR -mutant lung cancer
26341921_8	0	Chemical	53,53	TKIs
26341921_8	0	Limited_variation	7,9	EGFR -mutant
26341921_8	0	Disease	31,40	EGFR ( L858R ) - induced lung adenocarcinomas
25319571_4	0	Chemical	10,18	(S)-3,5-dihydroxyphenylglycine
25319571_4	0	Gene_or_protein	38,39	Drd1
25319571_4	0	Gene_or_protein	44,45	Drd2
25319571_4	0	Chemical	20,20	DHPG
25319571_4	0	Chemical	6,18	group I mGluR agonist (S)-3,5-dihydroxyphenylglycine
25319571_4	0	Disease	24,24	LTD
25319571_4	0	Limited_variation	33,35,38,41	wild-type Drd1 -eGFP
25319571_4	0	Limited_variation	37,41	hemizygous Drd1 -eGFP
25319571_4	0	Limited_variation	33,35,44,47	wild-type Drd2 -eGFP
25319571_4	0	Limited_variation	37,37,44,47	hemizygous Drd2 -eGFP
24387766_10	0	Phenotype	16,18	expression of hepcidin
24387766_10	0	Gene_or_protein	18,18	hepcidin
24387766_10	0	Chemical	7,9	black soyabean extract
24387766_10	0	Pharmacokinetic_phenotype	11,12	Fe metabolism
24387766_10	0	Chemical	11,11	Fe
15813023_1	0	Phenotype	3,6	MDR1 polymorphic expression
15813023_1	0	Gene_or_protein	3,4	MDR1
15813023_1	0	Chemical	11,12	cyclosporine A
15813023_1	0	Pharmacokinetic_phenotype	9,12	disposition of cyclosporine A
18252229_3	0	Gene_or_protein	0,3	CYP2C9
18252229_3	0	Haplotype	9,13	p.R144C
18252229_3	0	Gene_or_protein	16,19	CYP2C9
18252229_3	0	Haplotype	25,29	p.I359L
18252229_3	0	Genomic_factor	34,36	VKORC1 promoter
18252229_3	0	Gene_or_protein	34,35	VKORC1
18252229_3	0	Chemical	55,55	warfarin
18252229_3	0	Limited_variation	67,70	VKORC1 missense mutations
18252229_3	0	Gene_or_protein	67,68	VKORC1
18252229_3	0	Chemical	72,72	warfarin
18252229_3	0	Pharmacodynamic_phenotype	55,58	warfarin " sensitive "
18252229_3	0	Pharmacodynamic_phenotype	72,75	warfarin " resistant "
18252229_3	0	Haplotype	0,7	CYP2C9 ( * ) 2
18252229_3	0	Haplotype	16,23	CYP2C9 ( * ) 3
18252229_3	0	Limited_variation	34,48	VKORC1 promoter ( g.-1639G-->A ) polymorphisms
18252229_3	0	Pharmacodynamic_phenotype	78,79	higher doses
18252229_3	0	Pharmacodynamic_phenotype	61,62	lower doses
23778325_1	0	Gene_or_protein	11,12	COX2
23778325_1	0	Chemical	15,15	celecoxib
23778325_1	0	Limited_variation	2,3	genetic polymorphisms
23778325_1	0	Disease	5,5	adenoma
23778325_1	0	Phenotype	5,6	adenoma recurrence
23778325_1	0	Pharmacodynamic_phenotype	8,8,15,15	toxicity celecoxib
23778325_1	0	Chemical	11,13	COX2 inhibitor
23778325_1	0	Pharmacodynamic_phenotype	8,13	toxicity in a COX2 inhibitor
18666383_4	0	Limited_variation	4,6	polymorphisms of TPMT
18666383_4	0	Gene_or_protein	6,6	TPMT
18666383_4	0	Chemical	16,16	thiopurine
18666383_4	0	Pharmacodynamic_phenotype	10,16	clinical impact on the use of thiopurine
20121554_4	0	Disease	14,16	acute lymphoblastic leukemia
20121554_4	0	Gene_or_protein	20,21	methylenetetrahydrofolate reductase
20121554_4	0	Limited_variation	19,25	homozygous methylenetetrahydrofolate reductase C677T mutation
20121554_4	0	Chemical	30,30	methotrexate
20121554_4	0	Disease	35,37	cerebral venous thrombosis
20121554_4	0	Chemical	41,41	methotrexate
20121554_4	0	Pharmacodynamic_phenotype	30,33	methotrexate -induced toxicity
20121554_4	0	Pharmacodynamic_phenotype	33,33	toxicity
21346370_3	0	Gene_or_protein	8,11	SLC22A2
21346370_3	0	Gene_or_protein	22,23	OCT2
21346370_3	0	Chemical	55,55	aspirin
21346370_3	0	Gene_or_protein	0,6	Solute carrier family 22, member 2
21346370_3	0	Gene_or_protein	17,20	organic cation transporter 2
21346370_3	0	Chemical	46,46	prostaglandins
10098858_5	0	Chemical	6,6	amphetamine
10098858_5	0	Phenotype	8,10	RGS2 expression
10098858_5	0	Gene_or_protein	8,9	RGS2
10098858_5	0	Chemical	19,19	amphetamine
10098858_5	0	Pharmacodynamic_phenotype	3,6	effects of repeated amphetamine
22955794_3	0	Limited_variation	0,15	Variation in the cytochrome P450 2C19 ( CYP2C19 ) gene
22955794_3	0	Gene_or_protein	3,8	cytochrome P450 2C19
22955794_3	0	Gene_or_protein	10,13	CYP2C19
22955794_3	0	Gene_or_protein	19,22	CYP2C19
22955794_3	0	Chemical	35,35	clopidogrel
22955794_3	0	Pharmacodynamic_phenotype	32,35	variable response to clopidogrel
11417444_12	0	Chemical	4,4	azathioprine
11417444_12	0	Phenotype	7,8	TPMT activity
11417444_12	0	Gene_or_protein	7,7	TPMT
11417444_12	0	Chemical	21,21	azathioprine
27025877_4	0	Phenotype	0,2	JAK2 inhibition
27025877_4	0	Gene_or_protein	0,1	JAK2
27025877_4	0	Pharmacodynamic_phenotype	4,9	sensitivity to the EGFR inhibitor erlotinib
27025877_4	0	Chemical	9,9	erlotinib
27025877_4	0	Gene_or_protein	7,7	EGFR
27025877_4	0	Gene_or_protein	20,20	EGFR
27025877_4	0	Disease	20,27	EGFR -mutant TKI -resistant lung cancer
27025877_4	0	Chemical	7,8	EGFR inhibitor
27025877_4	0	Limited_variation	20,22	EGFR -mutant
27025877_4	0	Chemical	11,11	TKI
27025877_4	0	Chemical	23,23	TKI
27025877_4	0	Phenotype	11,13	TKI -resistant
19932784_15	0	Disease	6,8	acute coronary syndrome
19932784_15	0	Disease	10,11	diabetes mellitus
19932784_15	0	Gene_or_protein	14,17	CYP2C19
19932784_15	0	Chemical	31,31	clopidogrel
19932784_15	0	Phenotype	3,4	high BMI
19932784_15	0	Haplotype	14,18	CYP2C19 2
19932784_15	0	Pharmacodynamic_phenotype	22,22	HTPR
16473917_1	0	Limited_variation	2,7	CYP1A2 deficiency polymorphism
16473917_1	0	Gene_or_protein	2,5	CYP1A2
16473917_1	0	Chemical	13,41	4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one
16473917_1	0	Chemical	43,45	YM-64227
16473917_1	0	Pharmacokinetic_phenotype	11,46	pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one ( YM-64227 )
16473917_1	0	Chemical	49,52	phosphodiesterase type 4 inhibitor
22572645_4	0	Chemical	8,8	folate
22572645_4	0	Chemical	18,19	folic acid
22572645_4	0	Limited_variation	26,27	MTHFR genotype
22572645_4	0	Gene_or_protein	26,26	MTHFR
22572645_4	0	Phenotype	11,12	child problems
22572645_4	0	Pharmacodynamic_phenotype	8,9	folate status
19147553_3	0	Chemical	0,2	Nutlin-3
19147553_3	0	Gene_or_protein	5,6	MDM2
19147553_3	0	Gene_or_protein	16,17	p53
19147553_3	0	Disease	20,20	cancer
19147553_3	0	Chemical	5,7	MDM2 inhibitor
19147553_3	0	Chemical	13,17	activator of the p53
19566775_5	0	Limited_variation	6,18	rs16147 of the NPY gene ( -485C>T )
19566775_5	0	Gene_or_protein	10,10	NPY
19566775_5	0	Limited_variation	3,5,20,32	single nucleotide polymorphisms rs7687423 of the NPY receptor Y1 ( NPY1R )
19566775_5	0	Gene_or_protein	29,31	NPY1R
19566775_5	0	Chemical	40,40	methamphetamine
19566775_5	0	Disease	43,43	psychosis
19566775_5	0	Gene_or_protein	24,27	NPY receptor Y1
19566775_5	0	Disease	40,41	methamphetamine dependence
19566775_5	0	Limited_variation	3,18	single nucleotide polymorphisms rs16147 of the NPY gene ( -485C>T )
19566775_5	0	Limited_variation	20,21	rs7687423
24966969_2	0	Limited_variation	0,16	Single nucleotide polymorphisms ( SNPs ) of VKORC ( 1173T/C , rs9934438 )
24966969_2	0	Limited_variation	0,6,18,30	Single nucleotide polymorphisms ( SNPs ) of CYP2C9 ( 1075A/C , rs1057910 )
24966969_2	0	Gene_or_protein	18,21	CYP2C9
24966969_2	0	Pharmacodynamic_phenotype	37,39	sensitivity of warfarin
24966969_2	0	Chemical	39,39	warfarin
24966969_2	0	Gene_or_protein	7,7	VKORC
10223777_10	0	Gene_or_protein	26,29	CYP2D6
10223777_10	0	Limited_variation	21,24	R296C polymorphism
10223777_10	0	Gene_or_protein	33,36	CYP2D6
10223777_10	0	Pharmacodynamic_phenotype	6,7	plasma concentration
10223777_10	0	Pharmacokinetic_phenotype	10,14	urinary alpha-hydroxymetoprolol excretion
10223777_10	0	Haplotype	26,31	CYP2D6 * 1
10223777_10	0	Haplotype	33,38	CYP2D6 * 2
10223777_10	0	Chemical	11,13	alpha-hydroxymetoprolol
9654649_8	0	Chemical	0,3	G-Rg1
9654649_8	0	Gene_or_protein	14,14	GR
9654649_8	0	Pharmacodynamic_phenotype	22,24	effect of Dex
9654649_8	0	Phenotype	13,15	intracellular GR content
9654649_8	0	Chemical	24,24	Dex
21135276_3	0	Gene_or_protein	11,12	HER2
21135276_3	0	Chemical	18,18	lapatinib
21135276_3	0	Gene_or_protein	26,27	HER2
21135276_3	0	Gene_or_protein	37,38	HER2
21135276_3	0	Gene_or_protein	4,9	human epidermal growth factor receptor 2
21135276_3	0	Chemical	0,0	Trastuzumab
21135276_3	0	Gene_or_protein	21,24	epidermal growth factor receptor
21135276_3	0	Chemical	21,30	epidermal growth factor receptor / HER2 tyrosine kinase inhibitor
21135276_3	0	Disease	37,42	HER2 -overexpressing breast cancers
21135276_3	0	Chemical	4,15	human epidermal growth factor receptor 2 ( HER2 ) monoclonal antibody
21135276_3	0	Phenotype	37,40	HER2 -overexpressing
14654539_7	0	Chemical	13,15	5-fluorouracil
14654539_7	0	Chemical	17,17	mitomycin
14654539_7	0	Gene_or_protein	30,31	p53
14654539_7	0	Limited_variation	19,32	mutations affecting the L2/L3 domains of the p53 protein
14654539_7	0	Pharmacodynamic_phenotype	9,15	lack of response to 5-fluorouracil
14654539_7	0	Pharmacodynamic_phenotype	9,12,17,17	lack of response to mitomycin
21508389_3	0	Gene_or_protein	6,7	Kirsten ras
21508389_3	0	Gene_or_protein	9,9	KRAS
21508389_3	0	Disease	13,14	colorectal tumour
21508389_3	0	Chemical	17,17	oxaliplatin
21508389_3	0	Chemical	19,19	capecitabine
21508389_3	0	Gene_or_protein	30,31	TP53
21508389_3	0	Gene_or_protein	25,28	tumour suppressor p53
21508389_3	0	Limited_variation	22,32	wild-type tumour suppressor p53 ( TP53 )
11956176_1	0	Chemical	0,1	Cyclosporine a
11956176_1	0	Chemical	3,4	FK506
11956176_1	0	Phenotype	6,12	transcriptional activity of the human mineralocorticoid receptor
11956176_1	0	Gene_or_protein	11,12	mineralocorticoid receptor
11956176_1	0	Pharmacodynamic_phenotype	22,23	aldosterone resistance
11956176_1	0	Chemical	22,22	aldosterone
11956176_1	0	Disease	25,26	kidney transplantation
24597466_4	0	Gene_or_protein	4,6	HLA-B
24597466_4	0	Chemical	17,17	CBZ
24597466_4	0	Gene_or_protein	36,38	HLA-B
24597466_4	0	Pharmacodynamic_phenotype	51,52	hypersensitivity syndrome
24597466_4	0	Chemical	48,48	CBZ
24597466_4	0	Pharmacodynamic_phenotype	54,54	HSS
24597466_4	0	Disease	57,58	maculopapular exanthema
24597466_4	0	Disease	60,60	MPE
24597466_4	0	Pharmacodynamic_phenotype	17,32	CBZ -induced Stevens-Johnson syndrome / toxic epidermal necrolysis ( SJS / TEN )
24597466_4	0	Pharmacodynamic_phenotype	29,31	SJS / TEN
24597466_4	0	Haplotype	4,10	HLA-B * 15:02
24597466_4	0	Limited_variation	36,42	HLA-B * 15:02
24597466_4	0	Pharmacodynamic_phenotype	48,52	CBZ -induced hypersensitivity syndrome
24597466_4	0	Pharmacodynamic_phenotype	20,27	Stevens-Johnson syndrome / toxic epidermal necrolysis
17986837_5	0	Limited_variation	1,6	TPH1 779A/C
17986837_5	0	Gene_or_protein	1,2	TPH1
17986837_5	0	Disease	22,23	nicotine dependence
17986837_5	0	Chemical	22,22	nicotine
15226679_4	0	Limited_variation	10,13	genotypes of MDR1
15226679_4	0	Gene_or_protein	12,13	MDR1
15226679_4	0	Gene_or_protein	15,22	cytochrome P450 (CYP) 3A
15226679_4	0	Chemical	38,38	tacrolimus
15226679_4	0	Limited_variation	10,11,15,22	genotypes of cytochrome P450 (CYP) 3A
15226679_4	0	Phenotype	34,35	mRNA expression
15226679_4	0	Pharmacodynamic_phenotype	38,47	tacrolimus concentration/dose ( C/D ) ratio
15226679_4	0	Disease	54,55	liver transplantation
16818870_9	0	Gene_or_protein	38,42	catechol-O-methyltransferase
16818870_9	0	Limited_variation	38,46	catechol-O-methyltransferase Val158Met polymorphisms
16818870_9	0	Chemical	55,55	raclopride
16818870_9	0	Phenotype	55,57	raclopride binding potential
16818870_9	0	Genomic_variation	12,17	dopamine transporter variable nucleotide tandem repeat
16818870_9	0	Limited_variation	19,27	D2 receptor Taq A1/A2
16818870_9	0	Genomic_variation	29,35	D4 receptor variable nucleotide tandem repeat
16818870_9	0	Genomic_variation	4,9	Gene variants of dopamine system components
16818870_9	0	Gene_or_protein	12,13	dopamine transporter
16818870_9	0	Gene_or_protein	19,22	D2 receptor Taq
16818870_9	0	Gene_or_protein	29,31	D4 receptor
8099817_5	0	Phenotype	5,7	expression of preprodynorphin
8099817_5	0	Gene_or_protein	7,7	preprodynorphin
8099817_5	0	Gene_or_protein	11,13	c-fos
8099817_5	0	Chemical	24,24	cocaine
8099817_5	0	Phenotype	5,6,11,13	expression of c-fos
8099817_5	0	Phenotype	24,27	cocaine self-administration
16419387_1	0	Haplotype	9,17	cytochrome P450 3A4 * 1B
16419387_1	0	Chemical	26,26	fentanyl
16419387_1	0	Haplotype	9,11,19,23	cytochrome P450 3A5 * 3
16419387_1	0	Gene_or_protein	9,14	cytochrome P450 3A4
16419387_1	0	Gene_or_protein	9,11,19,21	cytochrome P450 3A5
16419387_1	0	Pharmacodynamic_phenotype	6,6	toxicology
26791794_6	0	Gene_or_protein	18,20	PIK3CA
26791794_6	0	Limited_variation	18,26	PIK3CA - p.Glu545Lys
26791794_6	0	Chemical	32,32	crizotinib
26791794_6	0	Gene_or_protein	9,9	MET
26791794_6	0	Limited_variation	9,13	MET exon 14 skipping mutation
26791794_6	0	Pharmacodynamic_phenotype	38,38	response
26791794_6	0	Genomic_factor	9,11	MET exon 14
22329763_1	0	Gene_or_protein	0,5	17-Hydroxysteroid dehydrogenase type 5
22329763_1	0	Gene_or_protein	14,17	HSD17B5
22329763_1	0	Disease	27,27	PCOS
22329763_1	0	Limited_variation	9,17	-71 A/G HSD17B5
22329763_1	0	Chemical	23,24	oral contraceptive
22329763_1	0	Limited_variation	0,19	17-Hydroxysteroid dehydrogenase type 5 gene polymorphism ( -71 A/G HSD17B5 SNP )
24598368_5	0	Disease	10,11	anaplastic lymphoma
24598368_5	0	Chemical	15,15	crizotinib
24598368_5	0	Disease	27,32	non-small cell lung cancer
24598368_5	0	Disease	35,35	tumors
24598368_5	0	Gene_or_protein	37,38	EML4
24598368_5	0	Gene_or_protein	40,40	ALK
24598368_5	0	Genomic_variation	37,41	EML4 / ALK translocations
24598368_5	0	Chemical	10,13	anaplastic lymphoma kinase inhibitor
24598368_5	0	Pharmacodynamic_phenotype	22,23	response rate
15247556_13	0	Chemical	0,0	Phenytoin
15247556_13	0	Chemical	4,4	LPV
15247556_13	0	Phenotype	7,11	CYP3A4 induction
15247556_13	0	Gene_or_protein	7,10	CYP3A4
15247556_13	0	Chemical	24,24	RTV
15247556_13	0	Pharmacokinetic_phenotype	4,5	LPV clearance
21503919_2	0	Gene_or_protein	16,16	ITPA
21503919_2	0	Chemical	28,28	ribavirin
21503919_2	0	Disease	34,41	chronic hepatitis C virus (HCV) infection
21503919_2	0	Gene_or_protein	12,14	inosine triphosphate pyrophosphatase
21503919_2	0	Chemical	24,26	peg-interferon
21503919_2	0	Chemical	24,29	peg-interferon plus ribavirin combination
21503919_2	0	Limited_variation	4,17	single nucleotide polymorphism ( SNP ) in the inosine triphosphate pyrophosphatase ( ITPA )
21503919_2	0	Phenotype	20,22	reduction of hemoglobin
17700364_10	0	Limited_variation	2,7	Single nucleotide polymorphisms of ABCA1
17700364_10	0	Gene_or_protein	6,7	ABCA1
17700364_10	0	Limited_variation	2,5,9,10	Single nucleotide polymorphisms of APOA5
17700364_10	0	Gene_or_protein	12,13	APOC3
17700364_10	0	Gene_or_protein	15,15	APOE
17700364_10	0	Gene_or_protein	18,18	CETP
17700364_10	0	Limited_variation	2,5,12,13	Single nucleotide polymorphisms of APOC3
17700364_10	0	Limited_variation	2,5,15,15	Single nucleotide polymorphisms of APOE
17700364_10	0	Limited_variation	2,5,18,18	Single nucleotide polymorphisms of CETP
17700364_10	0	Phenotype	24,30	high-density lipoprotein- cholesterol levels
17700364_10	0	Phenotype	21,22	plasma triglyceride
17700364_10	0	Gene_or_protein	9,10	APOA5
17700364_10	0	Chemical	32,32	antiretroviral
23942539_1	0	Limited_variation	2,4	dihydropyrimidine dehydrogenase genotypes
23942539_1	0	Gene_or_protein	2,3	dihydropyrimidine dehydrogenase
23942539_1	0	Chemical	7,9	5-fluorouracil
23942539_1	0	Disease	12,13	colorectal cancer
8834233_1	0	Gene_or_protein	6,7	alcohol dehydrogenase
8834233_1	0	Pharmacodynamic_phenotype	11,12	alcohol sensitivity
8834233_1	0	Chemical	11,11	alcohol
8834233_1	0	Limited_variation	3,9	polymorphism in the alcohol dehydrogenase beta subunit
8834233_1	0	Genomic_factor	6,9	alcohol dehydrogenase beta subunit
18602406_7	0	Gene_or_protein	1,2	beta3
18602406_7	0	Chemical	16,17	valerenic acid
18602406_7	0	Pharmacodynamic_phenotype	13,17	anxiolytic activity of valerenic acid
18602406_7	0	Limited_variation	1,10	beta3 ( N265M ) point-mutated
10628896_8	0	Chemical	0,0	Haloperidol
10628896_8	0	Gene_or_protein	5,8	CYP3A4
10628896_8	0	Gene_or_protein	20,23	CYP2D6
12419746_1	0	Chemical	11,11	paclitaxel
12419746_1	0	Chemical	13,13	Taxol
12419746_1	0	Chemical	16,16	docetaxel
12419746_1	0	Chemical	18,18	Taxotere
12419746_1	0	Gene_or_protein	21,22	HER2
12419746_1	0	Chemical	5,5	trastuzumab
12419746_1	0	Chemical	7,7	Herceptin
12419746_1	0	Disease	21,27	HER2 -expressing human breast cancer
12419746_1	0	Chemical	5,14	trastuzumab ( Herceptin ) combined with paclitaxel ( Taxol )
12419746_1	0	Chemical	5,10,16,19	trastuzumab ( Herceptin ) combined with docetaxel ( Taxotere )
12419746_1	0	Phenotype	21,24	HER2 -expressing
24766650_6	0	Chemical	7,7	heroin
24766650_6	0	Limited_variation	23,42	missense SNP rs5376 ( Asn334Ser ) in the galanin receptor type 1 gene ( GALR1 )
24766650_6	0	Gene_or_protein	34,37	galanin receptor type 1
24766650_6	0	Gene_or_protein	40,41	GALR1
24766650_6	0	Limited_variation	46,51	FKBP5 intronic SNP rs1360780
24766650_6	0	Gene_or_protein	46,47	FKBP5
24766650_6	0	Disease	7,8	heroin addiction
24766650_6	0	Limited_variation	1,1	SNPs
22118006_7	0	Gene_or_protein	1,4	CYP2C19
22118006_7	0	Disease	25,27	coronary artery disease
22118006_7	0	Chemical	29,29	clopidogrel
22118006_7	0	Haplotype	1,6	CYP2C19 * 2
22118006_7	0	Disease	16,16	ST
22118006_7	0	Disease	18,20	coronary stent placement
22588607_3	0	Limited_variation	19,23	p.Gly143Glu
22588607_3	0	Limited_variation	25,26	rs121912777
22588607_3	0	Chemical	36,36	oseltamivir
22588607_3	0	Limited_variation	41,46	c.428G>A
22588607_3	0	Gene_or_protein	10,11	CES1
22588607_3	0	Limited_variation	10,17	CES1 c.428G>A
15188667_7	0	Disease	1,1	GISTs
15188667_7	0	Chemical	4,5	imatinib mesylate
15188667_7	0	Gene_or_protein	11,11	KIT
15188667_7	0	Gene_or_protein	13,13	PDGFRA
15188667_7	0	Disease	26,26	GIST
23503720_9	0	Chemical	4,4	silibinin
23503720_9	0	Gene_or_protein	9,10	Smad2
23503720_9	0	Gene_or_protein	12,13	Smad3
23503720_9	0	Gene_or_protein	19,22	TGF-b1
23503720_9	0	Phenotype	7,10	translocation of Smad2
23503720_9	0	Phenotype	7,8,12,13	translocation of Smad3
23503720_9	0	Disease	25,25	HSFs
18058343_7	0	Chemical	4,4	bupropion
18058343_7	0	Limited_variation	19,28	DRD2 Taq1 A2/A2 genotype
18058343_7	0	Gene_or_protein	19,20	DRD2
18058343_7	0	Phenotype	9,10	smoking cessation
22509987_5	0	Limited_variation	6,12	genetic variation in COMT Val158Met
22509987_5	0	Gene_or_protein	9,9	COMT
22509987_5	0	Gene_or_protein	14,15	DRD2
22509987_5	0	Gene_or_protein	17,18	ANKK1
22509987_5	0	Chemical	29,29	alcohol
22509987_5	0	Disease	29,30	alcohol dependence
22509987_5	0	Limited_variation	14,21	DRD2 / ANKK1 Taq1A
21280081_10	0	Pharmacodynamic_phenotype	0,3	COMT inhibition by entacapone
21280081_10	0	Gene_or_protein	0,0	COMT
21280081_10	0	Chemical	3,3	entacapone
21280081_10	0	Gene_or_protein	7,7	COMT
21280081_10	0	Gene_or_protein	13,13	COMT
21280081_10	0	Limited_variation	7,10	COMT ( HH )
21280081_10	0	Limited_variation	13,16	COMT ( LL )
23246478_11	0	Phenotype	20,23	prostate specific antigen concentration
23246478_11	0	Gene_or_protein	20,22	prostate specific antigen
23246478_11	0	Limited_variation	7,9	single nucleotide polymorphisms
25594941_4	0	Limited_variation	0,1	rs9923231
25594941_4	0	Gene_or_protein	3,4	VKORC1
25594941_4	0	Limited_variation	7,8	rs7294
25594941_4	0	Gene_or_protein	10,11	VKORC1
25594941_4	0	Limited_variation	14,15	rs1057910
25594941_4	0	Gene_or_protein	17,20	CYP2C9
25594941_4	0	Limited_variation	23,24	rs2108622
25594941_4	0	Gene_or_protein	26,29	CYP4F2
25594941_4	0	Limited_variation	33,34	rs699664
25594941_4	0	Gene_or_protein	36,36	GGCX
25594941_4	0	Pharmacodynamic_phenotype	41,42	warfarin action
25594941_4	0	Chemical	47,48	vitamin K
25594941_4	0	Chemical	65,65	warfarin
25594941_4	0	Pharmacokinetic_phenotype	63,65	pharmacokinetics of warfarin
25594941_4	0	Pharmacodynamic_phenotype	61,61,64,65	pharmacodynamics of warfarin
25594941_4	0	Pharmacodynamic_phenotype	46,48	circulatory vitamin K
25594941_4	0	Chemical	41,41	warfarin
16800828_1	0	Gene_or_protein	2,3	GABABR1
16800828_1	0	Limited_variation	2,6	GABABR1 T1974C
16800828_1	0	Limited_variation	8,9	rs29230
16800828_1	0	Disease	23,23	alcoholism
16800828_1	0	Chemical	25,25	alcohol
16800828_1	0	Gene_or_protein	13,14	GABAB receptor
16800828_1	0	Phenotype	25,27	alcohol withdrawal seizures
8487953_6	0	Phenotype	6,10	expression of KROX-24
8487953_6	0	Gene_or_protein	8,10	KROX-24
8487953_6	0	Chemical	15,17	MK-801
8487953_6	0	Gene_or_protein	30,30	FOS
8487953_6	0	Gene_or_protein	32,32	JUN
8487953_6	0	Phenotype	24,30	expression pattern similar to that of FOS
8487953_6	0	Phenotype	24,29,32,32	expression pattern similar to that of JUN
24956250_1	0	Gene_or_protein	3,5	HLA-B
24956250_1	0	Pharmacodynamic_phenotype	15,16	abacavir hypersensitivity
24956250_1	0	Chemical	15,15	abacavir
24956250_1	0	Haplotype	3,9	HLA-B * 57:01
20922562_4	0	Limited_variation	6,10	polymorphisms of KIF3A
20922562_4	0	Gene_or_protein	8,10	KIF3A
20922562_4	0	Disease	15,15	AIA
20922562_4	0	Chemical	58,58	aspirin
20922562_4	0	Phenotype	44,49	forced expiratory volume at 1 s
20922562_4	0	Phenotype	51,54	FEV ( 1 )
27040858_7	0	Chemical	7,7	Icotinib
27040858_7	0	Chemical	10,10	crizotinib
27040858_7	0	Limited_variation	15,16	EGFR mutation
27040858_7	0	Gene_or_protein	15,15	EGFR
27040858_7	0	Gene_or_protein	22,23	ROS1
27040858_7	0	Limited_variation	26,27	KRAS mutation
27040858_7	0	Gene_or_protein	26,26	KRAS
27040858_7	0	Pharmacodynamic_phenotype	5,7	response to Icotinib
27040858_7	0	Pharmacodynamic_phenotype	5,6,10,10	response to crizotinib
27040858_7	0	Genomic_factor	22,24	ROS1 fusion
19813492_5	0	Gene_or_protein	5,10	cytochrome P450 3A4
19813492_5	0	Gene_or_protein	19,24	cytochrome P450 3A4
19813492_5	0	Chemical	31,31	tacrolimus
19813492_5	0	Chemical	17,24	inducers of cytochrome P450 3A4
19813492_5	0	Chemical	3,10	substrates of cytochrome P450 3A4
19813492_5	0	Pharmacodynamic_phenotype	29,31	interactions with tacrolimus
19813492_5	0	Chemical	15,15,18,24	inhibitors of cytochrome P450 3A4
26086150_9	0	Chemical	3,5	co-trimoxazole
26086150_9	0	Gene_or_protein	15,17	HLA-B
26086150_9	0	Gene_or_protein	23,25	HLA-C
26086150_9	0	Gene_or_protein	32,34	HLA-C
26086150_9	0	Pharmacodynamic_phenotype	3,10	co-trimoxazole -induced SJS / TEN
26086150_9	0	Haplotype	15,21	HLA-B * 15:02
26086150_9	0	Haplotype	23,29	HLA-C * 06:02
26086150_9	0	Haplotype	32,38	HLA-C * 08:01
26086150_9	0	Pharmacodynamic_phenotype	8,10	SJS / TEN
21801714_9	0	Gene_or_protein	1,2	Nrf2
21801714_9	0	Chemical	8,8	Cln
21801714_9	0	Phenotype	12,16	UGT1A1 activity
21801714_9	0	Gene_or_protein	12,15	UGT1A1
21801714_9	0	Gene_or_protein	18,19	Nrf2
21801714_9	0	Genomic_variation	1,5	Nrf2 knock-out
27378608_1	0	Chemical	14,14	lapatinib
27378608_1	0	Gene_or_protein	16,17	HER2
27378608_1	0	Gene_or_protein	0,4	Immunoglobulin G fragment C receptor
27378608_1	0	Limited_variation	0,5	Immunoglobulin G fragment C receptor polymorphisms
27378608_1	0	Pharmacodynamic_phenotype	7,14	efficacy of preoperative chemotherapy plus trastuzumab and lapatinib
27378608_1	0	Chemical	12,12	trastuzumab
27378608_1	0	Disease	16,21	HER2 -positive breast cancer
27378608_1	0	Chemical	10,10	chemotherapy
27378608_1	0	Chemical	10,14	chemotherapy plus trastuzumab and lapatinib
27378608_1	0	Phenotype	16,19	HER2 -positive
12218660_1	0	Limited_variation	3,8	polymorphisms in the serotonin transporter gene
12218660_1	0	Gene_or_protein	6,7	serotonin transporter
12218660_1	0	Chemical	12,12	cocaine
12218660_1	0	Disease	12,13	cocaine dependence
26736037_7	0	Gene_or_protein	1,1	CREB
26736037_7	0	Chemical	20,20	methamphetamine
26736037_7	0	Gene_or_protein	28,28	CREB
26736037_7	0	Chemical	35,35	methamphetamine
26736037_7	0	Phenotype	12,16	chronic use of multiple drugs
26736037_7	0	Pharmacodynamic_phenotype	40,43	outcomes of outpatient treatment
26736037_7	0	Phenotype	32,35	pretreatment frequency of methamphetamine
26736037_7	0	Phenotype	7,9	gene expression changes
26736037_7	0	Phenotype	18,18	abuse
19377049_12	0	Gene_or_protein	6,6	DHFR
19377049_12	0	Chemical	9,9	corticosteroids
19377049_12	0	Gene_or_protein	14,15	AML1
19377049_12	0	Gene_or_protein	17,17	ETO
19377049_12	0	Phenotype	14,19	AML1 - ETO -positive
19377049_12	0	Chemical	6,7	DHFR inhibitors
19377049_12	0	Disease	14,20	AML1 - ETO -positive disease
7875180_1	0	Chemical	0,0	Metoprolol
7875180_1	0	Chemical	9,9	debrizoquine
7875180_1	0	Limited_variation	9,17	debrizoquine oxidation ( CYP2D6 ) polymorphism
7875180_1	0	Gene_or_protein	12,15	CYP2D6
7875180_1	0	Pharmacokinetic_phenotype	0,3	Metoprolol alpha-hydroxylation
7875180_1	0	Pharmacokinetic_phenotype	9,10	debrizoquine oxidation
23275005_7	0	Chemical	7,9	4-HNE
23275005_7	0	Gene_or_protein	35,36	Nrf2
23275005_7	0	Chemical	52,54	4-HNE
23275005_7	0	Genomic_factor	35,38	Nrf2 - ARE
23275005_7	0	Chemical	35,41	Nrf2 - ARE -activating compounds
23275005_7	0	Pharmacodynamic_phenotype	45,45,51,54	resistance to 4-HNE
23275005_7	0	Genomic_factor	19,21,26,27	complex I - driven respiration
23275005_7	0	Genomic_factor	23,27	complex II- driven respiration
17445431_11	0	Gene_or_protein	2,2	DPYD
17445431_11	0	Gene_or_protein	10,10	DPYD
17445431_11	0	Chemical	14,16	5-FU
17445431_11	0	Chemical	26,28	5-FU
17445431_11	0	Pharmacodynamic_phenotype	30,31	chemotherapeutic toxicity
17445431_11	0	Disease	37,38	colonic carcinoma
17445431_11	0	Phenotype	10,12	DPYD enzyme activity
17445431_11	0	Pharmacokinetic_phenotype	14,18	5-FU dyes metabolism
17445431_11	0	Pharmacokinetic_phenotype	24,28	accumulation of 5-FU
17445431_11	0	Haplotype	2,4	DPYD * 5
17445431_11	0	Chemical	30,30	chemotherapeutic
17445431_11	0	Disease	35,35,38,38	gastric carcinoma
21975350_4	0	Gene_or_protein	0,3	CYP2A6
21975350_4	0	Gene_or_protein	5,7	CYP3A
21975350_4	0	Chemical	11,11	letrozole
21975350_4	0	Pharmacokinetic_phenotype	11,12	letrozole metabolism
25872644_1	0	Limited_variation	5,8	ADORA2A polymorphisms
25872644_1	0	Gene_or_protein	5,7	ADORA2A
25872644_1	0	Chemical	10,10	levodopa
25872644_1	0	Disease	15,18	Parkinson's disease
25872644_1	0	Pharmacodynamic_phenotype	10,13	levodopa -induced dyskinesia
25872644_1	0	Disease	13,13	dyskinesia
16395124_1	0	Gene_or_protein	5,6	GABRA2
16395124_1	0	Chemical	9,9	alcohol
16395124_1	0	Disease	9,10	alcohol dependence
23982262_11	0	Chemical	4,4	nevirapine
23982262_11	0	Limited_variation	21,22	rs3745274
23982262_11	0	Gene_or_protein	14,17	CYP2B6
23982262_11	0	Limited_variation	24,26	Q172H
23982262_11	0	Pharmacokinetic_phenotype	4,5	nevirapine AUC
23982262_11	0	Limited_variation	14,19	CYP2B6 516TT
24519039_8	0	Chemical	7,7	ribavirin
24519039_8	0	Limited_variation	12,14	polymorphisms at ITPA
24519039_8	0	Gene_or_protein	14,14	ITPA
24519039_8	0	Disease	19,21	chronic hepatitis C
24519039_8	0	Pharmacodynamic_phenotype	16,17	treatment efficacy
24519039_8	0	Phenotype	25,26	relapse risk
19514905_1	0	Gene_or_protein	0,2	HLA-B
19514905_1	0	Chemical	8,8	abacavir
19514905_1	0	Haplotype	0,4	HLA-B * 5701
23909652_2	0	Chemical	0,0	Vemurafenib
23909652_2	0	Gene_or_protein	4,4	BRAF
23909652_2	0	Disease	31,32	metastatic melanomas
23909652_2	0	Gene_or_protein	35,35	BRAF
23909652_2	0	Limited_variation	35,38	BRAF V600E
23909652_2	0	Gene_or_protein	6,15	v-raf murine sarcoma viral oncogene homologue B1
23909652_2	0	Chemical	4,18	BRAF ( v-raf murine sarcoma viral oncogene homologue B1 ) kinase inhibitor
23909652_2	0	Phenotype	27,27	survival
23909652_2	0	Chemical	23,24	targeted biotherapy
18983505_3	0	Chemical	11,11	paroxetine
18983505_3	0	Gene_or_protein	17,18	serotonin transporter
18983505_3	0	Gene_or_protein	21,24	SLC6A4
18983505_3	0	Phenotype	34,35	platelet function
18983505_3	0	Limited_variation	17,27	serotonin transporter gene ( SLC6A4 ) promoter polymorphism
18983505_3	0	Limited_variation	29,31	5-HTTLPR
18983505_3	0	Genomic_factor	17,19,26,26	serotonin transporter gene promoter
18983505_3	0	Pharmacodynamic_phenotype	6,11	dose-response effects of paroxetine
16944116_13	0	Limited_variation	2,6	CYP2D6 genotype
16944116_13	0	Gene_or_protein	2,5	CYP2D6
16944116_13	0	Chemical	25,25	flecainide
16944116_13	0	Disease	31,32	supraventricular tachyarrhythmia
16944116_13	0	Phenotype	15,16	body weight
16944116_13	0	Phenotype	18,18	age
16944116_13	0	Phenotype	20,20	sex
16944116_13	0	Pharmacokinetic_phenotype	25,26	flecainide pharmacokinetics
16944116_13	0	Phenotype	23,23	Scr
16944116_13	0	Pharmacokinetic_phenotype	10,10	IMs
15379981_6	0	Chemical	3,3	lycopene
15379981_6	0	Gene_or_protein	13,14	CD80
15379981_6	0	Gene_or_protein	16,17	CD86
15379981_6	0	Gene_or_protein	20,24	major histocompatibility complex type II
15379981_6	0	Phenotype	8,18	expression of costimulatory molecules ( CD80 and CD86 )
15379981_6	0	Phenotype	8,9,20,24	expression of major histocompatibility complex type II
15379981_6	0	Gene_or_protein	10,11	costimulatory molecules
15589566_1	0	Limited_variation	6,10	5-HTTLPR S allele
15589566_1	0	Gene_or_protein	6,8	5-HTTLPR
15589566_1	0	Chemical	15,15	alcohol
15589566_1	0	Disease	15,17	alcohol -dependent
15589566_1	0	Phenotype	12,13	suicide attempts
22995156_8	0	Phenotype	3,5	B-Cd
22995156_8	0	Limited_variation	16,23	MT1A rs11076161 A-alleles
22995156_8	0	Gene_or_protein	16,18	MT1A
22995156_8	0	Phenotype	28,30	highly polluted group
22995156_8	0	Limited_variation	19,20	rs11076161
22995156_8	0	Phenotype	47,47	age
22995156_8	0	Phenotype	49,49	sex
22995156_8	0	Phenotype	52,52	smoking
24355137_1	0	Limited_variation	3,12	5-HTR2A -1438A/G
24355137_1	0	Gene_or_protein	19,19	MAOA
24355137_1	0	Disease	33,35	borderline personality disorder
24355137_1	0	Chemical	38,38	heroin
24355137_1	0	Gene_or_protein	3,7	5-HTR2A
24355137_1	0	Limited_variation	14,17	COMT Val158Met
24355137_1	0	Limited_variation	19,21	MAOA -LPR
24355137_1	0	Limited_variation	23,24	DAT VNTR
24355137_1	0	Limited_variation	26,29	5-HTT VNTR
24355137_1	0	Disease	38,40	heroin -dependent
24355137_1	0	Gene_or_protein	14,14	COMT
24355137_1	0	Gene_or_protein	23,23	DAT
24355137_1	0	Gene_or_protein	26,28	5-HTT
19442155_5	0	Chemical	5,5	lithium
19442155_5	0	Gene_or_protein	19,22	GSK-3 beta
19442155_5	0	Chemical	26,26	lithium
19442155_5	0	Pharmacodynamic_phenotype	14,15	inositol depletion
19442155_5	0	Chemical	14,14	inositol
19442155_5	0	Pharmacodynamic_phenotype	26,27	lithium action
1734875_1	0	Chemical	3,3	phosphatidylinositol
1734875_1	0	Gene_or_protein	5,7	c-myc
1734875_1	0	Disease	5,13	c-myc gene-expressed human renal cancer
1734875_1	0	Phenotype	5,10	c-myc gene-expressed
26485092_1	0	Chemical	4,4	Tacrolimus
26485092_1	0	Limited_variation	14,18	CYP3A5 Alleles
26485092_1	0	Gene_or_protein	14,17	CYP3A5
26485092_1	0	Pharmacodynamic_phenotype	4,5	Tacrolimus Concentrations
14570538_1	0	Limited_variation	2,3,6,6	dopamine transporter polymorphisms
14570538_1	0	Gene_or_protein	2,3	dopamine transporter
14570538_1	0	Gene_or_protein	2,2,5,5	dopamine receptor
14570538_1	0	Limited_variation	5,6	receptor polymorphisms
14570538_1	0	Chemical	12,12	bupropion
14570538_1	0	Phenotype	8,9	smoking cessation
24692733_2	0	Gene_or_protein	26,26	KRAS
24692733_2	0	Gene_or_protein	40,40	BRAF
24692733_2	0	Gene_or_protein	42,44	PIK3CA
24692733_2	0	Limited_variation	26,29	KRAS wild-type
24692733_2	0	Disease	30,30	mCRC
24692733_2	0	Chemical	23,23	FOLFIRI
24692733_2	0	Chemical	14,21	folinic acid / 5-fluorouracil / irinotecan
24692733_2	0	Chemical	12,12	cetuximab
24692733_2	0	Disease	26,30	KRAS wild-type mCRC
24692733_2	0	Chemical	12,21	cetuximab plus folinic acid / 5-fluorouracil / irinotecan
17030231_1	0	Chemical	0,0	Salmeterol
17030231_1	0	Gene_or_protein	6,10	beta2-adrenergic receptor
17030231_1	0	Disease	16,16	asthma
17030231_1	0	Pharmacodynamic_phenotype	0,1	Salmeterol response
17030231_1	0	Limited_variation	6,11	beta2-adrenergic receptor genotype
21955998_9	0	Chemical	13,13	BSC
21955998_9	0	Gene_or_protein	18,18	EGFR
21955998_9	0	Chemical	16,20,23,23	anti- EGFR mAb with BSC
21955998_9	0	Disease	43,47	wild-type KRAS tumors
21955998_9	0	Gene_or_protein	46,46	KRAS
21955998_9	0	Chemical	11,11	chemotherapy
21955998_9	0	Chemical	16,21	anti- EGFR mAb with chemotherapy
21955998_9	0	Phenotype	28,28,31,32	progression of mCRC
21955998_9	0	Phenotype	30,32	death of mCRC
21955998_9	0	Limited_variation	43,46	wild-type KRAS
21955998_9	0	Chemical	16,19	anti- EGFR mAb
21955998_9	0	Disease	32,32	mCRC
26045855_1	0	Gene_or_protein	0,0	BRAF
26045855_1	0	Limited_variation	0,5	BRAF (V600 ) mutant
26045855_1	0	Disease	0,12	BRAF (V600 ) mutant non-small-cell lung cancer
26045855_1	0	Chemical	15,15	Vemurafenib
26045855_1	0	Pharmacodynamic_phenotype	13,15	resistant to Vemurafenib
20628391_2	0	Gene_or_protein	5,6	thymidylate synthase
20628391_2	0	Gene_or_protein	8,8	TYMS
20628391_2	0	Limited_variation	11,22	UDP-glucoronosyltransferase 1A ( UGT1A ) germline polymorphisms
20628391_2	0	Gene_or_protein	11,15	UDP-glucoronosyltransferase 1A
20628391_2	0	Gene_or_protein	17,19	UGT1A
20628391_2	0	Disease	30,30	CRC
20628391_2	0	Disease	27,28	colorectal cancer
20628391_2	0	Chemical	35,35	irinotecan
20628391_2	0	Chemical	37,39	5-fluorouracil
20628391_2	0	Chemical	41,41	irinotecan
20628391_2	0	Phenotype	25,31	outcome of colorectal cancer ( CRC )
20628391_2	0	Limited_variation	5,9,21,22	thymidylate synthase ( TYMS ) germline polymorphisms
20628391_2	0	Chemical	43,44	5FU
20628391_2	0	Chemical	35,39	irinotecan plus 5-fluorouracil
20628391_2	0	Chemical	41,44	irinotecan / 5FU
21873787_2	0	Gene_or_protein	10,15	RAS association domain family 1A
21873787_2	0	Gene_or_protein	17,19	RASSF1A
21873787_2	0	Disease	24,27	advanced epithelial ovarian cancer
21873787_2	0	Chemical	33,33	cisplatin
21873787_2	0	Phenotype	7,20	methylation status of RAS association domain family 1A ( RASSF1A )
21873787_2	0	Pharmacodynamic_phenotype	31,36	efficacy of cisplatin based neoadjuvant therapy
21873787_2	0	Chemical	33,36	cisplatin based neoadjuvant therapy
19067682_7	0	Chemical	8,8	tacrolimus
19067682_7	0	Gene_or_protein	16,19	CYP3A5
19067682_7	0	Gene_or_protein	28,31	CYP3A5
19067682_7	0	Haplotype	16,24	CYP3A5 * 1 / * 1
19067682_7	0	Haplotype	28,36	CYP3A5 * 3 / * 3
19067682_7	0	Disease	6,6	transplantation
19067682_7	0	Pharmacodynamic_phenotype	8,10	tacrolimus daily dose
10656431_13	0	Chemical	3,3	paclitaxel
10656431_13	0	Phenotype	17,19	p53 deficiency
10656431_13	0	Gene_or_protein	17,18	p53
10656431_13	0	Phenotype	10,14	lack of G1 arrest
10656431_13	0	Pharmacodynamic_phenotype	1,3	efficiency of paclitaxel
25792135_8	0	Gene_or_protein	4,5	BICD1
25792135_8	0	Chemical	14,14	creatinine
25792135_8	0	Pharmacodynamic_phenotype	14,15	creatinine concentrations
25792135_8	0	Limited_variation	2,9	rs2630578 BICD1 gene polymorphism CC genotype
25792135_8	0	Limited_variation	21,21	CC
25792135_8	0	Limited_variation	24,24	GC
16799968_5	0	Disease	10,11	liver injury
16799968_5	0	Gene_or_protein	22,22	CAR
16799968_5	0	Chemical	19,19	TCPOBOP
16799968_5	0	Gene_or_protein	29,29	CAR
16799968_5	0	Phenotype	7,8	hepatocyte apoptosis
16799968_5	0	Limited_variation	22,25	CAR + / +
16799968_5	0	Limited_variation	29,32	CAR - / -
16799968_5	0	Phenotype	15,15	fatalities
16799968_5	0	Chemical	4,5	Jo2
15180166_10	0	Chemical	4,4	acetaminophen
15180166_10	0	Chemical	6,7	acetaminophen glucuronide
15180166_10	0	Gene_or_protein	9,12	UGT1A1
15180166_10	0	Limited_variation	9,14	UGT1A1 -wildtypes
15180166_10	0	Limited_variation	9,12,16,16	UGT1A1 heterozygotes
15180166_10	0	Limited_variation	9,12,18,18	UGT1A1 mutants
15180166_10	0	Pharmacokinetic_phenotype	1,7	metabolic ratios unchanged acetaminophen / acetaminophen glucuronide
19095777_1	0	Gene_or_protein	0,3	Epidermal growth factor receptor
19095777_1	0	Limited_variation	8,11	K-ras mutation
19095777_1	0	Gene_or_protein	8,10	K-ras
19095777_1	0	Chemical	19,21	5-FU
19095777_1	0	Disease	28,29	rectal cancer
19095777_1	0	Genomic_variation	0,6	Epidermal growth factor receptor gene copy number
19095777_1	0	Chemical	17,17	cetuximab
19095777_1	0	Pharmacodynamic_phenotype	13,17	pathological response to preoperative cetuximab
19095777_1	0	Pharmacodynamic_phenotype	13,16,19,21	pathological response to preoperative 5-FU
19095777_1	0	Pharmacodynamic_phenotype	13,16,23,24	pathological response to preoperative radiation therapy
19095777_1	0	Chemical	23,24	radiation therapy
12966314_1	0	Gene_or_protein	2,5	dopamine receptor D1
12966314_1	0	Chemical	13,13	alcohol
12966314_1	0	Limited_variation	2,8	dopamine receptor D1 gene DdeI polymorphism
12966314_1	0	Phenotype	10,11	sensation seeking
12966314_1	0	Disease	13,15	alcohol -dependent
18377430_8	0	Chemical	4,4	doxorubicin
18377430_8	0	Limited_variation	13,21	ABCG2 c.421C>A polymorphism
18377430_8	0	Gene_or_protein	13,14	ABCG2
18377430_8	0	Pharmacokinetic_phenotype	4,5	doxorubicin pharmacokinetic
27590272_3	0	Gene_or_protein	16,17	OCT2
27590272_3	0	Gene_or_protein	26,27	MATE1
27590272_3	0	Gene_or_protein	39,40	ABCB1
27590272_3	0	Gene_or_protein	53,54	ABCC2
27590272_3	0	Chemical	71,72	platinum drugs
27590272_3	0	Gene_or_protein	11,14	organic cation transporter 2
27590272_3	0	Gene_or_protein	20,24	multidrug and toxin extrusion 1
27590272_3	0	Gene_or_protein	30,37	ATP-binding cassette subfamily B member 1
27590272_3	0	Gene_or_protein	44,51	ATP-binding cassette subfamily C member 2
27590272_3	0	Pharmacodynamic_phenotype	66,66,70,72	efficacy of platinum drugs
27590272_3	0	Pharmacodynamic_phenotype	68,72	adverse effects of platinum drugs
27590272_3	0	Limited_variation	58,59	genetic polymorphisms
17267549_4	0	Gene_or_protein	8,12	Kv1.5 channel
17267549_4	0	Gene_or_protein	15,16	KCNA5
17267549_4	0	Chemical	43,45	4-aminopyridine
17267549_4	0	Phenotype	5,17	overexpression of the Kv1.5 channel gene ( KCNA5 )
17267549_4	0	Pharmacodynamic_phenotype	41,45	sensitive to 4-aminopyridine
7944879_2	0	Chemical	12,12	clozapine
7944879_2	0	Gene_or_protein	19,22	D4 dopamine receptor
7944879_2	0	Gene_or_protein	24,25	DRD4
7944879_2	0	Pharmacodynamic_phenotype	10,12	response to clozapine
7944879_2	0	Limited_variation	19,22,27,27	D4 dopamine receptor alleles
16759339_3	0	Limited_variation	21,35	Ser9Gly ( BalI ) polymorphism in exon 1 of the DRD3 gene
16759339_3	0	Chemical	38,38	alcohol
16759339_3	0	Disease	49,49	alcoholism
16759339_3	0	Limited_variation	3,18	-141 C Ins/Del polymorphism in the promoter region of the DRD2 gene
16759339_3	0	Gene_or_protein	16,17	DRD2
16759339_3	0	Gene_or_protein	33,34	DRD3
16759339_3	0	Disease	38,40	alcohol -dependent
16759339_3	0	Genomic_factor	46,49	genetic predisposition for alcoholism
16759339_3	0	Genomic_factor	12,18	promoter region of the DRD2 gene
16759339_3	0	Genomic_factor	29,35	exon 1 of the DRD3 gene
23258095_8	0	Chemical	14,14	PEG
23258095_8	0	Gene_or_protein	16,18	IFNa-2
23258095_8	0	Disease	24,24	HCC
23258095_8	0	Limited_variation	29,32	IL28B SNP
23258095_8	0	Gene_or_protein	29,31	IL28B
23258095_8	0	Disease	40,40	CHC
23258095_8	0	Chemical	14,19	PEG - IFNa-2 a
24728879_2	0	Gene_or_protein	8,12	(HLA)-B
24728879_2	0	Pharmacodynamic_phenotype	19,28	allopurinol -associated severe cutaneous adverse reactions ( SCAR )
24728879_2	0	Chemical	19,19	allopurinol
24728879_2	0	Pharmacokinetic_phenotype	27,27	SCAR
24728879_2	0	Haplotype	8,16	(HLA)-B * 58:01
24728879_2	0	Pharmacodynamic_phenotype	22,25	severe cutaneous adverse reactions
23846846_3	0	Limited_variation	4,7	DPYSL2 gene polymorphisms
23846846_3	0	Gene_or_protein	4,5	DPYSL2
23846846_3	0	Disease	16,16	AD
23846846_3	0	Disease	13,14	alcohol dependence
23846846_3	0	Chemical	13,13	alcohol
11893774_7	0	Chemical	3,3	estrogen
11893774_7	0	Gene_or_protein	15,15	HL
11893774_7	0	Pharmacodynamic_phenotype	3,4	estrogen responsiveness
11893774_7	0	Genomic_factor	8,16	-1557 / -1175 of the HL promoter
19251742_7	0	Chemical	15,16	SrCl2
19251742_7	0	Gene_or_protein	56,58	gammaH2AX
19251742_7	0	Phenotype	31,38	methylation status of histone H3 lysine 9
19251742_7	0	Genomic_variation	40,42	low chromosome damage
25227813_15	0	Limited_variation	2,3	mutant EGFR
25227813_15	0	Gene_or_protein	3,3	EGFR
25227813_15	0	Chemical	7,7	icotinib
25227813_15	0	Disease	17,18	tumor metastasis
25227813_15	0	Pharmacodynamic_phenotype	6,8	higher icotinib concentration
25227813_15	0	Phenotype	12,12	PFS
25227813_15	0	Phenotype	14,14	OS
17563401_7	0	Limited_variation	0,15	Polymorphisms in 3-hydroxy-3-methylglutaryl-coenzyme A reductase ( HMGCR )
17563401_7	0	Gene_or_protein	14,14	HMGCR
17563401_7	0	Gene_or_protein	2,12	3-hydroxy-3-methylglutaryl-coenzyme A reductase
17563401_7	0	Chemical	23,23	pravastatin
17563401_7	0	Chemical	37,37	fluvastatin
17563401_7	0	Pharmacodynamic_phenotype	21,23	efficacy of pravastatin
17563401_7	0	Pharmacodynamic_phenotype	32,37	reduction of LDL cholesterol by fluvastatin
17563401_7	0	Pharmacodynamic_phenotype	32,35	reduction of LDL cholesterol
16815314_8	0	Chemical	9,9	metoprolol
16815314_8	0	Limited_variation	55,57	Arg389Arg
16815314_8	0	Limited_variation	59,61	Gly389Arg
16815314_8	0	Limited_variation	64,66	Gly389Gly
16815314_8	0	Pharmacodynamic_phenotype	3,10	descent of systolic blood pressure after metoprolol administration
16815314_8	0	Pharmacodynamic_phenotype	5,7	systolic blood pressure
15094935_9	0	Limited_variation	0,4	CYP2C9 genotyping
15094935_9	0	Gene_or_protein	0,3	CYP2C9
15094935_9	0	Chemical	16,16	warfarin
15094935_9	0	Pharmacodynamic_phenotype	16,18	warfarin dosage requirements
18378882_9	0	Chemical	16,16	levodopa
18378882_9	0	Limited_variation	2,3	MUT +
18378882_9	0	Phenotype	8,9	axial signs
18378882_9	0	Limited_variation	12,13	MUT -
18378882_9	0	Pharmacodynamic_phenotype	16,16,23,25	levodopa resistant axial signs
18378882_9	0	Disease	42,42	surgery
19366808_1	0	Chemical	0,0	Sorafenib
19366808_1	0	Gene_or_protein	7,9	BCR/ABL
19366808_1	0	Phenotype	2,2	apoptosis
19366808_1	0	Phenotype	6,9	expressing BCR/ABL
19366808_1	0	Phenotype	13,14	kinase activity
22821000_4	0	Chemical	38,54	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
22821000_4	0	Chemical	56,56	MPTP
22821000_4	0	Disease	67,68	Parkinson disease
22821000_4	0	Gene_or_protein	5,6	Ranbp2
22821000_4	0	Genomic_variation	5,7	Ranbp2 haploinsufficiency
22821000_4	0	Phenotype	12,25	manifestations linked to tyrosine -hydroxylase ( TH ( + ) ) dopaminergic neurons
22821000_4	0	Gene_or_protein	19,22	TH ( + )
22821000_4	0	Gene_or_protein	15,17	tyrosine -hydroxylase
22821000_4	0	Chemical	60,61	parkinsonian neurotoxin
22821000_4	0	Phenotype	12,14,27,31	manifestations linked to glial cells of the brain
22821000_4	0	Phenotype	12,14,33,33	manifestations linked to retina
21149285_6	0	Limited_variation	6,9	HLA-A alleles
21149285_6	0	Gene_or_protein	6,8	HLA-A
21149285_6	0	Chemical	23,23	CBZ
21149285_6	0	Chemical	25,25	CBZ
21149285_6	0	Gene_or_protein	33,35	HLA-A
21149285_6	0	Chemical	54,54	CBZ
21149285_6	0	Chemical	73,73	CBZ
21149285_6	0	Gene_or_protein	125,127	HLA-A
21149285_6	0	Chemical	135,135	CBZ
21149285_6	0	Pharmacodynamic_phenotype	19,19	cADRs
21149285_6	0	Haplotype	33,37	HLA-A * 3101
21149285_6	0	Pharmacodynamic_phenotype	54,57	CBZ -induced cADRs
21149285_6	0	Haplotype	125,129	HLA-A * 3101
21149285_6	0	Pharmacodynamic_phenotype	135,138	CBZ -induced cADRs
21149285_6	0	Pharmacodynamic_phenotype	57,57	cADRs
21149285_6	0	Pharmacodynamic_phenotype	138,138	cADRs
12150448_4	0	Gene_or_protein	7,11	HER-2/neu
12150448_4	0	Gene_or_protein	13,14	HER2
12150448_4	0	Gene_or_protein	35,36	HER2
12150448_4	0	Phenotype	50,50	DTH
12150448_4	0	Pharmacodynamic_phenotype	32,38	immunogenicity of a HER2 peptide vaccine
12150448_4	0	Chemical	35,38	HER2 peptide vaccine
12150448_4	0	Chemical	56,56	antigens
12150448_4	0	Phenotype	45,46	immune competence
12150448_4	0	Disease	7,17,20,20	HER-2/neu ( HER2 ) overexpressing breast cancers
12150448_4	0	Disease	7,16,19,20	HER-2/neu ( HER2 ) overexpressing ovarian cancers
12150448_4	0	Phenotype	7,16	HER-2/neu ( HER2 ) overexpressing
17952745_4	0	Chemical	13,13	temozolomide
17952745_4	0	Gene_or_protein	40,40	MGMT
17952745_4	0	Phenotype	40,43	MGMT promotor methylation status
17952745_4	0	Genomic_variation	33,37	1p/19q
17952745_4	0	Phenotype	18,18	survival
17952745_4	0	Genomic_factor	40,41	MGMT promotor
27883280_1	0	Chemical	4,4	irinotecan
27883280_1	0	Disease	8,9	lung cancer
27883280_1	0	Gene_or_protein	13,16	UGT1A1
27883280_1	0	Haplotype	13,18	UGT1A1 * 28
27883280_1	0	Haplotype	13,16,20,21	UGT1A1 * 6
1225820_10	0	Gene_or_protein	14,15	ChF1
1225820_10	0	Gene_or_protein	17,18	ChS1
1225820_10	0	Phenotype	23,24,28,28	synthesis of cholinesterase
1225820_10	0	Gene_or_protein	28,28	cholinesterase
1225820_10	0	Disease	42,42	apnoea
1225820_10	0	Chemical	41,41	suxamethonium
1225820_10	0	Limited_variation	34,38	ChU1 ChD1 heterozygotes
1225820_10	0	Gene_or_protein	36,37	ChD1
1225820_10	0	Pharmacodynamic_phenotype	41,42	suxamethonium apnoea
1225820_10	0	Gene_or_protein	34,35	ChU1
23101464_3	0	Gene_or_protein	11,11	PDYN
23101464_3	0	Gene_or_protein	13,14	OPRK1
23101464_3	0	Chemical	18,18	alcohol
23101464_3	0	Phenotype	60,63	intensity of depressive symptoms
23101464_3	0	Disease	62,63	depressive symptoms
23101464_3	0	Disease	18,20	alcohol -dependent
23101464_3	0	Limited_variation	3,9,13,14	single nucleotide polymorphisms ( SNPs ) in OPRK1
23101464_3	0	Limited_variation	3,11	single nucleotide polymorphisms ( SNPs ) in the PDYN
23101464_3	0	Disease	54,54	depression
23101464_3	0	Phenotype	31,32	negative craving
20191296_1	0	Gene_or_protein	4,4	POMC
20191296_1	0	Chemical	12,12	alcohol
20191296_1	0	Phenotype	0,6	DNA methylation of the POMC gene promoter
20191296_1	0	Phenotype	10,13	craving in alcohol dependence
20191296_1	0	Genomic_factor	4,6	POMC gene promoter
20191296_1	0	Disease	12,13	alcohol dependence
22217332_2	0	Disease	15,15	polyps
22217332_2	0	Gene_or_protein	27,28	EMID2
22217332_2	0	Disease	40,41	nasal polyps
22217332_2	0	Chemical	45,45	aspirin
22217332_2	0	Gene_or_protein	18,25	emilin/multimerin domain-containing protein 2
22217332_2	0	Phenotype	6,8	protruded extracellular matrix
22217332_2	0	Disease	3,4	subepithelial fibrosis
22217332_2	0	Pharmacodynamic_phenotype	45,47	aspirin -hypersensitive
22217332_2	0	Disease	43,43	asthma
24022708_2	0	Chemical	27,27	lansoprazole
24022708_2	0	Chemical	29,29	LSZ
24022708_2	0	Gene_or_protein	44,47	CYP2C19
24022708_2	0	Chemical	59,59	LSZ
24022708_2	0	Chemical	63,67	5'-hydroxy lansoprazole
24022708_2	0	Chemical	69,69	HLSZ
24022708_2	0	Chemical	72,73	lansoprazole sulphone
24022708_2	0	Chemical	81,81	LSZ
24022708_2	0	Gene_or_protein	10,10	MDRI
24022708_2	0	Gene_or_protein	5,8	CYP2C19
24022708_2	0	Chemical	75,75	LSZS
24022708_2	0	Limited_variation	10,13	MDRI C3435T
24022708_2	0	Pharmacokinetic_phenotype	24,30	pharmacokinetic variability of lansoprazole ( LSZ )
24022708_2	0	Gene_or_protein	49,49	MDRI
24022708_2	0	Limited_variation	49,53	MDRI C3435T polymorphisms
24022708_2	0	Pharmacokinetic_phenotype	56,59	pharmacokinetics difference of LSZ
24022708_2	0	Limited_variation	3,8	genotypes of CYP2C19
24022708_2	0	Limited_variation	44,47,53,53	CYP2C19 polymorphisms
24022708_2	0	Pharmacodynamic_phenotype	56,58,63,70	pharmacokinetics difference of 5'-hydroxy lansoprazole ( HLSZ )
24022708_2	0	Pharmacodynamic_phenotype	56,58,72,76	pharmacokinetics difference of lansoprazole sulphone ( LSZS )
24055295_8	0	Chemical	2,3	JTC801
24055295_8	0	Gene_or_protein	12,12	FLG
24055295_8	0	Gene_or_protein	26,26	loricrin
24055295_8	0	Gene_or_protein	28,29	keratin 10
24055295_8	0	Gene_or_protein	32,33	transglutaminase 1
24055295_8	0	Phenotype	6,6,10,12	mRNA levels of FLG
24055295_8	0	Phenotype	8,12	protein expression levels of FLG
24055295_8	0	Phenotype	16,18,26,26	mRNA levels of loricrin
24055295_8	0	Phenotype	16,18,28,29	mRNA levels of keratin 10
24055295_8	0	Phenotype	16,18,32,33	mRNA levels of transglutaminase 1
24055295_8	0	Phenotype	16,23	mRNA levels of other makers for keratinocyte differentiation
21388237_3	0	Disease	15,15	Depression
21388237_3	0	Chemical	38,38	escitalopram
21388237_3	0	Chemical	43,43	nortriptyline
21388237_3	0	Gene_or_protein	22,23	serotonin transporter
21388237_3	0	Limited_variation	22,29	serotonin transporter gene promoter polymorphism 5-HTTLPR
21388237_3	0	Chemical	40,40	SSRI
21388237_3	0	Chemical	45,46	tricyclic antidepressant
21388237_3	0	Phenotype	31,32	sexual function
21388237_3	0	Genomic_factor	22,25	serotonin transporter gene promoter
18525109_3	0	Chemical	12,12	brazilin
18525109_3	0	Gene_or_protein	24,27	heme oxygenase-1
18525109_3	0	Gene_or_protein	29,31	HO-1
18525109_3	0	Chemical	6,10	C. sappan L.
18525109_3	0	Gene_or_protein	21,21	luciferase
18525109_3	0	Phenotype	21,22	luciferase activity
18525109_3	0	Phenotype	24,33	heme oxygenase-1 ( HO-1 ) expression
21747412_4	0	Limited_variation	6,7	MTHFR genotype
21747412_4	0	Gene_or_protein	6,6	MTHFR
21747412_4	0	Chemical	11,11	MTX
21747412_4	0	Disease	20,20	ALL
21747412_4	0	Disease	25,25	ALL
21747412_4	0	Pharmacodynamic_phenotype	11,12	MTX dosage
21498394_2	0	Gene_or_protein	7,8	dihydropyrimidine dehydrogenase
21498394_2	0	Chemical	23,23	capecitabine
21498394_2	0	Limited_variation	7,17	dihydropyrimidine dehydrogenase ( DPD ) single nucleotide polymorphisms ( SNP )
21498394_2	0	Haplotype	7,11,19,19	dihydropyrimidine dehydrogenase ( DPD ) haplotypes
21498394_2	0	Pharmacodynamic_phenotype	21,23	outcome of capecitabine
21498394_2	0	Gene_or_protein	10,10	DPD
15063162_7	0	Chemical	4,5	nitric oxide
15063162_7	0	Gene_or_protein	17,19	c-Fos
15063162_7	0	Chemical	14,14	lithium
15063162_7	0	Gene_or_protein	21,21	ICER
15063162_7	0	Chemical	31,32	nitric oxide
15063162_7	0	Chemical	40,41	nitric oxide
15063162_7	0	Chemical	43,43	lithium
15063162_7	0	Pharmacodynamic_phenotype	14,22	lithium -induced c-Fos / ICER expression
15063162_7	0	Pharmacodynamic_phenotype	43,49	lithium -induced activation of adrenal medulla
15063162_7	0	Pharmacokinetic_phenotype	17,22	c-Fos / ICER expression
15063162_7	0	Pharmacodynamic_phenotype	46,49	activation of adrenal medulla
18978522_8	0	Gene_or_protein	0,3	CYP3A7
18978522_8	0	Chemical	22,22	cyclosporine
18978522_8	0	Haplotype	0,6	CYP3A7 * 1C
18978522_8	0	Pharmacodynamic_phenotype	22,24	cyclosporine daily dose
18978522_8	0	Disease	30,30	transplantation
25242669_6	0	Gene_or_protein	14,14	EGFR
25242669_6	0	Gene_or_protein	23,23	EGFR
25242669_6	0	Chemical	68,68	gefitinib
25242669_6	0	Gene_or_protein	71,71	EGFR
25242669_6	0	Gene_or_protein	92,92	EGFR
25242669_6	0	Chemical	92,94	EGFR -TKIs
25242669_6	0	Disease	14,17	EGFR -mutated NSCLC
25242669_6	0	Chemical	23,25	EGFR -TKI
25242669_6	0	Disease	71,74	EGFR -mutated NSCLC
25242669_6	0	Chemical	82,89	TKI followed by a subsequent line of treatment
15896496_1	0	Limited_variation	6,19	( Val66Met ) polymorphism in the brain-derived neurotrophic factor gene
15896496_1	0	Gene_or_protein	14,18	brain-derived neurotrophic factor
15896496_1	0	Disease	21,22	alcohol dependence
15896496_1	0	Phenotype	24,25	extreme violence
15896496_1	0	Chemical	21,21	alcohol
11555846_6	0	Limited_variation	6,15	Gln27Glu beta ( 2 ) - adrenergic receptor
11555846_6	0	Chemical	28,28	glucose
11555846_6	0	Limited_variation	17,25	Pro12Ala peroxisome proliferator-activated receptor gamma
11555846_6	0	Gene_or_protein	20,25	peroxisome proliferator-activated receptor gamma
11555846_6	0	Gene_or_protein	9,15	beta ( 2 ) - adrenergic receptor
11555846_6	0	Pharmacokinetic_phenotype	30,32	insulin kinetic parameters
11555846_6	0	Chemical	30,30	insulin
11555846_6	0	Pharmacokinetic_phenotype	28,28,31,32	glucose kinetic parameters
20022477_10	0	Limited_variation	7,10	CCR3 genetic polymorphisms
20022477_10	0	Gene_or_protein	7,8	CCR3
20022477_10	0	Disease	18,18	AERD
20022477_10	0	Chemical	34,34	aspirin
20022477_10	0	Pharmacodynamic_phenotype	34,35	aspirin hypersensitivity
20025435_2	0	Limited_variation	5,8	polymorphisms in alcohol dehydrogenase
20025435_2	0	Gene_or_protein	10,11	ADH2
20025435_2	0	Gene_or_protein	13,15	ADH1B
20025435_2	0	Gene_or_protein	18,19	aldehyde dehydrogenase
20025435_2	0	Gene_or_protein	21,22	ALDH2
20025435_2	0	Chemical	26,26	alcohol
20025435_2	0	Chemical	39,39	alcohol
20025435_2	0	Disease	26,27	alcohol dependence
20025435_2	0	Gene_or_protein	7,8	alcohol dehydrogenase
20025435_2	0	Limited_variation	5,6,18,19	polymorphisms in aldehyde dehydrogenase
20025435_2	0	Disease	39,40	alcohol dependence
22735459_10	0	Gene_or_protein	6,9	CYP2C9
22735459_10	0	Gene_or_protein	16,19	CYP2C9
22735459_10	0	Chemical	32,34	E-3174
22735459_10	0	Chemical	36,36	losartan
22735459_10	0	Chemical	43,43	losartan
22735459_10	0	Gene_or_protein	49,52	CYP2C9
22735459_10	0	Gene_or_protein	59,62	CYP2C9
22735459_10	0	Haplotype	6,14	CYP2C9 * 1 / * 3
22735459_10	0	Haplotype	16,24	CYP2C9 * 1 / * 13
22735459_10	0	Pharmacodynamic_phenotype	41,43	effects of losartan
22735459_10	0	Pharmacokinetic_phenotype	30,36	formation of E-3174 from losartan
22735459_10	0	Haplotype	49,57	CYP2C9 * 1 / * 3
22735459_10	0	Haplotype	59,67	CYP2C9 * 1 / * 13
15608594_4	0	Limited_variation	10,13	A118G polymorphism
15608594_4	0	Chemical	22,22	alcohol
15608594_4	0	Pharmacodynamic_phenotype	17,22	sensitivity to the effects of alcohol
24394004_5	0	Genomic_factor	4,5	MSI status
24394004_5	0	Chemical	13,13	oxaliplatin
24394004_5	0	Pharmacodynamic_phenotype	8,9,13,16	efficacy of oxaliplatin -based chemotherapy
24394004_5	0	Chemical	13,16	oxaliplatin -based chemotherapy
27096382_17	0	Limited_variation	5,8	IL36RN mutations
27096382_17	0	Gene_or_protein	5,7	IL36RN
27096382_17	0	Chemical	18,19	retinoid acitretin
27096382_17	0	Pharmacodynamic_phenotype	1,1	response
25351929_1	0	Chemical	8,8	lapatinib
25351929_1	0	Chemical	10,10	vinorelbine
25351929_1	0	Disease	16,22	HER2 -positive metastatic breast cancer
25351929_1	0	Gene_or_protein	16,17	HER2
25351929_1	0	Chemical	8,10	lapatinib and vinorelbine
25351929_1	0	Phenotype	16,19	HER2 -positive
20079691_13	0	Gene_or_protein	6,7	HER2
20079691_13	0	Gene_or_protein	9,11	TOP2A
20079691_13	0	Chemical	32,32	anthracyclines
20079691_13	0	Genomic_variation	16,19	Ch17CEP duplication
20079691_13	0	Pharmacodynamic_phenotype	30,32	benefit from anthracyclines
20079691_13	0	Genomic_factor	13,14	chromosome 17
12563177_9	0	Pharmacokinetic_phenotype	11,15	PON1 activity towards diazoxon
12563177_9	0	Gene_or_protein	11,12	PON1
12563177_9	0	Chemical	15,15	diazoxon
12563177_9	0	Limited_variation	1,6	combination of R and L genotypes
12563177_9	0	Limited_variation	5,5	L
12563177_9	0	Limited_variation	3,3	R
12563177_9	0	Pharmacokinetic_phenotype	11,13	PON1 activity
22896000_13	0	Chemical	0,0	Omacetaxine
22896000_13	0	Disease	9,9	CML
22896000_13	0	Limited_variation	12,15	T315I mutation
23515680_8	0	Limited_variation	2,4	C1236T
23515680_8	0	Limited_variation	6,8	C3435T
23515680_8	0	Chemical	10,10	venlafaxine
23515680_8	0	Pharmacodynamic_phenotype	19,19	intoxication
23515680_8	0	Pharmacodynamic_phenotype	22,24	non-intoxications
25270523_1	0	Gene_or_protein	2,4	anaplastic lymphoma kinase
25270523_1	0	Disease	7,8	sarcomatoid carcinoma
25270523_1	0	Chemical	17,17	crizotinib
25270523_1	0	Genomic_variation	2,5	anaplastic lymphoma kinase translocation
25270523_1	0	Pharmacodynamic_phenotype	15,17	effect of crizotinib
23645737_3	0	Gene_or_protein	6,9	adenosine deaminase-like
23645737_3	0	Gene_or_protein	11,11	ADAL
23645737_3	0	Chemical	19,21	GS-9219
23645737_3	0	Pharmacokinetic_phenotype	16,21	intracellular activation of GS-9219
22521649_2	0	Gene_or_protein	2,5	Epidermal growth factor receptor
22521649_2	0	Gene_or_protein	7,7	EGFR
22521649_2	0	Disease	11,16	non-small cell lung cancer
22521649_2	0	Disease	18,18	NSCLC
22521649_2	0	Pharmacodynamic_phenotype	26,37	response to EGFR - tyrosine kinase inhibitors ( EGFR -TKIs )
22521649_2	0	Gene_or_protein	28,28	EGFR
22521649_2	0	Chemical	28,32	EGFR - tyrosine kinase inhibitors
22521649_2	0	Gene_or_protein	34,34	EGFR
22521649_2	0	Chemical	34,36	EGFR -TKIs
22521649_2	0	Limited_variation	2,9	Epidermal growth factor receptor ( EGFR ) mutations
11882352_1	0	Chemical	13,13	TCDD
11882352_1	0	Pharmacodynamic_phenotype	11,13	toxicity of TCDD
11882352_1	0	Gene_or_protein	18,20	c- src
11882352_1	0	Phenotype	2,4	src -deficiency
11882352_1	0	Gene_or_protein	2,2	src
11882352_1	0	Genomic_variation	18,21	c- src knockout
17636396_11	0	Chemical	12,14,19,20	anthracycline -based adjuvant chemotherapy
17636396_11	0	Chemical	16,20	taxane -based adjuvant chemotherapy
17636396_11	0	Phenotype	24,28	HER2 /neu status
17636396_11	0	Gene_or_protein	24,27	HER2 /neu
17636396_11	0	Disease	33,39	HER2 /neu -positive cancers
17636396_11	0	Gene_or_protein	33,36	HER2 /neu
17636396_11	0	Disease	48,54	HER2 /neu -negative cancers
17636396_11	0	Gene_or_protein	48,51	HER2 /neu
17636396_11	0	Phenotype	33,38	HER2 /neu -positive
17636396_11	0	Phenotype	48,53	HER2 /neu -negative
17636396_11	0	Chemical	12,12	anthracycline
17636396_11	0	Chemical	16,16	taxane
19636338_15	0	Gene_or_protein	2,5	CYP1A2
19636338_15	0	Chemical	21,21	olanzapine
19636338_15	0	Haplotype	2,8	CYP1A2 * 1F
19636338_15	0	Pharmacodynamic_phenotype	21,23	olanzapine serum concentrations
19636338_15	0	Pharmacodynamic_phenotype	26,27	treatment response
16407894_1	0	Genomic_variation	0,3	Knockout of ERK1
16407894_1	0	Chemical	5,5	cocaine
16407894_1	0	Pharmacodynamic_phenotype	5,11	cocaine -evoked immediate early gene expression
16407894_1	0	Phenotype	13,14	behavioral plasticity
16407894_1	0	Gene_or_protein	2,3	ERK1
16893904_1	0	Gene_or_protein	13,13	huntingtin
16893904_1	0	Disease	17,17	toxicity
16893904_1	0	Disease	19,22	Huntington's disease
16893904_1	0	Phenotype	13,14	huntingtin misfolding
16893904_1	0	Chemical	6,8	epigallocatechin-gallate
18429967_1	0	Chemical	2,2	tacrolimus
18429967_1	0	Gene_or_protein	6,9	CYP3A5
18429967_1	0	Pharmacokinetic_phenotype	2,4	tacrolimus circadian pharmacokinetics
18429967_1	0	Disease	19,20	renal transplant
23991619_3	0	Disease	3,3	APL
23991619_3	0	Gene_or_protein	6,6	PML
23991619_3	0	Gene_or_protein	10,11	bcr1
23991619_3	0	Gene_or_protein	14,15	WT1
23991619_3	0	Genomic_variation	6,12	PML / RARa ( bcr1 )
23991619_3	0	Genomic_variation	36,48	t ( 2 ; 3 ) ( p25 ; q21 )
23991619_3	0	Genomic_variation	50,62	t ( 15 ; 17 ) ( q22 ; q21 )
23991619_3	0	Gene_or_protein	22,26	Fms-like tyrosine kinase
23991619_3	0	Genomic_variation	22,31	Fms-like tyrosine kinase -internal tandem duplication mutation
23991619_3	0	Gene_or_protein	8,8	RARa
23991619_3	0	Phenotype	5,16	overexpressed PML / RARa ( bcr1 ) and WT1 genes
25303981_7	0	Limited_variation	7,11	DTNBP1 rs3213207 polymorphism
25303981_7	0	Disease	21,22	methamphetamine dependence
25303981_7	0	Gene_or_protein	7,8	DTNBP1
25303981_7	0	Chemical	21,21	methamphetamine
10102685_7	0	Chemical	8,8	STZ
10102685_7	0	Chemical	6,6	streptozotocin
10102685_7	0	Gene_or_protein	45,45	iNOS
10102685_7	0	Phenotype	31,38	blood glucose levels > 11 mmol/l
10102685_7	0	Limited_variation	45,48	iNOS - / -
14999690_13	0	Gene_or_protein	18,18	TNFalpha
14999690_13	0	Chemical	31,31	ethanol
14999690_13	0	Gene_or_protein	21,21	Ras
14999690_13	0	Phenotype	18,22	TNFalpha -induced Ras activation
14999690_13	0	Phenotype	9,11	hepatocellular oxidative stress
14999690_13	0	Phenotype	14,15	cell death
14999690_13	0	Phenotype	21,22	Ras activation
14999690_13	0	Phenotype	26,27	hepatic proliferation
14999690_13	0	Pharmacodynamic_phenotype	31,35	ethanol -induced liver injury
14999690_13	0	Pharmacodynamic_phenotype	34,35	liver injury
14506398_11	0	Gene_or_protein	13,16	ALDH1A1
14506398_11	0	Gene_or_protein	20,23	ALDH1A1
14506398_11	0	Haplotype	13,18	ALDH1A1 * 2
14506398_11	0	Haplotype	20,25	ALDH1A1 * 3
14506398_11	0	Disease	33,33	alcoholics
18186959_9	0	Chemical	8,8	erlotinib
18186959_9	0	Gene_or_protein	20,20	EGFR
18186959_9	0	Pharmacodynamic_phenotype	3,5	cell cycle arrest
18186959_9	0	Limited_variation	17,20	wild-type EGFR
18186959_9	0	Pharmacodynamic_phenotype	23,24	pharmacodynamic separation
25071141_1	0	Gene_or_protein	3,5	PI3K
25071141_1	0	Gene_or_protein	7,7	AKT
25071141_1	0	Chemical	11,11	tamoxifen
25071141_1	0	Chemical	12,12	exemestane
25071141_1	0	Chemical	11,12	tamoxifen exemestane
25060417_1	0	Chemical	2,2	diflunisal
25060417_1	0	Phenotype	4,5	autonomic dysfunction
25060417_1	0	Disease	10,12	familial amyloid polyneuropathy
25060417_1	0	Gene_or_protein	14,14	TTR
25060417_1	0	Limited_variation	14,17	TTR Val30Met
25060417_1	0	Pharmacodynamic_phenotype	0,2	Efficacy of diflunisal
22072145_4	0	Limited_variation	10,13	MMP-2 polymorphisms
22072145_4	0	Gene_or_protein	10,12	MMP-2
22072145_4	0	Disease	26,29	nonsmall cell lung cancer
22072145_4	0	Disease	31,31	NSCLC
22072145_4	0	Pharmacodynamic_phenotype	15,16	treatment efficacy
22072145_4	0	Chemical	40,43	platinum -based chemotherapy
22072145_4	0	Disease	21,22	severe toxicity
22072145_4	0	Chemical	40,40	platinum
23708314_10	0	Chemical	4,4	CRAd
23708314_10	0	Gene_or_protein	24,24	TRAIL
23708314_10	0	Gene_or_protein	26,27	DR5
23708314_10	0	Gene_or_protein	29,31	caspase-3
23708314_10	0	Gene_or_protein	33,35	caspase-8
23708314_10	0	Phenotype	22,24,36,36	expression of TRAIL mRNA
23708314_10	0	Phenotype	22,23,26,27,36,36	expression of DR5 mRNA
23708314_10	0	Phenotype	22,23,29,31,36,36	expression of caspase-3 mRNA
23708314_10	0	Phenotype	22,23,33,36	expression of caspase-8 mRNA
23708314_10	0	Phenotype	12,13	cell proliferation
23708314_10	0	Phenotype	16,17	cell apoptosis
23708314_10	0	Genomic_factor	33,36	caspase-8 mRNA
23708314_10	0	Genomic_factor	29,31,36,36	caspase-3 mRNA
23708314_10	0	Genomic_factor	26,27,36,36	DR5 mRNA
23708314_10	0	Genomic_factor	24,24,36,36	TRAIL mRNA
23708314_10	0	Phenotype	22,24,38,38	expression of TRAIL proteins
23708314_10	0	Phenotype	22,23,26,27,38,38	expression of DR5 proteins
23708314_10	0	Phenotype	22,23,29,31,38,38	expression of caspase-3 proteins
23708314_10	0	Phenotype	22,23,33,35,38,38	expression of caspase-8 proteins
24240480_7	0	Limited_variation	3,5	ABCB1 polymorphisms
24240480_7	0	Gene_or_protein	3,4	ABCB1
24240480_7	0	Limited_variation	3,4,7,12	ABCB1 c.1236C>T
24240480_7	0	Limited_variation	3,4,14,21	ABCB1 c.2677G>T/A
24240480_7	0	Limited_variation	3,4,24,29	ABCB1 c.3435C>T
24240480_7	0	Chemical	36,36	quetiapine
24240480_7	0	Gene_or_protein	46,47	ABCB1
24240480_7	0	Pharmacodynamic_phenotype	33,36	plasma levels of quetiapine
24240480_7	0	Limited_variation	46,48	ABCB1 genotype
24240480_7	0	Pharmacokinetic_phenotype	40,41	pharmacokinetic parameters
20648600_11	0	Chemical	0,0	LAM
20648600_11	0	Limited_variation	5,7	L180M
20648600_11	0	Limited_variation	10,12	M204V
20648600_11	0	Disease	27,27	viremia
20648600_11	0	Pharmacodynamic_phenotype	0,1	LAM resistance
20648600_11	0	Limited_variation	0,13	LAM resistance substitutions ( rt L180M + rt M204V )
17042920_1	0	Limited_variation	3,8	polymorphisms of CYP3A4
17042920_1	0	Gene_or_protein	5,8	CYP3A4
17042920_1	0	Gene_or_protein	10,13	CYP3A5
17042920_1	0	Gene_or_protein	15,16	MDR1
17042920_1	0	Chemical	18,18	cyclosporine
17042920_1	0	Limited_variation	2,4,10,13	genetic polymorphisms of CYP3A5
17042920_1	0	Limited_variation	2,4,15,16	genetic polymorphisms of MDR1
17042920_1	0	Pharmacokinetic_phenotype	18,19	cyclosporine pharmacokinetics
17042920_1	0	Disease	21,22	renal transplantation
12052467_7	0	Limited_variation	18,21	Stromelysin-1 polymorphism
12052467_7	0	Gene_or_protein	18,20	Stromelysin-1
12052467_7	0	Limited_variation	23,27,30,36	-455G/A polymorphisms of the beta-fibrinogen gene
12052467_7	0	Limited_variation	29,36	TaqI polymorphisms of the beta-fibrinogen gene
12052467_7	0	Gene_or_protein	33,35	beta-fibrinogen
12052467_7	0	Gene_or_protein	38,39	apoE4
12052467_7	0	Limited_variation	41,51	Asp(9)Asn mutation in the lipoprotein lipase gene
12052467_7	0	Gene_or_protein	49,50	lipoprotein lipase
12052467_7	0	Gene_or_protein	60,61	hepatic lipase
12052467_7	0	Gene_or_protein	65,65	ACE
12052467_7	0	Gene_or_protein	12,15	Cholesteryl Ester Transfer Protein
12052467_7	0	Limited_variation	12,16	Cholesteryl Ester Transfer Protein polymorphism
12052467_7	0	Chemical	78,78	statins
12052467_7	0	Pharmacodynamic_phenotype	76,78	effects of statins
12052467_7	0	Limited_variation	54,62	-514 CT polymorphism in the hepatic lipase gene
12052467_7	0	Limited_variation	65,68	ACE deletion type gene
22026499_9	0	Gene_or_protein	10,10	SGCE
22026499_9	0	Disease	13,14	myoclonus dystonia
22026499_9	0	Disease	20,21	myoclonus dystonia
22026499_9	0	Pharmacodynamic_phenotype	25,28	alcohol -induced dystonia
22026499_9	0	Limited_variation	7,10	mutation in the SGCE
22026499_9	0	Chemical	25,25	alcohol
22026499_9	0	Pharmacodynamic_phenotype	28,28	dystonia
18467506_7	0	Phenotype	1,3	SCF mRNA levels
18467506_7	0	Gene_or_protein	1,1	SCF
18467506_7	0	Chemical	5,5	APAP
18467506_7	0	Chemical	19,19	APAP
18467506_7	0	Genomic_factor	1,2	SCF mRNA
18467506_7	0	Pharmacodynamic_phenotype	5,6	APAP injury
21338584_3	0	Phenotype	6,8	PDYN mRNA levels
21338584_3	0	Gene_or_protein	6,6	PDYN
21338584_3	0	Limited_variation	31,34	PDYN promoter SNP genotype
21338584_3	0	Gene_or_protein	31,31	PDYN
21338584_3	0	Chemical	36,36	alcohol
21338584_3	0	Phenotype	28,29	addictive behavior
21338584_3	0	Phenotype	25,26	cognitive control
21338584_3	0	Disease	36,38	alcohol -dependent
21338584_3	0	Genomic_factor	6,7	PDYN mRNA
21338584_3	0	Genomic_factor	31,32	PDYN promoter
19695401_14	0	Chemical	3,3	azathioprine
19695401_14	0	Gene_or_protein	13,13	TPMT
19695401_14	0	Haplotype	12,19	heterozygous TPMT * 1 / * 3C
19695401_14	0	Pharmacodynamic_phenotype	6,6	myelosuppression
19695401_14	0	Pharmacodynamic_phenotype	3,6	azathioprine -induced myelosuppression
19695401_14	0	Limited_variation	30,33	wild-type genotype
26946441_13	0	Chemical	12,12	oxycodone
26946441_13	0	Limited_variation	26,28	OPRK1 SNPs
26946441_13	0	Gene_or_protein	26,27	OPRK1
26946441_13	0	Pharmacodynamic_phenotype	9,12	analgesic response of oxycodone
26946441_13	0	Phenotype	21,23	muscle cuff pressure
26946441_13	0	Limited_variation	4,4	polymorphisms
15116260_11	0	Chemical	7,7	pravastatin
15116260_11	0	Gene_or_protein	3,5	HMG CoA reductase
15116260_11	0	Phenotype	9,12	progression of coronary atherosclerosis
15116260_11	0	Disease	11,12	coronary atherosclerosis
15116260_11	0	Chemical	3,6	HMG CoA reductase inhibitor
15116260_11	0	Phenotype	14,15	adverse events
27097364_3	0	Chemical	6,6	raltegravir
27097364_3	0	Limited_variation	9,14	single nucleotide polymorphism of ABCB1
27097364_3	0	Gene_or_protein	13,14	ABCB1
27097364_3	0	Gene_or_protein	16,17	ABCG2
27097364_3	0	Pharmacodynamic_phenotype	6,7	raltegravir concentrations
27097364_3	0	Limited_variation	9,12,16,17	single nucleotide polymorphism of ABCG2
16407894_3	0	Gene_or_protein	8,8	ERK
16407894_3	0	Chemical	23,23	cocaine
16407894_3	0	Gene_or_protein	6,6	MEK
16407894_3	0	Gene_or_protein	4,4	Raf
16407894_3	0	Gene_or_protein	1,1	Ras
16407894_3	0	Pharmacodynamic_phenotype	18,18,21,23	behavioral actions of cocaine
16407894_3	0	Pharmacodynamic_phenotype	20,23	neurobiological actions of cocaine
16407894_3	0	Genomic_factor	1,12	Ras -controlled Raf - MEK - ERK protein kinase signaling cascade
16407894_3	0	Gene_or_protein	10,10	kinase
12855658_2	0	Chemical	5,5	paclitaxel
12855658_2	0	Chemical	10,10	paclitaxel
12855658_2	0	Disease	17,18	ovarian cancer
12855658_2	0	Disease	27,28	cancer testis
12855658_2	0	Gene_or_protein	31,36	Taxol resistance -associated gene 3
12855658_2	0	Gene_or_protein	38,40	TRAG-3
12855658_2	0	Pharmacodynamic_phenotype	5,6	paclitaxel resistance
12855658_2	0	Gene_or_protein	5,7	paclitaxel resistance genes
12855658_2	0	Gene_or_protein	27,29	cancer testis antigen
12855658_2	0	Chemical	31,31	Taxol
12855658_2	0	Pharmacodynamic_phenotype	31,32	Taxol resistance
12855658_2	0	Pharmacodynamic_phenotype	10,12	paclitaxel -resistant
17559417_5	0	Chemical	14,14	cocaine
17559417_5	0	Gene_or_protein	27,33	5-HT(3A )
17559417_5	0	Gene_or_protein	38,44	5-HT(3A )
17559417_5	0	Pharmacodynamic_phenotype	8,14	effects of acute and chronic intermittent cocaine
17559417_5	0	Limited_variation	21,36	deletion of the gene for the 5-HT(3A ) - receptor subunit
17559417_5	0	Limited_variation	38,47	5-HT(3A ) - / -
10628896_5	0	Gene_or_protein	3,3	CYP
10628896_5	0	Gene_or_protein	10,13	CYP3A4
10628896_5	0	Chemical	25,25	haloperidol
10628896_5	0	Pharmacokinetic_phenotype	3,6	CYP -mediated disposition
22528326_10	0	Limited_variation	4,5	rs2108622
22528326_10	0	Gene_or_protein	0,3	CYP4F2
22528326_10	0	Chemical	13,13	warfarin
22528326_10	0	Pharmacodynamic_phenotype	13,15	warfarin stable dose
15322730_3	0	Chemical	0,0	Serotonin
15322730_3	0	Chemical	6,6	serotonin
15322730_3	0	Limited_variation	31,33	5-HTTLPR
15322730_3	0	Gene_or_protein	9,11	5-HTT
15322730_3	0	Gene_or_protein	6,7	serotonin transporter
15322730_3	0	Pharmacokinetic_phenotype	0,1	Serotonin reuptake
15322730_3	0	Limited_variation	17,21	functional insertion/deletion polymorphism
22634097_7	0	Gene_or_protein	6,7	RAD51
22634097_7	0	Limited_variation	6,11	RAD51 G172T polymorphism
22634097_7	0	Disease	14,15	cervical cancer
22634097_7	0	Chemical	20,23	platinum -based chemotherapy
22634097_7	0	Chemical	20,20	platinum
20136445_1	0	Pharmacodynamic_phenotype	5,11	hydrogen peroxide -induced p53 activity
20136445_1	0	Chemical	5,6	hydrogen peroxide
20136445_1	0	Gene_or_protein	9,10	p53
20136445_1	0	Chemical	3,3	polyphenolics
20136445_1	0	Pharmacodynamic_phenotype	9,11	p53 activity
25486952_12	0	Disease	2,2	PMF
25486952_12	0	Gene_or_protein	13,14	JAK2
25486952_12	0	Chemical	13,15	JAK2 inhibitors
17516068_1	0	Chemical	7,7	capecitabine
17516068_1	0	Disease	11,17	HER2 -overexpressing metastatic breast cancer
17516068_1	0	Gene_or_protein	11,12	HER2
17516068_1	0	Chemical	5,7	trastuzumab and capecitabine
17516068_1	0	Chemical	5,5	trastuzumab
17516068_1	0	Phenotype	11,14	HER2 -overexpressing
17516068_1	0	Disease	20,21	Breast Cancer
10949117_3	0	Gene_or_protein	8,8	hMOR
10949117_3	0	Chemical	15,15	alcohol
10949117_3	0	Limited_variation	8,11	hMOR exon 1 variants
10949117_3	0	Disease	15,16	alcohol dependence
10949117_3	0	Genomic_factor	8,10	hMOR exon 1
24601977_7	0	Limited_variation	2,6	CYP2C9 genotype
24601977_7	0	Gene_or_protein	2,5	CYP2C9
24601977_7	0	Limited_variation	8,10	VKORC1 genotype
24601977_7	0	Gene_or_protein	8,9	VKORC1
24601977_7	0	Phenotype	14,16	VKORC1 interaction
24601977_7	0	Gene_or_protein	14,15	VKORC1
24601977_7	0	Pharmacodynamic_phenotype	22,24	warfarin dose variability
24601977_7	0	Chemical	22,22	warfarin
24601977_7	0	Phenotype	0,0	Age
24601977_7	0	Phenotype	12,12	age
21182896_4	0	Gene_or_protein	4,6	tryptophan hydroxylase 2
21182896_4	0	Chemical	15,15	alcohol
21182896_4	0	Disease	13,13	suicide
21182896_4	0	Phenotype	15,18	alcohol -related suicide
25303299_10	0	Gene_or_protein	2,2	MTHFR
25303299_10	0	Gene_or_protein	7,8	ABCB1
25303299_10	0	Limited_variation	7,11	ABCB1 C3435T
25303299_10	0	Chemical	18,18	MTX
25303299_10	0	Limited_variation	2,5	MTHFR C677T
25303299_10	0	Pharmacodynamic_phenotype	18,20	MTX plasma concentrations
15897724_4	0	Disease	6,6	macrocytosis
15897724_4	0	Limited_variation	10,15	ALDH-2/2 genotype
15897724_4	0	Gene_or_protein	10,14	ALDH-2/2
15897724_4	0	Chemical	20,20	acetaldehyde
15897724_4	0	Pharmacokinetic_phenotype	20,21	acetaldehyde accumulation
21642685_12	0	Disease	6,6	melanoma
21642685_12	0	Gene_or_protein	8,8	KIT
21642685_12	0	Chemical	13,14	imatinib mesylate
21642685_12	0	Genomic_variation	8,9	KIT alterations
21642685_12	0	Pharmacodynamic_phenotype	17,19	significant clinical responses
18355347_4	0	Chemical	8,8	CsA
18355347_4	0	Disease	18,18	GO
18355347_4	0	Chemical	22,22	tacrolimus
18355347_4	0	Disease	29,29	GO
18355347_4	0	Disease	25,25	transplant
18355347_4	0	Disease	11,12	renal transplant
19429175_2	0	Chemical	1,1	morphine
19429175_2	0	Chemical	3,3	heroin
19429175_2	0	Gene_or_protein	15,17	MOR-1
19429175_2	0	Gene_or_protein	8,11	mu-opioid receptors
19429175_2	0	Pharmacodynamic_phenotype	3,4	heroin analgesia
19429175_2	0	Pharmacodynamic_phenotype	1,1,4,4	morphine analgesia
25121365_3	0	Gene_or_protein	24,26	P-gp
25121365_3	0	Pharmacodynamic_phenotype	3,6	variability in drug response
25121365_3	0	Gene_or_protein	21,22	drug transporters
25121365_3	0	Limited_variation	11,19	genetic polymorphism in genes encoding different drug metabolizing enzymes
25121365_3	0	Gene_or_protein	17,19	drug metabolizing enzymes
25121365_3	0	Gene_or_protein	30,30	enzymes
25121365_3	0	Limited_variation	11,16,21,27	genetic polymorphism in genes encoding different drug transporters ( P-gp )
25121365_3	0	Limited_variation	11,16,30,30	genetic polymorphism in genes encoding different enzymes
17708140_6	0	Chemical	2,2	warfarin
17708140_6	0	Gene_or_protein	14,16	cytochrome P450
17708140_6	0	Chemical	4,4	antidepressants
17708140_6	0	Chemical	6,6	antiepileptic
17708140_6	0	Chemical	10,10	statins
27382939_13	0	Gene_or_protein	2,4	IL28B
27382939_13	0	Chemical	7,9	PEG-IFN
27382939_13	0	Disease	14,15	CHD infection
27382939_13	0	Pharmacodynamic_phenotype	7,10	PEG-IFN response
20597903_1	0	Limited_variation	2,6	SLC6A12 variants
20597903_1	0	Gene_or_protein	2,5	SLC6A12
20597903_1	0	Chemical	8,8	aspirin
20597903_1	0	Disease	8,11	aspirin -intolerant asthma
20597903_1	0	Disease	11,11	asthma
24611967_4	0	Chemical	8,8	glucose
24611967_4	0	Gene_or_protein	30,31	alanine aminotransferase
24611967_4	0	Chemical	45,45	metformin
24611967_4	0	Chemical	58,58	metformin
24611967_4	0	Chemical	70,72	carnitine -orotate
24611967_4	0	Gene_or_protein	16,17	glycosylated hemoglobin
24611967_4	0	Gene_or_protein	19,21	HbA1c
24611967_4	0	Gene_or_protein	33,33	ALT
21109266_2	0	Disease	0,1	Pompe disease
21109266_2	0	Gene_or_protein	13,13	GAA
21109266_2	0	Chemical	20,20	glucose
21109266_2	0	Gene_or_protein	8,11	acid a-glucosidase
21109266_2	0	Chemical	18,18	glycogen
21109266_2	0	Phenotype	6,11	deficiency of acid a-glucosidase
18980981_6	0	Chemical	10,10	erlotinib
18980981_6	0	Gene_or_protein	13,13	EGFR
18980981_6	0	Disease	16,16	NSCLC
18980981_6	0	Chemical	28,28	platinum
18980981_6	0	Disease	35,35	NSCLC
18980981_6	0	Chemical	44,44	erlotinib
18980981_6	0	Pharmacodynamic_phenotype	42,44	response to erlotinib
18980981_6	0	Limited_variation	13,15	EGFR -mutant
18980981_6	0	Pharmacodynamic_phenotype	10,12	erlotinib -sensitive
18980981_6	0	Chemical	35,36	NSCLC chemotherapy
16721582_1	0	Phenotype	0,2	Recurrence of proteinuria
16721582_1	0	Disease	2,2	proteinuria
16721582_1	0	Disease	9,15	NPHS2 -associated focal segmental glomerulosclerosis
16721582_1	0	Gene_or_protein	9,10	NPHS2
16721582_1	0	Chemical	19,20	cyclosporin A
16721582_1	0	Chemical	22,22	sirolimus
16721582_1	0	Disease	7,7	transplant
20034695_6	0	Chemical	0,0	Cholestyramine
20034695_6	0	Disease	7,7	sitosterolemia
20034695_6	0	Gene_or_protein	9,10	ABCG5
20034695_6	0	Genomic_variation	9,13	ABCG5 /8 deficiency
23186157_3	0	Gene_or_protein	1,1	Abl
23186157_3	0	Disease	16,16	leukemias
23186157_3	0	Chemical	0,3	Selective Abl kinase inhibitors
23186157_3	0	Phenotype	12,16	Ph (+) leukemias
23186157_3	0	Limited_variation	12,15	Ph (+)
10750555_2	0	Gene_or_protein	0,3	Transforming growth factor beta
10750555_2	0	Gene_or_protein	5,7	TGF-beta
10750555_2	0	Chemical	24,24	estrogen
10750555_2	0	Chemical	26,27	vitamin D
10750555_2	0	Phenotype	14,15	bone metabolism
12777962_9	0	Chemical	7,7	nicotine
12777962_9	0	Chemical	10,10	alcohol
12777962_9	0	Gene_or_protein	15,18	CYP2E1
12777962_9	0	Haplotype	15,21	CYP2E1 * 1D
12777962_9	0	Disease	5,7	dependent on nicotine
12777962_9	0	Disease	5,6,10,10	dependent on alcohol
12777962_9	0	Chemical	40,40	nicotine
12777962_9	0	Disease	38,40	dependent on nicotine
18385200_4	0	Phenotype	0,2,5,6	C-MYC protein levels
18385200_4	0	Gene_or_protein	0,2	C-MYC
18385200_4	0	Gene_or_protein	4,4	DHFR
18385200_4	0	Chemical	21,21	MTX
18385200_4	0	Phenotype	4,6	DHFR protein levels
18385200_4	0	Chemical	39,42	four-drug regimen
18385200_4	0	Chemical	21,24	MTX -based protocol
10655277_2	0	Disease	5,8	chronic hepatitis B virus
10655277_2	0	Gene_or_protein	13,17	antibody to hepatitis B e
10655277_2	0	Gene_or_protein	30,31	alanine transaminase
10655277_2	0	Chemical	42,44	IFN-alpha
10655277_2	0	Chemical	57,57	ribavirin
10655277_2	0	Chemical	59,61	IFN-alpha
10655277_2	0	Gene_or_protein	20,22	anti-HBe
10655277_2	0	Limited_variation	25,27	HBV DNA positivity
10655277_2	0	Gene_or_protein	33,33	ALT
10655277_2	0	Phenotype	30,35	alanine transaminase ( ALT ) elevation
10655277_2	0	Chemical	39,40	interferon alfa
10655277_2	0	Chemical	54,61	combination therapy with ribavirin and IFN-alpha
10655277_2	0	Disease	10,10	HBV
2755460_1	0	Phenotype	0,2	Proenkephalin gene expression
2755460_1	0	Gene_or_protein	0,0	Proenkephalin
2755460_1	0	Chemical	10,10	estradiol
20179610_15	0	Limited_variation	0,2	A2143G
20179610_15	0	Pharmacodynamic_phenotype	12,13	clarithromycin resistance
20179610_15	0	Chemical	12,12	clarithromycin
20179610_15	0	Limited_variation	6,9	23S rRNA mutation
20179610_15	0	Genomic_factor	6,8	23S rRNA
20179610_15	0	Pharmacodynamic_phenotype	17,21	H. pylori eradication efficacy
22088980_6	0	Gene_or_protein	7,10	CYP2C19
22088980_6	0	Chemical	28,28	clopidogrel
22088980_6	0	Haplotype	7,12	CYP2C19 * 2
9592111_5	0	Chemical	6,6	alcohol
9592111_5	0	Phenotype	26,30	NGFI-B mRNA expression
9592111_5	0	Gene_or_protein	26,28	NGFI-B
9592111_5	0	Genomic_factor	26,29	NGFI-B mRNA
9592111_5	0	Chemical	39,39	ACTH
9592111_5	0	Pharmacokinetic_phenotype	39,40	ACTH secretion
25877443_1	0	Gene_or_protein	2,4	HLA-B
25877443_1	0	Pharmacodynamic_phenotype	9,13	abacavir -induced hypersensitivity reaction
25877443_1	0	Chemical	9,9	abacavir
25877443_1	0	Haplotype	2,6	HLA-B * 5701
25877443_1	0	Pharmacodynamic_phenotype	12,13	hypersensitivity reaction
12107202_1	0	Chemical	0,0	Hydrochlorothiazide
12107202_1	0	Gene_or_protein	19,22	calcium-sensing receptor
12107202_1	0	Limited_variation	11,23	gain-of-function mutations of the calcium-sensing receptor gene
12107202_1	0	Pharmacokinetic_phenotype	3,5	urinary calcium excretion
16338277_3	0	Chemical	6,12	5-HT ( 3 ) antagonists
16338277_3	0	Gene_or_protein	37,45	adenosine triphosphate -binding cassette subfamily B member 1
16338277_3	0	Gene_or_protein	47,48	ABCB1
16338277_3	0	Pharmacodynamic_phenotype	4,12	resistance to 5-HT ( 3 ) antagonists
16338277_3	0	Limited_variation	17,27,37,49	single-nucleotide polymorphism ( 3435C>T ) in adenosine triphosphate -binding cassette subfamily B member 1 ( ABCB1 )
16338277_3	0	Gene_or_protein	34,36	drug efflux transporter
14635204_12	0	Limited_variation	7,10	HFE coding region mutations
14635204_12	0	Gene_or_protein	7,7	HFE
14635204_12	0	Chemical	22,22	iron
14635204_12	0	Disease	27,27	SCD
14635204_12	0	Phenotype	22,23	iron overload
14635204_12	0	Chemical	29,31	chronic transfusion therapy
14635204_12	0	Genomic_factor	7,9	HFE coding region
15196685_4	0	Chemical	16,16	capsaicin
15196685_4	0	Phenotype	19,22	c-fos expression
15196685_4	0	Gene_or_protein	19,21	c-fos
20973798_3	0	Chemical	9,9	gefitinib
20973798_3	0	Chemical	11,11	erlotinib
20973798_3	0	Limited_variation	22,23	EGFR mutations
20973798_3	0	Gene_or_protein	22,22	EGFR
20973798_3	0	Disease	19,19	NSCLC
20973798_3	0	Phenotype	31,31	PFS
20973798_3	0	Phenotype	26,29	progression-free survival
20973798_3	0	Pharmacodynamic_phenotype	13,13	responses
22835516_5	0	Disease	1,3	malignant pleural effusions
22835516_5	0	Limited_variation	7,8	EGFR mutation
22835516_5	0	Gene_or_protein	7,7	EGFR
22835516_5	0	Disease	11,12	pleural effusions
22835516_5	0	Chemical	18,18	gefitinib
22835516_5	0	Chemical	21,21	erlotinib
22835516_5	0	Limited_variation	26,27	EGFR mutation
22835516_5	0	Gene_or_protein	26,26	EGFR
22835516_5	0	Chemical	16,16	chemotherapy
24277619_9	0	Limited_variation	1,2	rs671
24277619_9	0	Pharmacodynamic_phenotype	22,23	flushing response
24277619_9	0	Disease	39,39	AD
24277619_9	0	Disease	49,49	AD
24277619_9	0	Limited_variation	8,8	SNP
24277619_9	0	Chemical	26,26	alcohol
25042383_3	0	Gene_or_protein	12,14	TOP2A
25042383_3	0	Chemical	23,23	anthracycline
25042383_3	0	Disease	30,31	breast cancer
25042383_3	0	Pharmacodynamic_phenotype	18,23	efficacy of neo-adjuvant anthracycline
26437921_9	0	Chemical	13,13	methadone
26437921_9	0	Limited_variation	17,18	rs6265
26437921_9	0	Limited_variation	52,53	rs1799978
26437921_9	0	Phenotype	8,13	continued opioid use while on methadone
26437921_9	0	Limited_variation	1,2	genetic variants
20621700_3	0	Limited_variation	5,9	IL-28B polymorphisms
20621700_3	0	Gene_or_protein	5,8	IL-28B
20621700_3	0	Chemical	15,15	peginterferon
20621700_3	0	Chemical	17,17	ribavirin
20621700_3	0	Pharmacodynamic_phenotype	11,15	response to treatment with peginterferon
20621700_3	0	Pharmacodynamic_phenotype	11,14,17,17	response to treatment with ribavirin
25539912_1	0	Chemical	3,3	lithium
25539912_1	0	Limited_variation	5,7	TP53 mutation
25539912_1	0	Gene_or_protein	5,6	TP53
25539912_1	0	Disease	12,12	medulloblastoma
25539912_1	0	Phenotype	5,10	TP53 mutation associated radiation resistance
25539912_1	0	Pharmacodynamic_phenotype	0,3	WNT activation by lithium
25539912_1	0	Pharmacodynamic_phenotype	0,1	WNT activation
18485328_10	0	Limited_variation	10,14	p.Gly143Glu
18485328_10	0	Chemical	34,34	methylphenidate
18485328_10	0	Limited_variation	16,20	p.Asp260fs
18485328_10	0	Pharmacokinetic_phenotype	31,34	hydrolytic activity toward methylphenidate
21844885_11	0	Limited_variation	8,9	VEGF genotypes
21844885_11	0	Gene_or_protein	8,8	VEGF
21844885_11	0	Disease	13,15	metastatic colorectal cancer
21844885_11	0	Chemical	17,17	irinotecan
21844885_11	0	Chemical	22,22	bevacizumab
21844885_11	0	Chemical	17,22	irinotecan -based chemotherapy plus bevacizumab
21844885_11	0	Phenotype	27,27	RR
21844885_11	0	Phenotype	29,29	OS
21844885_11	0	Chemical	17,20	irinotecan -based chemotherapy
12165570_5	0	Gene_or_protein	12,12	CREB
12165570_5	0	Chemical	20,20	morphine
12165570_5	0	Chemical	29,29	sucrose
12165570_5	0	Phenotype	10,12	activity of CREB
12165570_5	0	Pharmacodynamic_phenotype	20,21	morphine reward
12165570_5	0	Phenotype	27,29	preference for sucrose
18602074_4	0	Chemical	0,0	Bisacurone
18602074_4	0	Phenotype	5,14	TNF-alpha -mediated expression of VCAM-1
18602074_4	0	Phenotype	10,14	expression of VCAM-1
18602074_4	0	Gene_or_protein	5,7	TNF-alpha
18602074_4	0	Gene_or_protein	12,14	VCAM-1
15902904_2	0	Chemical	7,7	ethanol
15902904_2	0	Chemical	18,18	acetylcholine
15902904_2	0	Chemical	30,30	acetylcholine
15902904_2	0	Gene_or_protein	37,38	CHRNA4
15902904_2	0	Chemical	47,47	ethanol
15902904_2	0	Gene_or_protein	29,34	nicotinic acetylcholine receptor alpha4 subunit
15902904_2	0	Pharmacodynamic_phenotype	41,47	enhancement of nicotinic receptor function by ethanol
15902904_2	0	Gene_or_protein	12,19	alpha4beta2 neuronal nicotinic acetylcholine receptor
15902904_2	0	Limited_variation	26,39	polymorphism of the nicotinic acetylcholine receptor alpha4 subunit gene ( CHRNA4 )
15902904_2	0	Phenotype	10,19	activity of alpha4beta2 neuronal nicotinic acetylcholine receptor
15902904_2	0	Gene_or_protein	43,44	nicotinic receptor
15902904_2	0	Pharmacodynamic_phenotype	43,45	nicotinic receptor function
10430972_10	0	Chemical	7,7	folate
10430972_10	0	Disease	11,11	hyperhomocysteinemia
10430972_10	0	Disease	15,15	ESRD
10430972_10	0	Limited_variation	24,34	677C-->T mutation in the MTHFR gene
10430972_10	0	Gene_or_protein	33,33	MTHFR
21747412_7	0	Limited_variation	7,8	MTHFR genotype
21747412_7	0	Gene_or_protein	7,7	MTHFR
21747412_7	0	Chemical	15,15	MTX
21747412_7	0	Disease	21,21	ALL
26385865_6	0	Gene_or_protein	12,13	POG1
26385865_6	0	Genomic_variation	2,2,12,13	knockdown POG1
26385865_6	0	Pharmacodynamic_phenotype	20,22	cytotoxicity of sunitinib
26385865_6	0	Chemical	22,22	sunitinib
18675355_8	0	Gene_or_protein	3,5	CD40L
18675355_8	0	Gene_or_protein	15,17	LFA-1
18675355_8	0	Gene_or_protein	20,21	CD4
18675355_8	0	Gene_or_protein	33,35	LFA-1
18675355_8	0	Chemical	37,37	everolimus
18675355_8	0	Chemical	39,39	DSG
18675355_8	0	Gene_or_protein	46,47	CD4
18675355_8	0	Chemical	30,39	combining anti- LFA-1 with everolimus or DSG
18675355_8	0	Chemical	31,35	anti- LFA-1
18675355_8	0	Chemical	1,5	anti- CD40L
18675355_8	0	Chemical	13,17	anti- LFA-1
18675355_8	0	Gene_or_protein	23,24	CD8
18675355_8	0	Phenotype	20,21,25,27	CD4 T cell proliferation
18675355_8	0	Phenotype	23,27	CD8 T cell proliferation
18675355_8	0	Phenotype	46,50	CD4 T cell proliferation
18675355_8	0	Phenotype	9,11	T cell proliferation
11054768_9	0	Chemical	4,4	heroin
11054768_9	0	Limited_variation	23,28	polymorphism in the DRD4 gene
11054768_9	0	Gene_or_protein	26,27	DRD4
11054768_9	0	Disease	4,6	heroin -abuse
11054768_9	0	Haplotype	23,27,31,31	polymorphism in the DRD4 haplotypes
21676164_1	0	Gene_or_protein	0,2	HLA-B
21676164_1	0	Pharmacodynamic_phenotype	10,13	Stevens-Johnson syndrome
21676164_1	0	Chemical	7,7	carbamazepine
21676164_1	0	Pharmacodynamic_phenotype	15,17	toxic epidermal necrolysis
21676164_1	0	Disease	22,23	neuropathic pain
21676164_1	0	Haplotype	0,4	HLA-B * 1502
21676164_1	0	Pharmacodynamic_phenotype	7,13	carbamazepine -induced Stevens-Johnson syndrome
21676164_1	0	Pharmacodynamic_phenotype	7,9,15,17	carbamazepine -induced toxic epidermal necrolysis
23306941_1	0	Chemical	22,22	peginterferon
23306941_1	0	Chemical	24,24	ribavirin
23306941_1	0	Limited_variation	30,33	IL28B allele
23306941_1	0	Disease	14,15	hepatitis C
23306941_1	0	Limited_variation	14,18	hepatitis C virus genotype 1
23306941_1	0	Phenotype	2,4	sustained virologic response
27430334_6	0	Chemical	4,5	AZD4619
27430334_6	0	Phenotype	7,10	ALT1 protein expression
27430334_6	0	Gene_or_protein	7,8	ALT1
16731130_12	0	Phenotype	1,5	expression of Bcl-2
16731130_12	0	Gene_or_protein	3,5	Bcl-2
16731130_12	0	Chemical	12,13	CoCl2
16731130_12	0	Phenotype	47,48	Bax expression
16731130_12	0	Gene_or_protein	47,47	Bax
19328219_11	0	Limited_variation	3,7	-1438A/G
19328219_11	0	Disease	9,10	alcohol dependence
19328219_11	0	Limited_variation	18,23	5-HTTLPR S/S
19328219_11	0	Limited_variation	28,33	5-HTTLPR L/S
19328219_11	0	Limited_variation	38,43	5-HTTLPR L/L
19328219_11	0	Genomic_factor	18,20	5-HTTLPR
19328219_11	0	Genomic_factor	28,30	5-HTTLPR
19328219_11	0	Genomic_factor	38,40	5-HTTLPR
16359811_6	0	Gene_or_protein	0,0	CREB
16359811_6	0	Chemical	8,8	cocaine
16359811_6	0	Chemical	12,12	cocaine
16359811_6	0	Phenotype	21,22	CREB levels
16359811_6	0	Gene_or_protein	21,21	CREB
16359811_6	0	Chemical	28,28	cocaine
16359811_6	0	Genomic_factor	0,1	CREB antisense
16359811_6	0	Pharmacodynamic_phenotype	25,28	incentive properties of cocaine
16359811_6	0	Pharmacodynamic_phenotype	5,8	threshold dose of cocaine
16359811_6	0	Phenotype	11,15	reinstating cocaine self-administration
12804863_11	0	Gene_or_protein	7,11	HER-2 / neu
12804863_11	0	Phenotype	25,30	CD8 + mediated immune response
12804863_11	0	Pharmacokinetic_phenotype	20,22	CTL epitope delivery
12804863_11	0	Chemical	14,15	CpG ODN
12804863_11	0	Gene_or_protein	25,26	CD8
2887298_6	0	Chemical	3,3	cyclophosphamide
2887298_6	0	Gene_or_protein	16,18	H-2
2887298_6	0	Gene_or_protein	20,22	YAC-1
2887298_6	0	Phenotype	14,22	cell surface H-2 on YAC-1
18364363_1	0	Gene_or_protein	5,6	serotonin transporter
18364363_1	0	Chemical	13,13	alcohol
18364363_1	0	Phenotype	11,14	relapse in alcohol dependence
18364363_1	0	Limited_variation	1,9	short allele of the serotonin transporter promote r polymorphism
18364363_1	0	Disease	13,14	alcohol dependence
18364363_1	0	Genomic_factor	5,7	serotonin transporter promote
11455387_7	0	Chemical	9,9	PAHs
11455387_7	0	Phenotype	12,14	expression of Bax
11455387_7	0	Gene_or_protein	14,14	Bax
11455387_7	0	Phenotype	20,20	apoptosis
25286744_4	0	Phenotype	4,8	CYP3A4 activity
25286744_4	0	Gene_or_protein	4,7	CYP3A4
25286744_4	0	Chemical	10,10	midazolam
21111586_1	0	Chemical	1,2	methylene chloride
21111586_1	0	Phenotype	11,15	activation of caspase-3
21111586_1	0	Gene_or_protein	13,15	caspase-3
21111586_1	0	Disease	19,20	breast cancer
21111586_1	0	Phenotype	8,8	apoptosis
21111586_1	0	Chemical	5,6	Saururus chinensis
21111586_1	0	Disease	17,17,20,20	prostate cancer
25978827_4	0	Chemical	11,11	alcohol
25978827_4	0	Limited_variation	26,27	rs886003
25978827_4	0	Limited_variation	41,42	rs17862325
25978827_4	0	Disease	11,12	alcohol dependence
25978827_4	0	Limited_variation	3,6	single-nucleotide polymorphisms
24491881_3	0	Gene_or_protein	9,10	methylenetetrahydrofolate reductase
24491881_3	0	Gene_or_protein	19,19	MTHFR
24491881_3	0	Chemical	24,24	homocysteine
24491881_3	0	Pharmacodynamic_phenotype	24,28	homocysteine ( Hcy ) levels
24491881_3	0	Gene_or_protein	12,12	MTHFR
24491881_3	0	Limited_variation	1,14	C-to-T mutation in the methylenetetrahydrofolate reductase ( MTHFR ) gene
24491881_3	0	Chemical	26,26	Hcy
24491881_3	0	Phenotype	18,19	thermolabile MTHFR
25039301_4	0	Gene_or_protein	18,19	OPRM1
25039301_4	0	Limited_variation	18,22	OPRM1 A118G
25039301_4	0	Pharmacodynamic_phenotype	26,28	responses to alcohol
25039301_4	0	Chemical	10,10	ethanol
25039301_4	0	Chemical	31,31	alcohol
25039301_4	0	Chemical	28,28	alcohol
18926911_12	0	Limited_variation	11,26	substitution ( S ) in one HLA-G allele in the HLA-G 0101
18926911_12	0	Gene_or_protein	17,19	HLA-G
18926911_12	0	Gene_or_protein	23,25	HLA-G
18926911_12	0	Haplotype	55,58	HLA-G010403
18926911_12	0	Haplotype	60,64	HLA- G0105N
18926911_12	0	Haplotype	23,26	HLA-G 0101
18926911_12	0	Haplotype	50,53	HLA- G010401
18926911_12	0	Limited_variation	38,48	substitution ( N/S ) on HLA- G0103
18926911_12	0	Disease	73,73	rejection
18926911_12	0	Limited_variation	38,44,50,53	substitution ( N/S ) on HLA- G010401
18926911_12	0	Limited_variation	38,44,55,58	substitution ( N/S ) on HLA-G010403
18926911_12	0	Limited_variation	38,44,60,64	substitution ( N/S ) on HLA- G0105N
18926911_12	0	Haplotype	45,48	HLA- G0103
26039043_12	0	Gene_or_protein	10,13	CYP3A4
26039043_12	0	Chemical	20,20	tacrolimus
26039043_12	0	Chemical	24,24	tacrolimus
26039043_12	0	Chemical	31,31	tacrolimus
26039043_12	0	Haplotype	10,16	CYP3A4 * 1B
26039043_12	0	Pharmacodynamic_phenotype	20,22	tacrolimus dose requirements
26039043_12	0	Pharmacodynamic_phenotype	24,34	tacrolimus trough concentration/weight-adjusted tacrolimus daily dose ratio
26039043_12	0	Disease	41,41	transplantation
23149441_14	0	Limited_variation	5,9	CYP3A5 polymorphism
23149441_14	0	Gene_or_protein	5,8	CYP3A5
23149441_14	0	Chemical	13,13	tacrolimus
23149441_14	0	Limited_variation	21,25	CYP3A5 polymorphism
23149441_14	0	Gene_or_protein	21,24	CYP3A5
23149441_14	0	Pharmacodynamic_phenotype	13,14	tacrolimus variability
26415139_12	0	Limited_variation	3,12	CYP2B6 g.15582C>T
26415139_12	0	Gene_or_protein	3,6	CYP2B6
26415139_12	0	Chemical	15,15	EFV
26415139_12	0	Disease	21,23	HIV / AIDS
26415139_12	0	Pharmacodynamic_phenotype	14,16	plasma EFV concentration
21507151_2	0	Gene_or_protein	9,10	OPRM1
21507151_2	0	Chemical	18,18	alcohol
21507151_2	0	Chemical	20,20	cocaine
21507151_2	0	Chemical	22,22	nicotine
21507151_2	0	Gene_or_protein	1,4	mu-opioid receptor
21507151_2	0	Chemical	16,16	opiate
21507151_2	0	Disease	18,18,23,23	alcohol addiction
21507151_2	0	Disease	16,16,23,23	opiate addiction
21507151_2	0	Disease	20,20,23,23	cocaine addiction
21507151_2	0	Disease	22,23	nicotine addiction
18370849_5	0	Pharmacodynamic_phenotype	4,5	carbamazepine hypersensitivity
18370849_5	0	Chemical	4,4	carbamazepine
18370849_5	0	Gene_or_protein	7,9	HLA-B
18370849_5	0	Haplotype	7,11	HLA-B * 1502
19330906_1	0	Chemical	0,0	Nebivolol
19330906_1	0	Gene_or_protein	7,9	estrogen receptor beta
19330906_1	0	Phenotype	2,4	endothelial cell stiffness
26471290_13	0	Gene_or_protein	2,2	KRAS
26471290_13	0	Disease	17,17	NSCLC
26471290_13	0	Chemical	25,28	platinum -based chemotherapy
26471290_13	0	Limited_variation	2,3	KRAS MT
26471290_13	0	Phenotype	9,11	progression-free
26471290_13	0	Phenotype	13,14	overall survival
26471290_13	0	Chemical	25,25	platinum
8524236_7	0	Chemical	6,6	chloramphenicol
8524236_7	0	Gene_or_protein	15,18	ER/ Sp1
8524236_7	0	Chemical	26,26	chloramphenicol
8524236_7	0	Chemical	35,35	TCDD
8524236_7	0	Gene_or_protein	44,51	ER/ Sp1 - " XRE "
8524236_7	0	Gene_or_protein	6,8	chloramphenicol acetyltransferase reporter
8524236_7	0	Limited_variation	12,20	wild-type ER/ Sp1 promoter sequence
8524236_7	0	Pharmacodynamic_phenotype	22,28	E2 -induced chloramphenicol acetyltransferase activity
8524236_7	0	Gene_or_protein	26,27	chloramphenicol acetyltransferase
8524236_7	0	Limited_variation	43,51	mutant ER/ Sp1 - " XRE "
8524236_7	0	Pharmacodynamic_phenotype	22,27,30,31	E2 -induced chloramphenicol acetyltransferase mRNA levels
8524236_7	0	Chemical	22,23	E2
8524236_7	0	Genomic_factor	26,27,30,30	chloramphenicol acetyltransferase mRNA
8524236_7	0	Pharmacodynamic_phenotype	26,28	chloramphenicol acetyltransferase activity
8524236_7	0	Pharmacodynamic_phenotype	26,27,30,31	chloramphenicol acetyltransferase mRNA levels
25712669_5	0	Phenotype	6,8	STAT3 phosphorylation
25712669_5	0	Gene_or_protein	6,7	STAT3
25712669_5	0	Chemical	15,15	matrine
25712669_5	0	Phenotype	0,4	Apoptosis-related molecular changes
25712669_5	0	Phenotype	10,11	transcriptional activities
25658497_11	0	Gene_or_protein	22,22	BDNF
25658497_11	0	Limited_variation	22,25	BDNF Val66Met
25658497_11	0	Chemical	10,10	antidepressants
25658497_11	0	Chemical	28,28	SSRI
25658497_11	0	Limited_variation	33,35	Val / Val
25658497_11	0	Chemical	38,40	SNRI/ TCA
25658497_11	0	Limited_variation	42,42	Met
25658497_11	0	Disease	15,17	major depressive disorder
18006783_9	0	Gene_or_protein	0,2	Cyclin D1
18006783_9	0	Chemical	17,17	celecoxib
18006783_9	0	Gene_or_protein	9,9	Ras
24809685_11	0	Gene_or_protein	10,12	MAO-A
24809685_11	0	Phenotype	24,24,29,29	serotonin availability
24809685_11	0	Phenotype	28,29	norepinephrine availability
24809685_11	0	Phenotype	7,14	CpG -specific MAO-A gene hypomethylation
24809685_11	0	Pharmacodynamic_phenotype	35,37	antidepressant treatment response
16475678_9	0	Chemical	5,5	paclitaxel
16475678_9	0	Phenotype	21,22	CHFR methylation
16475678_9	0	Gene_or_protein	21,21	CHFR
16475678_9	0	Chemical	31,31	paclitaxel
16475678_9	0	Phenotype	46,47	CHFR methylation
16475678_9	0	Gene_or_protein	46,46	CHFR
16475678_9	0	Chemical	52,52	paclitaxel
16475678_9	0	Pharmacodynamic_phenotype	25,31	partial response ( PR ) to paclitaxel
16475678_9	0	Pharmacodynamic_phenotype	50,52	PR to paclitaxel
16475678_9	0	Pharmacodynamic_phenotype	25,26	partial response
16475678_9	0	Pharmacodynamic_phenotype	28,28	PR
16475678_9	0	Pharmacodynamic_phenotype	50,50	PR
24265703_7	0	Limited_variation	3,5	RB1 status
24265703_7	0	Gene_or_protein	3,4	RB1
24265703_7	0	Pharmacodynamic_phenotype	9,9,18,18	sensitivity cisplatin
24265703_7	0	Chemical	18,18	cisplatin
24265703_7	0	Chemical	23,25	5-fluorouracil
24265703_7	0	Chemical	27,27	idarubicin
24265703_7	0	Chemical	29,29	epirubicin
24265703_7	0	Chemical	31,33	PRIMA-1
24265703_7	0	Chemical	38,38	fludarabine
24265703_7	0	Chemical	40,42	PD-0332991
24265703_7	0	Disease	51,51	TNBC
24265703_7	0	Chemical	20,20	CDDP
24265703_7	0	Disease	11,11	TNBC
24265703_7	0	Pharmacodynamic_phenotype	9,9,13,13,23,25	sensitivity to 5-fluorouracil
24265703_7	0	Pharmacodynamic_phenotype	9,9,13,13,27,27	sensitivity to idarubicin
24265703_7	0	Pharmacodynamic_phenotype	9,9,13,13,29,29	sensitivity to epirubicin
24265703_7	0	Pharmacodynamic_phenotype	9,9,13,13,31,33	sensitivity to PRIMA-1
24265703_7	0	Pharmacodynamic_phenotype	9,9,13,13,38,38	sensitivity to fludarabine
24265703_7	0	Pharmacodynamic_phenotype	9,9,13,13,40,42	sensitivity to PD-0332991
24265703_7	0	Chemical	14,16	multiple other drugs
24265703_7	0	Pharmacodynamic_phenotype	9,9,13,16	sensitivity to multiple other drugs
27467210_4	0	Chemical	2,3	AZD6244
27467210_4	0	Chemical	0,0	Selumetinib
27467210_4	0	Chemical	5,7	ARRY-142886
27467210_4	0	Gene_or_protein	16,19	MEK1/2
27467210_4	0	Gene_or_protein	32,32	KRAS
27467210_4	0	Limited_variation	32,33	KRAS mutant
27467210_4	0	Chemical	0,0,25,28	Selumetinib in combination with docetaxel
27467210_4	0	Disease	32,36	KRAS mutant pretreated advanced NSCLC
24585043_5	0	Limited_variation	13,14	rs6465084
24585043_5	0	Chemical	17,17	alcohol
24585043_5	0	Limited_variation	29,34	A allele of SNP rs6465084
24585043_5	0	Chemical	36,36	alcohol
24585043_5	0	Disease	17,19	alcohol -dependent
24585043_5	0	Disease	36,38	alcohol -dependent
24585043_5	0	Limited_variation	33,34	rs6465084
15345592_1	0	Disease	13,15	chronic myelogenous leukemia
15345592_1	0	Chemical	23,24	imatinib mesylate
15345592_1	0	Gene_or_protein	2,5	BCR-ABL kinase
15345592_1	0	Limited_variation	2,6	BCR-ABL kinase mutations
15345592_1	0	Phenotype	20,21	ytogenetic remission
24830941_7	0	Gene_or_protein	20,24	Jun N-terminal kinase
24830941_7	0	Chemical	28,28	tBHQ
24830941_7	0	Gene_or_protein	33,36	CYP2C9
24830941_7	0	Chemical	2,3	kinase inhibitors
24830941_7	0	Gene_or_protein	5,9	mitogen-activated protein kinase
24830941_7	0	Gene_or_protein	14,18	extracellular signal-regulated kinase
24830941_7	0	Pharmacodynamic_phenotype	28,36	tBHQ -induced expression of CYP2C9
24830941_7	0	Pharmacodynamic_phenotype	31,36	expression of CYP2C9
19682085_14	0	Gene_or_protein	2,2	ITPA
19682085_14	0	Chemical	15,15	AZA
19682085_14	0	Phenotype	21,24	flu -like symptoms
19682085_14	0	Disease	21,21	flu
19682085_14	0	Limited_variation	2,7	ITPA 94C>A homozygous
19682085_14	0	Pharmacodynamic_phenotype	15,19	AZA -related gastrointestinal toxicity
19682085_14	0	Pharmacodynamic_phenotype	18,19	gastrointestinal toxicity
21829065_1	0	Limited_variation	6,9	KRAS gene mutation status
21829065_1	0	Gene_or_protein	6,6	KRAS
21829065_1	0	Chemical	16,16	irinotecan
21829065_1	0	Disease	27,29	metastatic colorectal cancer
21829065_1	0	Chemical	14,14	cetuximab
21829065_1	0	Chemical	14,16	cetuximab plus irinotecan
21829065_1	0	Pharmacodynamic_phenotype	12,16	benefit of cetuximab plus irinotecan
21829065_1	0	Chemical	21,21	chemotherapy
15000558_1	0	Limited_variation	1,9	reverse transcriptase ( RT ) mutation V118I
15000558_1	0	Chemical	16,16	abacavir
15000558_1	0	Disease	25,28	HIV-1 infection
15000558_1	0	Gene_or_protein	1,2	reverse transcriptase
15000558_1	0	Gene_or_protein	4,4	RT
15000558_1	0	Chemical	16,20	abacavir -based antiretroviral treatment
15000558_1	0	Chemical	22,22	ART
15000558_1	0	Pharmacodynamic_phenotype	13,14	virologic failure
15983922_3	0	Chemical	4,4	lamivudine
15983922_3	0	Pharmacodynamic_phenotype	24,25	lamivudine resistance
15983922_3	0	Chemical	24,24	lamivudine
15983922_3	0	Pharmacodynamic_phenotype	8,9	viral suppression
15983922_3	0	Limited_variation	15,18	M184V mutations
26450467_1	0	Gene_or_protein	3,6	CYP3A5
26450467_1	0	Gene_or_protein	8,10	MDR-1
26450467_1	0	Chemical	13,13	Tacrolimus
26450467_1	0	Pharmacokinetic_phenotype	13,14	Tacrolimus Pharmacokinetics
26450467_1	0	Limited_variation	3,6,11,11	CYP3A5 Polymorphisms
26450467_1	0	Limited_variation	8,11	MDR-1 Polymorphisms
22900031_3	0	Limited_variation	5,18	genetic deletion of Pak1 ( Pak1 ( - / - ) )
22900031_3	0	Gene_or_protein	8,9	Pak1
22900031_3	0	Chemical	41,41	acetylcholine
22900031_3	0	Chemical	43,43	ACh
22900031_3	0	Gene_or_protein	26,26	Pak
22900031_3	0	Pharmacodynamic_phenotype	29,32	response of the airways
20878066_6	0	Phenotype	9,14	knock-down p53 expression
20878066_6	0	Gene_or_protein	12,13	p53
20878066_6	0	Chemical	21,21	amifostine
20878066_6	0	Chemical	24,24	paclitaxel
20878066_6	0	Gene_or_protein	30,31	p53
20878066_6	0	Pharmacodynamic_phenotype	24,28	paclitaxel 's anticancer effect
20878066_6	0	Genomic_variation	30,32	p53 status
20878066_6	0	Genomic_variation	9,13	knock-down p53
8947308_9	0	Limited_variation	10,16	deletion of the GST M1 gene
8947308_9	0	Gene_or_protein	13,15	GST M1
8947308_9	0	Disease	24,25	liver damage
8947308_9	0	Chemical	33,33	ethanol
8947308_9	0	Pharmacodynamic_phenotype	30,33	toxic effects of ethanol
25939871_12	0	Gene_or_protein	4,7	SLCO1B1
25939871_12	0	Chemical	23,25	6-MP
25939871_12	0	Disease	31,31	ALL
25939871_12	0	Limited_variation	4,13	SLCO1B1 c.521 T > C
25939871_12	0	Pharmacodynamic_phenotype	20,25	dose reduction of 6-MP
25939871_12	0	Chemical	28,28	chemotherapy
21172311_2	0	Gene_or_protein	1,5	human serotonin receptor 1B
21172311_2	0	Chemical	17,17	serotonin
21172311_2	0	Gene_or_protein	7,9	HRT1B
21172311_2	0	Phenotype	17,18	serotonin release
26013962_7	0	Phenotype	3,7	5-HTT mRNA levels
26013962_7	0	Gene_or_protein	3,5	5-HTT
26013962_7	0	Chemical	16,16	cocaine
26013962_7	0	Phenotype	12,14	executive WM performance
26013962_7	0	Genomic_factor	3,6	5-HTT mRNA
11888582_12	0	Chemical	3,3	abacavir
11888582_12	0	Gene_or_protein	15,17	HLA-B
11888582_12	0	Disease	37,37	hypersensitivity
11888582_12	0	Haplotype	15,19	HLA-B * 5701
11888582_12	0	Gene_or_protein	21,23	HLA-DR
11888582_12	0	Haplotype	27,30	HLA-DQ 3
11888582_12	0	Haplotype	21,24	HLA-DR 7
11888582_12	0	Gene_or_protein	27,29	HLA-DQ
24921970_1	0	Gene_or_protein	3,3	EGFR
24921970_1	0	Chemical	3,6	EGFR tyrosine kinase inhibitors
24921970_1	0	Disease	11,11	cancer
11320258_10	0	Gene_or_protein	1,1	serotonin
11320258_10	0	Chemical	4,4	cocaine
11320258_10	0	Gene_or_protein	7,7	DAT
11320258_10	0	Chemical	17,17	cocaine
11320258_10	0	Gene_or_protein	21,21	DAT
11320258_10	0	Gene_or_protein	23,23	SERT
11320258_10	0	Genomic_variation	7,8	DAT knockout
11320258_10	0	Genomic_variation	21,25	DAT / SERT double knockout
11320258_10	0	Phenotype	1,5	serotonin dependence of cocaine reward
11320258_10	0	Phenotype	17,19	cocaine place preference
21876500_1	0	Limited_variation	5,14	Val158Met catechol-O-methyltransferase gene polymorphism
21876500_1	0	Gene_or_protein	8,12	catechol-O-methyltransferase
21876500_1	0	Disease	16,17	methamphetamine dependence
21876500_1	0	Chemical	16,16	methamphetamine
2491158_6	0	Gene_or_protein	22,23	VH1
2491158_6	0	Chemical	12,12	phosphorylcholine
2491158_6	0	Gene_or_protein	27,29	S107 family
15349717_10	0	Chemical	4,4	azathioprine
15349717_10	0	Limited_variation	24,26	promoter TPMT polymorphisms
15349717_10	0	Limited_variation	22,22,25,26	coding TPMT polymorphisms
15349717_10	0	Pharmacodynamic_phenotype	29,30	dose tolerated
15349717_10	0	Gene_or_protein	25,25	TPMT
15349717_10	0	Genomic_factor	24,25	promoter TPMT
15349717_10	0	Genomic_factor	22,22,25,25	coding TPMT
20122728_2	0	Limited_variation	3,7	TNF-a promoter polymorphisms
20122728_2	0	Gene_or_protein	3,5	TNF-a
20122728_2	0	Disease	12,13	multiple myeloma
20122728_2	0	Disease	15,15	MM
20122728_2	0	Chemical	40,40	thalidomide
20122728_2	0	Chemical	42,42	dexamethasone
20122728_2	0	Chemical	40,42	thalidomide and dexamethasone
20122728_2	0	Genomic_factor	3,6	TNF-a promoter
20122728_2	0	Phenotype	31,32	clinical outcome
20122728_2	0	Chemical	44,46	Thal + Dex
19796663_8	0	Pharmacodynamic_phenotype	12,16	apomorphine -induced GH response
19796663_8	0	Chemical	12,12	apomorphine
19796663_8	0	Chemical	15,15	GH
19796663_8	0	Gene_or_protein	20,21	DRD2
19796663_8	0	Gene_or_protein	23,24	ANKK1
19796663_8	0	Chemical	26,26	alcohol
19796663_8	0	Disease	26,28	alcohol -dependent
19796663_8	0	Limited_variation	18,21	SNPs in DRD2
19796663_8	0	Limited_variation	18,19,23,24	SNPs in ANKK1
19796663_8	0	Pharmacodynamic_phenotype	15,16	GH response
26984388_6	0	Chemical	3,3	cobimetinib
26984388_6	0	Chemical	5,5	vemurafenib
26984388_6	0	Gene_or_protein	13,13	BRAF
26984388_6	0	Limited_variation	13,20	BRAF ( V600 ) mutation-positive
26984388_6	0	Disease	13,21,24,24	BRAF ( V600 ) mutation-positive unresectable melanoma
26984388_6	0	Chemical	3,5	cobimetinib plus vemurafenib
26984388_6	0	Disease	13,20,23,24	BRAF ( V600 ) mutation-positive metastatic melanoma
16818479_12	0	Limited_variation	2,3	EGFR mutations
16818479_12	0	Gene_or_protein	2,2	EGFR
16818479_12	0	Chemical	16,16	paclitaxel
16818479_12	0	Pharmacodynamic_phenotype	7,8,18,18	response to gemcitabine
16818479_12	0	Chemical	14,14	platinums
16818479_12	0	Pharmacodynamic_phenotype	7,8,14,14	response to platinums
16818479_12	0	Pharmacodynamic_phenotype	7,8,16,16	response to paclitaxel
16818479_12	0	Chemical	18,18	gemcitabine
16818479_12	0	Pharmacodynamic_phenotype	7,11	response to conventional chemotherapeutic agents
18645163_6	0	Phenotype	5,7	CPT II deficiency
18645163_6	0	Gene_or_protein	5,6	CPT II
18645163_6	0	Chemical	17,17	triheptanoin
19147553_8	0	Chemical	2,4	nutlin-3
19147553_8	0	Chemical	8,9	rhodamine 123
19147553_8	0	Gene_or_protein	18,20	P-gp
19147553_8	0	Pharmacokinetic_phenotype	6,9	efflux of rhodamine 123
19147553_8	0	Chemical	12,13	fluorescence dyes
25885881_4	0	Chemical	0,0	Thiopurines
25885881_4	0	Gene_or_protein	2,3	Rac1
25885881_4	0	Gene_or_protein	6,6	GTPase
25885881_4	0	Phenotype	10,11	antiapoptotic effect
16719540_4	0	Chemical	18,18	fluorouracil
16719540_4	0	Gene_or_protein	43,44	thymidylate synthase
16719540_4	0	Pharmacokinetic_phenotype	30,30	pharmacokinetics
16719540_4	0	Pharmacokinetic_phenotype	37,37	metabolism
16719540_4	0	Gene_or_protein	41,41	targets
16719540_4	0	Pharmacodynamic_phenotype	25,27	narrow therapeutic index
11368834_10	0	Limited_variation	4,9	CCK -45C>T
11368834_10	0	Gene_or_protein	4,4	CCK
11368834_10	0	Gene_or_protein	11,11	CCKBR
11368834_10	0	Limited_variation	11,14	CCKBR Val125Ile
11368834_10	0	Chemical	23,23	alcohol
11368834_10	0	Disease	23,24	alcohol dependence
20205660_5	0	Gene_or_protein	23,26	thiopurine S-methyltransferase
20205660_5	0	Limited_variation	9,14,20,21	genetic polymorphisms of genes encoding for xanthine oxidase
20205660_5	0	Limited_variation	9,14,23,26	genetic polymorphisms of genes encoding for thiopurine S-methyltransferase
20205660_5	0	Limited_variation	9,14,28,30	genetic polymorphisms of genes encoding for inosine triphosphate pyrophosphatase
20205660_5	0	Limited_variation	9,14,32,33	genetic polymorphisms of genes encoding for hypoxanthine phosphoribosyltransferase
20205660_5	0	Limited_variation	9,18	genetic polymorphisms of genes encoding for glutathione S -tranferases
20205660_5	0	Gene_or_protein	15,18	glutathione S -tranferases
20205660_5	0	Gene_or_protein	20,21	xanthine oxidase
20205660_5	0	Gene_or_protein	28,30	inosine triphosphate pyrophosphatase
20205660_5	0	Gene_or_protein	32,33	hypoxanthine phosphoribosyltransferase
20205660_5	0	Gene_or_protein	35,37	inosine monophosphate dehydrogenase
20205660_5	0	Pharmacodynamic_phenotype	39,40	multidrug resistance
20205660_5	0	Gene_or_protein	39,41	multidrug resistance proteins
20205660_5	0	Limited_variation	9,14,35,37	genetic polymorphisms of genes encoding for inosine monophosphate dehydrogenase
20205660_5	0	Limited_variation	9,14,39,41	genetic polymorphisms of genes encoding for multidrug resistance proteins
20205660_5	0	Chemical	39,39	multidrug
22011650_9	0	Chemical	15,15	gefitinib
22011650_9	0	Gene_or_protein	19,19	EGFR
22011650_9	0	Gene_or_protein	31,31	EGFR
22011650_9	0	Phenotype	2,2	HRQoL
22011650_9	0	Phenotype	4,5	symptom endpoints
22011650_9	0	Chemical	25,27	carboplatin / paclitaxel
22011650_9	0	Limited_variation	31,34	EGFR mutation-negative
22011650_9	0	Limited_variation	19,22	EGFR mutation-positive
22011650_9	0	Disease	19,23	EGFR mutation-positive tumors
22011650_9	0	Disease	31,35	EGFR mutation-negative tumors
22011650_9	0	Pharmacodynamic_phenotype	9,10	efficacy outcomes
22011650_9	0	Chemical	25,25	carboplatin
22011650_9	0	Chemical	27,27	paclitaxel
21388909_1	0	Limited_variation	2,4	ABCB1 polymorphism
21388909_1	0	Gene_or_protein	2,3	ABCB1
21388909_1	0	Chemical	8,9	sodium valproate
21388909_1	0	Disease	13,13	epilepsy
21388909_1	0	Pharmacodynamic_phenotype	6,9	response to sodium valproate
14582249_5	0	Gene_or_protein	4,5	GSTT1
14582249_5	0	Limited_variation	7,9	GSTM1 polymorphism
14582249_5	0	Gene_or_protein	7,8	GSTM1
14582249_5	0	Chemical	15,19	1,3-butadiene
14582249_5	0	Limited_variation	4,5,9,9	GSTT1 polymorphism
14582249_5	0	Pharmacodynamic_phenotype	12,19	biological indicators of 1,3-butadiene
23774940_5	0	Pharmacodynamic_phenotype	10,12	SJS / TEN
23774940_5	0	Chemical	7,7	NVP
23774940_5	0	Gene_or_protein	25,26	ABCB1
23774940_5	0	Gene_or_protein	28,29	ABCC10
23774940_5	0	Gene_or_protein	34,37	CYP2B6
23774940_5	0	Gene_or_protein	39,42	CYP3A4
23774940_5	0	Gene_or_protein	44,47	CYP3A5
23774940_5	0	Pharmacodynamic_phenotype	7,12	NVP -induced SJS / TEN
23774940_5	0	Limited_variation	44,50	CYP3A5 cytochrome gene variants
23774940_5	0	Limited_variation	39,42,48,50	CYP3A4 cytochrome gene variants
23774940_5	0	Limited_variation	34,37,48,50	CYP2B6 cytochrome gene variants
23774940_5	0	Limited_variation	28,31,50,50	ABCC10 transporter genes variants
23774940_5	0	Limited_variation	25,26,30,31,50,50	ABCB1 transporter genes variants
22819302_1	0	Chemical	5,5	silymarin
22819302_1	0	Chemical	7,7	doxorubicin
22819302_1	0	Phenotype	16,20	c-myc gene expression
22819302_1	0	Gene_or_protein	16,18	c-myc
22819302_1	0	Pharmacodynamic_phenotype	0,0,3,5	Preventive effects of silymarin
22819302_1	0	Pharmacodynamic_phenotype	7,11	doxorubicin -induced testicular damages
22819302_1	0	Pharmacodynamic_phenotype	2,5	protective effects of silymarin
22819302_1	0	Pharmacodynamic_phenotype	10,11	testicular damages
26940072_6	0	Chemical	11,11	warfarin
26940072_6	0	Gene_or_protein	15,18	CYP2C9
26940072_6	0	Gene_or_protein	28,29	VKORC1
26940072_6	0	Limited_variation	30,31	rs9923231
26940072_6	0	Limited_variation	33,34	rs9934438
26940072_6	0	Limited_variation	36,37	rs7294
26940072_6	0	Limited_variation	39,40	rs2884737
26940072_6	0	Haplotype	15,20	CYP2C9 * 1
26940072_6	0	Haplotype	15,18,22,23	CYP2C9 * 2
26940072_6	0	Haplotype	15,18,25,26	CYP2C9 * 3
12166950_3	0	Gene_or_protein	19,20	PDGFR receptor
12166950_3	0	Chemical	29,29	quinazoline
12166950_3	0	Chemical	11,14	small molecule kinase inhibitors
12166950_3	0	Gene_or_protein	13,13	kinase
19564049_1	0	Gene_or_protein	6,7	XBP1
19564049_1	0	Chemical	20,20	valproate
19564049_1	0	Disease	22,23	bipolar disorders
19564049_1	0	Limited_variation	6,12	XBP1 -116C/G
19564049_1	0	Pharmacodynamic_phenotype	15,16,20,20	response to valproate
22555197_1	0	Chemical	13,13	irinotecan
22555197_1	0	Disease	23,25	metastatic colorectal cancer
22555197_1	0	Limited_variation	30,33,39,39	UGT1A1 polymorphisms
22555197_1	0	Gene_or_protein	30,33	UGT1A1
22555197_1	0	Gene_or_protein	35,38	CYP2A6
22555197_1	0	Limited_variation	35,39	CYP2A6 polymorphisms
22555197_1	0	Chemical	15,17	S-1
22555197_1	0	Pharmacodynamic_phenotype	42,42	activity
28423012_11	0	Phenotype	2,7	induction of 15-PGDH expression
28423012_11	0	Gene_or_protein	4,6	15-PGDH
28423012_11	0	Chemical	11,17	15-keto-PGE2 analogue
28423012_11	0	Disease	26,32	endotoxin-associated liver inflammation /injury
22741564_4	0	Phenotype	2,9	thiopurine S-methyltransferase ( TPMT ) deficiency
22741564_4	0	Gene_or_protein	2,5	thiopurine S-methyltransferase
22741564_4	0	Gene_or_protein	7,7	TPMT
22741564_4	0	Chemical	20,20	azathioprine
22741564_4	0	Chemical	22,24	6-mercaptopurine
22741564_4	0	Disease	31,34	Crohn's disease
22741564_4	0	Disease	36,36	CD
22741564_4	0	Pharmacodynamic_phenotype	20,25	azathioprine or 6-mercaptopurine immunomodulation
17989208_5	0	Gene_or_protein	24,25	HCN1
17989208_5	0	Chemical	34,34	sulfhydryl
17989208_5	0	Genomic_variation	8,39	substitutions into the descending portion of the P loop ( residues 339-345 ) of HCN1 -R ( where R is resistance to sulfhydryl -reactive agents ) channels
17989208_5	0	Pharmacodynamic_phenotype	32,37	resistance to sulfhydryl -reactive agents
27710871_1	0	Chemical	0,0	Trabectedin
27710871_1	0	Phenotype	8,9	BRCA deficiency
27710871_1	0	Gene_or_protein	8,8	BRCA
27710871_1	0	Chemical	3,3	chemotherapy
20374216_1	0	Chemical	26,26	alcohol
20374216_1	0	Gene_or_protein	5,9	corticotropin releasing hormone receptor 1
20374216_1	0	Gene_or_protein	12,13	CRHR1
20374216_1	0	Limited_variation	0,14	Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene ( CRHR1 )
20374216_1	0	Disease	26,27	alcohol dependence
20374216_1	0	Phenotype	18,24	quantitative trait of event-related potential
15864124_1	0	Gene_or_protein	11,16	UDP-glucuronosyltransferase 1A1
15864124_1	0	Chemical	19,19	irinotecan
15864124_1	0	Pharmacodynamic_phenotype	19,20	irinotecan toxicity
15864124_1	0	Limited_variation	1,17	polymorphism in the phenobarbital -responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene
12668130_5	0	Gene_or_protein	4,4	MnSOD
12668130_5	0	Gene_or_protein	6,8	Cu/ZnSOD
12668130_5	0	Phenotype	29,30	infarct size
12668130_5	0	Disease	29,29	infarct
12668130_5	0	Chemical	32,32	malondialdehyde
12668130_5	0	Disease	12,15	I/R injury
12668130_5	0	Phenotype	24,27	serum creatine kinase levels
12668130_5	0	Pharmacodynamic_phenotype	32,33	malondialdehyde levels
12668130_5	0	Phenotype	36,38	apoptotic cell death
12668130_5	0	Phenotype	1,8	expression of both MnSOD and Cu/ZnSOD
12668130_5	0	Gene_or_protein	25,26	creatine kinase
27457818_7	0	Chemical	5,5	clonidine
27457818_7	0	Limited_variation	11,15	COMT low-activity alleles
27457818_7	0	Gene_or_protein	11,11	COMT
27457818_7	0	Chemical	7,7	placebo
20510210_2	0	Gene_or_protein	20,25	cytochrome P450 2C19
20510210_2	0	Limited_variation	20,32	cytochrome P450 2C19 ( CYP2C19 ) polymorphism
20510210_2	0	Gene_or_protein	27,30	CYP2C19
20510210_2	0	Chemical	37,37	clopidogrel
20510210_2	0	Pharmacodynamic_phenotype	34,37	antiplatelet effects of clopidogrel
27378608_9	0	Gene_or_protein	19,20	HER2
27378608_9	0	Gene_or_protein	6,6	FcyRIIIa
27378608_9	0	Limited_variation	6,7	FcyRIIIa V
27378608_9	0	Chemical	15,17	trastuzumab plus lapatinib
27378608_9	0	Disease	19,22	HER2 + BC
12777962_1	0	Gene_or_protein	0,3	CYP2E1
12777962_1	0	Chemical	12,12	alcohol
12777962_1	0	Chemical	14,14	nicotine
12777962_1	0	Disease	14,15	nicotine dependence
12777962_1	0	Haplotype	0,6	CYP2E1 * 1D
12777962_1	0	Disease	12,12,15,15	alcohol dependence
25726043_14	0	Disease	2,2	NSCLC
25726043_14	0	Gene_or_protein	10,10	EGFR
25726043_14	0	Pharmacodynamic_phenotype	19,21	response to gefitinib
25726043_14	0	Chemical	21,21	gefitinib
25726043_14	0	Limited_variation	10,13	EGFR L858R
25726043_14	0	Phenotype	6,6	smoking
18708376_7	0	Phenotype	3,6	ESR1 promoter hypermethylation
18708376_7	0	Gene_or_protein	3,4	ESR1
18708376_7	0	Phenotype	8,10	low ER expression
18708376_7	0	Gene_or_protein	9,9	ER
18708376_7	0	Chemical	23,23	tamoxifen
18708376_7	0	Phenotype	13,19	atypia in Random Periareolar Fine Needle Aspiration
18708376_7	0	Genomic_factor	3,5	ESR1 promoter
18382665_13	0	Limited_variation	17,22	ADH1B regulatory region polymorphism
18382665_13	0	Gene_or_protein	17,19	ADH1B
18382665_13	0	Gene_or_protein	31,33	ADH1B
18382665_13	0	Haplotype	31,36	ADH1B * 47His
18382665_13	0	Pharmacokinetic_phenotype	5,6	selection distribution
18382665_13	0	Genomic_factor	17,21	ADH1B regulatory region
11712813_1	0	Limited_variation	1,6	polymorphism of the XRCC1 gene
11712813_1	0	Gene_or_protein	4,5	XRCC1
11712813_1	0	Chemical	11,11	platinum
11712813_1	0	Disease	16,17	colorectal cancer
11712813_1	0	Pharmacodynamic_phenotype	9,11	response to platinum
18760346_3	0	Limited_variation	6,9	Ala- MnSOD allele
18760346_3	0	Gene_or_protein	8,8	MnSOD
18760346_3	0	Chemical	14,14	iron
18760346_3	0	Disease	21,22	hepatocellular carcinoma
18760346_3	0	Pharmacokinetic_phenotype	13,15	hepatic iron accumulation
18760346_3	0	Disease	1,2	alcoholic cirrhotic
16929515_2	0	Gene_or_protein	6,7	thymidylate synthase
16929515_2	0	Gene_or_protein	9,9	TS
16929515_2	0	Limited_variation	2,10	DNA polymorphisms in the thymidylate synthase ( TS )
16929515_2	0	Gene_or_protein	12,19	5,10-methylene-tetrahydrofolate reductase
16929515_2	0	Gene_or_protein	21,21	MTHFR
16929515_2	0	Limited_variation	2,5,12,22	DNA polymorphisms in the 5,10-methylene-tetrahydrofolate reductase ( MTHFR )
16929515_2	0	Disease	34,35	gastric cancer
16929515_2	0	Phenotype	30,30	survival
16929515_2	0	Chemical	38,46	5-FU based preoperative chemotherapy ( CTx )
16929515_2	0	Chemical	38,40	5-FU
16929515_2	0	Chemical	43,43	chemotherapy
16929515_2	0	Chemical	45,45	CTx
16929515_2	0	Pharmacodynamic_phenotype	28,28	response
18784465_9	0	Gene_or_protein	7,9	HLA-B
18784465_9	0	Haplotype	7,11	HLA-B * 5701
18784465_9	0	Phenotype	28,32	quality-adjusted life years
18784465_9	0	Chemical	2,5	Abacavir -based treatment
18784465_9	0	Phenotype	21,22	life expectancy
18784465_9	0	Chemical	2,2	Abacavir
18784465_9	0	Phenotype	39,40	lifetime cost
26352193_12	0	Gene_or_protein	1,3	5-HTTLPR
26352193_12	0	Disease	7,8	social anxiety
26352193_12	0	Disease	10,10	anxiety
26352193_12	0	Disease	13,13	depressive
26352193_12	0	Chemical	16,16	alcohol
26352193_12	0	Genomic_variation	0,3	Triallelic 5-HTTLPR
26352193_12	0	Disease	16,18	alcohol -dependent
22571356_5	0	Gene_or_protein	15,16	VKORC1
22571356_5	0	Chemical	50,50	warfarin
22571356_5	0	Phenotype	76,76	bleeding
22571356_5	0	Limited_variation	0,27	Homozygosity for the -1639 G>A single nucleotide functional promoter polymorphism of the VKORC1 gene ( genotype AA ; 14 5 % of cases )
22571356_5	0	Pharmacodynamic_phenotype	34,40	time to therapeutic INR > = 2
22571356_5	0	Pharmacodynamic_phenotype	49,51	stable warfarin dose
22571356_5	0	Phenotype	64,66	INRs > 5
22571356_5	0	Limited_variation	93,94	GG genotype
25034231_6	0	Chemical	1,1	xanthone
25034231_6	0	Phenotype	6,9	expression of CXCR4
25034231_6	0	Gene_or_protein	8,9	CXCR4
25034231_6	0	Disease	11,11	MM
15175841_1	0	Gene_or_protein	3,5	c-Fos
15175841_1	0	Chemical	17,17	morphine
15175841_1	0	Phenotype	0,6	Withdrawal-induced c-Fos expression
19383921_1	0	Gene_or_protein	0,8	Poly(ADP-ribose) polymerase-1
19383921_1	0	Gene_or_protein	16,17	p53
19383921_1	0	Phenotype	26,27	tumor relapse
19383921_1	0	Chemical	31,31	carboplatin
19383921_1	0	Chemical	0,9	Poly(ADP-ribose) polymerase-1 inhibitor
19383921_1	0	Disease	13,21	Brca2 / p53 -mutant mammary tumors
19383921_1	0	Limited_variation	13,19	Brca2 / p53 -mutant
19383921_1	0	Gene_or_protein	13,14	Brca2
19383921_1	0	Disease	26,26	tumor
19182535_2	0	Gene_or_protein	1,2	tyrosine kinase
19182535_2	0	Gene_or_protein	4,4	TK
19182535_2	0	Chemical	8,8	imatinib
19182535_2	0	Disease	14,14	malignancies
19182535_2	0	Gene_or_protein	25,27	c-abl
19182535_2	0	Gene_or_protein	29,31	c-kit
19182535_2	0	Gene_or_protein	33,35	PDGF-R
19182535_2	0	Chemical	1,6	tyrosine kinase ( TK ) inhibitor
19182535_2	0	Gene_or_protein	23,23	kinases
18480244_5	0	Chemical	9,11	TLR7 ligand
18480244_5	0	Gene_or_protein	9,10	TLR7
18480244_5	0	Chemical	30,31	SM360320
18480244_5	0	Chemical	13,28	9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine
18480244_5	0	Phenotype	43,45	TLR7 activation
18480244_5	0	Gene_or_protein	43,44	TLR7
18480244_5	0	Chemical	33,35	1V136
25404639_1	0	Gene_or_protein	4,5	p50
25404639_1	0	Chemical	11,12	eriocalyxin B
12504868_8	0	Gene_or_protein	0,4	Intercellular adhesion molecule-1
12504868_8	0	Gene_or_protein	28,28	Tat
12504868_8	0	Phenotype	0,6	Intercellular adhesion molecule-1 gene expression
12504868_8	0	Chemical	28,31	Tat combined with METH
12504868_8	0	Chemical	31,31	METH
24092646_1	0	Gene_or_protein	5,6	MDR1
24092646_1	0	Gene_or_protein	8,9	EPHX1
24092646_1	0	Chemical	18,18	warfarin
24092646_1	0	Gene_or_protein	11,12	protein Z
24092646_1	0	Pharmacodynamic_phenotype	16,19	modulation of warfarin dosage
24092646_1	0	Limited_variation	5,6,13,14	MDR1 gene variants
24092646_1	0	Limited_variation	8,9,13,14	EPHX1 gene variants
24092646_1	0	Limited_variation	11,14	protein Z gene variants
19615284_8	0	Gene_or_protein	0,1	BRCA1
19615284_8	0	Chemical	10,14	anthracycline -based neoadjuvant chemotherapy
19615284_8	0	Disease	17,18	breast cancer
19615284_8	0	Phenotype	0,3	BRCA1 methylation status
19615284_8	0	Chemical	10,10	anthracycline
26216193_4	0	Chemical	9,11	5-fluorouracil
26216193_4	0	Chemical	19,25	5-fluorouracil-5-FUDR
26216193_4	0	Gene_or_protein	37,37	DPYD
26216193_4	0	Pharmacokinetic_phenotype	16,25	degradation rate of 5-fluorouracil-5-FUDR
26216193_4	0	Gene_or_protein	33,34	dihydropyrimidine dehydrogenase
26216193_4	0	Pharmacokinetic_phenotype	9,12	5-fluorouracil metabolism
26216193_4	0	Limited_variation	30,35	polymorphisms in the dihydropyrimidine dehydrogenase gene
15589566_3	0	Limited_variation	11,15	5-HTTLPR S allele
15589566_3	0	Gene_or_protein	11,13	5-HTTLPR
15589566_3	0	Chemical	17,17	alcohol
15589566_3	0	Disease	17,19	alcohol -dependent
15589566_3	0	Phenotype	7,8	suicide attempts
20663035_7	0	Chemical	3,4	Kainic acid
20663035_7	0	Phenotype	9,14	expression of c-fos mRNA
20663035_7	0	Genomic_factor	11,14	c-fos mRNA
20663035_7	0	Gene_or_protein	11,13	c-fos
22521649_12	0	Disease	7,8	lung cancer
22521649_12	0	Gene_or_protein	11,11	EGFR
22521649_12	0	Chemical	18,18	taxane
22521649_12	0	Chemical	20,20	gemcitabine
22521649_12	0	Limited_variation	11,13	EGFR -mutations
22521649_12	0	Phenotype	16,16	PFS
22521649_12	0	Chemical	24,28	platinum -based doublet regimen
22521649_12	0	Chemical	24,24	platinum
25589624_2	0	Chemical	2,2	Veliparib
25589624_2	0	Gene_or_protein	5,5	PARP
25589624_2	0	Chemical	15,15	cyclophosphamide
25589624_2	0	Gene_or_protein	19,19	BRCA
25589624_2	0	Chemical	2,2,11,15	Veliparib in combination with oral cyclophosphamide
25589624_2	0	Disease	19,23	BRCA -mutant solid tumors
25589624_2	0	Chemical	5,6	PARP inhibitor
25589624_2	0	Limited_variation	19,21	BRCA -mutant
12700947_8	0	Gene_or_protein	19,19	CEA
12700947_8	0	Phenotype	17,20	anti- CEA immunity
12700947_8	0	Chemical	9,11	CpG ODN 1826
12700947_8	0	Chemical	4,6	3H1
12700947_8	0	Chemical	4,11	3H1 mixed with CpG ODN 1826
26325438_9	0	Chemical	1,1	tacrolimus
26325438_9	0	Gene_or_protein	5,8	CYP3A5
26325438_9	0	Limited_variation	3,4	rs776746
26325438_9	0	Gene_or_protein	15,18	CYP3A5
26325438_9	0	Gene_or_protein	31,34	CYP3A5
26325438_9	0	Haplotype	5,13	CYP3A5 * 3 / * 3
26325438_9	0	Haplotype	15,23	CYP3A5 * 3 / * 1
26325438_9	0	Haplotype	31,39	CYP3A5 * 1 / * 1
26325438_9	0	Pharmacodynamic_phenotype	28,29	blood levels
24651609_2	0	Chemical	11,11	OEA
24651609_2	0	Chemical	7,9	N-oleoylethanolamine
24651609_2	0	Gene_or_protein	20,25	peroxisome proliferator-activated receptor alpha
24651609_2	0	Gene_or_protein	27,27	PPARa
24651609_2	0	Chemical	32,33	sulfamoyl analogs
19179882_9	0	Phenotype	5,7	MDR2 expression
19179882_9	0	Gene_or_protein	5,6	MDR2
19179882_9	0	Chemical	19,19	phosphatidylcholine
19179882_9	0	Gene_or_protein	26,27	MDR2
19179882_9	0	Phenotype	18,20	bile phosphatidylcholine content
19179882_9	0	Chemical	2,2	TPN
20424113_3	0	Chemical	11,11	copper
20424113_3	0	Chemical	13,13	Cu
20424113_3	0	Chemical	18,18	DSF
20424113_3	0	Chemical	16,16	disulfiram
20424113_3	0	Disease	30,31	breast cancer
20424113_3	0	Genomic_variation	37,40	PIK3CA status
20424113_3	0	Gene_or_protein	37,39	PIK3CA
20424113_3	0	Chemical	24,25	antialcoholism drug
20424113_3	0	Phenotype	30,33	breast cancer cell growth
15259893_9	0	Chemical	4,4	amprenavir
15259893_9	0	Limited_variation	9,11	I50V
15259893_9	0	Chemical	19,19	lopinavir
15259893_9	0	Pharmacodynamic_phenotype	0,4	Resistance during exposure to amprenavir
15259893_9	0	Pharmacodynamic_phenotype	17,19	resistance to lopinavir
25894531_2	0	Gene_or_protein	22,23	ADRB2
25894531_2	0	Limited_variation	25,26	rs1042713
25894531_2	0	Limited_variation	29,30	rs1042714
25894531_2	0	Gene_or_protein	38,40	SCNN1A
25894531_2	0	Limited_variation	42,43	rs2228576
25894531_2	0	Pharmacodynamic_phenotype	46,52	cycling performance after the inhalation of salbutamol
25894531_2	0	Gene_or_protein	15,20	adrenergic b2-receptor gene
25894531_2	0	Gene_or_protein	33,36	epithelial Na channel gene
25894531_2	0	Chemical	52,52	salbutamol
25894531_2	0	Limited_variation	7,20	single nucleotide polymorphisms ( SNPs ) in the adrenergic b2-receptor gene
25894531_2	0	Limited_variation	7,14,33,36	single nucleotide polymorphisms ( SNPs ) in the epithelial Na channel gene
17089107_1	0	Gene_or_protein	2,5	CYP2D6
17089107_1	0	Pharmacodynamic_phenotype	15,15	hypersomnia
17089107_1	0	Chemical	9,12	H1-antihistamine
17089107_1	0	Haplotype	2,7	CYP2D6 * 10
17089107_1	0	Pharmacodynamic_phenotype	9,15	H1-antihistamine -induced hypersomnia
24285256_8	0	Chemical	4,4	sirolimus
24285256_8	0	Limited_variation	14,19	ABCB1 1236C>T
24285256_8	0	Gene_or_protein	14,15	ABCB1
24285256_8	0	Limited_variation	14,15,21,26	ABCB1 2677G>T /A
24285256_8	0	Limited_variation	14,15,28,31	ABCB1 3435C>T
24285256_8	0	Pharmacokinetic_phenotype	4,9	sirolimus C0/D ratios
21790903_11	0	Limited_variation	24,27	polymorphisms in CNR1
21790903_11	0	Gene_or_protein	26,27	CNR1
21790903_11	0	Chemical	39,39	cocaine
21790903_11	0	Disease	39,40	cocaine addiction
21790903_11	0	Disease	10,10	CD
21790903_11	0	Disease	13,15	drugs of abuse
21790903_11	0	Pharmacodynamic_phenotype	31,34	susceptibility to substance dependence
19299582_7	0	Chemical	4,4	sirtinol
19299582_7	0	Gene_or_protein	8,9	SIRT1
19299582_7	0	Gene_or_protein	15,16	SIRT1
19299582_7	0	Gene_or_protein	21,22	SIRT1
19299582_7	0	Gene_or_protein	25,26	SIRT1
19299582_7	0	Gene_or_protein	30,32	TNF-alpha
19299582_7	0	Gene_or_protein	39,40	SIRT1
19299582_7	0	Phenotype	44,47	TNF-alpha secretion
19299582_7	0	Gene_or_protein	44,46	TNF-alpha
19299582_7	0	Gene_or_protein	25,27	SIRT1 shRNA
19299582_7	0	Chemical	8,10	SIRT1 inhibitor
19299582_7	0	Genomic_variation	13,16	knocking down SIRT1
25035107_1	0	Phenotype	10,13	MAO-B activity
25035107_1	0	Gene_or_protein	10,12	MAO-B
25035107_1	0	Chemical	15,15	alcohol
25035107_1	0	Chemical	18,18	alcohol
25035107_1	0	Disease	15,16	alcohol dependence
25035107_1	0	Phenotype	18,22	alcohol dependence -related phenotypes
25035107_1	0	Limited_variation	2,7	gene polymorphisms encoding dopaminergic system components
25035107_1	0	Gene_or_protein	5,7	dopaminergic system components
25035107_1	0	Disease	18,19	alcohol dependence
21561767_1	0	Chemical	2,10	5-(arenethynyl) hetero-monocyclic derivatives
21561767_1	0	Limited_variation	20,24	T315I gatekeeper mutant
21561767_1	0	Gene_or_protein	15,17	BCR-ABL
8963481_9	0	Limited_variation	10,14	CYP2D6 polymorphism
8963481_9	0	Gene_or_protein	10,13	CYP2D6
8963481_9	0	Chemical	21,21	dextromethorphan
8963481_9	0	Pharmacokinetic_phenotype	30,31	poor metabolizers
8963481_9	0	Pharmacokinetic_phenotype	35,36	extensive metabolizers
8963481_9	0	Phenotype	21,22	dextromethorphan phenotyping
8963481_9	0	Pharmacokinetic_phenotype	1,2	pharmacokinetic parameters
18666383_8	0	Phenotype	4,8	low levels of TPMT activity
18666383_8	0	Gene_or_protein	7,7	TPMT
18666383_8	0	Pharmacodynamic_phenotype	18,18	toxicity
18666383_8	0	Chemical	15,15	thiopurine
18666383_8	0	Pharmacodynamic_phenotype	15,18	thiopurine -induced toxicity
18666383_8	0	Pharmacodynamic_phenotype	21,21	myelosuppression
18666383_8	0	Phenotype	35,37	very high activity
11361019_12	0	Phenotype	6,7	cell survival
11361019_12	0	Chemical	12,13	CB 1954
11361019_12	0	Gene_or_protein	19,21	DT-diaphorase
11361019_12	0	Phenotype	19,22	DT-diaphorase activity
22137367_6	0	Phenotype	4,7	IGF-1 value
22137367_6	0	Gene_or_protein	4,6	IGF-1
22137367_6	0	Chemical	17,17	rGH
26807589_1	0	Limited_variation	1,7	Single-Nucleotide Polymorphism in ABCC4
26807589_1	0	Gene_or_protein	6,7	ABCC4
26807589_1	0	Chemical	11,11	Tenofovir
26807589_1	0	Disease	11,17	Tenofovir -Related Beta2 -Microglobulinuria
26807589_1	0	Disease	22,24	HIV-1
22297576_10	0	Chemical	2,4	5-HT
22297576_10	0	Chemical	11,11	GABA
22297576_10	0	Chemical	13,13	glutamate
22297576_10	0	Chemical	15,15	CRF
22297576_10	0	Phenotype	18,19	aggressive behaviors
22297576_10	0	Phenotype	0,5	Modulation of 5-HT neurons
18187595_3	0	Gene_or_protein	2,5	SLCO1B1
18187595_3	0	Limited_variation	2,10	SLCO1B1 c. 521 CC genotype
18187595_3	0	Pharmacokinetic_phenotype	38,47	mean area under the plasma repaglinide concentration-time curve
18187595_3	0	Chemical	43,43	repaglinide
18187595_3	0	Pharmacokinetic_phenotype	49,49	AUC
18187595_3	0	Limited_variation	59,62,78,78	c. 521TC genotypes
18187595_3	0	Limited_variation	69,72,78,78	c. 521TT genotypes
17178263_13	0	Gene_or_protein	3,4	PTGS2
17178263_13	0	Limited_variation	3,13	PTGS2 -765G>C single-nucleotide polymorphism
17178263_13	0	Gene_or_protein	17,19	COX-2
17178263_13	0	Chemical	23,23	celecoxib
17178263_13	0	Pharmacodynamic_phenotype	17,23	COX-2 inhibitory effects of celecoxib
11340648_2	0	Gene_or_protein	0,1	Neuropeptide Y
11340648_2	0	Gene_or_protein	3,3	NPY
11340648_2	0	Chemical	16,16	morphine
11340648_2	0	Phenotype	13,17	behavioral signs of morphine withdrawal
20303013_3	0	Gene_or_protein	12,13	GSTM1
20303013_3	0	Gene_or_protein	15,16	GSTT1
20303013_3	0	Gene_or_protein	19,20	GSTP1
20303013_3	0	Limited_variation	11,13	polymorphisms GSTM1
20303013_3	0	Limited_variation	11,11,15,16	polymorphisms GSTT1
20303013_3	0	Limited_variation	11,11,19,20	polymorphisms GSTP1
20303013_3	0	Pharmacodynamic_phenotype	22,23	treatment response
20303013_3	0	Disease	29,36	de novo diffuse large B-cell lymphoma
20303013_3	0	Chemical	41,49	rituximab plus cyclophosphamide / doxorubicin / vincristine / prednisone
20303013_3	0	Chemical	41,41	rituximab
20303013_3	0	Chemical	43,43	cyclophosphamide
20303013_3	0	Chemical	45,45	doxorubicin
20303013_3	0	Chemical	47,47	vincristine
20303013_3	0	Chemical	49,49	prednisone
23159001_11	0	Chemical	3,4	icotinib hydrochloride
23159001_11	0	Limited_variation	16,17	EGFR mutation
23159001_11	0	Gene_or_protein	16,16	EGFR
23159001_11	0	Pharmacodynamic_phenotype	1,4	efficacy of icotinib hydrochloride
23159001_11	0	Phenotype	9,11	ECOG performance status
23159001_11	0	Phenotype	19,19	rash
23159001_11	0	Phenotype	13,14	smoking history
23792648_11	0	Chemical	8,8	doxorubicin
23792648_11	0	Chemical	10,10	oxaliplatin
23792648_11	0	Chemical	12,12	methotrexate
23792648_11	0	Disease	15,16	stomach carcinoma
23792648_11	0	Gene_or_protein	22,25	BCL2L12
23792648_11	0	Gene_or_protein	27,27	BAX
23792648_11	0	Gene_or_protein	30,32	BCL-2
23792648_11	0	Phenotype	22,25,33,34	BCL2L12 expression profiles
23792648_11	0	Phenotype	27,27,33,34	BAX expression profiles
23792648_11	0	Phenotype	30,34	BCL-2 expression profiles
23792648_11	0	Chemical	42,42	chemotherapy
23792648_11	0	Phenotype	37,42	molecular signaling pathways triggered by chemotherapy
23792648_11	0	Pharmacodynamic_phenotype	4,8	growth suppressive effects of doxorubicin
23792648_11	0	Pharmacodynamic_phenotype	4,6,10,10	growth suppressive effects oxaliplatin
23792648_11	0	Pharmacodynamic_phenotype	4,6,12,12	growth suppressive effects methotrexate
15900282_1	0	Limited_variation	1,6	genetic variants of microsomal epoxide hydrolase
15900282_1	0	Gene_or_protein	4,6	microsomal epoxide hydrolase
15900282_1	0	Chemical	8,8	warfarin
15900282_1	0	Gene_or_protein	15,20	cytochrome P450 2C9
15900282_1	0	Pharmacodynamic_phenotype	8,10	warfarin dose requirements
15900282_1	0	Pharmacodynamic_phenotype	13,20	effect of cytochrome P450 2C9
23415432_1	0	Phenotype	0,1	Lipoprotein abnormalities
23415432_1	0	Phenotype	5,7	lipoprotein lipase deficiency
23415432_1	0	Gene_or_protein	5,6	lipoprotein lipase
23415432_1	0	Chemical	17,17	orlistat
15790782_1	0	Gene_or_protein	0,5	Cytochrome P450 2C9
15790782_1	0	Gene_or_protein	7,10	CYP2C9
15790782_1	0	Gene_or_protein	13,16	vitamin K epoxide reductase
15790782_1	0	Gene_or_protein	18,19	VKORC1
15790782_1	0	Pharmacodynamic_phenotype	25,26	acenocoumarol sensitivity
15790782_1	0	Chemical	25,25	acenocoumarol
15790782_1	0	Limited_variation	0,11,21,21	Cytochrome P450 2C9 ( CYP2C9 ) genotypes
15790782_1	0	Limited_variation	13,21	vitamin K epoxide reductase ( VKORC1 ) genotypes
15707696_5	0	Disease	6,7	chronic ethanol
15707696_5	0	Gene_or_protein	11,11	CpG
15707696_5	0	Phenotype	33,38	expression of the NR2B
15707696_5	0	Gene_or_protein	36,38	NR2B
15707696_5	0	Phenotype	9,11	demethylation in CpG
15707696_5	0	Genomic_factor	15,20	regions ( 5843-6276 )
15707696_5	0	Genomic_factor	22,26	( 6477-6763 )
15707696_5	0	Chemical	7,7	ethanol
19530960_6	0	Haplotype	0,1	DPYD haplotypes
19530960_6	0	Gene_or_protein	0,0	DPYD
19530960_6	0	Chemical	9,11	5-FU
19530960_6	0	Pharmacodynamic_phenotype	9,12	5-FU toxicity
15834213_3	0	Gene_or_protein	9,10	GABRA2
15834213_3	0	Chemical	14,14	alcohol
15834213_3	0	Chemical	21,21	alcohol
15834213_3	0	Disease	14,15	alcohol dependence
15834213_3	0	Disease	21,23	alcohol -dependent
18829024_9	0	Limited_variation	11,13	StAR gene mutations
18829024_9	0	Gene_or_protein	11,11	StAR
18829024_9	0	Chemical	18,18	estrogens
18829024_9	0	Phenotype	5,5	Pregnancy
18829024_9	0	Phenotype	22,23	placental function
18084327_10	0	Chemical	6,7	AZD1152
18084327_10	0	Disease	10,10	tumor
18084327_10	0	Gene_or_protein	27,28	p53
18084327_10	0	Disease	27,31	p53 -deficient cancer
18084327_10	0	Phenotype	27,30	p53 -deficient
18324624_6	0	Phenotype	2,3,8,8	expression of MCJ
18324624_6	0	Gene_or_protein	4,6	MDR-1
18324624_6	0	Gene_or_protein	8,8	MCJ
18324624_6	0	Pharmacodynamic_phenotype	13,22	sensitivity of Sk-Ov-3 cells to paclitaxel
18324624_6	0	Chemical	22,22	paclitaxel
18324624_6	0	Phenotype	26,28	expression of Src
18324624_6	0	Gene_or_protein	28,28	Src
18324624_6	0	Gene_or_protein	30,32	Bcl-2
18324624_6	0	Gene_or_protein	34,39	Bcl-X(L)
18324624_6	0	Pharmacodynamic_phenotype	42,51	sensitivity of Sk-Ov-3 cells to carboplatin
18324624_6	0	Chemical	51,51	carboplatin
18324624_6	0	Phenotype	2,6	expression of MDR-1
18324624_6	0	Phenotype	26,27,30,32	expression of Bcl-2
18324624_6	0	Phenotype	26,27,34,39	expression of Bcl-X(L)
18519658_5	0	Disease	0,1	Breast cancer
18519658_5	0	Limited_variation	10,16	Asp299Gly polymorphism of TLR4
18519658_5	0	Gene_or_protein	15,16	TLR4
18519658_5	0	Chemical	21,24	anthracycline -based chemotherapy
18519658_5	0	Chemical	21,21	anthracycline
25687192_2	0	Limited_variation	4,18	single-nucleotide polymorphism ( SNP ) rs12979860 in the IL28B gene
25687192_2	0	Limited_variation	11,12	rs12979860
25687192_2	0	Gene_or_protein	15,17	IL28B
25687192_2	0	Disease	34,34	CHC
25687192_2	0	Disease	42,42	CHC
25687192_2	0	Chemical	59,59	peginterferon
25687192_2	0	Chemical	61,61	ribavirin
25687192_2	0	Disease	30,32	chronic hepatitis C
25687192_2	0	Pharmacodynamic_phenotype	25,35	virological response to treatment of chronic hepatitis C ( CHC )
25687192_2	0	Chemical	59,61	peginterferon plus ribavirin
25687192_2	0	Chemical	28,32	treatment of chronic hepatitis C
25687192_2	0	Limited_variation	46,48	favorable C allele
25687192_2	0	Pharmacodynamic_phenotype	54,55	virological response
25687192_2	0	Pharmacodynamic_phenotype	25,26	virological response
16041239_4	0	Gene_or_protein	13,14	ABCB1
16041239_4	0	Gene_or_protein	18,19	ABCC1
16041239_4	0	Gene_or_protein	23,24	ABCC2
16041239_4	0	Gene_or_protein	29,30	ABCG2
16041239_4	0	Chemical	49,49	nelfinavir
16041239_4	0	Limited_variation	11,14	SNPs in ABCB1
16041239_4	0	Limited_variation	11,11,17,19	SNPs in ABCC1
16041239_4	0	Limited_variation	11,11,22,24	SNPs in ABCC2
16041239_4	0	Limited_variation	11,11,28,30	SNPs in ABCG2
16041239_4	0	Haplotype	35,35	haplotypes
16041239_4	0	Limited_variation	6,8	single nucleotide polymorphisms
16041239_4	0	Genomic_variation	43,44	genetic variants
26116794_11	0	Gene_or_protein	6,7	GABRA2
26116794_11	0	Pharmacodynamic_phenotype	10,15	alcohol dependence -related aggressive behavior
26116794_11	0	Chemical	10,10	alcohol
26116794_11	0	Disease	10,11	alcohol dependence
26116794_11	0	Phenotype	14,15	aggressive behavior
19820367_1	0	Limited_variation	3,6	K-ras mutation
19820367_1	0	Gene_or_protein	3,5	K-ras
19820367_1	0	Chemical	8,8	tamoxifen
19820367_1	0	Disease	13,14	breast cancer
22708928_2	0	Gene_or_protein	7,10	SULT1A1
22708928_2	0	Gene_or_protein	2,5	Sulfotransferase 1A1
22708928_2	0	Chemical	17,21	4-hydroxy-tamoxifen
22708928_2	0	Chemical	23,27	4-OH-TAM
22708928_2	0	Chemical	39,39	tamoxifen
22708928_2	0	Chemical	41,41	TAM
22708928_2	0	Pharmacokinetic_phenotype	15,21	elimination of 4-hydroxy-tamoxifen
15341704_2	0	Chemical	0,0	Warfarin
15341704_2	0	Disease	13,14	thromboembolic disease
15341704_2	0	Gene_or_protein	20,23	CYP2C9
15341704_2	0	Chemical	5,5	anticoagulant
15341704_2	0	Gene_or_protein	28,30	hepatic microsomal enzymes
24672032_3	0	Limited_variation	0,9	IFNL3 ( lambda-3 interferon gene ) polymorphisms
24672032_3	0	Gene_or_protein	3,6	lambda-3 interferon
24672032_3	0	Gene_or_protein	0,1	IFNL3
24672032_3	0	Phenotype	12,16	expression of miR-122
24672032_3	0	Gene_or_protein	14,16	miR-122
24672032_3	0	Chemical	33,33	ribavirin
24672032_3	0	Disease	41,41	CHC
24672032_3	0	Phenotype	21,23	sustained virological response
24672032_3	0	Phenotype	25,25	SVR
24672032_3	0	Chemical	30,33	pegylated interferon plus ribavirin
24672032_3	0	Disease	38,39	hepatitis C
24672032_3	0	Chemical	30,31	pegylated interferon
21418871_10	0	Disease	2,3	Gastric cancer
21418871_10	0	Limited_variation	6,12	ERCC1 -118 C/C
21418871_10	0	Gene_or_protein	6,7	ERCC1
21418871_10	0	Gene_or_protein	15,16	XRCC1
21418871_10	0	Chemical	31,35	oxaliplatin -based adjuvant chemotherapy
21418871_10	0	Limited_variation	15,21	XRCC1 -399A / G
21418871_10	0	Limited_variation	15,16,23,25	XRCC1 A/A
21418871_10	0	Chemical	31,31	oxaliplatin
23237192_10	0	Limited_variation	3,6	1494C> T
23237192_10	0	Disease	15,15	NSHL
23237192_10	0	Chemical	24,24	aminoglycoside
23237192_10	0	Phenotype	29,33	hearing of the mutation carriers
23237192_10	0	Limited_variation	32,32	mutation
24401102_11	0	Limited_variation	6,7	rs4952
24401102_11	0	Chemical	13,13	nicotine
24401102_11	0	Limited_variation	22,23	rs13273442
24401102_11	0	Disease	13,14	nicotine dependence
24401102_11	0	Limited_variation	1,4	SNP in the region
18784465_7	0	Chemical	8,8	abacavir
18784465_7	0	Chemical	10,10	lamivudine
18784465_7	0	Chemical	13,13	efavirenz
18784465_7	0	Gene_or_protein	16,18	HLA-B
18784465_7	0	Gene_or_protein	27,29	HLA-B
18784465_7	0	Chemical	38,38	tenofovir
18784465_7	0	Chemical	40,40	emtricitabine
18784465_7	0	Chemical	43,43	efavirenz
18784465_7	0	Limited_variation	16,20	HLA-B * 5701
18784465_7	0	Limited_variation	27,31	HLA-B * 5701
22935222_7	0	Chemical	5,5	naringenin
22935222_7	0	Gene_or_protein	7,10	CYP1B1
22935222_7	0	Phenotype	18,22	CYP1A1 activity
22935222_7	0	Gene_or_protein	18,21	CYP1A1
19536092_9	0	Gene_or_protein	5,5	ATM
19536092_9	0	Gene_or_protein	7,8	ERCC5
19536092_9	0	Chemical	14,14	oxaliplatin
19536092_9	0	Disease	17,17	ACC
19536092_9	0	Pharmacodynamic_phenotype	14,15	oxaliplatin efficacy
19398669_11	0	Limited_variation	2,9	Genetic polymorphism 677 C>T on MTHFR
19398669_11	0	Gene_or_protein	9,9	MTHFR
19398669_11	0	Chemical	12,14	5-MTHF
19398669_11	0	Chemical	18,18	homocysteine
19398669_11	0	Chemical	34,36	5-MTHF
19398669_11	0	Chemical	38,38	homocysteine
19398669_11	0	Pharmacodynamic_phenotype	30,36,39,41	chronic effects of vascular 5-MTHF on vascular wall
19398669_11	0	Pharmacodynamic_phenotype	30,32,38,41	chronic effects of homocysteine on vascular wall
21288822_9	0	Gene_or_protein	8,9	pfmdr1
21288822_9	0	Chemical	11,11	amodiaquine
21288822_9	0	Pharmacodynamic_phenotype	13,14	mefloquine resistance
21288822_9	0	Chemical	13,13	mefloquine
21288822_9	0	Gene_or_protein	19,20	pfmdr1
21288822_9	0	Pharmacodynamic_phenotype	11,11,14,14	amodiaquine resistance
17112802_1	0	Limited_variation	0,4	CYP2A6 genotype
17112802_1	0	Gene_or_protein	0,3	CYP2A6
17112802_1	0	Chemical	12,12	nicotine
17112802_1	0	Pharmacokinetic_phenotype	9,12	disposition kinetics of nicotine
17112802_1	0	Pharmacokinetic_phenotype	7,7,10,12	metabolism kinetics of nicotine
27864013_5	0	Limited_variation	22,29	BRAF ( V600E ) - mutant
27864013_5	0	Gene_or_protein	22,22	BRAF
27864013_5	0	Gene_or_protein	31,31	BRAF
27864013_5	0	Limited_variation	31,38	BRAF ( V600K ) - mutant
27864013_5	0	Disease	31,40	BRAF ( V600K ) - mutant metastatic melanoma
27864013_5	0	Chemical	47,47	dabrafenib
27864013_5	0	Chemical	53,53	trametinib
27864013_5	0	Disease	22,29,39,40	BRAF ( V600E ) - mutant metastatic melanoma
27864013_5	0	Chemical	47,47,52,53	dabrafenib plus trametinib
14558439_3	0	Chemical	4,19	4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
14558439_3	0	Gene_or_protein	1,2	JAK3
14558439_3	0	Chemical	21,26	CAS 202475-60-3
14558439_3	0	Gene_or_protein	48,49	JAK3
14558439_3	0	Chemical	28,30	JANEX-1
14558439_3	0	Chemical	32,35	WHI-P131
14558439_3	0	Phenotype	39,42	rejection of islet allografts
14558439_3	0	Chemical	1,3	JAK3 inhibitor
14558439_3	0	Phenotype	48,51	JAK3 expression status
20015348_11	0	Chemical	10,10	GCV
20015348_11	0	Phenotype	18,21	caspase3 protein expression
20015348_11	0	Gene_or_protein	18,19	caspase3
20015348_11	0	Chemical	6,8	BI-TK
20015348_11	0	Chemical	6,10	BI-TK / GCV
16146333_7	0	Chemical	26,30	estrone-3-sulfate
16146333_7	0	Chemical	32,44	17beta-estradiol 17-(beta-D-glucuronide )
16146333_7	0	Chemical	47,47	methotrexate
16146333_7	0	Pharmacodynamic_phenotype	7,10	resistance against chemotherapeutic agents
16146333_7	0	Chemical	9,10	chemotherapeutic agents
16146333_7	0	Gene_or_protein	12,12	BCRP
16146333_7	0	Chemical	17,18	organic molecules
19273354_4	0	Disease	8,8	diabetes
19273354_4	0	Limited_variation	11,13	TCF1 mutations
19273354_4	0	Gene_or_protein	11,12	TCF1
19273354_4	0	Pharmacodynamic_phenotype	20,23	hypoglycaemic effects of sulphonylureas
19273354_4	0	Limited_variation	26,27,31,31	KCNJ11 mutations
19273354_4	0	Gene_or_protein	26,27	KCNJ11
19273354_4	0	Gene_or_protein	29,30	ABCC8
19273354_4	0	Chemical	34,34	sulphonylureas
19273354_4	0	Limited_variation	29,31	ABCC8 mutations
19273354_4	0	Chemical	23,23	sulphonylureas
19273354_4	0	Chemical	41,41	insulin
17919354_6	0	Limited_variation	3,4	HFE mutations
17919354_6	0	Gene_or_protein	3,3	HFE
17919354_6	0	Chemical	6,6	anastrozole
17919354_6	0	Chemical	8,8	tamoxifen
17919354_6	0	Disease	23,24	breast cancer
17919354_6	0	Chemical	12,12	chemotherapy
25350163_8	0	Limited_variation	7,12	F508del - CFTR homozygous
25350163_8	0	Gene_or_protein	11,11	CFTR
25350163_8	0	Disease	7,13	F508del - CFTR homozygous CF
25350163_8	0	Chemical	17,21	combination of cysteamine and EGCG
25350163_8	0	Chemical	21,21	EGCG
25350163_8	0	Gene_or_protein	23,24	BECN1
25350163_8	0	Phenotype	27,29	SQSTM1 levels
25350163_8	0	Gene_or_protein	27,28	SQSTM1
25350163_8	0	Phenotype	32,33	CFTR function
25350163_8	0	Gene_or_protein	32,32	CFTR
25350163_8	0	Chemical	46,46	chloride
25350163_8	0	Gene_or_protein	61,65	TNF / TNF-alpha
25350163_8	0	Disease	67,67	tumor
25350163_8	0	Gene_or_protein	75,85	chemokine [C-X-C motif] ligand 8
25350163_8	0	Gene_or_protein	72,73	CXCL8
25350163_8	0	Phenotype	92,92,96,97	TNF protein levels
25350163_8	0	Gene_or_protein	92,92	TNF
25350163_8	0	Gene_or_protein	94,95	CXCL8
25350163_8	0	Chemical	19,19	cysteamine
25350163_8	0	Pharmacodynamic_phenotype	46,49	chloride concentrations in sweat
25350163_8	0	Phenotype	23,24,29,29	BECN1 levels
25350163_8	0	Phenotype	59,65,87,87	abundance of TNF / TNF-alpha transcripts
25350163_8	0	Gene_or_protein	67,69	tumor necrosis factor
25350163_8	0	Phenotype	59,60,72,73,87,87	abundance of CXCL8 transcripts
25350163_8	0	Phenotype	94,97	CXCL8 protein levels
16115938_12	0	Disease	14,14	tumor
16115938_12	0	Disease	21,21	cancer
16115938_12	0	Chemical	2,9	antisense PKA RIalpha and CpG immunomer in combination
16115938_12	0	Chemical	6,7	CpG immunomer
16115938_12	0	Chemical	14,17	tumor -targeted therapeutics
16115938_12	0	Chemical	2,4	antisense PKA RIalpha
20028383_1	0	Chemical	4,4	irinotecan
20028383_1	0	Chemical	6,6	doxifluridine
20028383_1	0	Disease	8,10	metastatic colorectal cancer
20028383_1	0	Gene_or_protein	14,17	UGT1A1
20028383_1	0	Chemical	4,6	irinotecan and doxifluridine
20028383_1	0	Haplotype	14,19	UGT1A1 * 28
19884861_11	0	Limited_variation	3,4	EGFR mutations
19884861_11	0	Gene_or_protein	3,3	EGFR
19884861_11	0	Disease	21,21	NSCLC
19884861_11	0	Chemical	26,26	erlotinib
19884861_11	0	Chemical	23,23	docetaxel
19884861_11	0	Phenotype	15,16	favorable outcomes
19884861_11	0	Chemical	23,26	docetaxel plus intercalated erlotinib
24040330_2	0	Chemical	8,8	glutathione
24040330_2	0	Gene_or_protein	16,17	GSTT1
24040330_2	0	Gene_or_protein	19,20	GSTP1
24040330_2	0	Limited_variation	22,23	rs1695
24040330_2	0	Limited_variation	28,29	rs4925
24040330_2	0	Gene_or_protein	25,26	GSTO1
24040330_2	0	Gene_or_protein	31,32	GSTO2
24040330_2	0	Limited_variation	34,35	rs156697
24040330_2	0	Gene_or_protein	37,38	GSTM1
24040330_2	0	Gene_or_protein	40,41	GSTA1
24040330_2	0	Limited_variation	43,44	rs3957357
24040330_2	0	Disease	54,55	bladder cancer
24040330_2	0	Gene_or_protein	8,9	glutathione transferase
24040330_2	0	Gene_or_protein	11,11	GST
24040330_2	0	Limited_variation	8,14	glutathione transferase ( GST ) gene polymorphisms
24040330_2	0	Phenotype	48,48	survival
24040330_2	0	Chemical	62,62	chemotherapy
24040330_2	0	Pharmacodynamic_phenotype	60,62	effect on chemotherapy
23918539_1	0	Limited_variation	0,5	Genetic variation in NOS2A
23918539_1	0	Gene_or_protein	3,5	NOS2A
23918539_1	0	Chemical	16,16	ribavirin
23918539_1	0	Disease	19,21	chronic hepatitis C
23918539_1	0	Pharmacodynamic_phenotype	10,17	sustained virological response to peginterferon plus ribavirin therapy
23918539_1	0	Chemical	14,14	peginterferon
23918539_1	0	Chemical	14,17	peginterferon plus ribavirin therapy
12893983_9	0	Gene_or_protein	5,6	GNB3
12893983_9	0	Limited_variation	5,10	GNB3 C825T polymorphism
12893983_9	0	Disease	18,18	obese
12893983_9	0	Chemical	24,24	sibutramine
19663671_7	0	Limited_variation	4,9,36,39	c.1236C>T SNPs of ABCB1
19663671_7	0	Limited_variation	15,20,36,39	c.2677G>T SNPs of ABCB1
19663671_7	0	Limited_variation	26,31,36,39	c.3435C>T SNPs of ABCB1
19663671_7	0	Gene_or_protein	38,39	ABCB1
19663671_7	0	Chemical	50,50	clozapine
19663671_7	0	Chemical	52,52	norclozapine
19663671_7	0	Chemical	106,106	clozapine
19663671_7	0	Pharmacodynamic_phenotype	47,50	plasma levels of clozapine
19663671_7	0	Pharmacodynamic_phenotype	47,49,52,52	plasma levels of norclozapine
19663671_7	0	Genomic_factor	11,12	exon 12
19663671_7	0	Genomic_factor	22,23	exon 21
19663671_7	0	Genomic_factor	33,34	exon 26
19891556_6	0	Chemical	8,8	clopidogrel
19891556_6	0	Limited_variation	18,22	CYP2C19 genotype
19891556_6	0	Gene_or_protein	18,21	CYP2C19
19891556_6	0	Chemical	24,24	clopidogrel
19891556_6	0	Pharmacokinetic_phenotype	24,25	clopidogrel pharmacokinetics
19891556_6	0	Pharmacodynamic_phenotype	24,24,27,27	clopidogrel pharmacodynamics
19891556_6	0	Pharmacodynamic_phenotype	24,24,29,30	clopidogrel clinical response
11238813_6	0	Chemical	1,2	diallyl disulfide
11238813_6	0	Gene_or_protein	7,9	H-ras
11238813_6	0	Gene_or_protein	19,20	p21
11238813_6	0	Gene_or_protein	22,24	H-ras
11238813_6	0	Pharmacodynamic_phenotype	1,10	diallyl disulfide -mediated inhibition of H-ras oncogene
11238813_6	0	Phenotype	17,27	inhibition of p21 ( H-ras ) membrane association
11238813_6	0	Phenotype	12,13	tumor growth
11238813_6	0	Disease	12,12	tumor
11238813_6	0	Pharmacodynamic_phenotype	5,10	inhibition of H-ras oncogene
22942289_9	0	Chemical	5,7	VX-770
22942289_9	0	Gene_or_protein	10,10	CFTR
19396436_11	0	Gene_or_protein	2,3	DRD3
19396436_11	0	Limited_variation	2,7	DRD3 Ser9Gly polymorphisms
19396436_11	0	Pharmacodynamic_phenotype	14,16	efficacy of pramipexole
19396436_11	0	Chemical	16,16	pramipexole
19396436_11	0	Disease	21,21	PD
23736108_9	0	Gene_or_protein	12,12	TAPBP
23736108_9	0	Limited_variation	13,14	rs2071888
23736108_9	0	Limited_variation	41,42	rs1059288
23736108_9	0	Disease	56,56	AERD
23736108_9	0	Chemical	61,61	aspirin
23736108_9	0	Disease	64,64	asthma
23736108_9	0	Disease	61,64	aspirin -tolerant asthma
26773964_3	0	Limited_variation	11,15	CYP3A5 polymorphism
26773964_3	0	Gene_or_protein	11,14	CYP3A5
26773964_3	0	Phenotype	20,23	CYP3A activity
26773964_3	0	Gene_or_protein	20,22	CYP3A
26773964_3	0	Chemical	35,38	4b-hydroxycholesterol
26773964_3	0	Pharmacodynamic_phenotype	32,38	plasma concentration of 4b-hydroxycholesterol
26773964_3	0	Disease	26,27	kidney transplantation
22418828_5	0	Gene_or_protein	4,7	CYP2C19
22418828_5	0	Chemical	35,35	pantoprazole
22418828_5	0	Gene_or_protein	43,46	CYP2C19
22418828_5	0	Haplotype	4,12	CYP2C19 * 2 / * 2
22418828_5	0	Pharmacodynamic_phenotype	32,35	plasma concentrations of pantoprazole
22418828_5	0	Haplotype	43,51	CYP2C19 * 1 / * 1
22418828_5	0	Limited_variation	39,51	wild-type ( CYP2C19 * 1 / * 1
21908221_3	0	Chemical	7,8	hormone therapy
21908221_3	0	Chemical	10,10	HT
21908221_3	0	Chemical	19,21	8-OHdG
21908221_3	0	Chemical	28,30	8-OHdG
21908221_3	0	Gene_or_protein	35,36	OGG1
21908221_3	0	Limited_variation	35,39	OGG1 S326C
21908221_3	0	Chemical	45,45	HT
21908221_3	0	Pharmacodynamic_phenotype	18,22	urinary 8-OHdG levels
21908221_3	0	Pharmacodynamic_phenotype	16,16,19,22	blood 8-OHdG levels
21908221_3	0	Pharmacodynamic_phenotype	26,30	level of 8-OHdG
19481104_8	0	Gene_or_protein	9,10	Gsta2
19481104_8	0	Gene_or_protein	12,15	Sult2a1
19481104_8	0	Gene_or_protein	17,18	Fgl1
19481104_8	0	Chemical	34,37	CCl(4)
19481104_8	0	Gene_or_protein	20,21	C6
19481104_8	0	Pharmacodynamic_phenotype	34,39	CCl(4) - hepatotoxicity
19391036_8	0	Gene_or_protein	5,7	A1298C
19391036_8	0	Limited_variation	12,15	C677T polymorphism
19391036_8	0	Chemical	19,19	MTX
19391036_8	0	Pharmacodynamic_phenotype	19,22	MTX -related toxicity
18654768_9	0	Gene_or_protein	9,12	CYP2C19
18654768_9	0	Chemical	23,23	escitalopram
18654768_9	0	Chemical	25,25	omeprazole
18654768_9	0	Pharmacokinetic_phenotype	25,26	omeprazole kinetics
18654768_9	0	Pharmacokinetic_phenotype	23,23,26,26	escitalopram kinetics
18654768_9	0	Chemical	9,13	CYP2C19 substrates
18654768_9	0	Limited_variation	29,29	genotypes
22401810_16	0	Limited_variation	5,7	FSHR gene variations
22401810_16	0	Gene_or_protein	5,5	FSHR
22401810_16	0	Limited_variation	10,12	Asn680Ser
22401810_16	0	Limited_variation	18,20	Thr449Ile
22401810_16	0	Limited_variation	23,25	Ile160Thr
22401810_16	0	Gene_or_protein	48,48	AMH
22401810_16	0	Limited_variation	14,16	Ala189Val
22401810_16	0	Pharmacodynamic_phenotype	36,39	response to fertility treatment
22401810_16	0	Phenotype	43,45	low ovarian reserve
27217047_12	0	Gene_or_protein	16,19	CYP3A5
27217047_12	0	Gene_or_protein	27,30	CYP3A5
27217047_12	0	Haplotype	27,32	CYP3A5 * 1
27217047_12	0	Pharmacodynamic_phenotype	3,8	daily dosage of Tac -QD
27217047_12	0	Haplotype	16,24	CYP3A5 * 3 / * 3
27217047_12	0	Chemical	6,8	Tac -QD
26418006_3	0	Chemical	3,3	gemcitabine
26418006_3	0	Phenotype	7,10	activities of cytidine deaminase
26418006_3	0	Gene_or_protein	12,12	CDA
26418006_3	0	Gene_or_protein	9,10	cytidine deaminase
26418006_3	0	Gene_or_protein	21,22	hENT1
26418006_3	0	Gene_or_protein	25,26	deoxycytidine kinase
26418006_3	0	Gene_or_protein	28,28	DCK
26418006_3	0	Gene_or_protein	32,35	ribonucleotide reductase M1
26418006_3	0	Gene_or_protein	37,38	RRM1
26418006_3	0	Gene_or_protein	16,19	equilibrative nucleoside transporter 1
26418006_3	0	Pharmacodynamic_phenotype	3,4	gemcitabine response
26418006_3	0	Phenotype	7,8,15,19	activities of human equilibrative nucleoside transporter 1
26418006_3	0	Phenotype	7,8,25,26	activities of deoxycytidine kinase
26418006_3	0	Phenotype	7,8,32,35	activities of ribonucleotide reductase M1
19190113_1	0	Limited_variation	1,6	variation in the DIO2 gene
19190113_1	0	Gene_or_protein	4,5	DIO2
19190113_1	0	Chemical	17,17	thyroxine
19190113_1	0	Chemical	19,19	triiodothyronine
19190113_1	0	Disease	22,22	hypothyroid
19190113_1	0	Pharmacodynamic_phenotype	14,19	response to combination thyroxine plus triiodothyronine
19190113_1	0	Chemical	16,19	combination thyroxine plus triiodothyronine
19190113_1	0	Phenotype	9,12	psychological well-being
23127338_3	0	Gene_or_protein	16,18	eIF3a
23127338_3	0	Limited_variation	24,28	eIF3a mutation status
23127338_3	0	Gene_or_protein	24,26	eIF3a
23127338_3	0	Chemical	35,35	platinum
23127338_3	0	Limited_variation	9,11,14,19	mutations in promoter regions of eIF3a gene
23127338_3	0	Limited_variation	9,10,13,19	mutations in exon regions of eIF3a gene
23127338_3	0	Chemical	35,38	platinum -based chemotherapeutic
23127338_3	0	Disease	39,40	lung cancer
23127338_3	0	Genomic_factor	13,19	exon regions of eIF3a gene
23127338_3	0	Genomic_factor	11,11,14,19	promoter regions of eIF3a gene
22329352_1	0	Chemical	0,0	Thalidomide
22329352_1	0	Disease	8,8	myeloma
22329352_1	0	Gene_or_protein	18,22	fibroblast growth factor receptor 3
22329352_1	0	Phenotype	10,10,16,22	normal expression of fibroblast growth factor receptor 3
22329352_1	0	Phenotype	3,8	progression-free survival in myeloma
22329352_1	0	Disease	28,28	Leukaemia
22329352_1	0	Disease	30,30	Lymphoma
22329352_1	0	Phenotype	13,22	up-regulated expression of fibroblast growth factor receptor 3
16550163_3	0	Chemical	12,12	thiopurine
16550163_3	0	Gene_or_protein	18,18	TPMT
26056325_2	0	Chemical	2,2	Vemurafenib
26056325_2	0	Chemical	4,4	dabrafenib
26056325_2	0	Disease	22,22	melanoma
26056325_2	0	Limited_variation	24,30	BRAF (V600E ) mutation
26056325_2	0	Gene_or_protein	24,24	BRAF
26103436_16	0	Disease	12,12	MCL
26103436_16	0	Chemical	16,16	bortezomib
26103436_16	0	Chemical	22,22	lenalidamide
26103436_16	0	Gene_or_protein	31,35	Bruton's Tyrosine Kinase
26103436_16	0	Chemical	29,29	Ibruitinib
26103436_16	0	Gene_or_protein	37,37	BTK
26103436_16	0	Disease	47,47	MCL
26103436_16	0	Chemical	18,19	NFkB inhibitor
26103436_16	0	Chemical	31,39	Bruton's Tyrosine Kinase [ BTK ] inhibitor
26103436_16	0	Chemical	24,26	anti-angiogenesis
15650426_10	0	Chemical	2,2	MVA
15650426_10	0	Gene_or_protein	23,23	Env
15650426_10	0	Gene_or_protein	13,14	CD8
15650426_10	0	Gene_or_protein	10,11	CD4
15650426_10	0	Pharmacodynamic_phenotype	10,11,15,17	CD4 T cell responses
15650426_10	0	Pharmacodynamic_phenotype	13,17	CD8 T cell responses
15650426_10	0	Pharmacodynamic_phenotype	21,25	anti- Env Ab titers
17555717_6	0	Gene_or_protein	2,3	DTNBP1
17555717_6	0	Pharmacodynamic_phenotype	8,9	methamphetamine psychosis
17555717_6	0	Chemical	8,8	methamphetamine
17555717_6	0	Limited_variation	11,14	polymorphisms of P1635
17555717_6	0	Chemical	13,14	P1635
17555717_6	0	Limited_variation	11,12,25,25	polymorphisms of SNPA
17555717_6	0	Haplotype	40,52	haplotype of P1655 ( rs2619539 ) - P1635- SNPA
17555717_6	0	Gene_or_protein	25,25	SNPA
17555717_6	0	Limited_variation	16,17	rs3213207
17555717_6	0	Limited_variation	27,28	rs2619538
17555717_6	0	Limited_variation	45,46	rs2619539
16819620_6	0	Gene_or_protein	16,17	DRD4
16819620_6	0	Chemical	34,34	alcohol
16819620_6	0	Gene_or_protein	24,26	5-HTT
16819620_6	0	Gene_or_protein	11,14	DA D4 receptor
16819620_6	0	Gene_or_protein	21,22	serotonin transporter
16819620_6	0	Limited_variation	11,18,28,28	DA D4 receptor ( DRD4 ) genotype
16819620_6	0	Limited_variation	21,28	serotonin transporter ( 5-HTT ) genotype
16819620_6	0	Chemical	36,36	tobacco
11967152_6	0	Chemical	11,11	CPP
11967152_6	0	Gene_or_protein	26,27	alpha CaMKII
11967152_6	0	Limited_variation	26,35	alpha CaMKII ( T286A + / - )
11967152_6	0	Limited_variation	20,20	WT
11967152_6	0	Phenotype	38,42	hippocampal long-term potentiation
11967152_6	0	Phenotype	44,44	LTP
19179437_6	0	Chemical	5,5	leptin
19179437_6	0	Gene_or_protein	9,16	signal transducer and activator of transcription-3
19179437_6	0	Pharmacodynamic_phenotype	9,17	signal transducer and activator of transcription-3 expression
19179437_6	0	Pharmacodynamic_phenotype	5,17	leptin -induced robust signal transducer and activator of transcription-3 expression
17559964_9	0	Limited_variation	3,6	GNB3 CC genotype
17559964_9	0	Gene_or_protein	3,4	GNB3
17559964_9	0	Limited_variation	18,21	non- CC genotype
17559964_9	0	Phenotype	10,10	SVR
22095536_2	0	Chemical	19,21	PEG-IFN
22095536_2	0	Gene_or_protein	34,36	IL28B
22095536_2	0	Chemical	17,17	peginterferon
22095536_2	0	Chemical	17,25	peginterferon ( PEG-IFN ) and ribavirin combination
22095536_2	0	Limited_variation	30,37	genetic polymorphisms near the IL28B gene
22095536_2	0	Phenotype	8,10	early viral dynamics
22095536_2	0	Pharmacodynamic_phenotype	15,26	outcome of peginterferon ( PEG-IFN ) and ribavirin combination therapy
22095536_2	0	Chemical	24,24	ribavirin
22095536_2	0	Pharmacodynamic_phenotype	44,47	response to this therapy
21995595_10	0	Gene_or_protein	5,6	ENO2
21995595_10	0	Phenotype	16,20	reduced ENO2 gene expression
21995595_10	0	Gene_or_protein	17,18	ENO2
21995595_10	0	Disease	12,13	heroin dependence
21995595_10	0	Disease	26,27	heroin dependence
21995595_10	0	Chemical	12,12	heroin
21995595_10	0	Chemical	26,26	heroin
18647087_1	0	Chemical	1,4	PEG - PEI copolymers
18647087_1	0	Chemical	3,3	PEI
18647087_1	0	Phenotype	12,13	dystrophin expression
18647087_1	0	Gene_or_protein	12,12	dystrophin
18647087_1	0	Chemical	1,1	PEG
14604772_9	0	Gene_or_protein	1,3	TNF-alpha
14604772_9	0	Chemical	15,15	ibudilast
14604772_9	0	Phenotype	1,5	TNF-alpha immunoreactive glia
25637161_10	0	Phenotype	2,7	overexpression of antiapoptotic BCL-2
25637161_10	0	Gene_or_protein	5,7	BCL-2
25637161_10	0	Pharmacodynamic_phenotype	14,20	BEZ235 / CQ -induced apoptosis
25637161_10	0	Pharmacodynamic_phenotype	33,40	BEZ235 / CQ -induced cell death
25637161_10	0	Chemical	14,17	BEZ235 / CQ
25637161_10	0	Pharmacodynamic_phenotype	20,20	apoptosis
25637161_10	0	Pharmacodynamic_phenotype	39,40	cell death
25637161_10	0	Chemical	33,36	BEZ235 / CQ
24782176_7	0	Chemical	11,11	MTX
24782176_7	0	Pharmacodynamic_phenotype	11,11,14,14	MTX toxicity
24782176_7	0	Gene_or_protein	23,24	RFC1
24782176_7	0	Limited_variation	17,30	reduced folate carrier 1 gene ( RFC1 ) variant 80G>A
24782176_7	0	Limited_variation	38,39	rs1051266
24782176_7	0	Gene_or_protein	17,21	reduced folate carrier 1 gene
24782176_7	0	Pharmacodynamic_phenotype	11,12	MTX efficacy
27717041_2	0	Chemical	2,2	Alcohol
27717041_2	0	Limited_variation	8,14	single-nucleotide polymorphisms in GABRA2
27717041_2	0	Gene_or_protein	13,14	GABRA2
27717041_2	0	Disease	2,4	Alcohol use disorders
27717041_2	0	Gene_or_protein	20,25	GABAA receptor a2-subunit
12057079_3	0	Gene_or_protein	2,3	HER2
12057079_3	0	Chemical	32,33	hormonal agents
12057079_3	0	Phenotype	8,9	malignant transformation
12057079_3	0	Pharmacodynamic_phenotype	23,30	resistant to non- anthracycline -based therapies
12057079_3	0	Pharmacodynamic_phenotype	23,24,32,33	resistant to hormonal agents
12057079_3	0	Disease	17,18	breast cancer
12057079_3	0	Chemical	38,40	targeted molecular therapy
12057079_3	0	Chemical	25,30	non- anthracycline -based therapies
17062187_6	0	Limited_variation	3,5	M184V
17062187_6	0	Limited_variation	7,9	Q151M
17062187_6	0	Chemical	13,16	nucleoside reverse transcriptase inhibitors
17062187_6	0	Limited_variation	33,35	V71I
17062187_6	0	Limited_variation	37,39	L90M
17062187_6	0	Chemical	43,43	nelfinavir
17062187_6	0	Chemical	18,18	NRTIs
17062187_6	0	Disease	21,24	HIV-1 infection
17062187_6	0	Chemical	41,41	indinavir
17062187_6	0	Pharmacodynamic_phenotype	11,19	resistance to nucleoside reverse transcriptase inhibitors ( NRTIs )
17062187_6	0	Pharmacodynamic_phenotype	43,44	nelfinavir resistance
17062187_6	0	Pharmacodynamic_phenotype	41,41,44,44	indinavir resistance
16153394_11	0	Chemical	3,3	terbutaline
16153394_11	0	Gene_or_protein	7,10	beta2-AR
16153394_11	0	Haplotype	19,28	haplotype A ( Arg 16Gln27Thr164 )
16153394_11	0	Haplotype	33,42	haplotype B ( Gly16Gln27Thr164 )
16153394_11	0	Haplotype	49,58	haplotype C ( Gly16Glu27Thr164 )
16153394_11	0	Pharmacodynamic_phenotype	5,10	desensitizes venous beta2-AR
17190370_3	0	Gene_or_protein	12,13	ABCB1
17190370_3	0	Chemical	21,25	( R ) - lansoprazole
17190370_3	0	Phenotype	32,37	CYP2C19 extensive metabolizers
17190370_3	0	Phenotype	43,44	gastroesophageal symptoms
17190370_3	0	Chemical	50,50	tacrolimus
17190370_3	0	Limited_variation	12,16	ABCB1 C3435Tpolymorphism
17190370_3	0	Pharmacokinetic_phenotype	19,25	pharmacokinetics of ( R ) - lansoprazole
17190370_3	0	Phenotype	39,39	EMs
17190370_3	0	Gene_or_protein	32,35	CYP2C19
17190370_3	0	Disease	46,47	renal transplant
24886060_7	0	Phenotype	2,5	Expression of NQO1
24886060_7	0	Gene_or_protein	4,5	NQO1
24886060_7	0	Pharmacodynamic_phenotype	8,12	sensitivity to 17-AAG
24886060_7	0	Chemical	10,12	17-AAG
24886060_7	0	Disease	15,15	OSCC
24886060_7	0	Gene_or_protein	25,26	HSP90
24886060_7	0	Chemical	36,38	17-AAG
24886060_7	0	Phenotype	24,26	expressed HSP90
24886060_7	0	Pharmacodynamic_phenotype	34,38	resistant to 17-AAG
23959853_1	0	Chemical	6,6	cefadroxil
23959853_1	0	Gene_or_protein	16,17	PepT1
23959853_1	0	Pharmacokinetic_phenotype	4,6	disposition of cefadroxil
23959853_1	0	Limited_variation	12,14,16,17	wild-type PepT1
23959853_1	0	Genomic_variation	16,18	PepT1 knockout
23959853_1	0	Pharmacokinetic_phenotype	2,2,5,6	absorption of cefadroxil
19912163_13	0	Chemical	15,15	mizoribine
19912163_13	0	Limited_variation	24,26	G565A
19912163_13	0	Pharmacodynamic_phenotype	7,15	dose-normalized C ( 12 ) of mizoribine
19912163_13	0	Pharmacokinetic_phenotype	17,21	substitute CL ( MZ )
17548696_4	0	Phenotype	7,8	skin lesions
17548696_4	0	Gene_or_protein	18,23	glutathione S-transferase omega1
17548696_4	0	Gene_or_protein	25,26	methylenetetrahydrofolate reductase
17548696_4	0	Chemical	32,33	monomethylarsonous acid
17548696_4	0	Chemical	36,36	MMA
17548696_4	0	Chemical	43,43	DMA
17548696_4	0	Chemical	39,40	dimethylarsinic acid
17548696_4	0	Chemical	52,52	MMA
17548696_4	0	Chemical	55,55	arsenic
17548696_4	0	Chemical	57,57	DMA
17548696_4	0	Chemical	59,59	MMA
17548696_4	0	Limited_variation	15,23	polymorphisms in the glutathione S-transferase omega1
17548696_4	0	Limited_variation	15,17,25,26	polymorphisms in the methylenetetrahydrofolate reductase
17548696_4	0	Phenotype	50,55	ratios of MMA to inorganic arsenic
17548696_4	0	Phenotype	50,51,57,59	ratios of DMA to MMA
17548696_4	0	Phenotype	30,33,45,46	percentage of monomethylarsonous acid in urine
17548696_4	0	Phenotype	30,31,39,40,45,46	percentage of dimethylarsinic acid in urine
17548696_4	0	Phenotype	35,36	% MMA
17548696_4	0	Phenotype	42,43	% DMA
17586618_1	0	Chemical	0,0	Homocysteine
17586618_1	0	Phenotype	2,6	VCAM-1 gene expression
17586618_1	0	Gene_or_protein	2,4	VCAM-1
17586618_1	0	Phenotype	12,18	NAD(P)H oxidase activation
17586618_1	0	Gene_or_protein	12,17	NAD(P)H oxidase
17586618_1	0	Gene_or_protein	8,10	NF-kappaB
17586618_1	0	Phenotype	8,10,18,18	NF-kappaB activation
17586618_1	0	Chemical	25,26	polyphenolic antioxidants
12824799_5	0	Pharmacodynamic_phenotype	20,21	stavudine resistance
12824799_5	0	Limited_variation	5,11	Y181I /C RT changes
12824799_5	0	Gene_or_protein	10,10	RT
12824799_5	0	Chemical	14,14	nevirapine
12824799_5	0	Chemical	20,20	stavudine
12824799_5	0	Chemical	17,17	NNRTI
20306339_17	0	Chemical	9,9	capecitabine
20306339_17	0	Disease	12,13	pancreatic cancer
20306339_17	0	Gene_or_protein	17,17	TYMS
20306339_17	0	Limited_variation	17,23	TYMS * 2 / * 2 variant
20306339_17	0	Pharmacodynamic_phenotype	29,32	non-hematologic toxicity
17430486_2	0	Gene_or_protein	0,2	CYP3A
17430486_2	0	Chemical	9,9	TAC
17430486_2	0	Pharmacokinetic_phenotype	9,10	TAC metabolism
25261422_8	0	Chemical	11,11	tenofovir
25261422_8	0	Chemical	13,13	emtricitabine
25261422_8	0	Limited_variation	24,26	M41L
25261422_8	0	Disease	20,22	HIV-1
25261422_8	0	Disease	20,26	HIV-1 harbouring M41L
9761125_9	0	Limited_variation	5,7	p53 mutation
9761125_9	0	Gene_or_protein	5,6	p53
9761125_9	0	Chemical	18,18	phenacetin
9761125_9	0	Phenotype	18,19	phenacetin abuse
9761125_9	0	Phenotype	21,21	smoking
22501025_4	0	Chemical	17,17	alcohol
22501025_4	0	Limited_variation	22,25	variation in GABRA2
22501025_4	0	Gene_or_protein	24,25	GABRA2
22501025_4	0	Pharmacodynamic_phenotype	15,17	effects of alcohol
22501025_4	0	Phenotype	6,8	differences in SRs
8834564_2	0	Disease	5,6	spontaneous abortion
8834564_2	0	Gene_or_protein	13,16	glutathione S-transferase
8834564_2	0	Gene_or_protein	18,19	GSTM1
8834564_2	0	Gene_or_protein	26,27	NAT2
8834564_2	0	Gene_or_protein	22,24	N -acetyltransferase
8834564_2	0	Limited_variation	8,9,13,16	polymorphisms in glutathione S-transferase
8834564_2	0	Limited_variation	8,9,22,24	polymorphisms in N -acetyltransferase
8834564_2	0	Chemical	37,37	xenobiotics
8834564_2	0	Pharmacokinetic_phenotype	35,37	metabolism of xenobiotics
17558305_5	0	Haplotype	4,7	UGT1A haplotypes
17558305_5	0	Chemical	16,19	SN-38 glucuronide
17558305_5	0	Pharmacodynamic_phenotype	26,26	toxicities
17558305_5	0	Disease	32,32	cancer
17558305_5	0	Chemical	36,36	irinotecan
17558305_5	0	Pharmacokinetic_phenotype	10,24	area under concentration curve ratio ( SN-38 glucuronide / SN -38 )
17558305_5	0	Chemical	21,23	SN -38
17558305_5	0	Chemical	44,44	chemotherapy
17558305_5	0	Gene_or_protein	4,6	UGT1A
23617284_5	0	Gene_or_protein	8,11	xeroderma pigmentosum group A
23617284_5	0	Gene_or_protein	13,13	XPA
23617284_5	0	Gene_or_protein	18,21	xeroderma pigmentosum group D
23617284_5	0	Gene_or_protein	23,23	XPD
23617284_5	0	Chemical	38,40	platinum based chemotherapy
23617284_5	0	Disease	43,43	NSCLC
23617284_5	0	Limited_variation	18,33	xeroderma pigmentosum group D ( XPD ) codon751 single-nucleotide polymorphisms ( SNPs )
23617284_5	0	Limited_variation	8,16,27,33	xeroderma pigmentosum group A ( XPA ) codon23 single-nucleotide polymorphisms ( SNPs )
23617284_5	0	Pharmacodynamic_phenotype	36,40	response to platinum based chemotherapy
23617284_5	0	Chemical	38,38	platinum
17898154_8	0	Chemical	2,10	3'-azido-3'-deoxythymidine
17898154_8	0	Chemical	14,14	estradiol
17898154_8	0	Chemical	16,18	17-OH
17898154_8	0	Chemical	22,23	ethinyl estradiol
17898154_8	0	Chemical	25,27	17-OH
17898154_8	0	Limited_variation	40,44	UGT1A1 genotype
17898154_8	0	Gene_or_protein	40,43	UGT1A1
17898154_8	0	Chemical	0,0	Acetaminophen
17898154_8	0	Chemical	12,12	muraglitazar
17898154_8	0	Pharmacokinetic_phenotype	35,37	rates of metabolism
19549911_9	0	Chemical	2,2	fludarabine
19549911_9	0	Gene_or_protein	4,4	SYK
19549911_9	0	Disease	11,11	cytotoxicity
19549911_9	0	Chemical	14,14	fludarabine
19549911_9	0	Chemical	4,6	SYK Inhibitor II
19549911_9	0	Chemical	8,9	R406
19549911_9	0	Chemical	0,6	Combination of fludarabine with SYK Inhibitor II
19549911_9	0	Chemical	0,3,8,9	Combination of fludarabine with R406
21849660_11	0	Chemical	2,2	Statin
21849660_11	0	Phenotype	16,16	RFS
21849660_11	0	Phenotype	19,19	OS
21849660_11	0	Disease	23,26	stage III colon cancer
21849660_11	0	Limited_variation	30,32	KRAS mutation status
21849660_11	0	Gene_or_protein	30,30	KRAS
21849660_11	0	Phenotype	14,14	DFS
21849660_11	0	Chemical	8,8	chemotherapy
24901049_9	0	Chemical	0,0	Dabrafenib
24901049_9	0	Phenotype	7,20	Ser358 phosphorylation of mixed lineage kinase domain-like protein ( MLKL )
24901049_9	0	Gene_or_protein	3,4	RIP3
24901049_9	0	Gene_or_protein	11,17	mixed lineage kinase domain-like protein
24901049_9	0	Gene_or_protein	19,19	MLKL
24901049_9	0	Phenotype	24,29	interaction between RIP3 and MLKL
24901049_9	0	Gene_or_protein	26,27	RIP3
24901049_9	0	Gene_or_protein	29,29	MLKL
27573423_1	0	Chemical	0,1	AC0010
27573423_1	0	Gene_or_protein	5,5	EGFR
27573423_1	0	Gene_or_protein	10,10	EGFR
27573423_1	0	Limited_variation	13,15	T790M
27573423_1	0	Disease	23,24	Lung Cancer
27573423_1	0	Limited_variation	9,10	Mutated EGFR
27573423_1	0	Chemical	5,6	EGFR Inhibitor
27573423_1	0	Phenotype	13,18	T790M -Induced Resistance
27573423_1	0	Phenotype	18,18	Resistance
16485141_7	0	Phenotype	8,12,32,32	high- nic o tine consumers
16485141_7	0	Chemical	28,28	nicotine
16485141_7	0	Gene_or_protein	35,38	CYP2A5
16485141_7	0	Chemical	59,59	nicotine
16485141_7	0	Gene_or_protein	84,87	CYP2A5
16485141_7	0	Chemical	11,11	o
16485141_7	0	Phenotype	43,43,63,63	low consumers
14654666_9	0	Chemical	27,28	BH4
14654666_9	0	Pharmacodynamic_phenotype	35,36	Phe tolerance
14654666_9	0	Chemical	35,35	Phe
14654666_9	0	Chemical	48,48	Phe
14654666_9	0	Limited_variation	17,24	genotype Y414C / R408W
14654666_9	0	Pharmacodynamic_phenotype	47,54	blood Phe levels < 200 micromol/L
14654666_9	0	Phenotype	7,8	3 years
14654666_9	0	Pharmacodynamic_phenotype	3,3	nonresponders
14654666_9	0	Pharmacodynamic_phenotype	14,15	clear response
21672908_11	0	Chemical	7,7	warfarin
21672908_11	0	Pharmacodynamic_phenotype	18,20	warfarin stable dose
21672908_11	0	Gene_or_protein	25,26	VKORC1
21672908_11	0	Gene_or_protein	28,31	CYP2C9
21672908_11	0	Limited_variation	22,26	genetic variants in VKORC1
21672908_11	0	Limited_variation	22,24,28,31	genetic variants in CYP2C9
21672908_11	0	Chemical	18,18	warfarin
18281523_8	0	Chemical	0,0	Gefitinib
18281523_8	0	Disease	7,7	tumor
18281523_8	0	Limited_variation	16,17	EGFR status
18281523_8	0	Gene_or_protein	16,16	EGFR
18281523_8	0	Disease	20,20	tumors
18281523_8	0	Pharmacokinetic_phenotype	3,4	PK properties
18281523_8	0	Pharmacodynamic_phenotype	11,12	PD characteristics
20308030_10	0	Pharmacodynamic_phenotype	11,11	neuropathy
20308030_10	0	Chemical	8,8	oxaliplatin
20308030_10	0	Gene_or_protein	14,15	GSTP1
20308030_10	0	Gene_or_protein	22,22	AGXT
20308030_10	0	Pharmacodynamic_phenotype	8,11	oxaliplatin -induced neuropathy
20308030_10	0	Limited_variation	14,20	GSTP1 Ile ( 105 ) Val
20308030_10	0	Limited_variation	22,27	AGXT Ile ( 340 ) Met
21187469_8	0	Chemical	4,6	5-azacytidine
21187469_8	0	Gene_or_protein	9,13	p16INK4a
26313006_9	0	Gene_or_protein	2,3	CyclinB1
26313006_9	0	Chemical	6,6	Cycloheximide
26313006_9	0	Gene_or_protein	8,9	CDK1
26313006_9	0	Chemical	12,12	Roscovitine
26313006_9	0	Pharmacodynamic_phenotype	15,19	FQI -induced mitotic arrest
26313006_9	0	Phenotype	2,4	CyclinB1 induction
26313006_9	0	Phenotype	8,10	CDK1 activity
26313006_9	0	Chemical	15,15	FQI
26313006_9	0	Pharmacodynamic_phenotype	18,19	mitotic arrest
18282182_12	0	Gene_or_protein	0,3	MEK1/2
18282182_12	0	Gene_or_protein	8,11	ERK1/2
18282182_12	0	Chemical	17,18	PD98059
18282182_12	0	Gene_or_protein	14,15	MEK1
18282182_12	0	Phenotype	22,25	COX-2 expression
18282182_12	0	Gene_or_protein	22,24	COX-2
18282182_12	0	Chemical	33,34	U0126
18282182_12	0	Gene_or_protein	28,31	MEK1/2
18282182_12	0	Phenotype	40,43	COX-2 expression
18282182_12	0	Gene_or_protein	40,42	COX-2
18282182_12	0	Chemical	14,16	MEK1 inhibitor
18282182_12	0	Chemical	28,32	MEK1/2 inhibitor
19183407_9	0	Chemical	4,6	AKR-501
19183407_9	0	Chemical	12,12	TPO
19183407_9	0	Disease	25,25	thrombocytopenia
19183407_9	0	Gene_or_protein	12,13	TPO receptor
19042106_4	0	Gene_or_protein	0,4	Catechol-O-methyltransferase
19042106_4	0	Gene_or_protein	6,6	COMT
19042106_4	0	Chemical	14,14	Ecstasy
19042106_4	0	Pharmacokinetic_phenotype	12,14	catabolism of Ecstasy
10911933_8	0	Gene_or_protein	9,9	CYP
10911933_8	0	Gene_or_protein	17,20	CYP2D6
10911933_8	0	Chemical	17,24	CYP2D6 metabolized drugs of abuse
10911933_8	0	Limited_variation	9,9,12,12	CYP genotype
10911933_8	0	Phenotype	9,10	CYP phenotype
12095411_10	0	Gene_or_protein	18,18	angiotensinogen
12095411_10	0	Phenotype	30,30	stenosis
12095411_10	0	Limited_variation	13,19	235T allele of the angiotensinogen gene
12095411_10	0	Chemical	22,22	cholesterol
19671633_2	0	Gene_or_protein	10,14	delta-aminolevulinic acid dehydratase
19671633_2	0	Gene_or_protein	16,16	ALAD
19671633_2	0	Limited_variation	19,28	matrix gamma-carboxyglutamic acid ( MGP ) gene polymorphisms
19671633_2	0	Gene_or_protein	19,23	matrix gamma-carboxyglutamic acid
19671633_2	0	Gene_or_protein	25,25	MGP
19671633_2	0	Pharmacodynamic_phenotype	33,34	lead toxicity
19671633_2	0	Limited_variation	10,17,27,28	delta-aminolevulinic acid dehydratase ( ALAD ) gene polymorphisms
19671633_2	0	Chemical	33,33	lead
22179630_14	0	Limited_variation	5,12	C/T genotype of BAG-1
22179630_14	0	Gene_or_protein	10,12	BAG-1
22179630_14	0	Gene_or_protein	22,24	Bag-1
22179630_14	0	Limited_variation	17,26	C/C genotype at Bag-1 codon 324
22179630_14	0	Chemical	31,34	platinum -based chemotherapy
22179630_14	0	Pharmacodynamic_phenotype	29,34	responses to platinum -based chemotherapy
22179630_14	0	Chemical	31,31	platinum
23757001_2	0	Gene_or_protein	21,22	serotonin transporter
23757001_2	0	Gene_or_protein	36,38	HTR3A
23757001_2	0	Gene_or_protein	40,42	HTR3B
23757001_2	0	Gene_or_protein	45,48	SLC6A4
23757001_2	0	Chemical	53,53	alcohol
23757001_2	0	Disease	56,56	AD
23757001_2	0	Disease	53,54	alcohol dependence
23757001_2	0	Gene_or_protein	13,17	5-HT3AB
23757001_2	0	Phenotype	10,11	drinking behavior
23757001_2	0	Limited_variation	31,38	genetic variations in the genes HTR3A
23757001_2	0	Limited_variation	31,35,45,48	genetic variations in the genes SLC6A4
23757001_2	0	Limited_variation	31,35,40,42	genetic variations in the genes HTR3B
20205700_9	0	Gene_or_protein	8,11	ALDH1b1
20205700_9	0	Pharmacodynamic_phenotype	26,26	hypersensitivity
20205700_9	0	Pharmacodynamic_phenotype	23,26	alcohol -induced hypersensitivity
20205700_9	0	Chemical	23,23	alcohol
20205700_9	0	Limited_variation	6,15	SNP encoding ALDH1b1 ( rs2228093 )
20205700_9	0	Limited_variation	13,14	rs2228093
22379998_2	0	Chemical	5,5	carbamazepine
22379998_2	0	Gene_or_protein	10,12	HLA-A
22379998_2	0	Pharmacodynamic_phenotype	5,8	carbamazepine -induced hypersensitivity
22379998_2	0	Haplotype	10,14	HLA-A * 3101
22379998_2	0	Pharmacodynamic_phenotype	8,8	hypersensitivity
25565175_4	0	Gene_or_protein	2,4	HLA-B
25565175_4	0	Chemical	8,8	abacavir
25565175_4	0	Pharmacodynamic_phenotype	8,10	abacavir hypersensitivity reactions
25565175_4	0	Limited_variation	2,5	HLA-B 5701
18940228_4	0	Chemical	3,3	HCH
18940228_4	0	Chemical	20,20	glutathione
18940228_4	0	Chemical	22,22	GSH
18940228_4	0	Gene_or_protein	33,33	catalase
18940228_4	0	Gene_or_protein	35,40	glucose-6-phosphate dehydrogenase
18940228_4	0	Gene_or_protein	30,30	SOD
18940228_4	0	Phenotype	10,12	hepatic lipid peroxidation
18940228_4	0	Pharmacodynamic_phenotype	18,23	levels of glutathione ( GSH )
18940228_4	0	Phenotype	25,28	activity of superoxide dismutase
18940228_4	0	Phenotype	25,26,33,33	activity of catalase
18940228_4	0	Gene_or_protein	27,28	superoxide dismutase
18940228_4	0	Phenotype	25,26,35,40	activity of glucose-6-phosphate dehydrogenase
10716965_3	0	Gene_or_protein	7,7	CRBP
10716965_3	0	Pharmacokinetic_phenotype	21,21	uptake
10716965_3	0	Gene_or_protein	1,5	cellular retinol -binding protein
10716965_3	0	Pharmacokinetic_phenotype	23,23	metabolism
10716965_3	0	Chemical	10,11	vitamin A
17680654_7	0	Chemical	6,6	telaprevir
17680654_7	0	Chemical	10,10	telaprevir
17680654_7	0	Chemical	12,19	PEG-IFN-alpha-2a
17680654_7	0	Limited_variation	22,27	A156V /T variant
17680654_7	0	Chemical	6,6,9,19	telaprevir with telaprevir / PEG-IFN-alpha-2a
17680654_7	0	Phenotype	35,36	viral levels
9164419_8	0	Chemical	9,9	lansoprazole
9164419_8	0	Limited_variation	15,28	S-mephenytoin 4'-hydroxylation ( CYP2C19 ) polymorphism
9164419_8	0	Gene_or_protein	23,26	CYP2C19
9164419_8	0	Pharmacokinetic_phenotype	7,9	hydroxylation of lansoprazole
9164419_8	0	Pharmacokinetic_phenotype	15,21	S-mephenytoin 4'-hydroxylation
9164419_8	0	Chemical	15,17	S-mephenytoin
11122156_8	0	Phenotype	10,13	alpha-globin deficiency
11122156_8	0	Gene_or_protein	10,12	alpha-globin
11122156_8	0	Disease	23,23	anaemia
11122156_8	0	Disease	32,33	Hb H
11122156_8	0	Phenotype	15,18	high Hb H levels
11122156_8	0	Limited_variation	35,39	alpha-thalassaemic haemoglobin variants
11122156_8	0	Phenotype	27,28	tissue oxygenation
11122156_8	0	Phenotype	43,45	red cell survival
11122156_8	0	Gene_or_protein	38,38	haemoglobin
11122156_8	0	Disease	16,17	Hb H
19037200_5	0	Gene_or_protein	6,6	COMT
19037200_5	0	Gene_or_protein	0,4	Catechol-O-methyltransferase
19037200_5	0	Chemical	13,13	dopamine
19037200_5	0	Pharmacokinetic_phenotype	10,13	breakdown of cerebral dopamine
24905729_3	0	Gene_or_protein	17,19	pregnane X receptor
24905729_3	0	Gene_or_protein	21,21	PXR
24905729_3	0	Chemical	25,25	rifampicin
24905729_3	0	Disease	5,8	persistent hepatocellular secretory failure
24905729_3	0	Disease	10,10	PHSF
24905729_3	0	Chemical	17,23	pregnane X receptor ( PXR ) agonist
10945855_3	0	Chemical	3,5	p-fluorofentanyl
10945855_3	0	Gene_or_protein	12,13	GIRK2
10945855_3	0	Chemical	19,19	fentanyl
10945855_3	0	Chemical	23,25	p-fluoro
10945855_3	0	Chemical	39,39	fentanyl
10945855_3	0	Chemical	50,52	p- fluorofentanyl
10945855_3	0	Gene_or_protein	16,17	opioid receptors
10945855_3	0	Gene_or_protein	9,10	GIRK1
10945855_3	0	Chemical	16,16	opioid
10864974_1	0	Phenotype	0,1	Nigrostriatal lesions
10864974_1	0	Disease	3,4	oral dyskinesia
10864974_1	0	Phenotype	6,9	c-Fos expression
10864974_1	0	Gene_or_protein	6,8	c-Fos
10864974_1	0	Chemical	15,22	1-(m-chlorophenyl)piperazine
10864974_1	0	Chemical	13,14	serotonin agonist
22077505_8	0	Pharmacodynamic_phenotype	17,17	neutropenia
22077505_8	0	Chemical	14,14	irinotecan
22077505_8	0	Gene_or_protein	20,23	UGT1A1
22077505_8	0	Pharmacodynamic_phenotype	14,17	irinotecan -induced neutropenia
22077505_8	0	Haplotype	20,25	UGT1A1 * 6
23666583_9	0	Chemical	5,5	tacrolimus
23666583_9	0	Gene_or_protein	11,14	CYP3A5
23666583_9	0	Pharmacokinetic_phenotype	5,6	tacrolimus clearance
23666583_9	0	Limited_variation	11,15	CYP3A5 genotype
22842957_3	0	Gene_or_protein	8,11	CYP2C9
22842957_3	0	Limited_variation	13,17	SLCO1B1 polymorphisms
22842957_3	0	Gene_or_protein	13,16	SLCO1B1
22842957_3	0	Chemical	22,22	nateglinide
22842957_3	0	Limited_variation	8,11,17,17	CYP2C9 polymorphisms
22842957_3	0	Pharmacokinetic_phenotype	20,22	metabolism of nateglinide
21187469_5	0	Chemical	19,21	I3C
21187469_5	0	Chemical	24,26	I3C
21187469_5	0	Gene_or_protein	32,36	p16INK4a
21187469_5	0	Disease	29,29	tumor
21187469_5	0	Disease	38,39	pancreatic cancer
17094454_10	0	Limited_variation	5,11	PSA -158 G/A polymorphism
17094454_10	0	Gene_or_protein	5,5	PSA
17094454_10	0	Genomic_factor	17,18	PSA promoter
17094454_10	0	Phenotype	17,19	PSA promoter activity
17094454_10	0	Phenotype	27,29	serum PSA level
17094454_10	0	Limited_variation	40,44	GG genotype of ARE1
17094454_10	0	Gene_or_protein	43,44	ARE1
17094454_10	0	Pharmacodynamic_phenotype	48,52	sensitive to androgen ablation therapy
17094454_10	0	Chemical	50,52	androgen ablation therapy
17094454_10	0	Gene_or_protein	17,17	PSA
17094454_10	0	Gene_or_protein	28,28	PSA
18349392_2	0	Gene_or_protein	4,7	epidermal growth factor receptor
18349392_2	0	Gene_or_protein	9,9	EGFR
18349392_2	0	Chemical	23,23	cetuximab
18349392_2	0	Disease	28,30	metastatic colorectal cancer
18349392_2	0	Disease	32,32	MCRC
18349392_2	0	Pharmacodynamic_phenotype	21,24	activity of cetuximab therapy
27350677_12	0	Limited_variation	6,12	genetic variants within the PDLIM5 gene
27350677_12	0	Gene_or_protein	10,11	PDLIM5
27350677_12	0	Chemical	21,21	steroid
27350677_12	0	Disease	24,24	cancer
27350677_12	0	Limited_variation	16,19	PLDIM5 gene polymorphisms
27350677_12	0	Gene_or_protein	16,17	PLDIM5
21890455_6	0	Chemical	0,0	IMO
21890455_6	0	Gene_or_protein	3,3	EGFR
21890455_6	0	Phenotype	11,16	interaction between TLR9 and EGFR
21890455_6	0	Gene_or_protein	13,14	TLR9
21890455_6	0	Gene_or_protein	16,16	EGFR
21890455_6	0	Phenotype	3,6	EGFR -dependent signaling
22995765_7	0	Chemical	21,21	heroin
22995765_7	0	Limited_variation	9,13	AA homozygotes of rs6943555
22995765_7	0	Disease	21,22	heroin dependent
22995765_7	0	Limited_variation	12,13	rs6943555
22102708_4	0	Limited_variation	15,17	V617F
22102708_4	0	Disease	26,27	polycythemia vera
22102708_4	0	Chemical	62,62	hydroxyurea
22102708_4	0	Chemical	69,69	imatinib
22102708_4	0	Chemical	76,76	dasatinib
22102708_4	0	Chemical	83,83	busulfan
22102708_4	0	Chemical	91,92	radioactive phosphorus
22102708_4	0	Chemical	31,31	interferon
22102708_4	0	Chemical	33,47	rIFNa-2b : 28 , Peg-rIFNa-2a : 18
22102708_4	0	Chemical	50,53	non-interferon drugs
22102708_4	0	Pharmacodynamic_phenotype	9,10	hematologic responses
22102708_4	0	Pharmacodynamic_phenotype	7,7,10,10	clinical responses
21880305_9	0	Limited_variation	8,9	rs6265
21880305_9	0	Chemical	13,13	sertraline
21880305_9	0	Limited_variation	5,9	A allele of rs6265
21880305_9	0	Pharmacodynamic_phenotype	10,14	responded better to sertraline treatment
18377430_1	0	Gene_or_protein	2,3	ABCB1
18377430_1	0	Limited_variation	5,7	ABCG2 polymorphisms
18377430_1	0	Gene_or_protein	5,6	ABCG2
18377430_1	0	Chemical	9,9	doxorubicin
18377430_1	0	Disease	13,14	breast cancer
18377430_1	0	Limited_variation	2,3,7,7	ABCB1 polymorphisms
18377430_1	0	Pharmacokinetic_phenotype	9,10	doxorubicin disposition
22134241_7	0	Chemical	6,7	AZD7762
22134241_7	0	Gene_or_protein	14,15	p53
22134241_7	0	Chemical	9,9	olaparib
22134241_7	0	Chemical	4,9	combination of AZD7762 and olaparib
22134241_7	0	Disease	14,18	p53 mutant pancreatic cancer
22134241_7	0	Limited_variation	14,16	p53 mutant
22134241_7	0	Phenotype	12,12	radiosensitization
22134241_7	0	Genomic_factor	25,25	isogenic
22134241_7	0	Disease	25,26	isogenic cancer
17477907_6	0	Gene_or_protein	3,5	P-gp
17477907_6	0	Chemical	20,20	doxorubicin
17477907_6	0	Chemical	22,22	vinblastine
17477907_6	0	Phenotype	3,8	P-gp -expressing MDR
17477907_6	0	Pharmacodynamic_phenotype	17,18,20,20	sensitivity to doxorubicin
17477907_6	0	Pharmacodynamic_phenotype	17,18,22,22	sensitivity to vinblastine
17477907_6	0	Phenotype	46,47	MDR phenotype
17477907_6	0	Phenotype	12,15	serum from immunized mice
10785598_1	0	Phenotype	4,7	induction of thymidylate synthase
10785598_1	0	Gene_or_protein	6,7	thymidylate synthase
10785598_1	0	Gene_or_protein	14,15	p53
10785598_1	0	Disease	11,17	wild-type p53 colon cancer
10785598_1	0	Chemical	23,25	5-fluorouracil
10785598_1	0	Gene_or_protein	28,29	thymidylate synthase
10785598_1	0	Limited_variation	11,15	wild-type p53
10785598_1	0	Chemical	31,31	raltitrexed
10785598_1	0	Limited_variation	9,9,14,15	mutant p53
10785598_1	0	Genomic_variation	0,2	Molecular downstream events
10785598_1	0	Disease	9,9,14,17	mutant p53 colon cancer
10785598_1	0	Chemical	28,30	thymidylate synthase inhibitor
7748323_2	0	Phenotype	1,6	expression of c-fos mRNA
7748323_2	0	Gene_or_protein	3,5	c-fos
7748323_2	0	Chemical	19,25	N-methyl-D-aspartate
7748323_2	0	Chemical	27,27	NMDA
7748323_2	0	Chemical	42,42	caffeine
7748323_2	0	Gene_or_protein	38,39	glutamate receptors
7748323_2	0	Gene_or_protein	47,48	adenosine receptors
7748323_2	0	Genomic_factor	3,6	c-fos mRNA
7748323_2	0	Chemical	30,31	kainic acid
7748323_2	0	Chemical	45,48	antagonist of adenosine receptors
7748323_2	0	Chemical	33,39	agonists of different classes of glutamate receptors
17899045_8	0	Chemical	6,6	warfarin
17899045_8	0	Gene_or_protein	48,49	VKORC1
17899045_8	0	Gene_or_protein	74,77	CYP2C9
17899045_8	0	Gene_or_protein	79,80	VKORC1
17899045_8	0	Pharmacodynamic_phenotype	6,7	warfarin dose
17899045_8	0	Phenotype	30,30	weight
17899045_8	0	Limited_variation	48,50	VKORC1 genotype
17899045_8	0	Phenotype	71,71	weight
17899045_8	0	Limited_variation	74,81	CYP2C9 and VKORC1 genotype
17899045_8	0	Phenotype	69,69	age
17899045_8	0	Phenotype	12,12	age
22252093_2	0	Chemical	4,4	acenocoumarol
22252093_2	0	Limited_variation	17,20,24,24	CYP2C9 genotypes
22252093_2	0	Gene_or_protein	17,20	CYP2C9
22252093_2	0	Gene_or_protein	22,23	VKORC1
22252093_2	0	Phenotype	10,10	underanticoagulation
22252093_2	0	Phenotype	12,12	overanticoagulation
22252093_2	0	Limited_variation	22,24	VKORC1 genotypes
22252093_2	0	Pharmacodynamic_phenotype	3,5	required acenocoumarol dose
25367959_2	0	Gene_or_protein	11,11	EGFR
25367959_2	0	Chemical	3,5	erlotinib and bevacizumab
25367959_2	0	Phenotype	7,7	PFS
25367959_2	0	Limited_variation	11,13	EGFR -mutant
25367959_2	0	Disease	11,14	EGFR -mutant NSCLC
25367959_2	0	Chemical	3,3	erlotinib
25367959_2	0	Chemical	5,5	bevacizumab
23501331_2	0	Limited_variation	11,20	polymorphisms in genes involved in cholesterol homeostasis and statin metabolism
23501331_2	0	Chemical	16,16	cholesterol
23501331_2	0	Gene_or_protein	24,27	CYP3A4
23501331_2	0	Gene_or_protein	29,32	CYP3A5
23501331_2	0	Chemical	19,19	statin
23501331_2	0	Pharmacodynamic_phenotype	4,6	response to statins
23501331_2	0	Chemical	6,6	statins
23501331_2	0	Pharmacokinetic_phenotype	16,17	cholesterol homeostasis
23501331_2	0	Pharmacokinetic_phenotype	19,20	statin metabolism
25391641_1	0	Gene_or_protein	2,5	CYP2B6
25391641_1	0	Gene_or_protein	7,10	CYP2A6
25391641_1	0	Gene_or_protein	12,15	UGT2B7
25391641_1	0	Chemical	25,25	efavirenz
25391641_1	0	Chemical	27,27	nevirapine
25391641_1	0	Disease	17,17	HIV
25391641_1	0	Chemical	17,18	HIV treatment
17884271_6	0	Limited_variation	8,11	MAO-A genotypes
17884271_6	0	Gene_or_protein	8,10	MAO-A
17884271_6	0	Disease	39,40	Major Depression
17884271_6	0	Pharmacodynamic_phenotype	24,26	antidepressant treatment response
17884271_6	0	Chemical	24,24	antidepressant
17884271_6	0	Chemical	16,16	serotonin
17884271_6	0	Chemical	20,20	norepinephrine
17884271_6	0	Pharmacokinetic_phenotype	16,16,21,21	serotonin availability
17884271_6	0	Pharmacokinetic_phenotype	20,21	norepinephrine availability
25589623_11	0	Limited_variation	0,1	rs11085735
25589623_11	0	Phenotype	4,4	RFS
25589623_11	0	Chemical	7,7	tamoxifen
8873217_7	0	Limited_variation	2,7	6G-->T
8873217_7	0	Chemical	14,14	serotonin
8873217_7	0	Pharmacodynamic_phenotype	13,15	platelet serotonin levels
21623265_3	0	Chemical	5,5	crizotinib
21623265_3	0	Disease	12,17	non-small cell lung cancer
21623265_3	0	Gene_or_protein	10,10	ALK
21623265_3	0	Disease	19,19	NSCLC
21623265_3	0	Genomic_variation	10,11	ALK rearranged
21623265_3	0	Disease	10,20	ALK rearranged non-small cell lung cancer ( NSCLC )
22394056_8	0	Gene_or_protein	17,17	BDNF
22394056_8	0	Chemical	29,29	cocaine
22394056_8	0	Phenotype	4,7	deficit in fear extinction
22394056_8	0	Limited_variation	17,22	BDNF ( Val /Met )
22394056_8	0	Pharmacodynamic_phenotype	27,30	extinction of cocaine responding
16001112_10	0	Gene_or_protein	0,1	Beta2
16001112_10	0	Chemical	16,16	nicotine
16001112_10	0	Pharmacodynamic_phenotype	20,20	supersensitive
16001112_10	0	Limited_variation	0,4	Beta2 - / -
16001112_10	0	Pharmacodynamic_phenotype	24,24	tolerance
11287760_4	0	Limited_variation	9,11	MTHFR gene polymorphism
11287760_4	0	Gene_or_protein	9,9	MTHFR
11287760_4	0	Phenotype	24,31	intima-media thickness of common carotid artery
11287760_4	0	Phenotype	33,35	CC-IMT
11287760_4	0	Gene_or_protein	15,15	homocysteine
11287760_4	0	Gene_or_protein	17,17	Hcy
11287760_4	0	Phenotype	14,19	plasma homocysteine ( Hcy ) level
26411491_2	0	Chemical	2,4	6-mercaptopurine
26411491_2	0	Gene_or_protein	8,8	TPMT
26411491_2	0	Genomic_factor	13,14	TPMT promoter
26411491_2	0	Phenotype	8,10	TPMT gene expression
26411491_2	0	Gene_or_protein	13,13	TPMT
23337555_13	0	Limited_variation	4,6	alleles for CFH
23337555_13	0	Gene_or_protein	6,6	CFH
23337555_13	0	Gene_or_protein	8,9	ARMS2
23337555_13	0	Gene_or_protein	11,12	HTRA1
23337555_13	0	Disease	22,22	AMD
23337555_13	0	Gene_or_protein	32,35	vascular endothelial growth factor
23337555_13	0	Limited_variation	4,5,11,12	alleles for HTRA1
23337555_13	0	Limited_variation	4,5,8,9	alleles for ARMS2
23337555_13	0	Limited_variation	4,5,15,16	alleles for C3
23337555_13	0	Gene_or_protein	15,16	C3
23337555_13	0	Pharmacodynamic_phenotype	28,36	response to anti- vascular endothelial growth factor therapy
23337555_13	0	Chemical	30,36	anti- vascular endothelial growth factor therapy
17558310_2	0	Limited_variation	1,12	1976C>T polymorphism in the adenosine A2A receptor
17558310_2	0	Gene_or_protein	8,12	adenosine A2A receptor
17558310_2	0	Gene_or_protein	15,17	ADORA2A
17558310_2	0	Chemical	30,30	caffeine
17558310_2	0	Chemical	27,29	adenosine receptor antagonist
17558310_2	0	Pharmacodynamic_phenotype	21,23,30,30	psychological response to caffeine
24993285_12	0	Limited_variation	6,7	BDNF SNPs
24993285_12	0	Gene_or_protein	6,6	BDNF
24993285_12	0	Disease	18,18	schizophrenia
24993285_12	0	Disease	39,39	schizophrenia
24993285_12	0	Disease	14,18	comorbid alcohol dependence in schizophrenia
24993285_12	0	Chemical	15,15	alcohol
24993285_12	0	Chemical	31,31	alcohol
24993285_12	0	Disease	31,33	alcohol -dependent
24993285_12	0	Disease	15,16	alcohol dependence
24993285_12	0	Disease	31,39	alcohol -dependent patients who do not have schizophrenia
16144943_13	0	Chemical	9,13	SAHA in combination with docetaxel
16144943_13	0	Chemical	13,13	docetaxel
16144943_13	0	Disease	19,25	Her-2 -amplified breast cancer
16144943_13	0	Gene_or_protein	19,21	Her-2
16144943_13	0	Chemical	9,12,17,17	SAHA in combination with trastuzumab
16144943_13	0	Chemical	9,9	SAHA
16144943_13	0	Chemical	9,17	SAHA in combination with docetaxel and/or trastuzumab
16144943_13	0	Genomic_variation	19,23	Her-2 -amplified
10864974_5	0	Disease	12,13	oral dyskinesia
10864974_5	0	Phenotype	15,17	Fos protein expression
10864974_5	0	Gene_or_protein	15,15	Fos
10864974_5	0	Chemical	32,39	1-(m-chlorophenyl)piperazine
10864974_5	0	Chemical	41,43	m-CPP
10864974_5	0	Chemical	24,31	5-HT(2C ) agonist
10864974_5	0	Phenotype	5,10	unilateral lesions of nigrostriatal DA neurons
23598060_11	0	Phenotype	3,4	P50
23598060_11	0	Phenotype	6,6	PPI
23598060_11	0	Limited_variation	12,13	rs4680
23598060_11	0	Gene_or_protein	11,11	COMT
23598060_11	0	Disease	16,16	schizophrenia
23598060_11	0	Phenotype	24,25	P50
23598060_11	0	Gene_or_protein	30,30	COMT
23598060_11	0	Limited_variation	31,32	rs737865
23598060_11	0	Phenotype	35,35	PPI
23598060_11	0	Limited_variation	41,42	rs165599
23598060_11	0	Gene_or_protein	40,40	COMT
23598060_11	0	Disease	45,45	schizophrenia
23598060_11	0	Phenotype	54,65	reduction of the risk of P50 or PPI defects in schizophrenia
23598060_11	0	Disease	65,65	schizophrenia
23598060_11	0	Phenotype	59,60	P50
23598060_11	0	Phenotype	62,62	PPI
12509456_18	0	Phenotype	2,5	BRCA1 mRNA expression
12509456_18	0	Gene_or_protein	2,3	BRCA1
12509456_18	0	Disease	10,11	breast cancer
12509456_18	0	Gene_or_protein	20,21	BRCA1
12509456_18	0	Genomic_variation	16,21	C -terminally truncated BRCA1
12509456_18	0	Chemical	30,31	CL4
12509456_18	0	Chemical	28,28	LAM
12509456_18	0	Genomic_factor	2,4	BRCA1 mRNA
25666034_12	0	Gene_or_protein	5,5	TRb
25666034_12	0	Chemical	12,12	nicotine
25666034_12	0	Phenotype	14,17	hippocampus-dependent memory
25666034_12	0	Pharmacodynamic_phenotype	9,12	effect of acute nicotine
20871262_15	0	Gene_or_protein	8,8	EGFR
20871262_15	0	Chemical	19,19	everolimus
20871262_15	0	Disease	6,10	non- EGFR mutant tumors
20871262_15	0	Pharmacodynamic_phenotype	1,2	response rate
20871262_15	0	Limited_variation	6,9	non- EGFR mutant
21946895_6	0	Chemical	3,3	naltrexone
21946895_6	0	Chemical	9,9	alcohol
21946895_6	0	Gene_or_protein	13,14	OPRM1
21946895_6	0	Limited_variation	13,18	OPRM1 A118G genotype
21946895_6	0	Disease	9,10	alcohol dependence
17963417_12	0	Disease	12,13	diabetes mellitus
17963417_12	0	Chemical	17,17	acarbose
17963417_12	0	Gene_or_protein	25,25	adiponectin
17963417_12	0	Gene_or_protein	27,27	ADIPOQ
17963417_12	0	Phenotype	10,13	conversion to diabetes mellitus
17963417_12	0	Limited_variation	25,30	adiponectin ( ADIPOQ ) gene polymorphism
17963417_12	0	Limited_variation	5,5	polymorphism
22716779_2	0	Limited_variation	2,3	rs1260326
22716779_2	0	Limited_variation	10,11	rs1799884
22716779_2	0	Gene_or_protein	21,23	glucokinase regulatory protein
22716779_2	0	Gene_or_protein	25,25	GCKR
22716779_2	0	Gene_or_protein	28,28	glucokinase
22716779_2	0	Gene_or_protein	30,30	GCK
22716779_2	0	Chemical	43,43	TAG
22716779_2	0	Chemical	45,45	glucose
22716779_2	0	Pharmacodynamic_phenotype	43,43,46,46	TAG concentrations
22716779_2	0	Pharmacodynamic_phenotype	45,46	glucose concentrations
12149232_3	0	Gene_or_protein	4,4	HFE
12149232_3	0	Chemical	6,6	iron
12149232_3	0	Limited_variation	14,17	C282Y mutation
12149232_3	0	Phenotype	24,32	expression of the human hemachromatosis protein ( HFE )
12149232_3	0	Chemical	36,36	iron
12149232_3	0	Gene_or_protein	27,29	human hemachromatosis protein
12149232_3	0	Gene_or_protein	31,31	HFE
12149232_3	0	Pharmacokinetic_phenotype	34,36	hyperabsorption of iron
12149232_3	0	Pharmacokinetic_phenotype	6,7	iron absorption
16940443_5	0	Chemical	6,8	prostaglandin E2
16940443_5	0	Chemical	15,20	dibutyryl ( Bt2 ) cAMP
16940443_5	0	Chemical	22,27	phorbol 12, 13-diacetate
16940443_5	0	Chemical	29,29	PDA
16940443_5	0	Phenotype	33,35	BRCA1 levels
16940443_5	0	Gene_or_protein	33,34	BRCA1
16940443_5	0	Gene_or_protein	38,38	aromatase
16940443_5	0	Phenotype	38,40	aromatase mRNA levels
16940443_5	0	Chemical	15,30	dibutyryl ( Bt2 ) cAMP plus phorbol 12, 13-diacetate ( PDA )
16940443_5	0	Genomic_factor	38,39	aromatase mRNA
16940443_5	0	Disease	4,4	BAFs
16184603_4	0	Limited_variation	10,12	prodynorphin promoter polymorphism
16184603_4	0	Gene_or_protein	10,10	prodynorphin
16184603_4	0	Chemical	14,14	cocaine
16184603_4	0	Disease	14,15	cocaine dependent
16184603_4	0	Genomic_factor	10,11	prodynorphin promoter
12768192_8	0	Gene_or_protein	4,6	ICAM-1
12768192_8	0	Chemical	28,28	DMXAA
12768192_8	0	Phenotype	20,21	antitumor immunity
12768192_8	0	Genomic_variation	3,6	nonfunctional ICAM-1
24733796_3	0	Disease	6,9,12,13	HER2 -positive breast cancer
24733796_3	0	Gene_or_protein	6,7	HER2
24733796_3	0	Disease	6,9,15,15	HER2 -positive MBC
24733796_3	0	Phenotype	6,9	HER2 -positive
24733796_3	0	Chemical	27,30	DM1 plus pertuzumab
23147740_1	0	Chemical	0,0	Posaconazole
23147740_1	0	Gene_or_protein	9,10	Cyp51
23147740_1	0	Disease	22,24	invasive pulmonary aspergillosis
23147740_1	0	Limited_variation	9,11	Cyp51 mutant
23147740_1	0	Limited_variation	5,7,9,10	wild-type Cyp51
19031955_1	0	Disease	1,1	encephalopathy
19031955_1	0	Chemical	4,4	MTX
19031955_1	0	Chemical	10,10	methotrexate
19031955_1	0	Limited_variation	15,22	homozygous for the MTHFR C677T polymorphism
19031955_1	0	Gene_or_protein	18,18	MTHFR
19031955_1	0	Pharmacokinetic_phenotype	4,5	MTX clearance
26402671_3	0	Phenotype	32,38	BCR - ABL 1 tyrosine kinase activity
26402671_3	0	Gene_or_protein	32,32	BCR
26402671_3	0	Chemical	41,41	TKIs
26402671_3	0	Chemical	32,39	BCR - ABL 1 tyrosine kinase activity inhibitors
26402671_3	0	Gene_or_protein	34,34	ABL
26402671_3	0	Pharmacodynamic_phenotype	30,39	pharmacodynamics of BCR - ABL 1 tyrosine kinase activity inhibitors
26402671_3	0	Pharmacokinetic_phenotype	28,28,31,39	pharmacokinetics of BCR - ABL 1 tyrosine kinase activity inhibitors
26402671_3	0	Gene_or_protein	10,10	genes
26402671_3	0	Limited_variation	13,13	variants
26402671_3	0	Limited_variation	20,20	polymorphisms
26402671_3	0	Gene_or_protein	25,25	proteins
16357205_4	0	Chemical	8,8	tetracycline
16357205_4	0	Phenotype	22,24	hematopoietic mesoderm specification
16357205_4	0	Phenotype	27,29	hematopoietic progenitor formation
16357205_4	0	Phenotype	39,41	multilineage hematopoietic engraftment
16357205_4	0	Gene_or_protein	11,12	Cdx4
16357205_4	0	Gene_or_protein	18,19	Cdx4
16357205_4	0	Phenotype	18,20	Cdx4 expression
16357205_4	0	Gene_or_protein	35,36	HoxB4
16357205_4	0	Genomic_factor	8,12	tetracycline -inducible Cdx4
16357205_4	0	Phenotype	18,20,33,36	Cdx4 expression together with HoxB4
24769646_6	0	Chemical	3,8	dimethyl histone H3 lysine 4
24769646_6	0	Gene_or_protein	19,19	RARa
24769646_6	0	Gene_or_protein	25,27	PU.1
24769646_6	0	Gene_or_protein	35,36	RUNX1
24769646_6	0	Gene_or_protein	47,47	MLL
24769646_6	0	Gene_or_protein	49,50	AF9
24769646_6	0	Gene_or_protein	56,56	MLL
24769646_6	0	Gene_or_protein	58,59	AF4
24769646_6	0	Pharmacodynamic_phenotype	81,82	ATRA sensitivity
24769646_6	0	Chemical	81,81	ATRA
24769646_6	0	Gene_or_protein	84,84	MLL
24769646_6	0	Gene_or_protein	86,87	AF4
24769646_6	0	Chemical	10,15	H3K4me2
24769646_6	0	Genomic_factor	25,33	PU.1 upstream regulatory region ( URE )
24769646_6	0	Genomic_factor	35,43	RUNX1 +24 / +25 intronic enhancer
24769646_6	0	Gene_or_protein	66,70	lysine -specific demethylase 1
24769646_6	0	Genomic_factor	19,23	RARa gene-promoter region
24769646_6	0	Pharmacodynamic_phenotype	1,16	level of dimethyl histone H3 lysine 4 ( H3K4me2 )
24769646_6	0	Phenotype	84,89	MLL - AF4 -positive
24769646_6	0	Phenotype	47,52	MLL - AF9 -positive
24769646_6	0	Phenotype	56,61	MLL - AF4 -positive
26086347_5	0	Gene_or_protein	4,5	ABCG2
26086347_5	0	Pharmacodynamic_phenotype	20,24	atorvastatin dose-dependent ADRs
26086347_5	0	Chemical	20,20	atorvastatin
26086347_5	0	Gene_or_protein	53,54	ABCG2
26086347_5	0	Limited_variation	4,7	ABCG2 421 CA
26086347_5	0	Limited_variation	53,56	ABCG2 421CC
26086347_5	0	Limited_variation	4,6,9,9	ABCG2 421 AA
26086347_5	0	Pharmacodynamic_phenotype	24,24	ADRs
12361551_1	0	Disease	20,20	alcoholic
12361551_1	0	Chemical	25,25	iron
12361551_1	0	Phenotype	25,26	iron overload
12361551_1	0	Gene_or_protein	4,4	HFE
12361551_1	0	Limited_variation	1,5,7,9	Mutations in the HFE gene C282Y
12361551_1	0	Limited_variation	1,5,11,13	Mutations in the HFE gene H63D
12361551_1	0	Limited_variation	1,5,15,17	Mutations in the HFE gene S65C
9724909_1	0	Gene_or_protein	5,6	MDR1
9724909_1	0	Chemical	3,3	adriamycin
9724909_1	0	Disease	13,14	ovarian carcinoma
9724909_1	0	Phenotype	5,9	MDR1 gene encoded resistance
9724909_1	0	Chemical	0,3	HPMA copolymer bound adriamycin
19712599_4	0	Chemical	16,16	abacavir
19712599_4	0	Gene_or_protein	19,21	HLA-B
19712599_4	0	Pharmacodynamic_phenotype	13,16	hypersensitivity reaction to abacavir
19712599_4	0	Haplotype	19,23	HLA-B * 5701
26566708_5	0	Limited_variation	6,13	HO-1 ( GT ) n polymorphism
26566708_5	0	Gene_or_protein	6,8	HO-1
26566708_5	0	Disease	15,15	cancer
26566708_5	0	Chemical	19,19	arsenic
23982599_5	0	Chemical	1,1	afatinib
23982599_5	0	Chemical	3,3	Gilotrif
23982599_5	0	Disease	21,27	non-small-cell lung cancer
23982599_5	0	Disease	29,29	NSCLC
23982599_5	0	Disease	33,33	tumours
23982599_5	0	Gene_or_protein	35,35	EGFR
23982599_5	0	Limited_variation	35,38	EGFR exon 19 deletions
23982599_5	0	Limited_variation	35,35,40,47	EGFR exon 21 ( L858R ) substitution
23982599_5	0	Genomic_factor	35,37	EGFR exon 19
19578241_10	0	Chemical	6,7	3TC
19578241_10	0	Limited_variation	19,21	rtA 181T
19578241_10	0	Gene_or_protein	19,19	rtA
19578241_10	0	Pharmacodynamic_phenotype	6,8	3TC resistance
19578241_10	0	Chemical	1,1	ADV
19578241_10	0	Chemical	32,32	ADV
19578241_10	0	Pharmacodynamic_phenotype	32,34	ADV -resistant
19578241_10	0	Limited_variation	0,10	Before ADV treatment , apart from 3TC resistance signature mutations
26603945_15	0	Gene_or_protein	12,12	DPYD
26603945_15	0	Limited_variation	12,12,17,22	DPYD c.2846A>T
26603945_15	0	Disease	33,33	cancer
26603945_15	0	Chemical	36,36	fluoropyrimidines
26603945_15	0	Haplotype	12,15	DPYD * 2A
26239294_9	0	Limited_variation	10,13	CHRNA5 coding variants
26239294_9	0	Gene_or_protein	10,11	CHRNA5
26239294_9	0	Chemical	18,18	nicotine
26239294_9	0	Disease	18,19	nicotine dependence
16251483_10	0	Chemical	3,3	arsenic
16251483_10	0	Gene_or_protein	14,15	p53
16251483_10	0	Gene_or_protein	17,18	p16
16251483_10	0	Disease	24,24	carcinogenesis
16251483_10	0	Phenotype	9,15	DNA methylation patterns in gene p53
16251483_10	0	Phenotype	9,13,17,18	DNA methylation patterns in gene p16
11587712_3	0	Chemical	10,11	naloxone methiodide
11587712_3	0	Phenotype	14,15	Fos expression
11587712_3	0	Gene_or_protein	14,14	Fos
11587712_3	0	Chemical	31,31	naloxone
11587712_3	0	Chemical	7,8	opioid antagonist
11587712_3	0	Phenotype	23,24	neuronal activation
21531995_4	0	Limited_variation	1,3	SCARB1 SNPs
21531995_4	0	Gene_or_protein	1,2	SCARB1
21531995_4	0	Pharmacodynamic_phenotype	7,8	progesterone levels
23739923_9	0	Phenotype	0,3	IFN-a production
23739923_9	0	Gene_or_protein	0,2	IFN-a
23739923_9	0	Chemical	13,14	deferoxamine mesylate
23739923_9	0	Gene_or_protein	23,26	von Hippel-Lindau
23739923_9	0	Gene_or_protein	28,28	VHL
23739923_9	0	Gene_or_protein	45,45	VHL
23739923_9	0	Limited_variation	44,45	mutant VHL
23739923_9	0	Limited_variation	20,26	wild-type von Hippel-Lindau
23739923_9	0	Disease	9,9	hypoxia
15944732_4	0	Gene_or_protein	11,14	HER2 / neu
15944732_4	0	Chemical	19,21	S-27609
15944732_4	0	Disease	30,31	mammary tumours
15944732_4	0	Chemical	17,17	Imiquimod
15944732_4	0	Phenotype	30,31,36,36	mammary tumours incidence
15944732_4	0	Chemical	4,21	DNA vaccine encoding a portion of rat HER2 / neu with either Imiquimod or S-27609
15944732_4	0	Chemical	41,42	DNA vaccination
28258422_9	0	Gene_or_protein	4,4	EGFR
28258422_9	0	Disease	29,29	ILD
28258422_9	0	Chemical	34,34	prednisolone
28258422_9	0	Chemical	4,6	EGFR -TKI
28258422_9	0	Pharmacodynamic_phenotype	1,6	adverse events of EGFR -TKI
28258422_9	0	Gene_or_protein	15,15	EGFR
28258422_9	0	Chemical	15,17	EGFR -TKI
21692767_12	0	Gene_or_protein	13,14	IL18
21692767_12	0	Disease	22,24	acute cutaneous inflammation
21692767_12	0	Chemical	27,27	aspirin
21692767_12	0	Pharmacodynamic_phenotype	35,35	AIAU
21692767_12	0	Haplotype	6,14	ht1 [ CG ] of the IL18
21692767_12	0	Pharmacodynamic_phenotype	22,27	acute cutaneous inflammation sensitive to aspirin
18754843_2	0	Limited_variation	10,15	CYP2D6 genetic polymorphism
18754843_2	0	Gene_or_protein	10,13	CYP2D6
18754843_2	0	Chemical	20,20	flecainide
18754843_2	0	Chemical	31,31	paroxetine
18754843_2	0	Gene_or_protein	34,37	CYP2D6
18754843_2	0	Pharmacokinetic_phenotype	18,20	pharmacokinetics of flecainide
18754843_2	0	Chemical	34,38	CYP2D6 inhibitor
15163695_4	0	Gene_or_protein	4,4	CREB
15163695_4	0	Chemical	17,17	ethanol
15163695_4	0	Phenotype	15,16,21,21	preference for sucrose
15163695_4	0	Genomic_variation	4,6	CREB -haplodeficient
15163695_4	0	Phenotype	15,17	preference for ethanol
15163695_4	0	Chemical	21,21	sucrose
15163695_4	0	Genomic_variation	24,26	wild-type
19448895_12	0	Limited_variation	7,7,10,14	AC CYP7A1 genotypes
19448895_12	0	Gene_or_protein	10,13	CYP7A1
19448895_12	0	Chemical	26,26	triglyceride
19448895_12	0	Chemical	38,38	triglyceride
19448895_12	0	Limited_variation	9,14	CC CYP7A1 genotypes
19448895_12	0	Pharmacodynamic_phenotype	26,27	triglyceride concentration
19448895_12	0	Pharmacodynamic_phenotype	38,39	triglyceride concentration
22348413_12	0	Chemical	3,3	statins
22348413_12	0	Gene_or_protein	5,8	CYP3A4
22348413_12	0	Pharmacokinetic_phenotype	1,3	interactions affecting statins
22348413_12	0	Chemical	13,13	transporters
17596442_8	0	Chemical	0,0	Cocaine
17596442_8	0	Gene_or_protein	9,11	glutamate receptor 1
17596442_8	0	Gene_or_protein	18,21	CB1-R
17596442_8	0	Chemical	27,28	AM251
17596442_8	0	Pharmacodynamic_phenotype	0,11	Cocaine -induced c AMP -dependent phosphorylation of glutamate receptor 1
17596442_8	0	Limited_variation	18,22	CB1-R mutant
17596442_8	0	Chemical	3,4	c AMP
17596442_8	0	Pharmacodynamic_phenotype	3,11	c AMP -dependent phosphorylation of glutamate receptor 1
17596442_8	0	Pharmacodynamic_phenotype	7,11	phosphorylation of glutamate receptor 1
20694283_8	0	Limited_variation	1,2	rs11676382
20694283_8	0	Gene_or_protein	0,0	GGCX
20694283_8	0	Chemical	9,9	warfarin
20694283_8	0	Pharmacodynamic_phenotype	9,10	warfarin dose
9205829_7	0	Chemical	2,2	Proguanil
9205829_7	0	Limited_variation	11,16	CYP2C19 genetic polymorphism
9205829_7	0	Gene_or_protein	11,14	CYP2C19
9205829_7	0	Pharmacokinetic_phenotype	30,30,33,33	poor metabolisers
9205829_7	0	Pharmacokinetic_phenotype	32,33	extensive metabolisers
9205829_7	0	Phenotype	24,26	urinary metabolic ratio
24322002_4	0	Limited_variation	13,16	FCGR3A polymorphism
24322002_4	0	Gene_or_protein	13,15	FCGR3A
24322002_4	0	Chemical	33,35	r-ATG
24322002_4	0	Phenotype	21,22	lymphocyte depletion
24322002_4	0	Chemical	29,31	rabbit antithymocyte globulin
24322002_4	0	Disease	24,25	kidney transplant
24152157_15	0	Chemical	14,14	allopurinol
24152157_15	0	Chemical	20,20	oxypurinol
24152157_15	0	Pharmacodynamic_phenotype	5,9	Type B adverse drug reactions
24152157_15	0	Pharmacodynamic_phenotype	14,15	allopurinol hypersensitivity
24152157_15	0	Pharmacodynamic_phenotype	20,25	oxypurinol -specific T cell response
24152157_15	0	Haplotype	38,44	HLA-B * 58:01
24152157_15	0	Gene_or_protein	38,40	HLA-B
25499099_6	0	Chemical	5,7	S-warfarin
25499099_6	0	Limited_variation	16,17	rs7089580
25499099_6	0	Pharmacokinetic_phenotype	2,7	oral clearance of S-warfarin
25499099_6	0	Limited_variation	16,21	rs7089580 allele ( T )
25499099_6	0	Limited_variation	24,27	wild-type homozygotes
21709633_9	0	Phenotype	9,9	FPG
21709633_9	0	Chemical	15,20	sulphonylurea treatment in addition to metformin
21709633_9	0	Disease	24,26	type 2 diabetes
21709633_9	0	Gene_or_protein	33,34	KCNQ1
21709633_9	0	Limited_variation	31,34	variation in KCNQ1
21709633_9	0	Chemical	15,15	sulphonylurea
21709633_9	0	Chemical	20,20	metformin
2134689_3	0	Chemical	6,8	S-mephenytoin
2134689_3	0	Chemical	13,15	R- mephenytoin
2134689_3	0	Gene_or_protein	23,29	cytochrome P-450 human-2
2134689_3	0	Pharmacokinetic_phenotype	4,8	hydroxylation of S-mephenytoin
2134689_3	0	Pharmacokinetic_phenotype	4,5,13,15	hydroxylation of R- mephenytoin
19929252_7	0	Limited_variation	4,6	DRD2 polymorphisms
19929252_7	0	Gene_or_protein	4,5	DRD2
19929252_7	0	Pharmacodynamic_phenotype	18,23	response to dopamine -agonists treatment
19929252_7	0	Chemical	20,23	dopamine -agonists treatment
19929252_7	0	Pharmacodynamic_phenotype	16,16,19,23	susceptibility to dopamine -agonists treatment
17042920_15	0	Chemical	2,2	cyclosporine
17042920_15	0	Gene_or_protein	11,14	CYP3A5
17042920_15	0	Disease	25,26	renal transplantation
17042920_15	0	Phenotype	11,17	CYP3A5 non-expressors
17042920_15	0	Pharmacokinetic_phenotype	2,7	cyclosporine dose-adjusted C0
17042920_15	0	Phenotype	11,14,19,19	CYP3A5 expressors
24681963_1	0	Limited_variation	4,9	Gly16Arg ADRB2 polymorphism
24681963_1	0	Gene_or_protein	7,8	ADRB2
24681963_1	0	Chemical	13,13	salmeterol
24681963_1	0	Chemical	15,15	montelukast
24681963_1	0	Disease	22,22	asthma
24681963_1	0	Pharmacodynamic_phenotype	11,13	responses to salmeterol
24681963_1	0	Pharmacodynamic_phenotype	11,12,15,15	responses to montelukast
23702428_7	0	Chemical	6,6	heroin
23702428_7	0	Phenotype	10,12	expression of MOR
23702428_7	0	Gene_or_protein	12,12	MOR
23702428_7	0	Gene_or_protein	28,29	ELK1
23702428_7	0	Disease	6,7	heroin abusers
23702428_7	0	Phenotype	14,18	extracellular regulated kinase signaling networks
23702428_7	0	Phenotype	22,29	dysregulation of the downstream transcription factor ELK1
23702428_7	0	Gene_or_protein	14,16	extracellular regulated kinase
12125044_5	0	Gene_or_protein	4,4	Jun
12125044_5	0	Chemical	18,18	amphetamine
12125044_5	0	Chemical	27,27	haloperidol
12125044_5	0	Gene_or_protein	6,9	35-kDa FRA
18991847_9	0	Limited_variation	7,14	genetic variant of the CSNK1E gene
18991847_9	0	Gene_or_protein	11,13	CSNK1E
18991847_9	0	Chemical	20,20	methamphetamine
18991847_9	0	Disease	23,23	psychosis
18991847_9	0	Disease	20,21	methamphetamine dependence
27498738_5	0	Gene_or_protein	0,4	Thiopurine S-methyl transferase
27498738_5	0	Gene_or_protein	6,6	TPMT
27498738_5	0	Chemical	14,16	6-mercaptopurine
27498738_5	0	Chemical	18,20	6-MP
27498738_5	0	Pharmacodynamic_phenotype	14,22	6-mercaptopurine ( 6-MP ) sensitivity
21366650_6	0	Chemical	39,39	tacrolimus
21366650_6	0	Gene_or_protein	41,44	CYP2C19
21366650_6	0	Gene_or_protein	54,57	CYP3A5
21366650_6	0	Limited_variation	41,45	CYP2C19 genotype
21366650_6	0	Pharmacodynamic_phenotype	29,31,38,39	maximum plasma concentration of tacrolimus
21366650_6	0	Pharmacokinetic_phenotype	12,19,39,39	area under the plasma concentration-time curve tacrolimus
21366650_6	0	Limited_variation	54,58	CYP3A5 genotypes
21366650_6	0	Chemical	133,133	lansoprazole
12851836_12	0	Limited_variation	6,7	DPYD mutation
12851836_12	0	Gene_or_protein	6,6	DPYD
12851836_12	0	Phenotype	10,13	lack of DPD activity
12851836_12	0	Gene_or_protein	12,12	DPD
12851836_12	0	Disease	28,28	cancer
12851836_12	0	Chemical	34,36	5-FU
12851836_12	0	Limited_variation	26,26	mutations
16595709_5	0	Limited_variation	6,14	UGT1A9 I399C>T
16595709_5	0	Gene_or_protein	6,9	UGT1A9
16595709_5	0	Chemical	29,32	SN-38G
16595709_5	0	Chemical	23,27	SN-38-glucuronide
16595709_5	0	Pharmacodynamic_phenotype	21,33	change in SN-38-glucuronide ( SN-38G )
16595709_5	0	Limited_variation	3,3	variants
22989574_5	0	Chemical	0,0	Crizotinib
22989574_5	0	Gene_or_protein	7,7	ALK
22989574_5	0	Disease	13,13	tumor
22989574_5	0	Gene_or_protein	19,19	ALK
22989574_5	0	Gene_or_protein	9,9	MET
22989574_5	0	Gene_or_protein	21,21	MET
22989574_5	0	Chemical	9,10	MET inhibitor
22989574_5	0	Chemical	7,7,10,10	ALK inhibitor
22989574_5	0	Limited_variation	17,19	alteration in ALK
22989574_5	0	Limited_variation	17,18,21,21	alteration in MET
21723857_2	0	Phenotype	4,5	TPMT deficiency
21723857_2	0	Gene_or_protein	4,4	TPMT
21723857_2	0	Chemical	11,11	AZA
21723857_2	0	Chemical	9,9	azathioprine
21723857_2	0	Pharmacodynamic_phenotype	9,18	azathioprine ( AZA ) - induced myelosuppression ( MS )
21723857_2	0	Pharmacodynamic_phenotype	17,17	MS
21723857_2	0	Pharmacodynamic_phenotype	15,15	myelosuppression
25495407_5	0	Chemical	1,1	paclitaxel
25495407_5	0	Gene_or_protein	4,7	CYP2C8
25495407_5	0	Limited_variation	10,15	CYP2C8 rs1934951
25495407_5	0	Gene_or_protein	10,13	CYP2C8
25495407_5	0	Disease	19,19	anemia
25495407_5	0	Limited_variation	22,26	ERCC1 Gln504Lys
25495407_5	0	Gene_or_protein	22,23	ERCC1
25495407_5	0	Disease	28,28	neuropathy
25495407_5	0	Pharmacodynamic_phenotype	1,2	paclitaxel toxicity
25495407_5	0	Limited_variation	4,8	CYP2C8 HapC
23147740_4	0	Chemical	8,8	posaconazole
23147740_4	0	Chemical	15,15	IPA
23147740_4	0	Gene_or_protein	25,26	Cyp51
23147740_4	0	Limited_variation	35,37	Cyp51 mutations
23147740_4	0	Gene_or_protein	35,36	Cyp51
23147740_4	0	Chemical	39,39	azole
23147740_4	0	Pharmacodynamic_phenotype	39,40	azole resistance
23147740_4	0	Limited_variation	25,29	Cyp51 wild-type
12518032_6	0	Chemical	5,6	T0901317
12518032_6	0	Gene_or_protein	10,10	LXR
12518032_6	0	Gene_or_protein	21,22	Angptl3
12518032_6	0	Phenotype	16,19	levels of plasma lipids
12518032_6	0	Phenotype	16,17,21,23	levels of Angptl3 mRNA
12518032_6	0	Chemical	10,13	LXR -selective agonist
12518032_6	0	Genomic_factor	21,23	Angptl3 mRNA
14683587_2	0	Gene_or_protein	10,11	p53
14683587_2	0	Limited_variation	10,12	p53 wt
14683587_2	0	Chemical	17,17	cisplatin
14683587_2	0	Limited_variation	44,46	p53 status
14683587_2	0	Disease	30,30,39,39	prostatic carcinoma
14683587_2	0	Gene_or_protein	44,45	p53
14683587_2	0	Disease	20,20,39,39	colorectal carcinoma
24702251_4	0	Chemical	0,0	Hydralazine
24702251_4	0	Gene_or_protein	7,10	N-acetyltransferase 2
26518936_1	0	Gene_or_protein	6,9	Cyp3a5
26518936_1	0	Chemical	18,18	Tacrolimus
26518936_1	0	Haplotype	6,11	Cyp3a5 * 1
26518936_1	0	Pharmacodynamic_phenotype	14,18	Need More Doses of Tacrolimus
21995462_17	0	Limited_variation	10,16	IVS4+76G>A
21995462_17	0	Limited_variation	18,26	699G>A ( Met233Ile )
21995462_17	0	Limited_variation	28,34	IVS12-5676A>G
21995462_17	0	Limited_variation	37,42	*347_*348insA
21995462_17	0	Chemical	50,50	docetaxel
21995462_17	0	Pharmacokinetic_phenotype	48,51	variability in docetaxel disposition
21995462_17	0	Pharmacokinetic_phenotype	53,53	clearance
21995462_17	0	Pharmacokinetic_phenotype	55,62	area under the plasma concentration-time curve
20159992_1	0	Limited_variation	1,6	FLT3 internal tandem duplication mutation
20159992_1	0	Gene_or_protein	1,2	FLT3
20159992_1	0	Chemical	17,20	AZD1152-HQPA
20159992_1	0	Disease	22,24	acute myelogenous leukemia
20159992_1	0	Gene_or_protein	13,15	aurora B kinase
20159992_1	0	Chemical	13,16	aurora B kinase inhibitor
17030231_4	0	Gene_or_protein	12,16	beta2-adrenergic receptor
17030231_4	0	Gene_or_protein	19,20	ADRB2
17030231_4	0	Limited_variation	9,21	variation in the beta2-adrenergic receptor gene ( ADRB2 )
17030231_4	0	Chemical	26,30	salmeterol administered with fluticasone propionate
17030231_4	0	Pharmacodynamic_phenotype	24,30	response to salmeterol administered with fluticasone propionate
17030231_4	0	Chemical	26,26	salmeterol
17030231_4	0	Chemical	29,30	fluticasone propionate
11491416_8	0	Chemical	13,13	zidovudine
11491416_8	0	Limited_variation	26,28	wild-type
11491416_8	0	Limited_variation	13,16	zidovudine -associated mutation
11491416_8	0	Limited_variation	18,20	M184V
11491416_8	0	Phenotype	5,6	replication capacity
18794726_7	0	Chemical	4,4	atenolol
18794726_7	0	Limited_variation	13,25	beta1-AR ( Ser49Gly , Arg389Gly )
18794726_7	0	Gene_or_protein	13,16	beta1-AR
18794726_7	0	Gene_or_protein	27,31	alpha2C-AR
18794726_7	0	Limited_variation	27,37	alpha2C-AR ( del322-325 )
18794726_7	0	Pharmacodynamic_phenotype	3,5	plasma atenolol concentrations
20043790_1	0	Chemical	5,5	spinosad
20043790_1	0	Chemical	7,10	milbemycin 5-oxime
20043790_1	0	Limited_variation	17,20	MDR1 gene mutation
20043790_1	0	Gene_or_protein	17,18	MDR1
20043790_1	0	Pharmacodynamic_phenotype	3,5	safety of spinosad
20043790_1	0	Pharmacodynamic_phenotype	3,4,7,10	safety of milbemycin 5-oxime
19021634_8	0	Limited_variation	3,5	CHEK2 mutation
19021634_8	0	Gene_or_protein	3,4	CHEK2
19021634_8	0	Gene_or_protein	14,14	ER
19021634_8	0	Chemical	24,24	tamoxifen
19021634_8	0	Disease	14,18	ER -positive breast cancer
19021634_8	0	Phenotype	14,16	ER -positive
19021634_8	0	Chemical	24,25	tamoxifen chemoprevention
22394227_9	0	Gene_or_protein	18,18	AhR
22394227_9	0	Chemical	36,36	polyphenol
22394227_9	0	Chemical	18,19	AhR antagonists
22394227_9	0	Pharmacodynamic_phenotype	33,34	antioxidative activity
26450446_1	0	Chemical	0,1	AZD9291
26450446_1	0	Gene_or_protein	3,3	EGFR
26450446_1	0	Disease	3,13	EGFR -mutant advanced non-small-cell lung cancer
26450446_1	0	Limited_variation	3,5	EGFR -mutant
23737969_11	0	Gene_or_protein	9,12	UGT1A1
23737969_11	0	Haplotype	9,14	UGT1A1 * 6
23737969_11	0	Phenotype	19,20	creatinine elevation
23737969_11	0	Phenotype	0,5	Body weight > = 40 kg
11888518_8	0	Chemical	6,8	BO-653
11888518_8	0	Chemical	12,12	probucol
11888518_8	0	Phenotype	16,19	c-myc induction
11888518_8	0	Gene_or_protein	16,18	c-myc
11888518_8	0	Phenotype	3,4	gene expression
12958193_8	0	Gene_or_protein	7,10	CYP3a13
12958193_8	0	Chemical	12,12	dexamethasone
12958193_8	0	Gene_or_protein	16,18	pregnane X receptor
12958193_8	0	Pharmacodynamic_phenotype	5,12	induction of CYP3a13 by dexamethasone
12958193_8	0	Genomic_variation	16,19	pregnane X receptor null
21107535_6	0	Chemical	6,9	MnCl(2)
21107535_6	0	Gene_or_protein	21,22	Nrf2
21107535_6	0	Gene_or_protein	28,29	Nrf2
21107535_6	0	Gene_or_protein	32,34	HO-1
21107535_6	0	Phenotype	41,42,50,52	expression of HO-1
21107535_6	0	Gene_or_protein	44,48	Nrf2 -regulated gene
21107535_6	0	Gene_or_protein	50,52	HO-1
21107535_6	0	Phenotype	16,16,19,22	cytosolic accumulation of Nrf2
21107535_6	0	Phenotype	18,22	nuclear accumulation of Nrf2
21107535_6	0	Phenotype	26,34	binding of Nrf2 to the HO-1
21107535_6	0	Gene_or_protein	44,45	Nrf2
19000371_7	0	Phenotype	1,5,12,12	levels of c-fos mRNA
19000371_7	0	Gene_or_protein	3,5	c-fos
19000371_7	0	Gene_or_protein	7,9	c-jun
19000371_7	0	Chemical	39,39	doxorubicin
19000371_7	0	Phenotype	1,2,7,9,12,12	levels of c-jun mRNA
19000371_7	0	Gene_or_protein	20,20	rsGFP
19000371_7	0	Phenotype	18,21	levels of rsGFP protein
19000371_7	0	Phenotype	1,2,11,12	levels of rsGFP mRNA
19000371_7	0	Gene_or_protein	11,11	rsGFP
19000371_7	0	Genomic_factor	11,12	rsGFP mRNA
19000371_7	0	Genomic_factor	7,9,12,12	c-jun mRNA
19000371_7	0	Genomic_factor	3,5,12,12	c-fos mRNA
8530458_13	0	Chemical	4,4	streptozotocin
8530458_13	0	Genomic_factor	21,22	FAS promoter
8530458_13	0	Chemical	0,0	Insulin
8530458_13	0	Gene_or_protein	11,11	CAT
8530458_13	0	Phenotype	11,12	CAT activity
8530458_13	0	Phenotype	14,16	CAT mRNA levels
8530458_13	0	Gene_or_protein	14,14	CAT
8530458_13	0	Disease	4,6	streptozotocin - diabetic
8530458_13	0	Gene_or_protein	21,21	FAS
8530458_13	0	Genomic_factor	14,15	CAT mRNA
23752130_11	0	Chemical	5,6	butyric acid
23752130_11	0	Gene_or_protein	15,18	MFG-E8
23752130_11	0	Disease	25,25	colitis
23752130_11	0	Pharmacodynamic_phenotype	20,25	DSS -induced murine experimental colitis
23752130_11	0	Chemical	20,20	DSS
23752130_11	0	Pharmacodynamic_phenotype	9,12	anti-inflammatory effects
15717164_13	0	Gene_or_protein	1,4	GST-M1
15717164_13	0	Chemical	8,8	cyclophosphamide
15717164_13	0	Limited_variation	11,15	GST-P1 polymorphism
15717164_13	0	Gene_or_protein	11,14	GST-P1
15717164_13	0	Limited_variation	1,5	GST-M1 null
15717164_13	0	Pharmacodynamic_phenotype	8,9	cyclophosphamide efficacy
15717164_13	0	Phenotype	22,25	susceptibility to further relapses
15998902_8	0	Chemical	0,0	Temsirolimus
15998902_8	0	Chemical	8,8	sirolimus
15998902_8	0	Gene_or_protein	23,24	p450
15998902_8	0	Pharmacodynamic_phenotype	0,5	Temsirolimus peak concentration ( Cmax )
15998902_8	0	Pharmacodynamic_phenotype	8,9	sirolimus Cmax
15998902_8	0	Pharmacokinetic_phenotype	8,8,11,17	sirolimus area under the concentration-time curve
15998902_8	0	Chemical	23,28	p450 enzyme-inducing anticonvulsants
15998902_8	0	Chemical	30,30	EIACs
23756537_2	0	Gene_or_protein	7,8	MDR1
23756537_2	0	Limited_variation	7,11	MDR1 C3435T
23756537_2	0	Chemical	22,22	cyclosporine
23756537_2	0	Chemical	24,24	CsA
23756537_2	0	Disease	36,37	gingival hyperplasia
23756537_2	0	Disease	39,39	GH
23756537_2	0	Phenotype	34,37	degree of gingival hyperplasia
23756537_2	0	Disease	17,18	renal transplant
18161298_22	0	Phenotype	1,6	expression of cleaved Caspase-3
18161298_22	0	Gene_or_protein	4,6	Caspase-3
18161298_22	0	Chemical	8,8	WCA
18161298_22	0	Chemical	11,13	5-FU
18161298_22	0	Genomic_factor	3,6	cleaved Caspase-3
23225895_8	0	Gene_or_protein	6,7	pfmdr1
23225895_8	0	Chemical	21,21	lumefantrine
23225895_8	0	Pharmacodynamic_phenotype	21,23	lumefantrine blood concentrations
23225895_8	0	Haplotype	6,16	pfmdr1 N86/184F/D1246 haplotype
23225895_8	0	Haplotype	32,40	86Y/Y184/1246Y haplotype
24673480_4	0	Gene_or_protein	16,19	CYP2D6
24673480_4	0	Pharmacodynamic_phenotype	3,4	effective dose
24673480_4	0	Pharmacodynamic_phenotype	7,9	adverse drug reactions
24673480_4	0	Pharmacodynamic_phenotype	11,11	ADRs
24673480_4	0	Limited_variation	16,20	CYP2D6 genotype
24673480_4	0	Chemical	23,23	carvedilol
24458010_2	0	Chemical	0,0	Codeine
24458010_2	0	Chemical	4,4	morphine
24458010_2	0	Gene_or_protein	14,19	cytochrome P450 2D6
24458010_2	0	Gene_or_protein	21,24	CYP2D6
24458010_2	0	Chemical	34,34	codeine
24458010_2	0	Phenotype	38,42	CYP2D6 activity
24458010_2	0	Gene_or_protein	38,41	CYP2D6
24458010_2	0	Chemical	8,8	opioid
24458010_2	0	Chemical	8,9	opioid agonist
24458010_2	0	Pharmacodynamic_phenotype	30,30,33,34	efficacy of codeine
24458010_2	0	Pharmacodynamic_phenotype	32,34	safety of codeine
15265979_11	0	Chemical	12,12	amiodarone
15265979_11	0	Gene_or_protein	16,16	PPARalpha
15265979_11	0	Chemical	19,19	amiodarone
15265979_11	0	Pharmacodynamic_phenotype	9,12	hepatotoxic effects of amiodarone
15265979_11	0	Pharmacodynamic_phenotype	19,22	amiodarone -induced hepatotoxicity
15265979_11	0	Disease	22,22	hepatotoxicity
12021632_1	0	Gene_or_protein	10,12	MDR1 gene
12021632_1	0	Chemical	14,14	cyclosporine
12021632_1	0	Genomic_factor	5,12	exon 26 of the human MDR1 gene
12021632_1	0	Limited_variation	0,12	C3435T mutation in exon 26 of the human MDR1 gene
12021632_1	0	Pharmacokinetic_phenotype	14,15	cyclosporine pharmacokinetics
20216107_11	0	Gene_or_protein	4,4	COMT
20216107_11	0	Chemical	13,13	propranolol
20216107_11	0	Phenotype	15,16	pain perception
20216107_11	0	Haplotype	4,7	COMT high activity haplotype
20216107_11	0	Limited_variation	33,33	heterozygotes
20216107_11	0	Limited_variation	42,42	homozygotes
20216107_11	0	Pharmacodynamic_phenotype	11,16	effect of propranolol on pain perception
20216107_11	0	Haplotype	24,24	haplotype
15217301_7	0	Pharmacokinetic_phenotype	22,23	disposition kinetics
15217301_7	0	Gene_or_protein	9,10	MDR1
15217301_7	0	Chemical	35,35	fexofenadine
15217301_7	0	Chemical	37,37	ciclosporin
15217301_7	0	Chemical	39,39	talinolol
15217301_7	0	Limited_variation	6,10	polymorphisms of the MDR1
15217301_7	0	Chemical	33,33	digoxin
22811313_10	0	Chemical	1,1	androgen
22811313_10	0	Limited_variation	15,17	FMR1 genotypes
22811313_10	0	Gene_or_protein	15,16	FMR1
22811313_10	0	Chemical	28,28	testosterone
22811313_10	0	Pharmacodynamic_phenotype	1,2	androgen concentrations
22811313_10	0	Phenotype	7,7	pregnancy
22811313_10	0	Limited_variation	24,25	normal genotype
22811313_10	0	Phenotype	32,33	pregnancy potential
24977443_10	0	Gene_or_protein	18,21	UGT1A1
24977443_10	0	Chemical	36,36	irinorecan
24977443_10	0	Chemical	45,45	irinotecan
24977443_10	0	Disease	51,52	colorectal cancer
24977443_10	0	Phenotype	18,22	UGT1A1 deficiency
24704376_7	0	Limited_variation	6,7	rs35349697
24704376_7	0	Disease	14,15	opioid addiction
24704376_7	0	Disease	20,21	alcohol addiction
24704376_7	0	Chemical	20,20	alcohol
24704376_7	0	Chemical	14,14	opioid
24704376_7	0	Limited_variation	1,4	SNP in exon 3
24704376_7	0	Genomic_factor	3,4	exon 3
22771883_2	0	Chemical	31,32	gadoxetic acid
22771883_2	0	Chemical	46,47	gadoxetic acid
22771883_2	0	Limited_variation	5,18,23,26	genetic polymorphisms of liver-specific human organic anion transporting polypeptide ( OATP ) OATP1B3
22771883_2	0	Gene_or_protein	17,17	OATP
22771883_2	0	Limited_variation	5,21	genetic polymorphisms of liver-specific human organic anion transporting polypeptide ( OATP ) 1B1
22771883_2	0	Pharmacokinetic_phenotype	29,32	uptake of gadoxetic acid
22771883_2	0	Pharmacodynamic_phenotype	43,47	liver enhancement by gadoxetic acid
22771883_2	0	Gene_or_protein	12,15	organic anion transporting polypeptide
20226083_1	0	Limited_variation	0,11	RRM1 single nucleotide polymorphism -37C-->A
20226083_1	0	Gene_or_protein	0,1	RRM1
20226083_1	0	Disease	19,19	NSCLC
20226083_1	0	Chemical	22,22	gemcitabine
20226083_1	0	Phenotype	14,17	progression-free survival
20226083_1	0	Chemical	22,25	gemcitabine -based chemotherapy
19176891_5	0	Chemical	8,8	CCK
19176891_5	0	Chemical	39,39	CCK
19176891_5	0	Gene_or_protein	44,47	ERK1/2
19176891_5	0	Gene_or_protein	18,21	ERK1/2
19176891_5	0	Genomic_factor	23,26	pERK1/2
19176891_5	0	Genomic_factor	17,21	phosphorylated ERK1/2
19176891_5	0	Pharmacodynamic_phenotype	39,47	CCK -induced expression of ERK1/2
19176891_5	0	Pharmacodynamic_phenotype	42,47	expression of ERK1/2
19176891_5	0	Gene_or_protein	51,52	tyrosine hydroxylase
19176891_5	0	Phenotype	51,54	tyrosine hydroxylase -immunoreactive
15010519_9	0	Chemical	2,2	Lansoprazole
15010519_9	0	Gene_or_protein	9,12	CYP2C19
15010519_9	0	Gene_or_protein	14,17	CYP3A4
18805405_1	0	Phenotype	3,9	transcriptional activation of CYP3A4
18805405_1	0	Gene_or_protein	0,0	PXR
18805405_1	0	Gene_or_protein	6,9	CYP3A4
18805405_1	0	Chemical	11,11	cryptotanshinone
18805405_1	0	Chemical	13,14	tanshinone IIA
15020609_2	0	Gene_or_protein	7,11	multidrug resistance gene-1
15020609_2	0	Chemical	20,21	PSC 833
15020609_2	0	Gene_or_protein	13,15	MDR-1
15020609_2	0	Disease	41,43	acute myeloid leukemia
15020609_2	0	Disease	45,45	AML
15020609_2	0	Disease	51,52	myelodysplastic syndrome
15020609_2	0	Disease	54,54	MDS
15020609_2	0	Chemical	18,18	valspodar
15020609_2	0	Chemical	5,31	adding the multidrug resistance gene-1 ( MDR-1 ) modulator valspodar ( PSC 833 ; Novartis Pharmaceuticals , Hanover , NJ ) to chemotherapy
15020609_2	0	Pharmacodynamic_phenotype	33,34	clinical benefit
24293093_1	0	Gene_or_protein	3,6	CYP2B6
24293093_1	0	Disease	18,20	chronic myeloid leukemia
24293093_1	0	Chemical	24,24	imatinib
24293093_1	0	Limited_variation	0,9	Functional polymorphism of CYP2B6 G15631T
24293093_1	0	Pharmacodynamic_phenotype	15,16	cytogenetic response
24293093_1	0	Pharmacodynamic_phenotype	13,13,16,16	hematologic response
11849656_2	0	Disease	73,73	restenosis
11849656_2	0	Gene_or_protein	18,20	angiotensin converting enzyme
11849656_2	0	Gene_or_protein	22,22	ACE
11849656_2	0	Gene_or_protein	33,33	angiotensinogen
11849656_2	0	Gene_or_protein	35,35	AGT
11849656_2	0	Limited_variation	33,39	angiotensinogen ( AGT ) M253T
11849656_2	0	Gene_or_protein	41,45	angiotensin II type 1 receptor
11849656_2	0	Gene_or_protein	47,49	AT1R
11849656_2	0	Limited_variation	41,53	angiotensin II type 1 receptor ( AT1R ) A1166C
11849656_2	0	Chemical	59,59	quinapril
11849656_2	0	Gene_or_protein	62,62	ACE
11849656_2	0	Limited_variation	18,26	angiotensin converting enzyme ( ACE ) insertion/deletion
11849656_2	0	Pharmacodynamic_phenotype	57,59	effect of quinapril
11849656_2	0	Gene_or_protein	5,13	renin-angiotensin system ( RAS ) related gene
11849656_2	0	Limited_variation	5,14	renin-angiotensin system ( RAS ) related gene polymorphisms
11849656_2	0	Chemical	62,63	ACE inhibitor
11849656_2	0	Disease	75,77	percutaneous coronary intervention
11849656_2	0	Disease	79,79	PCI
26505400_7	0	Limited_variation	0,1	rs2115819
26505400_7	0	Limited_variation	3,4	rs9934438
26505400_7	0	Limited_variation	7,8	rs689466
26505400_7	0	Gene_or_protein	13,14	ALOX5
26505400_7	0	Gene_or_protein	16,19	arachidonate 5-lipoxygenase
26505400_7	0	Gene_or_protein	22,23	VKORC1
26505400_7	0	Chemical	25,27	vitamin K epoxide
26505400_7	0	Gene_or_protein	35,36	PTGS2
26505400_7	0	Gene_or_protein	38,42	prostaglandin-endoperoxide synthase 2
26505400_7	0	Gene_or_protein	25,32	vitamin K epoxide reductase complex , subunit 1
12846271_3	0	Limited_variation	5,11	aromatase gene ( CYP19 ) polymorphism
12846271_3	0	Gene_or_protein	8,9	CYP19
12846271_3	0	Chemical	14,14	estradiol
12846271_3	0	Phenotype	21,23	bone mineral density
12846271_3	0	Phenotype	25,25	BMD
12846271_3	0	Phenotype	31,31	fracture
12846271_3	0	Pharmacodynamic_phenotype	13,19	circulating estradiol ( E2 ) levels
12846271_3	0	Phenotype	28,29	BMD change
12846271_3	0	Gene_or_protein	5,6	aromatase gene
12846271_3	0	Chemical	16,17	E2
23030234_8	0	Chemical	3,3	MDMA
23030234_8	0	Gene_or_protein	35,37	serotonin reuptake transporter
23030234_8	0	Gene_or_protein	39,39	SERT
23030234_8	0	Pharmacodynamic_phenotype	3,5	MDMA plasma levels
23030234_8	0	Phenotype	14,15	blood pressure
23030234_8	0	Phenotype	17,18	heart rate
23030234_8	0	Phenotype	20,21	body temperature
23030234_8	0	Chemical	0,0	SSRIs
23030234_8	0	Pharmacodynamic_phenotype	31,40	pharmacodynamic interaction at the serotonin reuptake transporter ( SERT )
23030234_8	0	Pharmacodynamic_phenotype	3,3,7,8	MDMA clinical effects
23115637_2	0	Limited_variation	6,11	polymorphisms of the GABRA2 gene
23115637_2	0	Gene_or_protein	9,10	GABRA2
23115637_2	0	Gene_or_protein	14,21	GABA ( A ) a2-subunit
23115637_2	0	Chemical	25,25	ethanol
23115637_2	0	Disease	25,26	ethanol dependence
26240276_10	0	Phenotype	2,3	HAGE expression
26240276_10	0	Gene_or_protein	2,2	HAGE
26240276_10	0	Chemical	15,15	anthracycline
26240276_10	0	Disease	18,18	TNBC
26240276_10	0	Pharmacodynamic_phenotype	13,16	response to anthracycline treatment
28213291_1	0	Disease	10,15	oxidative stress -induced liver damage
28213291_1	0	Chemical	3,8	2'-O-galloylhyperin
28213291_1	0	Gene_or_protein	19,20	Nrf2
28213291_1	0	Pharmacodynamic_phenotype	0,8	Hepatoprotective effect of 2'-O-galloylhyperin
16402341_5	0	Disease	5,5	TD
16402341_5	0	Chemical	9,9	phenylalanine
16402341_5	0	Gene_or_protein	20,21	phenylalanine hydroxylase
16402341_5	0	Gene_or_protein	23,23	PAH
16402341_5	0	Chemical	35,35	phenylalanine
16402341_5	0	Disease	41,41	TD
16402341_5	0	Pharmacokinetic_phenotype	9,10	phenylalanine metabolism
16402341_5	0	Limited_variation	15,24	variants in the gene for phenylalanine hydroxylase ( PAH )
16402341_5	0	Pharmacokinetic_phenotype	33,35	catabolism of phenylalanine
27525598_2	0	Gene_or_protein	6,12	interleukin (IL)-28B
27525598_2	0	Chemical	33,36	pegylated interferon-alpha
27525598_2	0	Chemical	38,38	ribavirin
27525598_2	0	Disease	56,56	CHC
27525598_2	0	Limited_variation	3,12	polymorphism upstream of interleukin (IL)-28B
27525598_2	0	Disease	52,54	chronic hepatitis C
27525598_2	0	Chemical	33,38	pegylated interferon-alpha and ribavirin
27525598_2	0	Pharmacodynamic_phenotype	26,28,32,38	sustained virologic response to pegylated interferon-alpha and ribavirin
27525598_2	0	Disease	52,66	chronic hepatitis C ( CHC ) virus genotype 1 ( HCV-1 ) infection
27525598_2	0	Phenotype	30,30	SVR
27525598_2	0	Phenotype	26,28	sustained virologic response
20005399_5	0	Chemical	4,5	nitric oxide
20005399_5	0	Limited_variation	14,22	genetic variation in endothelial NO synthase ( eNOS )
20005399_5	0	Gene_or_protein	21,21	eNOS
20005399_5	0	Disease	27,27	hypertension
20005399_5	0	Disease	29,29	thrombosis
20005399_5	0	Disease	31,31	vasospasm
20005399_5	0	Disease	34,34	atherosclerosis
20005399_5	0	Disease	42,42	CAN
20005399_5	0	Chemical	7,7	NO
20005399_5	0	Gene_or_protein	17,19	endothelial NO synthase
20005399_5	0	Pharmacokinetic_phenotype	4,9	nitric oxide ( NO ) release
23515284_5	0	Chemical	0,0	PTH
23515284_5	0	Chemical	13,13	Pi
23515284_5	0	Chemical	20,20	Pi
23515284_5	0	Limited_variation	22,22	DD
23515284_5	0	Limited_variation	15,15	Wt
23515284_5	0	Pharmacodynamic_phenotype	12,13	serum Pi
23515284_5	0	Pharmacodynamic_phenotype	19,20	serum Pi
27217047_10	0	Chemical	16,16	tacrolimus
27217047_10	0	Gene_or_protein	36,39	CYP3A5
27217047_10	0	Gene_or_protein	61,64	CYP3A5
27217047_10	0	Gene_or_protein	77,80	CYP3A5
27217047_10	0	Haplotype	77,82	CYP3A5 * 1
27217047_10	0	Haplotype	23,31	CYP3A5 * 3 / * 3
27217047_10	0	Haplotype	36,41	CYP3A5 * 1
27217047_10	0	Haplotype	61,69	CYP3A5 * 3 / * 3
27217047_10	0	Chemical	9,9	AZ
27217047_10	0	Pharmacodynamic_phenotype	12,16	C0 values of tacrolimus
27217047_10	0	Pharmacodynamic_phenotype	52,57	daily doses of Tac-QD
27217047_10	0	Chemical	55,57	Tac-QD
27217047_10	0	Gene_or_protein	23,26	CYP3A5
9795138_10	0	Genomic_factor	20,23	zif/268 mRNA
9795138_10	0	Gene_or_protein	20,22	zif/268
9795138_10	0	Chemical	28,30	PVP and oPRL
9795138_10	0	Phenotype	12,23	average number of cells/animal which expressed zif/268 mRNA
21734808_2	0	Limited_variation	5,13	cytosine deaminase ( bCD ) mutant D314A
21734808_2	0	Chemical	15,17	5-fluorocytosine
21734808_2	0	Chemical	19,21	5-FC
21734808_2	0	Disease	26,27	colon cancer
21734808_2	0	Gene_or_protein	8,8	bCD
21734808_2	0	Gene_or_protein	5,6	cytosine deaminase
20512075_2	0	Chemical	9,9	gefitinib
20512075_2	0	Chemical	11,11	erlotinib
20512075_2	0	Disease	15,20	non-small cell lung cancers
20512075_2	0	Disease	22,22	NSCLCs
20512075_2	0	Limited_variation	25,33	epidermal growth factor receptor ( EGFR ) gene mutations
20512075_2	0	Gene_or_protein	25,28	epidermal growth factor receptor
20512075_2	0	Gene_or_protein	30,30	EGFR
20512075_2	0	Chemical	3,5	tyrosine kinase inhibitors
20512075_2	0	Chemical	7,7	TKIs
20512075_2	0	Gene_or_protein	3,4	tyrosine kinase
15099407_2	0	Gene_or_protein	0,1	Alcohol dehydrogenase
15099407_2	0	Gene_or_protein	3,3	ADH
15099407_2	0	Gene_or_protein	10,11	ALDH2
15099407_2	0	Chemical	20,20	ethanol
15099407_2	0	Chemical	35,35	ethanol
15099407_2	0	Gene_or_protein	6,8	mitochondrial aldehyde dehydrogenase
15099407_2	0	Pharmacokinetic_phenotype	35,36	ethanol elimination
8970671_3	0	Pharmacodynamic_phenotype	0,2	RESISTANCE TO SAQUINAVIR
8970671_3	0	Chemical	2,2	SAQUINAVIR
8970671_3	0	Pharmacodynamic_phenotype	4,6	Resistance to saquinavir
8970671_3	0	Chemical	6,6	saquinavir
8970671_3	0	Limited_variation	16,18,23,25	L90M in HIV protease
8970671_3	0	Limited_variation	20,25	G48V in HIV protease
8970671_3	0	Disease	24,24	HIV
8970671_3	0	Gene_or_protein	24,25	HIV protease
16485141_1	0	Chemical	0,0	Nicotine
16485141_1	0	Chemical	11,11	nicotine
16485141_1	0	Gene_or_protein	14,17	CYP2A5
16485141_1	0	Pharmacokinetic_phenotype	9,12	rates of nicotine inactivation
16485141_1	0	Phenotype	0,3	Nicotine self-administration
19620488_3	0	Gene_or_protein	6,7	HER2
19620488_3	0	Gene_or_protein	9,11	TOP2A
19620488_3	0	Disease	18,19	breast cancer
19620488_3	0	Chemical	29,29	cyclophosphamide
19620488_3	0	Chemical	24,24	doxorubicin
19620488_3	0	Genomic_variation	3,7	status of the HER2
19620488_3	0	Genomic_variation	3,5,9,11	status of the TOP2A
23569304_9	0	Pharmacodynamic_phenotype	1,3	resistance to vemurafenib
23569304_9	0	Chemical	3,3	vemurafenib
23569304_9	0	Phenotype	14,19	ERK1/2 phosphorylation levels
23569304_9	0	Gene_or_protein	14,17	ERK1/2
23569304_9	0	Gene_or_protein	28,28	NRAS
23569304_9	0	Gene_or_protein	35,36	MEK1
23569304_9	0	Limited_variation	35,41,50,50	MEK1 ( Q56P ) mutations
23569304_9	0	Gene_or_protein	43,48	MEK1(E203K
23569304_9	0	Gene_or_protein	8,8	MAPK
23569304_9	0	Phenotype	6,9	reactivation of MAPK signaling
23569304_9	0	Limited_variation	28,33	NRAS ( Q61 ) mutations
23569304_9	0	Limited_variation	43,50	MEK1(E203K ) mutations
22300961_11	0	Chemical	9,13	25-OH vitamin D
22300961_11	0	Gene_or_protein	27,30	NR1I1
22300961_11	0	Haplotype	27,31	NR1I1 CCA
22300961_11	0	Phenotype	17,18	virological response
22300961_11	0	Pharmacodynamic_phenotype	8,14	low 25-OH vitamin D levels
22300961_11	0	Haplotype	33,33	bAt
21139584_10	0	Chemical	2,4	GUT-70
21139584_10	0	Disease	10,15	MCL with mt- p53
21139584_10	0	Gene_or_protein	14,15	p53
21139584_10	0	Disease	23,23	MCL
21139584_10	0	Phenotype	26,28	Hsp90 inhibition
21139584_10	0	Gene_or_protein	26,27	Hsp90
21139584_10	0	Limited_variation	12,15	mt- p53
19695401_17	0	Gene_or_protein	12,12	TPMT
19695401_17	0	Chemical	23,23	azathioprine
19695401_17	0	Haplotype	12,15	TPMT * 3C
19695401_17	0	Pharmacodynamic_phenotype	23,26	azathioprine -induced myelosuppression
19695401_17	0	Disease	4,5	kidney transplant
19695401_17	0	Pharmacodynamic_phenotype	26,26	myelosuppression
26743855_3	0	Disease	14,14	adenocarcinoma
26743855_3	0	Gene_or_protein	20,20	EGFR
26743855_3	0	Chemical	30,32	platinum doublet chemotherapy
26743855_3	0	Limited_variation	20,22	EGFR mutation status
26743855_3	0	Phenotype	41,42	clinical outcomes
26743855_3	0	Phenotype	44,45	recurrence patterns
26743855_3	0	Chemical	30,30	platinum
26743855_3	0	Limited_variation	48,49	mutation status
17555608_2	0	Chemical	24,24	propofol
17555608_2	0	Chemical	41,41	propofol
17555608_2	0	Limited_variation	65,65,74,74	genotype GABRE
17555608_2	0	Gene_or_protein	74,74	GABRE
17555608_2	0	Limited_variation	93,93,98,101	genotype CYP2B6
17555608_2	0	Gene_or_protein	98,101	CYP2B6
17555608_2	0	Pharmacodynamic_phenotype	35,38	time to eye opening
17555608_2	0	Pharmacodynamic_phenotype	54,60	time to achieve bispectral index < 70
17555608_2	0	Pharmacokinetic_phenotype	84,87	time to eye opening
17555608_2	0	Pharmacodynamic_phenotype	29,32	bispectral index < 70
17555608_2	0	Pharmacokinetic_phenotype	81,81	clearance
25194407_11	0	Phenotype	7,10	serum level of PTH
25194407_11	0	Gene_or_protein	10,10	PTH
25194407_11	0	Gene_or_protein	13,15	fetuin-A
25194407_11	0	Chemical	17,18	vitamin D
25194407_11	0	Gene_or_protein	30,30	VDR
25194407_11	0	Phenotype	13,15,19,19	fetuin-A levels
25194407_11	0	Pharmacodynamic_phenotype	17,19	vitamin D levels
25194407_11	0	Disease	24,24	atherosclerosis
25194407_11	0	Limited_variation	30,32,35,35	VDR gene FokI polymorphisms
25194407_11	0	Limited_variation	30,31,34,35	VDR gene ApaI polymorphisms
16297086_5	0	Chemical	0,0	Tamoxifen
16297086_5	0	Disease	5,6	breast cancer
16297086_5	0	Gene_or_protein	8,10	BRCA-2
16297086_5	0	Gene_or_protein	17,19	BRCA-1
16297086_5	0	Limited_variation	8,11	BRCA-2 mutation
16297086_5	0	Limited_variation	17,20	BRCA-1 mutation
20487194_4	0	Gene_or_protein	20,22	HLA-B
20487194_4	0	Chemical	32,32	abacavir
20487194_4	0	Gene_or_protein	34,37	thiopurine S-methyltransferase
20487194_4	0	Gene_or_protein	39,39	TPMT
20487194_4	0	Chemical	44,44	thiopurine
20487194_4	0	Gene_or_protein	48,51	CYP2C9
20487194_4	0	Gene_or_protein	53,54	VKORC1
20487194_4	0	Chemical	62,62	warfarin
20487194_4	0	Haplotype	20,24	HLA-B * 5701
20487194_4	0	Pharmacodynamic_phenotype	28,32	hypersensitivity to the antiretroviral abacavir
20487194_4	0	Pharmacodynamic_phenotype	44,45	thiopurine toxicity
20487194_4	0	Pharmacodynamic_phenotype	58,62	dosing of the anticoagulant warfarin
20487194_4	0	Limited_variation	34,41	thiopurine S-methyltransferase ( TPMT ) genotyping
20487194_4	0	Limited_variation	53,55	VKORC1 genotyping
20487194_4	0	Limited_variation	48,51,55,55	CYP2C9 genotyping
20487194_4	0	Chemical	61,61	anticoagulant
26556583_1	0	Gene_or_protein	4,5	cytidine deaminase
26556583_1	0	Chemical	11,11	azacitidine
26556583_1	0	Pharmacodynamic_phenotype	9,11	response to azacitidine
18433425_8	0	Gene_or_protein	1,3	cytochrome P450
18433425_8	0	Chemical	6,6	yohimbine
18433425_8	0	Limited_variation	8,10	P450 genotypes
18433425_8	0	Gene_or_protein	8,9	P450
18433425_8	0	Gene_or_protein	12,15	CYP2D6
18433425_8	0	Gene_or_protein	17,20	CYP3A4
18429967_8	0	Gene_or_protein	1,4	CYP3A5
18429967_8	0	Gene_or_protein	10,13	CYP3A5
18429967_8	0	Gene_or_protein	103,106	CYP3A5
18429967_8	0	Limited_variation	114,119	CYP3A5 genetic variation
18429967_8	0	Gene_or_protein	114,117	CYP3A5
18429967_8	0	Chemical	123,123	tacrolimus
18429967_8	0	Haplotype	1,6	CYP3A5 * 1
18429967_8	0	Pharmacokinetic_phenotype	22,22	clearance
18429967_8	0	Pharmacokinetic_phenotype	123,124	tacrolimus chronopharmacokinetics
18429967_8	0	Phenotype	10,14	CYP3A5 expressers
18429967_8	0	Phenotype	103,109	CYP3A5 non-expressers
23962279_13	0	Gene_or_protein	0,0	TPMT
23962279_13	0	Gene_or_protein	16,16	TPMT
23962279_13	0	Chemical	24,24	thiopurine
23962279_13	0	Phenotype	16,17	TPMT deficient
15386371_15	0	Chemical	10,12	5-FU
15386371_15	0	Gene_or_protein	20,20	TS
15386371_15	0	Limited_variation	27,27	VNTR
15386371_15	0	Limited_variation	30,34	SNP located within the promoter
15386371_15	0	Limited_variation	20,21	TS genotype
19212337_5	0	Disease	14,17	CEL in blast crisis
19212337_5	0	Gene_or_protein	5,8	FIP1L1
19212337_5	0	Chemical	21,21	sorafenib
19212337_5	0	Limited_variation	5,13	FIP1L1 -PDGFRalpha T674I
19212337_5	0	Chemical	23,23	Nexavar
10911933_12	0	Gene_or_protein	1,4	CYP2A6
10911933_12	0	Chemical	10,10	tranylcypromine
10911933_12	0	Chemical	12,12	methoxsalen
10911933_12	0	Phenotype	18,20	activation of procarcinogens
10911933_12	0	Phenotype	15,15	smoking
11167824_1	0	Chemical	2,9	5-aza-2'-deoxycytidine
11167824_1	0	Disease	11,11	leukaemia
11167824_1	0	Gene_or_protein	14,14	MLL
11167824_1	0	Chemical	21,25	all-trans retinoic acid
11167824_1	0	Chemical	27,34	1alpha,25-dihydroxyvitamin D3
11167824_1	0	Genomic_variation	14,15	MLL abnormalities
11167824_1	0	Pharmacodynamic_phenotype	19,25	differentiation by all-trans retinoic acid
11167824_1	0	Pharmacodynamic_phenotype	19,20,27,34	differentiation by 1alpha,25-dihydroxyvitamin D3
11167824_1	0	Pharmacodynamic_phenotype	0,9	Sensitization by 5-aza-2'-deoxycytidine
22935916_9	0	Gene_or_protein	1,1	COMT
22935916_9	0	Limited_variation	1,7	COMT gene polymorphism , SNP rs9606186
22935916_9	0	Chemical	12,12	risperidone
22935916_9	0	Pharmacodynamic_phenotype	12,14	risperidone therapy efficiency
22935916_9	0	Limited_variation	6,7	rs9606186
21890455_1	0	Chemical	6,9	IMO cooperates with cetuximab
21890455_1	0	Gene_or_protein	0,4	Toll-like receptor 9
21890455_1	0	Gene_or_protein	11,13	K-ras
21890455_1	0	Limited_variation	11,14	K-ras mutant
21890455_1	0	Chemical	9,9	cetuximab
21890455_1	0	Chemical	6,6	IMO
21890455_1	0	Chemical	0,5	Toll-like receptor 9 agonist
21890455_1	0	Disease	11,15,18,18	K-ras mutant colorectal cancers
21890455_1	0	Disease	11,14,17,18	K-ras mutant pancreatic cancers
20680652_3	0	Limited_variation	6,10	rs622342 A > C
20680652_3	0	Chemical	22,22	metformin
20680652_3	0	Gene_or_protein	16,18	HbA1c
20680652_3	0	Phenotype	16,20	HbA1c lowering effect
20680652_3	0	Limited_variation	6,7	rs622342
16043828_13	0	Gene_or_protein	2,2	KRAS
16043828_13	0	Chemical	13,13	erlotinib
16043828_13	0	Limited_variation	2,4	KRAS -mutant
16043828_13	0	Chemical	15,15	chemotherapy
16043828_13	0	Chemical	13,15	erlotinib and chemotherapy
16043828_13	0	Pharmacodynamic_phenotype	8,9	clinical outcomes
16043828_13	0	Disease	2,5	KRAS -mutant NSCLC
17009149_5	0	Disease	13,14	colorectal cancer
17009149_5	0	Limited_variation	26,31	MTHFR polymorphisms in the MTHFR gene
17009149_5	0	Gene_or_protein	26,26	MTHFR
17009149_5	0	Limited_variation	33,38	677C-->T
17009149_5	0	Gene_or_protein	30,30	MTHFR
17009149_5	0	Limited_variation	40,44	Ala-->Val
17009149_5	0	Gene_or_protein	48,49	XRCC1
17009149_5	0	Limited_variation	48,61	XRCC1 gene ( Arg-->Gln substitution in exon 10 )
17009149_5	0	Phenotype	10,11	unresectable metastases
17009149_5	0	Chemical	21,21	FOLFOX
17009149_5	0	Chemical	18,22	chemotherapy with the FOLFOX regimen
17009149_5	0	Genomic_factor	59,60	exon 10
22486182_10	0	Gene_or_protein	13,14	VKORC1
22486182_10	0	Limited_variation	16,20	CYP2C9 genotypes
22486182_10	0	Gene_or_protein	16,19	CYP2C9
22486182_10	0	Chemical	31,31	acenocoumarol
22486182_10	0	Limited_variation	13,14,20,20	VKORC1 genotypes
22486182_10	0	Pharmacodynamic_phenotype	31,33	acenocoumarol dose requirement
22486182_10	0	Phenotype	9,11	International Normalized Ratio
16163519_2	0	Gene_or_protein	2,5	Dopamine beta-hydroxylase
16163519_2	0	Gene_or_protein	7,7	DBH
16163519_2	0	Chemical	10,10	dopamine
16163519_2	0	Chemical	15,15	norepinephrine
16163519_2	0	Chemical	26,26	catecholamine
16163519_2	0	Pharmacokinetic_phenotype	26,27	catecholamine metabolism
16163519_2	0	Chemical	12,12	DA
16163519_2	0	Chemical	17,17	NE
22085575_9	0	Gene_or_protein	14,17	EML4 - ALK
22085575_9	0	Genomic_variation	14,18	EML4 - ALK translocation
22085575_9	0	Gene_or_protein	25,25	ALK
22085575_9	0	Chemical	28,28	crozotinib
22085575_9	0	Chemical	25,26	ALK inhibitor
16084852_3	0	Haplotype	4,6	ABCB1 haplotypes
16084852_3	0	Gene_or_protein	4,5	ABCB1
16084852_3	0	Gene_or_protein	23,25	P-glycoprotein
16084852_3	0	Chemical	32,32	verapamil
16084852_3	0	Pharmacokinetic_phenotype	12,16	central nervous system drug distribution
16084852_3	0	Pharmacokinetic_phenotype	18,19	brain distribution
16084852_3	0	Chemical	22,26	model P-glycoprotein substrate
16084852_3	0	Chemical	29,31	calcium channel inhibitor
25902899_1	0	Chemical	4,4	pazopanib
25902899_1	0	Chemical	6,6	everolimus
25902899_1	0	Gene_or_protein	8,10	PIK3CA
25902899_1	0	Gene_or_protein	14,14	PTEN
25902899_1	0	Disease	19,20	solid tumors
25902899_1	0	Chemical	4,6	pazopanib and everolimus
25902899_1	0	Limited_variation	8,15	PIK3CA mutation positive/ PTEN loss
25902899_1	0	Pharmacodynamic_phenotype	19,24	solid tumors refractory to standard therapy
